Abstracts  by unknown
Abstracts
1
BRCA1 GERMLINE MUTATIONS AS A CAUSE OF PANCREATIC
CANCER
Wigdan Al-sukhni, MD, Heidi Rothenmund, MS, Ayelet Borgida, MS,
George Zogopoulos, MD, PhD, O’shea Anne Marie, MD, Steven Gallinger,
MD, FRCP
University of Toronto, Toronto, ON, Canada; Samuel Lunenfeld Research
Institute, Toronto, ON, Canada
Purpose. Patients with germline BRCA2 mutations are known to be at
higher risk for pancreatic cancer. Less is known about predisposition to
pancreas cancer due to BRCA1 mutations. In this study, we conduct a loss of
heterozygosity (LOH) analysis at BRCA1 locus in pancreatic adenocarci-
noma tissues from patients with germline BRCA1 mutations.
Methods. We identified five unrelated patients who were referred to the
Familial Gastrointestinal Cancer Registry (Ontario, Canada) with newly-
diagnosed pancreatic adenocarcinoma and who were found to carry a
germline BRCA1 mutation. Microdissected, high cellularity, formalin-fixed
paraffin-embedded DNA was extracted for tumor and normal tissue for each
patient, and DNA isolated from peripheral lymphocytes was also available for
4 patients. A polymorphic intragenic microsatellite marker in the BRCA1
gene, D17S855, was selected to test for LOH. Using fluorescently-labeled
forward primer and unlabeled reverse primer, tumor and normal DNA was
amplified separately for each patient. Automated sequencing for the marker
was performed, and the allelic peak intensities were compared between tumor
and normal DNA. LOH was calculated as (T1/T2)/(N1/N2) where T1, N1
are peak intensities for the larger allele and T2, N2 are peak intensities for the
smaller allele, and where Ttumor, Nnormal. A ratio of B0.70 or 1.43
was considered evidence of LOH.
Results. All 5 patients were male, and mean age at diagnosis with pancreatic
adenocarcinoma was 69.8 years. Four patients were of Ashkenazi Jewish
descent and 1 was Caucasian non-Jewish. Three patients carried the BRCA1
185delAG mutation, one the 5382insC mutation, and the other had a
2318delAG mutation. Three patients had another site of primary tumor in
addition to pancreas cancer (2 prostate, 1 colorectal), and there were two
families with 2 or more cases of pancreatic cancer. The frequency of
D17S855 marker polymorphism in this group was 3/5 (60%). All three
informative cases demonstrated LOH in tumor DNA (100%). Further
analyses with additional markers are ongoing.
Conclusions. This study demonstrates that loss of heterozygosity occurs in
tumor tissue of pancreatic cancer patients with germline BRCA1 mutations.
This suggests that the BRCA1 tumor suppressor gene is involved in
pancreatic cancer tumorigenesis, and that LOH may be a ‘‘second hit’’ event
that contributes to this process in these patients. Subjects with germline
BRCA1 mutations may be considered eligible for pancreas cancer screening
programs.
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SIGNIFICANCE OF AFPMRNA DETECTED BY REAL TIME PCR
ANALYSIS AFTER CURATIVE HEPATECTOMY FOR HEPATO-
CELLULAR CARCINOMA.
Toshiya Kamiyama, MD, PhD, Kazuaki Nakanishi, MD, PhD, Hideki
Yokoo, MD, PhD, Munenori Tahara, MD, PhD, Tsuyoshi Shimamura,
MD, PhD, Hiroyuki Furukawa, MD, PhD, Michiaki Matsushita, MD, PhD,
Satoru Todo, MD, PhD
Hokkaido University, Sapporo, Japan
Objective. The presence of cancer cells in peripheral blood and/or bone
marrow can predict the outcome of patients with malignant diseases. We
reported that detection of hepatocellular carcinoma (HCC) cells in bone
marrow by real time PCR targeting AFPmRNA before curative hepatectomy
correlates with HCC recurrence and patient survival. We verified the
significance of AFPmRNA in bone marrow by more patients and long follow
up period.
Methods. Between 7/2000 and 3/2007, 187 HCC patients underwent
primary curative hepatectomy. Bone marrow collected preoperatively was
subjected to real time PCR analysis using AFPmRNA as target molecule.
Median follow up was 46 months (range, 6- 86). Patient survival (PS),
disease-free survival (DFS), and clinicopathological features were compared
between patients with positive- and negative-AFPmRNA.
Results. Forty-five patients died (39 from HCC). HCC recurred in 118
patients (hepatic in 70 [59.3%]; hepatic and/or remote in 48 [40.7%]. Fifty-
one patients (37.5%) were positive for AFPmRNA; 136 (62.5%) were
negative. Positive-AFPmRNA in bone marrow correlated significantly with
portal vein invasion (), hepatic vein invasion (), intrahepatic metastasis
(), and AFP-L315% (p0.006,0.0363,0.0401,0.0196). Three- and 5-
year PS were 85.5% and 69.4%, respectively, with negative-AFPmRNA vs.
59.8% and 53.3%, respectively, with positive-AFPmRNA (p0.005).
AFPmRNA in bone marrow, AFPmRNA in postoperative peripheral blood,
serum albumin, AFP, AFP-L3 (%), protein induced by Vitamin K absence or
antagonist (PIVKA-II), portal vascular invasion, intrahepatic metastasis,
tumor size, tumor number, and Milan criteria significantly correlated with PS
by univariate analysis. AFPmRNA in bone marrow, serum albumin, and
AFP-L3 (%) and tumor size were independent factors for PS by multivariate
analysis. Positive-AFPmRNA in bone marrow was worst factor for PS (p
0.0149, Risk Ratio (RR)3.13, 95%Confidence Interval (CI)1.257.81).
Though 1-year recurrent rates was 49.8% with positive-AFPmRNA vs.
28.2% with negative-AFPmRNA, AFPmRNA in bone marrow did not
significantly correlate DFS by univariate analysis. In recurrent cases, positive-
AFPmRNA significantly tended to recur earlier in 1 year after operation than
negative-AFPmRNA (p0.0106).
Conclusion. AFPmRNA in bone marrow predicts patient survival and
recurrence after curative hepatic resection for HCC by verification with more
cases and longer follow up periods.
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INTRAHEPATIC CHOLANGIOCARCINOMA: RISING INCI-
DENCE, IMPROVED SURVIVAL AND DETERMINANTS OF OUT-
COME AFTER RESECTION
Itaru Endo, MD, Mithat Gonen, Qin Zhou, Kimberly Moore Dalal, MD,
Michael D’angelica, MD, Ronald P. Dematteo, MD, Yuman Fong, MD,
Lawrence Schwartz, MD, Nancy Kemeny, MD, Leslie H. Blumgart, MD,
William R. Jarnagin, MD
Memorial Sloan-Kettering Cancer Center, New York, NY
Background. Intrahepatic cholangiocarcinoma (IHC) remains a rare,
enigmatic disease. This study analyzes changes in IHC incidence and
outcome at a tertiary cancer referral center.
Methods. Consecutive patients with confirmed IHC were analyzed for
demographic, treatment and outcome variables. Changes over time were
assessed and compared to hilar cholangiocarcinoma patients (HCCA) seen
during the same period.
Results. From 12/90-7/06, 594 patients were evaluated (IHC270,
HCCA324). Over the study period, the average annual increase in new
IHC patients was 14.2% (Figure, p0.0006), a 3-fold increase relative to
HCCA (IHC/(IHCHCCA)) (Inset). Median survival for IHC increased
significantly since 2001 (Table); this trend was most striking for patients with
unresectable disease and was unrelated to differences in resectability or
disease stage. After resection of IHC (n82), multifocality (pB0.0001),
nodal involvement (p0.012) and large tumor size (p0.016) indepen-
dently predicted early recurrence. The presence of any 1 of these variables
negated the survival benefit of resection when compared to patients with
unresectable, locally advanced IHC.
Conclusion. IHC incidence has increased dramatically in the last 15 years.
The recent increase in survival appears largely due to improved non-operative
therapy for unresectable disease. Resection of large, node-positive or multi-
focal IHC is of questionable benefit.
ISSN 1365-182X print/ISSN 1477-2574 online # 2008 Taylor & Francis
DOI: 10.1080/13651820801953544
HPB, 2008; 10: 2885
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CLINICAL RESPONSE TO NOVEL DENDRITIC CELL BASED
VACCINE STRATEGY IN PANCREATIC CANCER PREDICTED
BY BIOLOGIC FACTORS
Emmanuel E. Zervos, MD, James J. Mule, PhD, Nasreen Vohra, MD,
Jennifer Cooper, MS, William Janssen, PhD, Domenico Coppola, MD,
Alexander Rosemurgy, MD
East Carolina University, Greenville, NC; H. Lee Moffitt Cancer Center and
Research Institute, Tampa, FL; University of South Florida, Tampa, FL; H.
Lee Moffitt Cancer Center and Research Institute, Tampa, FL
One year ago, we began a novel dendritic cell (DC) based vaccination strategy
for unresectable pancreatic cancer and have observed some clinical response.
The purpose of this study was to determine what biologic correlates predicted
clinical response to treatment.
Methods. Under IRB approval, 16 patients with locally advanced or low
volume metastatic PCA were enrolled. The treatment involved apoptosis
induction using TNFerade (a radiation inducible TNF producing adeno-
vector, GenVec, Inc.) followed by direct percutaneous injection of keyhole
limpit hemocyanin (KLH) pulsed DC over 3 consecutive weeks. Biologic
correlates included: immunoreactivity to KLH, T cell infiltration of tumor,%
tumor necrosis, CA 19-9 and PET reactivity.
Results. 15 patients initiated treatment with 13 completing 3 vaccinations.
Lymphocytes were available for KLH Elispot in 12 patients; tumor tissue to
determine T cell infiltration and degree of necrosis before and after treatment
in 8 patients. There were 3 responders; one had 50% tumor shrinkage with
total resolution of a liver metastasis, 2 downstaged to resectability, each alive
and NED 7 mos after diagnosis. All responders converted from KLH non-
response to response after treatment, had reduction in Ca 19-9, increase in T
cell infiltrate and reduction of metabolic activity of their tumors. These
characteristics were absent in non-responders and sporadic in those with
questionable response. (table)
Conclusions. Response to therapy was infrequent, dramatic and heralded by
immunocompetence, recruitment of T cells into the tumor, decrease in
metabolic activity and reduction in tumor markers. These findings may prove
useful in predicting the utility of resection in patients previously deemed
unresectable but with significant response to therapy.
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LIVER CELL ADENOMA: A MULTICENTER ANALYSIS OF RISK
FACTORS FOR RUPTURE IN 105 CASES
Jeremiah Deneve, DO, Timothy M Pawlik, MD, MPH, Steven Cunningham,
MD, Bryan M Clary, MD, Srinevas K Reddy, MD, Charles R. Scoggins,
MD, Robert C. G. Martin II, MD, Charles A Staley III, MD, David Kooby,
MD
Emory University, Atlanta, GA; Johns Hopkins, Baltimore, MD; Johns
Hopkins University, Baltimore, MD; Duke University, Durham, NC;
University of Louisville, Louisville, KY
Background. Liver cell adenoma (LCA) is a poorly characterized benign
hepatic tumor with propensity for spontaneous rupture. Risk factors for
rupture are not well defined.
Methods. A review was performed on all patients who underwent resection
of LCAs between 1997 and 2006 at 4 academic medical centers. Records
were reviewed for clinicopathologic factors. Using binomial logistic regres-
sion, patients who had histological evidence of tumor rupture were compared
with patients who had non-ruptured tumors.
Results. Data were available for 105 patients undergoing resection, of which
5 (5%) were men. Average age was 39911 yrs, 54% had a documented
history of exogenous hormone use, and 39% were actively taking some
form of hormone therapy at time of treatment. Rupture was observed in
29 (28%) cases, of which 14 (48%) were contained within the hepatic
parenchyma and 15 (52%) demonstrated peritoneal involvement. Ruptured
tumors were larger than non-ruptured tumors (10.894.4 cm vs. 7.39
4.6 cm, respectively, pB0.01); there were no ruptured tumors B5 cm.
History of hormonal therapy tended to be associated with risk of LCA
rupture (hormone use: 69% vs. no hormone use: 49%, p0.08). Patients
with ruptured LCAs were more likely to require preoperative blood
transfusion (35% vs. 11%, pB0.01), preoperative transarterial embolization
(17% vs. 0%, pB0.01), and undergo major (lobe or more) hepatic resection
(69% vs. 34%, pB0.01) compared with patients who had a non-ruptured
LCA. On multivariate analysis-after adjusting for patient age, hormone use
(yes vs. no), tumor size, and tumor number (1 vs. multiple)-increasing tumor
size (odds ratio 1.2 per cm diameter, 95% CI 1.11.3; pB0.01) and positive
hormone use (odds ratio 3.1, 1.18.7; p0.03,) remained independently
associated with risk of tumor rupture. On pathologic analysis, 3 (3%) LCA
cases had evidence of an underlying malignancy; the smallest lesion that
contained a malignancy was 8 cm. No ruptured tumor had histological
evidence of malignancy.
Conclusion. In this large, multicenter analysis of surgically-treated patients
with liver cell adenomas, risk of rupture correlated with patient hormone use
and increasing tumor size. Rupture is associated with greater risk of
preoperative blood transfusion and need for major hepatic resection. We
recommend all patients with known LCAs, who require hormonal therapy,
and those with tumors approaching 5 cm in diameter undergo surgical
therapy.
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INTENTION TO TREAT SURVIVAL FOLLOWING LIVER TRANS-
PLANTATION FOR HEPATOCELLULAR CARCINOMA WITHIN A
DONOR SERVICE AREA
Kevin P Charpentier, MD, Yee Lee Cheah, MD, Jason Machan, PhD,
Thomas Miner, MD, Paul Morrissey, MD, Anthony Monaco, MD
Rhode Island Hospital, Providence, RI
Purpose. This study aimed to assess the impact of wait times on patient
survival following liver transplantation for hepatocellular carcinoma (HCC)
in a single donor service area.
Methods. Patients listed in the New England Organ Bank (NEOB) from
19962005 for liver transplantation with a diagnosis of hepatoma/HCC,
hepatoma and cirrhosis, and fibrolamellar hepatocellular carcinoma were
identified from the United Network for Organ Sharing (UNOS) database.
The following data were extracted: date of listing for liver transplant, date
removed from the wait list, indication for removal from the waitlist, patient
death and date of last known follow-up. Survival rates were calculated from
the time of listing for transplant (ITT OLT) and compared to those
calculated from the date of transplant (OLT).
Results. There were sixty-three new registrations to the transplant list during
the 10-year study period. Sixty-one patients were removed from the waiting
list for the following indications: transplanted 41 (65%), death 7 (11%),
candidate condition deteriorated/too sick to transplant 8 (13%), medically
unsuitable 1 (2%) other 1 (2%), transferred to another center 2 (3%), and
transplanted at another center 1 (2%). Three year survival following liver
transplantation for primary liver cancer was approximately 78%; however,
when the results were analyzed using an intention to treat analysis (ITT
OLT) there was a 1020% decrease in survival rates at every time point due
to wait list drop-out (graph). In the years 20032004, Region I had the
longest median wait time for liver transplantation in the United States for
blood type O (1192 days) and the second longest wait time for blood type A
(1082 days).
Conclusion. Time to liver transplantation is influenced by organ availability,
which varies by region; therefore, the decision for transplant versus surgical
resection as first line therapy for stage I and II HCC should be in part based
on local/regional intention to treat survival rates for both therapies.
Wait list drop out adversely affects liver transplant survival in transplant
centers served by the New England Organ Bank. These data should be
considered when recommending transplant versus resection as first line
therapy for stage I or II HCC in NEOB.
Changes of outcome
19902000
(n112)
20012006
(n126) p value
Patients submitted to resection 34% 35% 0.9
Patients with Stage III/IV Tumors 66% 59% 0.2
Median survival (All IHC patients) 12 mo 22 mo 0.001
Median survival (Resected IHC
patients)
33 mo Not reached 0.04
Median survival (Non-resected IHC patients) 6 mo 15 mo 0.003
Biologic response to treatment
KLH response T cell infiltrate Ca 199 PET response %Necrosis Tumor size
Progression (n6) 50% decreased in 3/3 increased in 5/6 n.a. 380 increased in all
Stable (n6) 66% increased in 1/3 increased in 3/6 no change in 1 4080 stable at 3 months
Response (n3) 100% increased in 2/2 decreased in 3/3 resolution 2/2 6590 2 resected; 1 with 50% shrink
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DOES SCREENING FOR HEPATOCELLULAR CANCER AFFECT
OUTCOME?
Chet Hammill, MD, Linda L Wong, MD
University of Hawaii, Honolulu, HI; Hawaii Medical Center-East, Honolulu,
HI
Purpose. To determine if screening for hepatocellular cancer (HCC) has an
impact on outcome. Currently there are no definitive studies determining
whether screening patients with viral hepatitis or chronic liver disease for
HCC is effective. Despite this, screening with imaging and/or alpha-feto
protein (AFP) is frequently recommended and practiced.
Methods. In a prospectively-collected database of 457 HCC patients (1991
2007), we identified 408 patients with viral hepatitis or chronic liver disease
who would have qualified for screening. Patients were divided into two
groups: HCC diagnosed with screening (n46) and HCC found incidentally
or due to symptoms in patients who did not receive screening (n362).
Demographics, risk factors, tumor characteristics, treatment and survival
were compared between the groups. Subgroup analysis of patients with viral
hepatitis was also performed.
Results. There was no difference in age, sex, hepatitis C, smoking, alcohol
use, AFP, cirrhosis, or vascular invasion between the two groups. The
screened group had smaller tumors at the time of diagnosis (mean 3.81
versus 6.68 cm), and more patients who qualified for transplant (54% versus
33%) using the Milan criteria, which specify a single tumor less than five cm
or two to three tumors each less than three cm. Nevertheless, treatment
received did not differ between the two groups, including resections,
transplants and patients with advanced disease who did not receive treatment.
There was a 1-year survival benefit in the group that received screening (78%
versus 55%), but this disappeared by five years (23% versus 28%). The
screened group also had a lower proportion of patients with hepatitis B
compared to the group that did not receive screening (33% versus 48%).
Subgroup analysis of patients with viral hepatitis B or C did not show an
improvement in survival with screening at one or five years.
Conclusion. Screening for HCC in our cohort identified patients while they
still met transplant criteria, however this did not increase the likelihood of
definitive therapy with liver resection or transplant. Screening did appear to
improve 1-year survival, possibly due to lead-time bias, but did not impact 5-
year survival. Perhaps the benefit of screening will only be realized with more
available livers for transplant, but further studies will be needed to determine
this.
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NATURAL HISTORY AND SURGICAL TREATMENT OF NON-
FUNCTIONAL PANCREATIC NEUROENDOCRINE CARCI-
NOMA: POPULATION-BASED ANALYSIS
Jan Franko, MD, PhD, Linwah W Yip, MD, Kenneth K Lee, MD, Alyssa M
Krasinskas, MD, Herbert J Zeh III, MD, David L Bartlett, MD, Arthur J
Moser, MD
University of Pittsburgh Medical Center, Pittsburgh, PA
Objective. Pancreatic neuroendocrine cancer is a rare indolent malignancy
for which no effective systemic therapy is available. This population-based
analysis evaluated the hypothesis that long term survival benefit is greater
with aggressive rather than limited surgical therapy.
Methods. Non-functional pancreatic neuroendocrine cancer cases (NF-
pNEC) diagnosed in 19732004 were retrieved from the Surveillance,
Epidemiology and End Results Program.
Results. 2158 patients with NF-pNEC were identified (2% of all 109 811
pancreatic malignancies). The annual incidence increased from 1.4 to 3.0 per
million during the study period. Mean age at diagnosis was 59915 years with
29% of cases younger than 50. Tumors measured 59935 mm (median 50)
and were located in the pancreatic head (42%), body (11%), and tail (27%),
while 20% were diffuse. For patients with available data (n1573), 44%
were node-positive and 60% were metastatic. Overall 5, 10 and 20-year
survival rates were 33%, 17%, and 10%, respectively. Surgical removal of the
primary tumor was performed in 46% and significantly prolonged survival
(median 1.2 versus 8.4 years; pB0.001). Among the 944 patients with
documented distant metastases, removal of the primary tumor also signifi-
cantly prolonged survival (median 1.0 versus 4.8 years; pB0.001). Addi-
tionally, resection of metastatic sites was associated with improved survival
(median 2.3 versus 5.6 years; p0.017). Independent predictors of survival
identified by Cox proportional hazard model were age (hazard ratio 1.033;
pB0.001), metastases (HR 1.670; pB0.019), and primary tumor resection
(HR 0.291; pB0.001). Tumor size, location within pancreas, and enuclea-
tion versus resection of the primary tumor were not independent predictors.
Resection of metastases (HR 0.412; pB0.001) was an independent
predictors of survival among patients with metastatic disease.
Conslusion. Surgical therapy improves survival for patients with localized as
well as metastatic NF-pNEC. Metastectomy confers significant additional
benefit following removal of the primary tumor. Enucleation may be
oncologically equivalent to resection.
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TIMP-3 DOWN-REGULATES HEPATIC MRNA EXPRESSION OF
EXTRACELLULAR MATRIX PROTEIN AND ADHESION MOLE-
CULES GENES IN ISCHEMIA/REPERFUSION INJURY ANIMAL
MODEL: A RT-PCR ARRAY STUDY
Ari J Cohen, MD, Zhen-ya Tang, MD, Ian Carmody, MD, O. Rama Swamy,
PhD, George Loss, MD, PhD
Ochsner Clinic Foundation, New Orleans, LA
Aim. We have demonstrated that tissue inhibitor of metalloproteinase -3
(TIMP-3) ameliorated hepatic ischemia/reperfusion (1/R) injury through
inhibition of TNF–converting enzyme (TACE) in animal model. (Transplan-
tation 2006, 82:15181523). Since TIMP-3 has been reported to inhibit the
activity of matrix metalloproteinases (Mmps), it is necessary to investigate
whether Mmps and other cell adhesion molecules and extracellular matrix
proteins are involved in this circumstance.
Methods. RNA was extracted from liver tissues of animal treated with
TIMP-3 (1000 ng/Kg BW) or control (0.9% NaCL). Four RNA samples
from each group were pooled and subsequently subjected to real-time RT-
PCR array, which simultaneously detects 90 genes (RT Profiler PCR Array
Rat Extracellular Matrix and Adhesion Molecules, SuperArray Bioscience
Cooperation, Frederick, MD).
Results. After TIMP-3 treatment, hepatic mRNA expression of many cell
adhesion molecules and extracellular matrix protein genes were down-
regulated (25 folds). Several Mmps (Mmp1a, Mmp8, Mmp9, Mmp10,
Mmp11, Mmp12, Mmp13, Mmp14 and Mmp16) were down-regulated (23
folds), but not Mmp2, Mmp3. Mmp7and Mmp15. The expression of
TIMPs (TIMP-1, TIMP-2, and TIMP-3) was not effected.
Conclusion. This pilot study shows that TIMP-3 down-regulates hepatic
expression of many cell adhesion molecules and extracellular matrix protein
genes, especially the Mmps, implying that TIMP-3 may reduce hepatic I/R
injury through inhibition of cell adhesion molecules and extracellular matrix
proteins, in addition to TACE. Further studies of activity of Mmps and other
important molecules are required. Real-time RT-PCR array is a cost-effective
and feasible method to study gene expression.
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ALTERED AQUAPORIN-9 (AQP9) EXPRESSION AND LOCALI-
ZATION IN HUMAN HEPATOCELLULAR CARCINOMA (HCC)
AND ADJACENT LIVER.
David A Iannitti Sr, MD, Peter Banks, MD, B. Todd Heniford, MD, Mollie
Palilonis, B.Sc., Amy Lincourt, PhD, Mark Russo, MD, MPH, Iain
Mckillop, PhD
Carolinas Medical Center, Charlotte, NC; University of North Carolina at
Charlotte, Charlotte, NC
Background. Aquaporins (AQPs) represent transmembrane proteins that
form channels allowing rapid water movement along an osmotic gradient.
Aquaporin 9 is expressed on the basolateral membrane of hepatocytes and plays
a role in bile production as well as cell apoptosis. This study evaluates AQP9
expression and localization in human HCC and adjacent non-tumor liver.
Methods. 18 human HCC specimens (14 male, 4 female) and adjacent liver
were obtained. Immuno-fluorescent histochemistry (IFHC) was performed
using anti-AQP9 and F-488 labeled secondary antibodies. DAPI staining was
included for nuclear identification and localization. Samples were blind
scored and the data and correlated to patient pathology.
Results. Of seven HCCs arising in histologically ‘‘normal’’ liver, 4 had no
AQP9 expression in the tumor while having strong membrane AQP9 staining
with normal zonal distribution in lobules of the adjacent liver. In 2 of the
remaining samples (both female) equal staining was observed in the tumor
and adjacent liver but without zonal localization within the lobules. In the
final sample, membrane localization and zonal distribution was observed in
the normal liver and extensive staining with membrane localization was
detected in the tumor. In the micronodular cirrhosis patient group (n7),
the HCCs stained weakly for AQP 9 while in the adjacent cirrhotic liver AQP
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9 was detected at the plasma membrane with loss of zonal distribution. In the
remaining samples AQP9 detection did not demonstrate a consistent pattern
of staining relative to membrane localization or zonal distribution in tumor or
adjacent liver.
Conclusions. These data demonstrate decreased AQP9 expression in HCC
cirrhotic and non-cirrhotic livers. Additionally, micronodular cirrhosis is
associated with loss of zonal distribution of AQP9. These data may improve
our understanding of how changes in AQP expression relate to HCC
progression in terms of decreased normal liver function and potentially, in
the increased resistance to apoptosis in transformed hepatic cells.
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THE EXPRESSION OF INTERFERON RECEPTOR ALPHA/BETA
IS ESSENTIAL FOR TUMOR RESPONSE TO INTERFERON
ALPHA TREATMENT IN HUMAN PANCREATIC CANCER IM-
PLANTED IN NUDE MICE
Reza F. Saidi, MD, Ahmed Ahad, MD, Ilke Nalbantoglu, MD, Michael J
Jacobs, MD
Providence Hospital and Medical Centers, Southfield, MI; Wayne State
University, Detroit, MI
Introduction. Adjuvant interferon (IFN) therapy and chemoradiation status
post pancreatico-duodenectomy for patients with pancreatic cancer have
rendered promising results. In vitro studies have shown that interferon-
mediated apoptosis in pancreatic cancer cell lines is mediated through
interferon receptors. The aim of this study was to evaluate the in vivo effect of
interferon alpha on human pancreatic carcinoma implanted orthotopically
into nude mice.
Material and Methods. Human pancreatic cancer cell lines MiaPaCa-2 and
Panc-1 were used. MiaPaCa-2 is known to express the interferon alpha/beta
receptor and Panc-1 cells do not. The cells were implanted into the pancreas
of nude mice and treatment was initiated seven days later. Ten mice were
equally divided into two regimens. Regimen I consisted of intraperitoneal
single-agent gemcitabine (125-mg/kg biweekly) and Regimen II consisted of
IFN-alpha (10,000-units daily, subcutaneously) and gemcitabine biweekly
for 30 days. Animals were sacrificed after 30 days or if they became
moribund. Body weight was determined and the primary tumors in the
pancreas were excised, measured, and weighed. Visible metastases or
adjacent organ invasion were counted and processed for H&E staining. All
macroscopically enlarged regional (celiac and para-aortal) lymph nodes were
harvested and the presence of metastatic disease was confirmed by histology.
Results. The mice that were implanted with MiaPaCa-2 cells showed a more
dramatic response to Regimen II when compared to Panc-1 implanted mice.
The MiaPaCa-2 group that was treated with Regimen II showed an 87%
reduction in tumor volume compared to 50% in the Panc-1 group treated
with the same regimen (pB0.001). Mice implanted with MiaPaCa-2 and
treated with Regimen II showed less metastasis, less local invasion, and a
longer survival compared to mice implanted with Panc-1 treated with same
regimen. Regimen II was more effective on MiaPaCa-2 compared to
Regimen I (pB.001). There were no differences between regimen I and II
in the Panc-1 group.
Conclusions. Treatment of human pancreatic cancer in nude mice with
interferon alpha and gemcitabine was associated with a reduction in tumor
volume. This process occurs in those cells that express the appropriate
interferon receptors. The expression of interferon alpha in pancreatic cancer
is therefore essential to the tumor response seen with interferon treatment.
Gemcitabine and interferon alpha may be an effective adjuvant treatment for
pancreatic cancer when the interferon alpha/beta receptor is present.
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CELL DEATH INDUCED BY AN HERB MEDICINE PTERIS
SEMIPINNATA L IS MAINLY INVOLVED IN BCL-2 FAMILY
MEMBERS IN HEPATOCELLULAR CARCINOMA
George G Chen, MD, PhD, Nian-ci Liang, Ursula Pf Chan, Liao Cui,
Taiping He, Paul Bs Lai
The Chinese University of Hong Kong, Hong Kong, Hong Kong; Guang-
dong Medical College,, Zhanjiang, Guangdong, China; Guangdong Medical
College, Zhanjiang, Guangdong, China
Pteris semipinnata L (PSL) is an herb medicine which has been used to
subside lumps and to improve a variety of inflammatory conditions. We have
isolated an active compound (5F) from PSL and in this study we tested how
5F induced cell death in hepatocellular carcinoma (HCC). Two HCC cell
lines, HepG2 and SKHep1 were used for the study. Cell death was reflected
by the reduction in cell viability as detected by MTT assay and cell death-
related molecules were determined by Western blot. The result showed that
5F significantly induced the cell death of both HepG2 and SKHep1 but not
the other 3 cell lines in a time- and dose-dependent manner, indicating that
5F is an effective molecule that responsible for the anti-tumor effect of PSL.
Our study further showed that the mode of cell death caused by 5F was
mainly in the format of apoptosis. The pro-apoptotic effect of 5F was
comparable to that of 5-fluorouracil (5Fu), a well-known chemotherapeutic
agent. Screening a number of cell death-related molecules, we found that the
Bcl-2 family members were the main target of 5F, as 5F stimulated the
expression of pro-apoptotic Bax protein but reduced the level of anti-
apoptotic Mcl1 protein. The imbalance between increased Bax and decreased
Mc11, promoting the release of cytochrome C from the mitochondria and
eventually leading to apoptosis of HCC cells. Taken together, 5F is a
potential anti-HCC agent which induces apoptosis of HCC cells via
enhancing pro-apoptotic Bax but reducing anti-apoptotic Mc11.
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HUMAN GALLBLADDER MUSCLE RESPONDS SYNCHRO-
NUSLY
Abhishek Mathur, MD, Hayder H Al-azzawi, MD, Kyle W Yancey, MD,
Attila Nakeeb, MD, Henry A Pitt, MD
Indiana University, Indianapolis, IN
Introduction. The human gallbladder has an interlaced network of smooth
muscle which responds in concert to neuronal and hormonal stimuli.
Circular and longitudinal muscles oriented at 908 to one another are present
in both the fundus and neck of the gallbladder. Considerable animal and
human data suggest that abnormalities of gallbladder motility play a key role
in gallstone pathogenesis. However, a systematic analysis of circular and
longitudinal muscle response in the fundus and neck of the human
gallbladder has not been performed. Therefore, we designed a study to test
the hypothesis that circular and longitudinal muscle responses would be
similar in both the fundus and neck of the gallbladder.
Methods. Gallbladders were obtained from 17 patients undergoing chole-
cystectomy as part of another procedure (n4, normal), for chronic
acalcuolus cholecystitis (n4) or for symptomatic cholelithiasis (n9).
Patients with acute cholecystitis, an occluded cystic duct, abnormal liver
function tests or prolonged fasting were excluded. Circular and longitudinal
muscle strips were obtained from the fundus and neck of each gallbladder
and placed in 95% O2/5% CO2 Krebs solution. The four strips from each
gallbladder were rapidly placed in a muscle bath for determination of optimal
tension, the maximal response to acetylcholine (Ach) 105 M, as well as
response to cholecystokinin (CCK) at 108 and 107 M. Data were
analyzed by ANOVA and Student’s t test.
Results. Normalized gallbladder (GB) weight (g/cm2), optimal tension (mg),
and response to Ach and CCK (N/cm2) are presented in the Table.
No differences were observed among the patient groups.
Conclusion. These data suggest that gallbladder circular and longitudinal
muscle in both the fundus and neck have similar a) weights and optimal
tensions as well as b) responses to neuronal (Ach) and hormonal (CCK)
stimuli. We conclude that circular and longitudinal muscle in the fundus and
neck of the gallbladder respond synchronously.
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CRITERIA FOR TRANSFUSION OF FRESH FROZEN PLASMA
AFTER HEPATECTOMY FOR HEPATOCELLULAR CARCINOMA
Yuki Kimura, MD, PhD, Kazuto Inoue, MD, PhD, Masamichi Moriguchi,
MD, PhD, Tadatoshi Takayama, MD, PhD
Nihon University, Tokyo, Japan
The purpose of this study was to evaluate our criteria for the use of
perioperative transfusion of fresh frozen plasma (FFP) after hepatectomy for
hepatocellular carcinoma (HCC). A retrospective analysis was performed on
127 consecutive patients undergoing hepatectomy for HCC. FFP was
administrated if the amount of blood loss exceeded 600 ml during surgery,
or to maintain the serum total protain level at 6.0 g/dl after surgery. Patients
who had received perioperative FFP transfusion (n108) and those who had
not (n19) were compared. The postoperative morbidity, mortality, and
duration of hospital stay were similar between the two groups of patients,
although those receving FFP demonstrated a significantly poorer indocianine
green retention at 15 min (P0.03), suffered more blood loss (P0.001),
and entailed higher medical costs (P0.01). Multivariate anlysis revealed
that FFP transfusion under our criteria was not identified as an independent
factor influencing postoperative morbidity. The recurrence-free survival in
the non-FFP transfusion group was significantly higher than that in the FFP
GB Muscle GB Weight Optimal Tension Ach 105 M CCK 108 M CCK 107 M
Circular- Fundus 0.790.1 292917 0.0390.01 0.0390.01 0.0790.02
Cir‘cular- Neck 0.890.1 290923 0.0490.01 0.0690.02 0.1090.04
Longitudinal- Fundus 0.890.1 270919 0.0590.01 0.0790.02 0.0990.03
Longitudinal- Neck 0.890.1 279918 0.0490.01 0.0690.01 0.0990.02
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transfusion group (P0.03). In conclusion, the policy of FFP transfusion
might help to ensure the safety of hepatectomy for HCC.
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DEVELOPMENT AND VALIDATION OF A RELIABLE TECHNI-
QUE FOR INTRA-OPERATIVE SAMPLING OF PANCREATIC
DUCTAL JUICE DURING PANCREATICODUODENECTOMY
FOR CANCER.
Harsha R Hathurusinghe, MBBS, Melissa Cunha, Adrian Holt, Aali J Sheen,
MD, Ajith K Siriwardena, MD
Hepatobiliary Surgery Unit, Manchester Royal Infirmary, Manchester,
United Kingdom; Department of Clinical Biochemistry, Manchester Royal
Infirmary, Manchester, United Kingdom
Introduction. Intra-operative sampling of pancreatic ductal juice during
pancreaticoduodenectomy for cancer can provide a potentially invaluable
source for study of cancer-derived genetic or proteomic material. However,
the conventional technique of aspiration after transection results in spillage of
juice while introduction of a sampling tube into the duct may dislodge
epithelial cells. We report the development and validation of a new method
for intra-operative assay of pancreatic ductal juice during pancreaticoduode-
nectomy.
Aims & Methods. After mobilisation of the neck of the pancreas from the
portal/superior mesenteric vein confluence, a sling is passed under the gland.
After ligation of the gastroduodenal artery and the arteria pancreatica magna,
transection with diathermy is undertaken in a bloodless field to expose but
not open the duct of Wirsung. The exposed duct is then aspirated and fluid
obtained for analysis. Transection is completed in a standard fashion.
Aspirate sample volumes were recorded. Fluid was also inspected for
presence of contaminant red blood cells. Yield from this new technique
was compared to aspirates taken by the standard method of duct cannulation
after transection.
Results. The median volume of fresh pancreatic ductal juice obtained by the
standard technique of cannulation of the main duct after transection was 30
microliters (interquartile range [iqr] 1050). The median volume obtained by
the new method of duct aspiration after partial parenchymal transection was
1450 microliters (iqr 6002200). This difference was statistically significant
(P0.0008; Mann-Whitney U-test). No samples in the new technique were
contaminated with red blood cells.
Conclusion. Duct aspiration after partial parenchymal transection to
expose the main duct of Wirsung appears to be a simple and effective
means of obtaining good volumes of uncontaminated pancreatic ductal juice
(whilst this fluid is in continuity with the pancreatic tumour) for research
purposes.
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PROPHYLACTIC ADMINISTRATION OF OCTREOTIDE CON-
TINUOUS INFUSION TO PREVENT PANCREATIC ANASTOMO-
TIC FISTULA  A PILOT STUDY
Milton Lum, MD, Carmine M Volpe, MD
The Western Pennsylvania Hospital, Pittsburgh, PA
The recent reduction in operative mortality following pancreatic resection has
not been accompanied by a corresponding improvement in the rate of
pancreatic anastomotic fistula. Trials evaluating the perioperative subcuta-
neous administration of octreotide to reduce the incidence of pancreatic
anastomotic fistula report inconsistent Results. This study evaluated the
efficacy of perioperative continuous infusion octreotide in the prophylaxis of
pancreatic anastomotic fistula following pancreatic surgery for benign and
malignant pancreatic disease.
Pancreatic anastomotic fistulas were defined and graded according to
the classification scheme of the International Study Group on Pancreatic
Fistula (ISGPF, Table I). All patients undergoing surgical exploration
for pancreatic resection received 100 micrograms of octreotide subcuta-
neously within one hour prior to incision. Following pancreatic resection,
a continuous intravenous infusion of octreotide @ 25 mcg/hour was started
and continued for 7 days or until the patient was discharged, whichever
came first.
The study cohort consisted of 13 patients, 10 females and 3 males. The
median age was 67 years old (3178 years). The median followup time was 13
months (226 months). Seven distal pancreatectomies and 6 pancreatico-
duodenectomies were performed. The median estimated blood loss was 600
cc (2001700 cc). The texture of the pancreatic remnant was soft in 4
patients, firm in 6, and hard in 3 patients. Pancreatic adenocarcinoma was
the pathologic diagnosis in 7 patients, chronic pancreatitis in 3 patients, and
ampullary carcinoma, neuroendocrine tumor, and insulinoma in the remain-
ing 3 patients, respectively. The median length of hospital stay was 7 days (5
14 days).
Eleven patients (85%) had no evidence of fistula. Grade A fistulas occurred
in 2 patients (15%), no grade B or C fistulas occurred. Pancreatic drain was
removed at a median of 7 days (59 days). Octreotide infusion was continued
for a median of 6 days (47 days). The median number of days to resume oral
intake was 3 days. The 30 day operative mortality rate was 0%.
The prophylactic administration of octreotide continuous infusion following
pancreatic resection may decrease the incidence of clinically significant
pancreatic anastomotic fistula (Grades B and C).
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INTRAOPERATIVE FLUORESCENCE IMAGING OF WHOLE
PANCREATICODUODENAL TRANSPLANT ALLOGRAFTS
USING INDOCYANINE GREEN WITH LASER FLUORESCENCE:
A REPORT OF TWO CASES
Edmund Q Sanchez, MD, Srinath Chinnakotla, MBBS, Dmitriy Nikitin,
MD, Tariq Khan, MD, Henry Randall, MD, Greg Mckenna, MD, Richard
Ruiz, MD, Nicholas Onaca, MD, Marlon Levy, MD, Robert Goldstein, MD,
Goran Klintmalm, MD, PhD
Baylor University Medical Center, Dallas, TX; Baylor All Saints Medical
Center, Fort Worth, TX
Purpose. Vascular thrombosis is a cause of allograft loss after pancreas
transplantation. No specific modes of intraoperative imaging have been
utilized in assessing the patency of the vascular anastomoses. We present the
use of intraoperative fluorescence imaging (IFI) in two pancreas transplants.
Methods. The SPY imaging device (Novadaq Technologies Inc., Toronto,
Canada) was used to visualize the arterial and venous anastomoses and flow
of the pancreas allografts intraoperatively in two patients. Indocyanine green
(ICG) 2.5 mg/ml IV was fluoresced with the device to create the
intraoperative video sequences. ICG was injected on 3 separate occasions
to obtain sufficient images. Posttransplant follow-up of 60 days was
performed.
Results. The transplant pancreas arterial conduit, venous anastomosis, and
whole allograft perfusion were adequately visualized using the SPY device.
There were no observable adverse effects on the patient or the transplanted
allograft. The video sequences were recorded.
Conclusion. Real time SPY imaging on these two pancreas transplants did
not demonstrate adverse effects on patients or the transplanted allografts.
Utilization of this method of vascular imaging could prove itself useful in
improving short-term graft survival and possibly lowering the thrombosis
rates seen with pancreas transplantation. Long-term correlation studies
between intraoperative findings and graft survival must be performed to
confirm the utility of this method of imaging.
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LAPAROSCOPIC CHOLECYSTECTOMY IN PATIENTS WITH
LIVER CIRRHOSIS
Jaikish Jayaraj, Subramanian M
Sri Ramachandra Medical College & Research Institute, Chennai -117, India
Aim. To assess the safety and efficacy of laparoscopy in the treatment of
symptomatic gallstone in patients with cirrhosis.
Materials and Methods. Between March 2004 to April 2007,285
laparoscopic cholecystectomy for symptomatic gallstones were performed.
ISGPF Classification Scheme for Grading Pancreatic Fistula
Criteria No Fistula Grade A Grade B Grade C
Drain Amylase B3normal
serum amylase
3normal
serum amylase
3normal
serum amylase
3normal
serum amylase
Clinical condition Well Well Often well Appears ill
Treatment No No Yes/No Yes
US/CT () () (/) ()
Persistent drainage No No Usually Yes
Signs of infection No No Yes Yes
Readmission No No Yes/No Yes/No
Reoperation No No No Yes
Death related to fistula No No No Yes
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There were 15 cirrhotic patients (group A) and 45 age and sex match
controls (group B). All patients were well compensated cirrhosis (child’s class
A or B). We analyzed the occurrence of intraoperative and postoperative
complications.
Results. There was no operative mortality in both the group. Conversion
to open cholecystectomy was necessary in 1 patient in either group. Ope-
rative time in group A was 105 mins Vs 70 mins for group B. Mean blood loss
during surgery was 120 ml in group A and 35 ml in group B. No patients in
group B required any blood component transfusion in contrast to 1 patient in
group A. Postoperative complications were observed in 5 patients in group A
with 1 patient having reactionary hemorrhage needing re-exploration, 2
presented with ascites which led to a worsening of Child’s Class in one of
them and 2 had minor wound infection while in group B 3 patients had minor
wound infection. The hospital stay in group A and B was 7.5 and 4.5 days
respectively.
Conclusion. Laparoscopic cholecystectomy, once considered contraindi-
cated in patients with cirrhosis, is safe and effective in patients with
compensated cirrhosis who have symptomatic gallstones.
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VOLUNTARY AND INVOLUNTARY LIGATURE OF THE BILE
DUCT IN IATROGENIC INJURIES: A NON ADVISABLE AP-
PROACH
Miguel-angel Mercado, MD, Carlos Chan, MD, Juan-carlos Jacinto, MD,
Norberto Sanchez, MD, Alexandra Barajas, MD
Instituto Nacional de la Nutricio´n Salvador Zubira´n, Mexico City, Mexico
Abstract. Bile duct injuries related to laparoscopic and/or open cholecys-
tectomy have a constant rate of appearance. Complete obstruction of the
duct, with or without ablation requires surgical treatment. There are some
cases with complete obstruction, in which intentionally or unintentionally a
ligature or clip has been placed. The intentionally application is done with
‘‘two goals’’ according to the primary surgeon in the referral operative note:
a) facilitate identification of the duct and b) to obtain bile duct dilation. Here
in, we analyze the cases sent to our center with voluntary and involuntary
duct ligation, after iatrogenic bile duct injury.
Methods. Among patients referred to our hospital for surgical treatment of a
bile duct injury, we reviewed the files of those who had bile duct ligation
(voluntary or involuntary). Results of preoperative evaluation of the ducts,
operative treatment and postoperative results were analyzed.
Results. Between Jun 1990 and Dec 2006, a total of 413 patients were
referred for repair. Forty five patients were identified with complete
obstruction of the duct secondary to intentional and unintentional placement
of sutures and/or clips. Fifteen cases had a voluntary placement of the ligature
by the primary surgeon after identifying the complete transaction injury
(operative note) and in 30 cases the occlusion was involuntary placing clips
and or sutures either by misidentification of the duct and/or to stop a
hemorrhage.
Bile duct dilation (10 mm) was demonstrated in one case of voluntary
ligation (6%) and in three cases in the non voluntary ones (10%). The
remaining cases in both groups had no dilation of the duct, developing
necrosis at the level of the binded duct and leakage proximal to the ligature,
with different amount of bilioperitoneum and/or biloma. In all cases a Roux
en Y hepatojejunostomy was done.
Conclusion. Bile duct ligature produces dilation in a very small number of
patients (less than 10% of the cases). Ligature of the duct usually produces
necrosis of the binded stump with subsequent bile leakage. Placement of a
sub hepatic drain and transference of the patient to a qualified center for
reconstruction is the best approach if the primary surgeon is not able to do
the repair.
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SURGICAL MANAGEMENT OF HILAR CHOLANGIOCARCI-
NOMA: SINGLE CENTER EXPERIENCE
Yoshikazu Toyoki, Kenichi Hakamada, MD, PhD, Shunji Narumi, MD,
PhD, Masaki Nara, MD, PhD, Keinosuke Ishido, MD, PhD, Mutsuo Sasaki,
MD, PhD
Hirosaki University School of Medicine, Hirosaki, Japan
Background & Aim. Surgical resection is only therapeutic option that can
offer long-term survival for patients with hilar cholangiocarcinoma. However,
it is difficult to perform the curative resection due to longitudinal tumor
spread and vertical tumor invasion. As a result, there is low respectability,
curability and long-term survival rate. The aim of this study was to evaluate
whether an aggressive surgery was associated with improved survival outcome
and to analyze the prognostic factors.
Methods & patients. The medical records of 51 patients that treated for
hilar cholangiocarcinoma between January 1996 and December 2006 in our
center were retrospectively analyzed. Portal vein embolization was applied to
prevent liver failure before right-side hepatectomy since 2004 at our center.
All patients were divided into 2 groups; one was patients treated between
1996 and 2003 (period 1), another was patients treated between 2004 and
2006 (period 2).
Results. Six of the patients were not performed surgery. Nine of all
patients were performed only bypass operation. Thirty-six patients were
performed resection operation (including 28 patients with macroscopic
curative resection and 8 patients without curative resection). The 1, 3,
5-year survival rate of the patients performed resection (36 patients)
was 87.2%, 52.6% and 31.6%. On the other hand, the 1, 3, 5-year survival
rate of the patients with no surgery were 0%, 0% and 0%, and that of
the patients with bypass operation were 42.9%, 0% and 0%. As a results
of analysis of curative resection patients, factors influencing survival rate
were major vessel invasion (p0.0485) and perineural invasion (pB0.0001).
The other factors had no statistical difference for survival rate. Compared
patients in period 1 with patients in period 2, the surgical resection
and curative resection rate was significantly higher in period 2 than in period
2 (p0.0021, p0.0011). The 1, 3-year survival rate of the patients
in period 1 and in period 2 were 63.0%, 29.6%, and 93.8%, 71.6%
(p0.0317).
Conclusions. Our data suggested that major vessel invasion and perineural
invasion were prognostic predictors and an aggressive surgical approach using
portal vein embolization was associated with improved operative and survival
outcomes for patients with hilar cholangiocarcinoma.
22
ENDOSCOPIC MANAGEMENT OF RECURRENT PRIMARY BILE
DUCT STONES
Geoffrey P Kohn, MBBS, A Sayed Hassen, MBBS, Simon W Banting,
MBBS, Sean Mackay, MBBS, Richard J Cade, MBBS
University of North Carolina, Chapel Hill, NC; Box Hill Hospital,
Melbourne, Australia
Background. The management of recurrent choledocholithiasis today
remains as challenging as in the pre-endoscopic era. Two to seven percent
of affected patients have historically required open surgical intervention for
the treatment of recurrent or retained choledocholithiasis and of these, as
many as 24 percent will develop biliary complications. To avoid open surgery,
repeated endoscopic management of the problem has been advocated. In this
study we evaluate our policy of repeated endoscopic management of
recurrent primary bile duct stones.
Methods. This study examined a cohort of nine patients identified
from a prospective database with recurrent choledocholithiasis. Demo-
graphic, clinical and investigative details were recorded and data
were analysed. Complications were determined from a review of the patient’s
file.
Results. There were nine patients and sixty-six procedures were
performed. Mean age at time of first endoscopy was 70.1 years [3691].
Three patients were male (33.3%). The mean number of endoscopies
performed per patient was 7.3 [313]. Failure to completely clear the duct
occurred in 36.4% of all endoscopies. No periprocedural complications
occurred.
Conclusions. Repeated endoscopic stone extraction with repeated endo-
scopic sphincterotomy when required is a safe policy. However, this
technique will only provide temporary relief from primary ductal stones
and repeated endoscopic treatment, again safe, will be required.
Key words. Choledocholithiasis, Cholangiopancreatography, Endoscopic
Sphincterotomy, Biliary Tract Surgical Procedures, Endoscopy
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STRASBERG ‘‘D’’ INJURY. SPECTRUM AND THERAPEUTIC
CHOICES
Miguel-angel Mercado, MD, Carlos Chan, MD
Instituto Nacional de la Nutricio´n Salvador Zubira´n, Mexico City, Mexico
Introduction. Bile duct injuries frequency, related to laparoscopic chole-
cystectomy is constant. The injuries done at medial aspects of the
hepatocholedochus are described only in the Strasberg classification. Injury
mechanism is heterogeneous but usually includes extreme traction of
the main duct, dissecting it from the hepatic hilus and consequent
desvascularization with perforation of the duct. The duct maintains con-
tinuity in this type of injury. The frequency, spectrum and results of
treatment are analyzed.
Methods. We analyzed the files of the patients referred for surgical repair
of bile duct injuries at our hospital (tertiary case, academic uni-
versity hospital). Patients classified as having a type D Strasberg injury
were selected and general data, clinical data and therapeutic choices were
analyzed.
Results. In a 16 year period, 405 patients were referred for surgical
treatment. In 31 cases (8%) patients were classified as having a type D
injury. In 25 cases (80%) the injury was identified at the index operation.
In the remaining cases it appeared in the early postoperative period as
biloma and/or biliperitoneum. Four of the cases had an injury at the level
of the left hepatic duct, three of them at the medial aspect of the
confluence and the remaining 24 at the hepatocholedochus level. In all
cases, Roux en Y hepatojejunostomy was done. In the left hepatic injuries,
two bilioenteric anastomosis were done and two concomitant hepatec-
tomies. No mortality was recorded in this subset of patients (overall
mortality: 4 out of 405 cases, B1%). Mean postoperative follow up was of
62 months (range 1 to 160). In only one case (3%), postoperative
recurrent cholangitis was observed, which required radiological and
surgical intervention.
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Clinical Strasberg D injury was observed in 8% of the cases (D1), adding
three subsets of patients: injuries at the lateral confluence level (D2) injuries
at the left duct alone (D3), and complete occlusion of the left duct (D4).
Conclusion. In our series, the frequency of Strasberg D injuries was
8%. The spectrum of injuries included four subtypes, thus proposing an
expansion of the current classification. In most of the cases the injury is
recognized at the index operation. Because of the concomitant devascular-
ization of the extrahepatic ducts and partial loss of continuity in an ischemic
duct, an intrahepatic Roux en Y hepatojejuno anastomosis is the treatment of
choice. This approach warrants a high quality (tension free, non ischemic,
wide) anastomosis. Extreme cases in which the left duct (intra or extra-
hepatic) was ischemic required concomitant left lateral hepatectomy.
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BILIARY CANCERS: INITIAL RESULTS FROM A MULTIDISCI-
PLINARY HMO BASED REFERRAL CENTER
Pascal R Fuchshuber, MD, PhD, Howard Young, MD, Paul Ho, MD, Sung
Cho, MD, Eugene Chan, MD, Ck Chang, MD
Kaiser Permanente Med. Center, Walnut Creek, CA
Introduction. Biliary cancers require a multimodality treatment approach
for best outcome. It is questionable if these complex cancers should be
treated in community hospitals.
Methods. We retrospectively reviewed 19 consecutive patients who under-
went resection of biliary cancers with curative intent between 2002 and 2007
at a community hospital hepatobiliary referral center for a large regional
HMO. Outcome measures analyzed were overall and disease-free survival
(OS, DFS), type of surgery, length of stay, histology, stage, recurrence, and
morbidity.
Results. 47% male and 53% female patients with a mean age of 64 yrs (range
3985) had 3 intrahepatic (16%), 8 perihilar (42%), 8 distal (42%) biliary
cancers resected. 14 patients had R0, 5 had R1 resections. Additional non-
surgical interventions included 12 ERCP’s, 4 liver biopsies, 5 biliary drainage
procedures, and 3 preoperative portal vein embolizations. Mean OS was 32
months. 1-year survival was 62%; 3-year survival was 58%. Ninety-day
mortality was 5% (1 death from respiratory failure after complete postop
recovery. Major complication rate was 16% (1 patient each with sepsis,
wound infection, and liver abscess). Mean EBL was 622 mL (range 75
1900), requiring blood transfusion in 32%. Patients undergoing liver
resection were more likely to have an EBL500 mL (pB 0.01). Two
patients developed metastatic disease on avg 1.5 yrs from resection. To date,
15 patients are alive, 1 with local recurrence successfully ablated, 1 with
metastatic disease and 10 with documented DFS for an avg of 346 days
(range 171189).
Conclusion. Although the small number of patients greatly reduces the
strength of the analysis and does not support log-rank calculation of prog-
nostic factors, we have shown that a community-based multimodality treat-
ment center can achieve reasonable outcomes for complex biliary cancers.
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A 14-YEAR FOLLOW-UP OF PATIENTS OBSERVED IN TWO
RCTS OF GALLSTONE DISEASE: PAIN ATTACKS OR ACUTE
CHOLECYSTITIS
Karl Sondenaa, MD, PhD, Malte Schmidt, Morten Vetrhus, MD, PhD
University of Bergen, Bergen N-5892, Norway; Stavanger University
Hospital, Stavanger N-4068, Norway
Introduction. We have examined the risk of having new events of
symptomatic gallstone disease (GSD) following observation in patients
randomized in two RCTs of gallstone pain attacks (GS-group) or acute
cholecystitis (AC-group).
Method. Around 1993, 184 patients (133 women (70.4%) and 51 men,
mean age 52-years) with US shown gallstones and clinical gallstone pain
attack (GS-group, n120) or acute cholecystitis (AC-group, n64) were
randomized to operative treatment (A) or observation (B). In 2007, a follow-
up study was done.
Results. In the GS-group, 9% (8 women, 3 men) had died, compared with
28% (7 women, 11 men) in the AC-group. A total of 44% (41/94)
randomized to observation (groups B) had had a cholecystectomy, i.e. in
GS-group-B 30 patients (49%), and in AC-group-B 11 (33%). In groups A,
88% (79/90) had had a cholecystectomy, i.e. in GS-group-A 52 patients
(88%), and in AC-group-A 27 (87%). Thus, 65.2% (120) of all study
patients in the two RCTs had the gallbladder removed during follow-up.
Events of GSD during follow-up occurred in GS-group-B in 18 patients
(29%), and in AC-group-B 12 (36%). GSD according to GS-group and AC-
group, respectively, occurred as follows: GS: 19 and 7, AC: 1 and 10, CBD
stone: 2 and 3, acute pancreatitis: 1 and 1. In patients who had had a
cholecystectomy, 12.5% (n15) experienced a postoperative event of
abdominal complaints.
Conclusions. Mortality because of GSD was not observed and was overall
markedly different according to RCT study GS vs. AC. The incidence of
GSD during observation in patients with GS or AC was slightly different but
may be age and gender dependant. Several factors important to long-term
outcome should be considered when cholecystectomy is recommended in
symptomatic patients.
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ESTABLISHING WHAT ARE ‘‘NORMAL’’ VALUES FOR LIVER
FUNCTION TESTS (LFTS) AFTER REPAIR OF BILIARY INJU-
RIES
Elizabeth A Fialkowski, MD, Emily R Winslow, MD, William G Hawkins,
MD, David C Linehan, MD, Steven M Strasberg, MD
Washington University School of Medicine, Saint Louis, MO
Introduction. Repair of biliary injury is usually accomplished by biliary-
enteric anastomosis. This allows reflux of some intestinal content into the
biliary tree. The effect of biliary-enteric anastomosis for biliary injury on
LFTs is not well described. Furthermore, the clinical significance of
moderate elevations above normal population values under these circum-
stances is unclear. It has been claimed that moderate elevations are indicative
of liver injury or anastomotic dysfunction but such values may in fact be
‘‘normal’’ for these patients. The aim of this study was to determine normal
liver function test values (especially the upper limit of normal) in persons who
have had a biliary-enteric anastomosis for repair of biliary injury and who
have had an excellent postoperative course for at least 5 years.
Methods. Of 113 patients in whom we have repaired biliary injuries, 27
patients were identified with the following characteristics: 1) LFTs available
at 5 years or later after repair. 2) No biliary tract symptoms for at least 5
years after repair 3) no evidence of biliary cirrhosis or underlying liver
disease at time of repair. Many of these patients also had LFTs at time
points less than 5 years after repair. When LFTs were performed at outside
facilities the results were normalized to Barnes-Jewish Hospital (BJH)
values.
Results. The table provides A) values for the upper limit of normal
of LFTs at BJH, and B) mean values and values for 2 and 3 standard
deviations (SD) from the mean for the study patients. Either 2 SD or
3 SD may be used to establish upper limits (95% CI or 99.7% CI
respectively).
TABLE
6 months to 2 years after repair
Lab value Upper limit of normal N Mean  2 SD (95% CI)  3 SD (99.7% CI)
ALP 126 IU/L 25 99 169 204
T Bili 1.1 mg/dL 24 0.6 1.1 1.3
ALT 53 IU/L 13 28 52 64
AST 47 IU/L 23 25 41 49
2 to 5 years after repair
Lab value Upper limit of normal N Mean  2 SD (95% CI)  3 SD (99.7% CI)
ALP 126 IU/L 22 92 126 143
T Bili 1.1 mg/dL 22 0.5 1.0 1.3
ALT 53 IU/L 12 30 58 72
AST 47 IU/L 22 26 42 50
5 years after repair to present
Lab value Upper limit of normal N Mean  2 SD (95% CI)  3 SD (99.7% CI)
ALP 126 IU/L 27 91 145 172
T Bili 1.1 mg/dL 27 0.5 1.4 1.9
ALT 53 IU/L 26 31 55 67
AST 47 IU/L 27 29 53 65
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Conclusions. For alkaline phosphatase (ALP): Moderate elevations
over normal population values are common after repair of a biliary injury
in patients who have had excellent Results. ALP values fall with time after
repair so that comparisons should be made taking into account time from
repair. For AST, ALT and total bilirubin (T Bili): Mild elevations over
normal population values are common after repair of a biliary injury in
patients who have had excellent Results. Elevations in the ranges described
above should not be taken as evidence of liver injury or anastomotic
dysfunction.
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LAPAROSCOPIC CHOLECYSTECOMY USING FLEXIBLE GAS-
TROSCOPE-THE FIRST STEP ON THE WAY TO NOTES
Yury Starkov, PhD, Kirill Shishin, Elena Solodinina, A.V
Vishnevsky Institute of Surgery, Moscow, Russian Federation; A.V.Vish-
nevsky Instiyute of Surgery, Moscow, Russian Federation
Introduction. Natural Orifice Translumenal Surgery is the latest trend of
endoscopic surgery. Availability of this kind of surgical approach in treatment
of different surgical diseases, e.g. calculous cholecystitis, was shown by good
results of experimental operations in animals. Hybrid operations with using of
flexible and laparoscopic endoscopy are transitional stage of application
NOTES to clinical practice.
Methods. 30/05/07 a 46-years-old man, with clinically and instrumentally
confirmed diagnosis of chronic calculous cholecystitis was operated with
using of combined surgical approach. Gastroscope was inserted into
abdominal cavity after creation of the pneumoperitoneum in umbilical point.
Further during the operation pneumoperitoneum was maintained through
trocar 5 mm inserted in the right hypohondrium region in the mid axillary
line. Consecutive dissection of the cystic duct and cystic artery was made
with the using of hot biopsy forceps and coagulation probe. Cystic duct and
cystic artery were cut after clipping with endoscopic clips (2 clips were left on
cystic duct stump and 2-on cystic artery stump). Following evacuation of
gall-stone gall-bladder was dissected with the help of coagulation probe and
IT-knife and removed from abdominal cavity. Gall-bladder bed was coagu-
lated. The operation time was 2 hours 15 minutes. There was no hemorrhage
during the operation.
Postoperative period was without any complications. Abdominal ultrasound
did not reveal any pathological changes. The patient was discharged two days
after operation, his status was satisfactory. Follow-up for three month after
operation did not reveal any peculiarities of the postoperative period.
Conclusion. This case report shows the ability of cholecystectomy perfor-
mance with the instruments conducted through the gastroscope channels. It
is our first step on the way to translumenal endoscopic surgery  the next
stage of minimally invasive surgery development.
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TOTALLY LAPAROSCOPIC CHOLEDOCHAL CYST EXCISION
WITH ROUX-EN-Y HEPATICOJEJUNOSTOMY: REPORT OF
EIGHT CASES.
Kee Hwan Kim, MD, Sang Kwon Lee, MD, Il Young Park, MD, Eung Guk
Kim, MD, Jeong Soo Kim, MD
Uijeongbu St. Mary’s Hospital, Catholic University Medical College,
Uijeongbu, Republic of Korea
Background. Type I choledochal cyst is a rare saccular or fusiform
congenital dilatation of the extrahepatic biliary tract. It is usually treated by
laparotomy at which the cyst is completely excised and a Roux-en-Y
hepaticojejunostomy is performed to establish biliary enteric drainage. With
increased familiarity with the laparoscopic anatomy of the biliary tract and
advances in minimally invasive techniques, surgeons have ventured further to
operate on technically difficult cases such as choledochal cyst that were until
recently managed by laparotomy.
Patients and Methods. From November 2004 to July 2007, eight adult
patients with the diagnosis of choledochal cyst (seven type 1 and one type 4a
according to the Alonzo-Lej classification) were successfully excised with
construction of a Roux-en-Y hepaticojejunostomy entirely laparoscopically.
Results. All patients had an uneventful recovery, with no major morbidity.
One patient had a bile leak, which resolved over 5 days. All patients were
discharged from 5th to 13th postoperative day.
Conclusion. Laparoscopic resection of congenital choledochal cyst and
hepaticojejunostomy in adult patient is feasible. We feel that there is a
considerable learning curve with the technique. Future studies will have to
prove the feasibility of laparoscopic Roux-en-Y bowel anastomosis without
the need for bowel exteriorization. In the near future, laparoscopic
choledochal cyst excision represents an alternative treatment option in
carefully selected patients.
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IS CIRRHOSIS A CONTRAINDICATION TO LAPAROSCOPIC
CHOLECYSTECTOMY-A SINGLE INSTITUTION REVIEW
Sapna Bazaz, MBBS, Nicole Weimert, PharmD, David J. Taber, PharmD,
Kenneth D. Chavin, MD, PhD
Medical University of South Carolina, Charleston, SC
Introduction. The safety of performing a laparoscopic cholecystectomy in a
patient with documented cirrhosis has not been reported. Therefore the aim
of this study is to compare safety outcomes of patients with and without
cirrhosis following open and laparoscopic (lap) cholecystectomies.
Methods. All patients who underwent a cholecystetomy between August
2002 and April 2007 were evaluated. Data collection was limited to those
procedures performed by the single surgeon who utilized both procedures.
Baseline characteristics, including race, age, gender, co-morbid diseases, and
cause of end stage liver disease were collected. Peri-procedure outcomes
including: blood loss, bile duct injury, and death were evaluated.
Results. A total of 42 cholecystectomies were performed during the study
period. Nineteen patients had cirrhosis and 74% underwent lap procedures
versus 10 patients (43%) in non-cirrhotic group. There was no difference in
baseline demographics between groups. No deaths or bile duct injuries
occurred in either group. Two patients in the cirrhotic group were converted
to open secondary to bleeding or adhesions. Two patients in the non-cirrhotic
group were also converted to open. Overall, blood loss was significantly less
in the lap group (1169122 mLs) versus the open group (6919886 mLs).
When lap cirrhotic patients were compared to non-cirrhotics there was no
difference in blood loss (p0.34). This was similar when open groups were
compared (p0.08).
Conclusion. This evaluation indicates that lap cholecystectomy is a safe and
effective procedure in both cirrhotic and non-cirrhotic patients.
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SHORT-TERM OUTCOME AFTER SPLENECTOMY FOR TREAT-
MENT OF SPLENOMEGALY DUE TO LIVER CIRRHOSIS
Takao Tamesa, MD, PhD, Kazuhiko Sakamoto, MD, PhD, Yoshihiro
Tokuhisa, MD
Masaaki Oka, Department of Surgery, Yamaguchi University Graduate
School of Medicine, Ube, Japan
Background. Many patients with liver cirrhosis were discontinued several
treatment because of pancytopnea.
Object. To evaluate the efficacy of slenectomy for liver cirrhosis.
Methods. Between May 2005 and December 2006, 27 patients underwent a
splenectomy for splenomegaly due to liver cirrhosis. We examined platelet
count (PLT), total buillirubin (TB), serum albumin (ALB), prothrombin
time (PT), and a diameter of the portal vein (DPV).
Result. Background disease were 12 pancytopnea, 13 pancytopnea
hepatocellular carcinoma (HCC) and 2 gastric varices. Etiology of cirrhosis
was hepatitis C in 17 patients, hepatitis B in 3, hepatitis C and B in 2,
idiopathic portal hypertension in 2, primary biliary cirrhosis in 1, and others
in 2. Seventeen patients were Child-Pugh A and 10 patients were Child-Pugh
B. Twenty patients underwent hand-assisted laparoscopic splenectomy and 7
patients underwent open splenectomy. Twelve patients had additional
operations (10 hepatectomy and 2 pericardiac devascularization). Between
preoperative state (pre) and 3 months after operation (3M), PLT (105/ml)
significantly improved (pre: 5.190.4, 3M: 18.691.5;pB0.001). PT (%) also
significantly elevated (pre: 69.892.6, 3M: 77.995.1;p0.027). TB and
ALB were not changed significantly. DPV (mm) was decreased significantly
(pre:15.790.8, postoperate: 13.790.8;p0.016). Ten complications was
observed (5 portal vein thrombus, 3 pancreatitis, 1 bleeding and 1 ascitis).
After operation, 5 patients had IFN therapy and 5 patients had a treatment
for HCC.
Conclusion. Splenectomy improved platelet count and liver function.
Splenectomy is effective for liver cirrhosis to continue several treatments,
but further long-term examination is necessary.
Non-cirrhotic (n23) Cirrhotic (n19)
Open (n13) Lap (n10) Open (n5) Lap (n14)
Age 39914 41911 48913 50914
Blood Loss (mLs) 4989661 87937 140091400 1369156
Male 54% (7/13) 30% (3/10) 20% (1/5) 57% (8/14)
ESRD 31% (4/13) 20% (2/10) 20% (1/5) 0% (0/14)
Lap converted to open 15% (2/13) 40% (2/5)
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STAGED LIVER PROCEDURES FOR COLORECTAL METAS-
TASES
Vladislav Treska, MD, MBA, Tomas Skalicky, MD, PhD, Alan Sutnar, MD,
Vaclav Liska, MD, JD
University Hospital, Plzen, Czech Republic
Background. Only 1520% of patients with colorectal liver metastases
(CRLM) can be radically operated on. Staged liver procedures with
combination of portal vein embolization (PVE), down-staging chemotherapy,
resection and/or radiofrequency ablation (RFA) can extend the patient
operability rate.
Aim of study. To assess outcome of staged liver procedures in the treatment
of patients with primary unresectable multiple CRLM.
Patients and Methods. 267 patients with CRLM were operated on between
January 1, 2000 and December 31, 2006. Staged liver procedures were
performed on 34 patients: PVE and liver resection (N19), down-staging
chemotherapy, resection and/or RFA (N8); RFA, PVE and liver resection
(N4); combination of liver resection with RFA (N3). Statistical analysis
was performed using software CRAN 2.4.0.
Results. Patient survival (PS) after single liver surgery was 87.4; 46.1 and
31.4% after 1, 3 and 5 years. PS after staged liver procedures was 62.5 and
20.8% after 1 and 3 years  pB0.15. PS after single RFA was 90.3 and 13.4%
after 1 and 3 years. In staged liver procedures with RFA one and two years of
PS was 66.7 and 44.1% -pB0.19. Disease free interval (DFI) after single
liver surgery was 72.1; 30.1 and 16.2% after 1, 3 and 5 years, in staged liver
procedures 50.8 and 12.7 years after 1 and 2 years (pB0.01). DFI after
single RFA was 38.1 and 10.3% after 1 and 2 years. DFI in staged liver
procedures with RFA was only 12.5% after the first year-pB0.0001.
Conclusion. This study provides further evidence that staged liver proce-
dures for initially unresectable CRLM have similar short-and long-term
results as single procedures in resectable CRLM. Staged radical liver
procedures (resections) have longer DFI in comparison with palliative
procedures (RFA).
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A TEN YEAR PROSPECTIVE AUDIT OF LIVER RESECTION FOR
COLORECTAL METASTASES IN A TERTIARY REFERRAL UNIT
Jeffrey T Lordan, MBBS, Nariman D Karanjia, MD, MBBS, Nial Quiney,
MBBS, William J Fawcett, MBBS, Tim R Worthington, MBBS, J Reming-
ton, B.Sc.
Royal Surrey County Hospital, Guildford, United Kingdom
Background. Metastatic colorectal cancer is a common cause of cancer
death. Hepatic resection offers the only potential cure. However, only a small
proportion of patients are suitable for resection, and the literature reports
high morbidity and mortality rates. We present a ten year prospective audit of
hepatic resections for colorectal metastases in a tertiary referral unit.
Methodology. All patients who underwent surgical treatment for colorectal
metastases over a ten year period were included. Patients were treated with
chemotherapy preoperatively for synchronous and early (B2 years) meta-
chronous metastases. Data were prospectively collected. End points were
overall and disease free survival, peri-operative morbidity and mortality.
Univariate and multivariate analyses were used to identify mortality risk
factors.
Results. 283 patients had hepatic resections with curative intent. Overall
survival at 1, 3 and 5 years were 90.02%, 59.23% and 46.14% respectively.
Disease free survival at 1, 3 and 5 years were 68.10%, 34.77% and 27.88%
respectively. Operative mortality was 2.1% and morbidity was 23.7%.
Patients with diaphragm invasion (p0.021), CEA100 (p0.0001),
systemic recurrence (p0.0054), tumour size 5 cm (p0.009) or a
segmentectomy versus hemi-hepatectomy (p0.002) had a significantly
worse long term outcome. Dukes’ stage had no effect on overall survival.
Conclusions. The 5 year survival of 46% is better than most series. Survival
is improving due to patient assessment, selection and the neo-adjuvant
chemotherapy regimen employed. Morbidity and mortality rates are falling
showing that liver resection is safe. These results should encourage surgeons
to adopt an ever more aggressive approach to treating/referring hepatic
colorectal metastases.
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A 10 YEAR PROSPECTIVE STUDY OF OUTCOME FOLLOWING
HEPATIC RESECTION FOR COLORECTAL LIVER METAS-
TASES-THE EFFECT OF EVALUATION IN A MULTI-DISCIPLIN-
ARY TEAM SETTING.
Jeffrey T Lordan, MBBS, Nariman D Karanjia, MD, MBBS, Nial Quiney,
MBBS, William J Fawcett, MBBS, Tim R Worthington, MBBS, Jacky
Remington, B.Sc.
Royal Surrey County Hospital, Guildford, United Kingdom
Background. Colorectal carcinoma is the second most common cause of
cancer death in the western world and nearly 50% of patients develop liver
metastases. Many cancers are managed via a multidisciplinary team process.
This study compares the long term outcome of patients with metastatic
colorectal cancer referred via a multidisciplinary team (MDT) process with
those referred directly to a tertiary hepato-biliary unit.
Patients and Method. This is a prospective audit of 331 consecutive
referrals made to a tertiary referral unit over ten years out of which 108
patients were referred via a formal MDT while 223 were referred directly.
Pre-operative assessment and management were standardised and short and
long term data were recorded. Synchronous and early (B2 years) tumours
were treated with neo-adjuvant chemotherapy.
Results. Patients referred via the MDT had 1, 3 and 5 year survival rates of
89.58%, 67.54% and 49.89% respectively and 1, 3 and 5 year disease free
survival of 65.43%, 31.03% and 27.15% respectively. Patients referred
directly had 1, 3 and 5 year survival rates of 90.27%, 54.12% and 43.27%
respectively and 1, 3 and 5 year disease free survival rates of 70.30%, 37.55%
and 27.87% respectively. The difference in overall survival was significant
(p0.0001), although the difference in disease free survival was not (p
0.21).
Conclusion. Assessing, managing and referring patients via a multidisci-
plinary team process with metastatic colorectal cancer significantly improves
overall survival.
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LAPAROSCOPIC CAUDATE RESECTION: A DIFFICULT AP-
PROACH
Ravi Nagubandi, MD, Mark Thomas, MD, Ravindra Kadiyala, MD, Amit
Tevar, MD, Steven Rudich, MD, Michael Marvin, MD, Joseph Buell, MD,
Jewish Hospital, University of Louisville, Louisville, KY, Louisville, KY
University of Cincinnati, Cincinnati, OH; Jewish Hospital, University of
Louisville, Louisville, KY
The most challenging resection to embark upon laparoscopically is the
caudate lobe resection. Laparoscopic techniques have been developed for
segmental and lobar resections. Limited reports of laparoscopic caudate lobe
resection exist. This is the first reported series of laparoscopic caudate lobe
resections.
Patients and Methods. All patients undergoing laparoscopic liver resection
between ‘01 and ‘07 were entered into a prospective database. Of the 300,
we identified 6 caudate lobe resections. We analyzed the demographics,
operative parameters, hospital stay, morbidity and follow up of these
patients.
Results. The median age of the patients was 32 years (range 2256); 4
women and 2 men. None had underlying liver disease. 4 had pure
laparoscopic resection while in 2 a hand assist device was utilized. Mean
operating time was 2.8 hours with an average estimated blood loss of 208 ml.
Two patients had additional liver resected (segment II and partial segments
IV, V and VI). The lesion size was 1 to 15 cm. One operative conversion was
required for a 12 cm. vascular adenoma when the main caudate branch was
avulsed from the cava. The majority of dissection was performed with clips,
harmonic scalpel, Tissuelink and electrosurgical technology. An average of 11
stapler loads were used for the resection. None of the patients required ICU
admission and the mean length of hospital stay was 2.4 days. Pathology was
FNH (n2) and adenoma (n2) and hemangioma (n1) and colorectal
metastasis (n1). The resected margin in the CRC was 0.5 cm.
At a median follow up of 21 months, all patients are alive with no post-
operative complications.
Conclusion. Caudate lobe liver resections, although technically challenging,
can be successfully performed. Complete resection with minimal blood loss is
possible. The use of electrosurgical technology is necessary compared to
lobar resections. The use of hand assist appears to be cumbersome and
intrusive for this particular operation but may be necessary for specimen
extraction.
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HAND-ASSISTED LAPAROSCOPIC LIVER RESECTIONS: A
LEARNING CURVE
Justin H Nguyen, MD
Mayo Clinic, Jacksonville, FL
Liver resections are performed for primary and metastatic tumors. Tradi-
tionally, liver resection with standard laparotomy is routinely performed.
Recently, hand-assisted laparoscopic (HAL) techniques are emerging to be
useful in liver resections. In this study, an early experience of HAL liver
resections is reviewed.
During 5/3/2007 to 8/20/2007, 8 consecutive liver resections were performed
using HAL approach. Capsular and parenchyma dissections were done with
Harmonic scalpel. Portal triad pedicle to and hepatic vein of the resecting
part of the liver were transected with US Surgical endoscopic staplers. Biliary
leak or bleeding on the resection surface was controlled with endocorporeal
suture ligations. The parenchyma cut surface was cauterized with Argon
beam. Patency and integrity of the portal hepatis to the remaining liver
remnant were intraoperatively confirmed by direct visualization and palpa-
tion. Postoperative Doppler was obtained.
The HAL liver resections that were performed included one right
hepatectomy, one VI segmentectomy, one VII segmentectomy, one left
hepatectomy, and 4 left lateral segmentectomies. The indications for liver
resections included 2 colon cancer metastases, 2 cholangiocarcinomas, 2
polycystic liver diseases, 1 hepatic adenoma, and 1 hepatocellular carci-
noma. Postoperative dopplers showed patent portal vein, hepatic artery, and
hepatic vein of the liver remnants. No postoperative bleeding and biliary
leakage occurred. Median values were 195 (122411) minutes for OR time,
12 (625) of number of staplers, 200 (501000) ml of estimated blood loss
(EBL), 5 (59) days of hospital stay, respectively. With the 5 consecutive
left liver resections including 4 LLS and 1 left hepatectomy, length of OR
time, number of required staplers, EBL, and hospital stay steadily decreased
(Figure).
In conclusion, with previous experience in traditional liver resection, HAL
liver techniques can be safely learned and practiced.
36
SURGICAL TREATMENT OF THE BENIGN LIVER LESIONS-A
SINGLE CENTRE STUDY.
Tomas Skalicky, MD, PhD, Vladislav Treska, MD, FRCP
University Hospital Pilsen, Charles University Prague, Pilsen, Czech
Republic
The purpose of this study was to evaluate a single centre results of surgical
treatment of the benign liver lesions.From January 2000 to July 2006 65
patients were admitted at our Department with benign liver lesions which
were indicated for open resection or laparoscopic procedure. There were
various benign liver lesions diagnosed preoperatively by ultrasound (USG),
computed tomography(CT) or magnetic resonance imaging (MRI). The
definitive diagnosis was confirmed by postoperative histological examina-
tion of specimens focal nodular hyperplasia (FNH), liver cell adenoma,
hemangioma,hamartoma and cystadenoma.In some cases there was some
problem with the correct preoperative diagnosis of FNH and patients were
indicated for surgical resection from suspicion from malignancy. The group
of 65 patients was analyzed with regard to diagnostic algorithm, indication
to surgery and the follow up period. Morbidity was 21,5% and mortality
was 0%. Surgical resection is the treatment of choice for patients with
adenoma 4 cm in diameter, in patients with symptomatic hemangioma
or symptomatic FNH. Laparoscopic procedure is a method of choice in
small benign liver lesions in the segments II., III., and V., VI.. With the
evolution of imaging methods it seems that the preoperative diagnosis of
FNH may be considered reliable,thereby avoiding unnesessary surgical
resection.
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SYMPTOMATIC POLYCYSTIC LIVER DISEASE: SURGICAL
MANAGEMENT AND LONG-TERM QUALITY OF LIFE OUT-
COMES
Robert T Russell, MD, Irene D Feurer, PhD, Panarut Wisawatapnimit, MS,
C Wright Pinson, MD, MBA
Vanderbilt University Medical Center, Nashville, TN
Background/Aims. Surgical management is the mainstay of treatment for
patients with symptomatic polycystic liver disease (PCLD). The aim of this
study was to analyze immediate and long-term outcomes along with post-
operative health-related quality of life (HRQOL) in patients undergoing
operation for symptomatic PCLD.
Methods. A retrospective analysis of clinical, operative, and follow-up data
was carried out for patients with symptomatic PCLD undergoing surgery
from May 1991 to March 2007. The primary outcome measures assessed
were mortality, recurrence of symptoms, and HRQOL. HRQOL data was
obtained by mailed questionnaire using the SF-36† Health Survey (SF-36).
Data are reported as mean9SD.
Results. 20 patients (age52911 years) underwent surgery for sympto-
matic PCLD. Comorbidities included polycystic kidney disease in 50% and
cerebral aneurysms in 5%. Thirteen patients had fenestration and resection,
six patients had fenestration only, and one patient underwent liver trans-
plantation. There was no operative mortality and the overall morbidity rate
was 35%. The mean follow-up was 74959 months. Six patients reported
recurrence of symptoms at a mean of six years, but none required repeat
operative intervention. Fifteen patients returned SF-36 health surveys (mean
follow-up92956 months). Overall, physical HRQOL scores (39914) were
one standard deviation below the general population mean while mental
HRQOL scores (4699) approximated the general population mean (50910
for PCS and MCS).
Conclusions. Fenestration, fenestration with resection and, much less
frequently, liver transplantation are acceptable management strategies
depending on the extent and distribution of the cysts. These twenty patients
had no operative mortality, reasonable morbidity, and good long term relief of
symptoms. Nevertheless, this disease process has a significant effect on
patients’ physical HRQOL. Mental HRQOL is maintained.
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HEPATIC RESECTION IN CANADA FROM 19952004: RATE,
GEOGRAPHIC VARIATION, AND HOSPITAL VOLUMES
Ryan J Mccoll, MD, Xiaoqing You, Elijah Dixon, MD
University of Calgary, Calgary, AB, Canada
Purpose. Liver resection is the only curative therapy for hepatic malignancy,
both primary and secondary. Despite this, the rates of hepatic resection
across Canada are unknown. This study sought to describe patient
characteristics and crude outcomes along with the rate and regional variation
of hepatic resection in Canada, its provinces, and census divisions from
19952004.
Methods. Discharge data from all hospitals across Canada except Quebec
were obtained from the Canadian Institute for Health Information for 1995
2004. All patients undergoing a hepatic resection were identified using ICD 9
and 10 codes. Rates and regional variations in rates of hepatic resection were
calculated and reported by province and census division using the postal code
conversion file. Baseline demographics, patient characteristics, and outcomes
are reported.
Results. The national age- and sex-adjusted hepatic resection rate per 100
000 people aged 18 years and older increased from 3.22 in 1995 to 5.86 in
2004. Provincial rates in 2004 varied from a low of 2.88 in Prince Edward
Island to a high of 8.91 in the Territories. For census divisions, rates varied
even more from a low of 0 in 76 divisions to a high of 94.85. There were 247
hospitals performing hepatic resections across Canada, with a range of 1
1185 cases per hospital. Eighty nine percent of cases took place at high-
volume centers (defined as those hospitals with case volumes in the 4th
quartile). There was a progressive decline in the in-hospital mortality rate
over the study period.
Conclusions. There is significant regional and geographic variation in the
rates of hepatic resection across Canada. Disparity in access to centers
performing hepatic resection may partially explain these Results. Our study
also demonstrates a pattern of regionalization which may be due to growing
evidence that high-volume centers have superior outcomes for complex
procedures.
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SUITABILITY OF PATIENTS WITH COLORECTAL LIVER ME-
TASTASES FOR LIVER RESECTION: A COHORT STUDY
Thomas S Helling, MD, Sumesh Kaswan, MD
Conemaugh Memorial Medical Center, Johnstown, PA
Resection of liver metastases (LM) from colorectal cancer (CRC) has
produced long-term survival in over 25% of patients. Despite newer and
more effective chemotherapeutic agents, surgery for LM in selected cases is
still the preferred approach. It has been reported that up to 25% of patients
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diagnosed with CRC will develop synchronous or metachronous liver
metastases, so the potential patient population eligible for resection could be
quite large. However, there are several factors involved in determining
resectability such as extra-hepatic disease, number of metastases, synchronous
and metachronous lesions, and age and comorbidity. We examined a local
population of patients with CRC and LM to assess how many might actually be
good candidates (low risk, high probability of cure) for resection. From 1996 to
2006 all patients with synchronous or metachronous LM from CRC were
identified through a rural tumor registry. There were 154 such subjects.
Sixteen patients were lost to follow-up and excluded. Of the 138 evaluable
patients, 36 were 80 years, 15 had extra-hepatic metastases, and one refused
surgery. These were not considered likely candidates. Eighty-six patients had
liver only metastases and represented possible candidates for resection. Of this
group 35 had 13 LM (19/35 had solitary LM), and 10/35 had metachronous
lesions. Of the 10 patients with metachronous lesions 4/10 had 4 or more
comorbidities and might be high risk for resection. Therefore, 6/138 (4%)
would be ideal candidates. Overall 11/138 (8%) actually had liver resection/
ablation, including 9/35 (26%) with 13 LM and 3/10 (30%) with 13
metachronous LM. In conclusion, relatively few patients with CRC LM may
be ideal candidates for liver resection. Even in ideal candidates comorbidity
may preclude liver resection in many patients. In this cohort liver resection/
ablation was used infrequently as treatment for LM. It is not clear whether
such results would be duplicated in more urban or suburban communities.
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A CASE OF HEPATIC ARTERY ANEURYSM IN A PATIENT WITH
PRUNE BELLY SYNDROME.
Abdulelah M Alhawsawi, Michele Molinari
Dalhousie University, Halifax, NS, Canada
Hepatic Artery Aneurysm (HAA) is a rare condition that can affect
Splanchnic Blood Vessels. It is the second most common Visceral Artery
Aneurysm(VAA) after those affecting the Splenic Artery with more males
involved than females.
HAA can be caused by many factors including atherosclerosis, arteritis, liver
transplantation, Collagen Vascular Disease, or trauma.
HAA are discovered incidentally in the majority of cases but some patients
can present with bleeding and shock.
On the other hand, Prune Belly Syndrome (PBS) is a very rare condition
characterized by: abdominal wall flaccidity, bilateral intra-abdominal cryp-
torchidism, and urologic abnormalities.
The etiology of PBS is unknown but it can be related to mesodermal arrest as
a consequence of an early intra uterine injury to the fetus. This could explain
the involvement of the genitourinary tract, the testis, and the abdominal wall
in these patients.
We present a very interesting case of HAA in a patient with PBS. It was the
first time in the literature that this unique association existed.
We hypothesized that the pathophysiology behind PBS could represent a rare
cause of VAA.
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SHORT-TERM AND LONG-TERM RESULTS OF LAPAROSCOPIC
OPERATIONS ON THE LIVER AT NON-PARASITIC CYSTS
Yury Starkov, PhD, Kirill Shishin, MD, Elena Solodinina, A.V.
Vishnevsky Institute of Surgery, Moscow, Russian Federation
99 patients with 169 non-parasitic liver cysts were operated in A.V.Vish-
nevsky Institute of Surgery from 1992 till 2006. Ninety one were females and
8-males; their age varied from 32 till 78 years (middle age was 63
years). Plural cysts were found at 32 patients and solitary-at 67. The
size of liver cysts varied from 4 up to 18 cm (average size  10.692 cm
(9SE). Complications occurred at 6 patients: 5 had cyst infection and
1- intracystic bleeding. There were no cases of cystobiliary fistulas in our
supervision.
Cyst fenestration with wide excision of its walls was performed for
subcapsular and superficial intraparenchymal cyst. The intraparenchymal
part of a cyst was deepitelised by various methods. Deep intraparenhimal
cysts depending on their size were underwent punctional or punctional-
drainage sclerotization. Atypical liver resections with wide excision of cystic
walls with doubtful blood supply was done for large superficial intrapar-
enchymal cysts in one or several segments.
The long liquid leakage on drainages within 57 days was marked in
the postoperative period at 11 patients. The bile leakage from 300 up to
100 cc per day occurred in one case after atypical liver resection for the big
cyst of 2, 3 and 4th segments and resolved spontaneously within 1 month.
Average duration of the postoperative period was 9 days (from 4 days till
1 month). Liquid congestions in a residual cavity were observed at 4 patients
and were successfully treated by a unitary puncture under the ultrasonic
control.
Long-term results from 1 to 10 years were observed at 45 patients, at whom
cyst sizes exceeded 5 cm. Residual cysts at the operation cite were found in
two cases 1.5 and 2 years after the operation in dorsal segments of the right
lobe of a liver, but their sizes were essentially less in comparison with
preoperative. Considering the absence of clinical signs the repeated inter-
vention was not performed.
Long-term experience shows, that laparoscopic treatment of non-parasitic
liver cysts liver is accompanied by good results with small quantity post-
operative complications and low rate of recurrences. Wide excision of
protruding cystic walls with deepitelization of a residual cavity is the most
widespread and effective operation. Laparoscopic atypical liver resections
with excision of thin, partially sclerotic functionally defective sites areas of
parenchyma is indicated at big and giant liver cysts. Laparoscopic punction
and punction-drainage methods of treatment are auxiliary in addition to
cystic excision. They provide radicalism of intervention at patients with plural
liver cysts with intraparenchymal or dorsal location.
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SUCCESSFUL TREATMENT FOR RIB METASTASIS FROM HE-
PATOCELLULAR CARCINOMA
Yuki Kimura, MD, PhD, Masamichi Moriguchi, MD, Kazuto Inoue, MD,
PhD, Tadatoshi Takayama, MD, PhD
Nihon University, Tokyo, Japan
We report a case of successful treatment using a combination of radiotherapy
and transcatheter arterial embolization (TAE) for rib metastasis from
hepatocellular carcinoma (HCC). A 64-year-old man with hepatitis B-related
HCC underwent hepatectomy at our hospital. The patient received TAE for
intrahepatic recurrence at 9 months after the operation. However, he
complained of right shoulder and back pain 3 months later. Radiological
findings demonstrated a metastasized lesion on the right side of the fifth rib
originating from HCC. Radiotherapy was performed at 50 Gy in 20 fractions.
However, the tumor size remained unchanged, although his pain was
gradually reduced. We performed TAE twice, and the metastasized lesion
completely disappeared after the TAE with relief of pain. The above
experience shows that TAE, a popular treatment for intrahepatic recurrence,
may also be useful for bone metastasis from HCC.
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HIGH SERUM ALPHA-FETOPROTEIN LEVEL IN PATIENTS
WITH HEPATOCELLULAR CARCINOMA
Masamichi Moriguchi, MD, Yuki Kimura, MD, PhD, Kazuto Inoue, MD,
PhD, Tadatoshi Takayama, MD, PhD
Nihon University, Tokyo, Japan
Patients with hepatocellular carcinoma (HCC) in high serum alpha-protein
(AFP) level have poor prognosis. To retrospectively evaluate high serum AFP
level in patients with HCC.
Two hundred and forty-two patients who were treated with resection or
endovascular therapy for HCC. The higher AFP (400 ng/ml) group was
compared with the lower AFP group concerning the caracteristics of patients,
treatment and survival.
There were significant differences in tumor size (PB.0001), vascular invasion
in imaging (P0.0007), tumor existence (P0.01), extrahepatic metastasis
(P0.03) and initial tratment (P0.001). The higher AFP group had
significantly worse overall survival than the lower AFP group (PB.0001).
The overall 1, 3 and 5-year survival rates were 67.9%, 34.7% and 0% in the
higer AFP group, 86.2%, 63.7% and 42.7% in the lower AFP group,
respectively. In patients with resection, there were no significant differences
between the two groups in overall and disease-free survival. On the other
hand, there were significant differences between the two groups in patients
with endovascular treatment (P0.0001).
Large size tumor or progressed tumor is frequent in HCC with more than
400 ng/ml in serum AFP level. However, if it is possible to resect, the
prognosis may be obtained similar to that of other HCCs.
44
PROTOTYPE OF AN ONLINE NAVIGATION SYSTEM FOR LA-
PAROSCOPIC RFA
Philipp Hildebrand, MD, Markus Kleemann, MD, Stefan Schlichting,
Armin Besirevic, Lutz Mirow, MD, Uwe Roblick, MD, PhD, Hans-peter
Bruch, MD
University of SChleswig-Holstein, Campus Lu¨beck, Lu¨beck, Germany;
University of Schleswig-Holstein, Campus Lu¨beck, Lu¨beck, Germany
Purpose. Laparoscopic Radiofrequency-ablation is a save and effective
method for tumor destruction in patients with unresectable liver tumors.
However, accurate probe placement using laparoscopic ultrasound guidance
is required to achieve complete tumor ablation. After development and
evaluation of laparoscopic navigation tools for radiofrequency ablation, we
are now presenting a prototype of a navigation- and documentation-system
for laparoscopic RFA.
Material and Methods. First a special adapter was developed to attach the
ultrasound- and electromagnetic-tracking-based navigation system to a
laparoscopic ultrasound probe. The laparoscopic online-navigation system
was studied in a laparoscopic tumor-mimic-model using perfused porcine
livers. Tumor-mimics were created by injection a mixture of 3% agarose, 3%
cellulose, 7% glycerol, creating hyperechoic lesions in ultrasound.
Results. This study showed that laparoscopic ultrasound-guided navigation
is technically feasible. Even in cases of angulation of the ultrasound probe no
disturbances of the navigation system could be detected. Tumor-mimics were
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clearly visible on laparoscopic ultrasound and not felt during placement of the
RFA probe. Anatomic landmarks and simulated ‘‘tumors’’ in the liver could
be safely reached.
Conclusion. Laparoscopic radiofrequency ablation requires advanced la-
paroscopic ultrasound skills for accurate placement of the RFA probe. The
use of an ultrasound-based, laparoscopic online-navigation system offers the
possibility of out-of-plane needle placement and could increase the safety and
accuracy of punctures. The perfused tumor-mimic model presented a
realistic model for the evaluation of this new technique.
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TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCI-
NOMA WITH GEMCITABINE-BASED TRANSCATHETER AR-
TERIAL CHEMOEMBOLIZATION
Jan Franko, MD, PhD, John S Hammond, MD, Shane E Holloway, MD,
Jason T Heckman, MD, Philip D Orons, DO, T. Clark Gamblin, MD
University of Pittsburgh Medical Center, Pittsburgh, PA
Background. Transcatheter arterial chemoembolization has been shown to
increase survival in patients with unresectable hepatocellular carcinoma
(HCC). Known efficacy and excellent tolerability of gemcitabine in treatment
of other foregut malignancies make it an attractive choice for HCC therapy.
Therefore, we evaluated gemcitabine-based TACE (gem-TACE) as a therapy
for unresectable HCC, including patients with poor prognostic features.
Methods. A retrospective analysis of all patients undergoing gem-TACE for
unresectable HCC was performed in 20022006. TACE was generally
administered in unilobar distribution every 810 weeks with typical starting
dose 1250 mg/m2. The primary outcome was survival from the first treatment
and the secondary outcome was radiologic response (RECIST Criteria).
Results. 65 patients (19 females) underwent a total of 232 gem-TACE
treatments (median 3, range 110) for unresectable HCC. Median age was
66 years (range 3387) with 11 patients (17%) older than 75 years.
Radiologic prognostic factors of cirrhosis, ascites, portal vein thrombosis,
and caval thrombosis were present in 78%, 15%, 28%, and 7%, respectively.
Liver transplantation was performed in 4 patients who received gem-TACE
therapy and 6 patients underwent hepatic resection following gem-TACE. Of
the 45 patients assessable using RECIST criteria, 11 (24%) demonstrated a
partial response and 26 (58%) had stable disease. There was one treatment-
related mortality and 6-week mortality after TACE was 9.2% (n6). Median
survival in those without liver transplant was 8.2 months (range 049) from
the first treatment, with 39% surviving 12 months and 14% surviving 24
months. Radiologic benefit was associated with significantly better survival
(p0.008). Cox proportional hazard model identified a total number of
TACE treatments (HR0.673; pB0.001), prognostic factor score (HR
1.421; p0.033) and liver transplantation (HR0.046; p0.003) as the
only independent predictors of survival.
Conclusions. Gemcitabine-based TACE is a feasible regional therapy for
unresectable HCC, even in a subset of patients with portal vein thrombosis.
Radiological benefit was seen in majority of patients and was associated with
improved survival. Further evaluation of gemcitabine-based TACE is
warranted.
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COMBINED HEPATOCELLULAR CHOLANGIOCARCINOMA
ORIGINATING IN A BACKGROUND OF FOCAL NODULAR
HYPERPLASIA: A CASE REPORT AND REVIEW OF LITERA-
TURE
Eugene Lim, MBBS, Kenneth Mak, MBBS
Alexandra Hospital, Singapore, Singapore
Aim. Focal Nodular Hyperplasia(FNH) is a benign liver tumor and normally
treated conservatively. However, there have been reports of possible
malignant transformation of FNH to Hepatocellular Carcinoma(HCC),
especially the Fibrolamellar type. A case of resected combined HCC and
cholangiocarcinoma in a background of FNH is described to highlight the
possibility of malignant transformation in FNH.
Case Report. A 67-year-old Chinese lady presented with abnormal liver
enzymes and found to have a mass in the right lobe of liver. Her hepatitis B
and C status was negative and Alphafetoprotein was normal. Initial CT and
MRI scans of the lesion revealed a large hypervascular mass measuring 9 cm
occupying nearly the entire right lobe of the liver. MRI findings of the mass
were an isodense T1 weighted image, slightly high T2 weighted image,
hypervascular with Gadolinium administration becoming isointense in
portalvenous and delayed phases. There was a central scar of high T2
weighted intensity with delayed enhancement. There were 2 other smaller
well-defined nodules within this lesion of low T1 and high T2 weighted
intensity with rim enhancement. This correlated with a diagnosis of FNH and
the patient opted for conservative management. She was reimaged with MRI
at 3 months. This revealed that the large mass had remained stable in size but
the 2 smaller nodules had increased in size of 3 to 4 cm and had heterogenous
enhancement. Due to the increase in size and suspicion of fibrolamellar
variant of HCC, the patient underwent a right hepatectomy. Histology of the
specimen revealed an area of FNH with a malignant lesion located within it.
The malignant component had a mixture of HCC merging with glandular
and sarcomatous areas. The glandular areas had an ‘angiomatoid’ appearance
consistent with cholangiocarcinoma. The resection margins were clear.
Discussion. It is debatable if malignant transformation of FNH can occur,
as the natural history of FNH is still unclear. However, there have been
reports of fibrolamellar variant of HCC arising from FNH and this case
highlights the possibility of HCC arising from FNH. In clinical practice,
patients diagnosed with FNH should have a follow-up with imaging at regular
intervals. This may allow those with a malignant potential to be selected out
of a group normally treated by observation alone.
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RESULTS OF RESECTION AND TRANSPLANTATION FOR HCC
IN CIRRHOSIS AND NON-CIRRHOSIS
Fadi Rayya, MD, Michael Bartels, MD, Johann Hauss, MD, Josef Fang-
mann, MD
University Hospital Leipzig, Leipzig, Germany
Background. Hepatocellular carcinoma (HCC) is one of the most common
cancer worldwide. Both resection and transplantation are surgical treatment
options depending on the size of tumours and the presence of cirrhosis. Liver
cirrhosis is the main reason for the high early postoperative mortality after
resection. Even in the Child A stage, extensive resections are not recom-
mended.
Objectives. This study presents the results of the surgical treatment (LR or
LT) for HCC in cirrhotic- and non cirrhotic livers.
Patients and Methods. We analysed the data of 76 patients who underwent
LR or LT for HCC from January 2001 to December 2006.
Results.In non cirrhotic livers the following resections were performed: 30
right and extended right hemihepatectomies (54,5%), 11 left hemihepatec-
tomies ( 20%) and 14 mono- or bisegmentectomies (25,5%). In cirrhotic
livers were performed in Child A stage 1 right hemihepatectomy, 1 extended
right hemihepatectomy, 1 extended left hemihepatectomy and 4 mono- or
bisegmentectomies and in Child B stage 3 mono- or bisegmentectomies. In
11 patients who underwent transplantation were 2 patients with tumors
exceeding the Milan criteria and 5 patients of them (5/11) were treated with
TACE before the transplantation.
Conclusion. Liver resection for HCC in cirrhosis should be performed with
caution (no long-term survival in our data). Our study confirms that
transplantation shows good long- term survival in early HCC stages.
However, this may also be true for stages above the Milan criteria. For
HCC in non-cirrhotic livers resection remains the treatment of choice,
justifying an extensive surgical approach. This achieves favourable long term
survival as demonstrated in the study presented
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TRANSITION FROM AN OPEN TO A MINIMALLY INVASIVE
LIVER RESECTION PRACTICE:SINGLE CENTER EXPERIENCE.
Alejandro Mejia, MD, Stephen Cheng, MD
Liver Institute at Methodist Dallas, Dallas, TX
Introduction. Minimmally Invasive Liver resection (MILR) has been shown
to be safe and beneficial to patients at few selected centers in the US,Europe
and Asia.It is considered a growing field within liver surgery and more series
are needed to confirm these results. In this study we present our single center
experience with the MILR versus the open approach.
Methods. A retrospective chart/database review was performed of all the
liver resections performed by our team between 1/2005 and 8/2007.The
MILR group was compared to the open group.Variables included diagno-
sis,type of resection,presence of cirrhosis,LOS,EBL and transfusion requir-
ements.Anova and t-tests were used for statistical analysis.
Results. In the study period 70 liver resections were performed: 32 (46%)
were MILR and 38 (54%) were open.The hand assisted technique was used
in 80% of the cases in the MILR group and pure laparoscopic was used for
smaller lesions.Overall, 60% of the lesions were benign and 40% were
malignant.Cirrhosis was present in 31% and 18% of patients in the MILR
and open groups,respectively.Conversion rate to open was 6%(2):1 due to
tumor rupture and 1 due to hepatic venous injury without adverse effects to
patient outcome.Group variable comparison is shown on table.
Conclusions. The MILR approach has been successfully implemented at
our program.By using a hand-assisted approach in most of our cases,the
transition to laparoscopic liver parenchymal transection has been kept within
a safety margin.This technique also resulted in significantly shorter lengths of
stay for our patient population when compared to the open counterpart.Of
interest is the fact that cirrhotics benefited from this approach and presented
no mortality and acceptable morbidity.
MILR group
(N32)
OPEN group
(N38) P
Length of stay (days) Mean 3.3 5.7 B0.001
EBL (cc) Mean 260 501 0.004
Mean tumor size (cm) 4.3 6.3 0.04
Mean Age (yrs) 52.8 51.6 NS
Cirrhosis (%) 31 18 NS
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CLINICAL EPIDEMIOLOGICAL ANALYSIS OF 309 ERCPS PER-
FORMED IN NOVA SCOTIA IN 2006 FOR CHOLEDOCHOLITHIA-
SIS AND GALLSTONE PANCREATITIS.
Michele Molinari, MD, Amy Nason, MS, Mark Joseph Walsh
Dalhousie University, Halifax, NS, Canada
Background. The ideal management of choledocholithiasis and gallstone
pancreatitis is controversial. With the improvement of diagnostic imaging
studies of the bilio-pancreatic duct, retrograde cholangiopancreatography
(ERCP) should ideally be performed only as a therapeutic modality. Referral
patterns for ERCP, and patients’ management are influenced by resources
and location. Limited information is currently available for clinical use and
results of ERCP in Atlantic Canada. Aim of this study was to assess the
diagnostic, therapeutic and success rates of ERCP performed in a high
volume tertiary medical center in Nova Scotia.
Methods. A retrospective observational study was performed over one year
period (January 1 to December 31, 2006) at the QEII hospital. ERCP data of
565 procedures were reviewed by two independent investigators and entered
into computerized databases. All data discrepancies were analyzed and
resolved. Demographic characteristics, indications for ERCP, interventions,
diagnosis and outcomes were captured. Procedures were then divided into 2
groups: therapeutic or diagnostic. Therapeutic ERCPs were defined when
successful stone extraction or sphincterotomy for sphincter dysfunction were
obtained.
Results. Within the 12 month period, 309 ERCPs were carried out for
presumed choledocholithiasis (No 273, 88.3%) or gall stone pancreatitis (No
36, 21.7%) on a population with mean age of 62 (SD917.9). Therapeutic
ERCP was performed in 175 (64.1%) patients with choledocholithiasis and
in 12 (33.4%) individuals with pre-ERCP diagnosis of pancreatitis. Inability
to cannulate the papilla was observed in 8 (2.9%) patients with choledocho-
lithiasis and 4 (11.1%) individuals with pre-ERCP diagnosis of pancreatitis.
Conclusion. Because ERCP is an invasive procedure, ideally it should be
indicated only as therapeutic modality. Our findings suggest that in Atlantic
Canada, diagnostic ERCPs are still performed in 35.9% of choledocholithia-
sis and 66.6% of gall stones pancreatitis. Implementing better referral
patterns and patient selection would optimize resources and decrease
complication rates for ERCP in the Maritimes.
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EXTENDED PANCREATECTOMY WITH RESECTION OF THE
CELIAC AXIS FOR LOCALLY ADVANCED CANCER OF THE
PANCREATIC BODY. SURGICAL ASPECTS RELATED WITH
THE RE-ARTERIALIZATION OF THE LIVER AND RESULTS
Emilio Vicente, MD, Yolanda Quijano, MD, Carmelo Loinaz, MD, Ramon
D. Conradi, MD, Manuel Marcello, MD, Pablo Galindo, MD, Enrique
Esteban, MD, Fernando Lapuente, MD, Rafael Alvarez, MD, Luis Cordoba,
MD, Raul Macedo, MD
Hospital Madrid Norte Sanchinarro, Madrid, Spain
Introduction. Locally advanced cancer of the pancreatic body is still
associated with a low resectability and dismal prognosis, mainly due to
invasion of major vessels.
Aim. To present different surgical techniques and results of liver arterializa-
tion after radical pancreatectomy with en bloc resection of the celiac axis in
patients with advanced pancreatic cancer.
Methods. 5 patients with carcinoma of the body (4) and head-body (1) of
the pancreas underwent radical resection. 2 had neoadjuvant radio and
chemotherapy. Vascular invasion was observed on preoperative workup.
Encasement of the celiac axis (5), common hepatic artery (5) and splenic
artery (5) were noted, as well as infiltration of superior mesenteric vein (1).
No regional or general dissemination was demonstrated. R0 resection was
achieved by body and tail pancreatectomy (4) and total pancreatoduode-
nectomy (1) with en bloc resection of the celiac axis, common hepatic,
splenic and left gastric arteries. Combined resection of superior mesenteric
vein was once required (1). Appleby operation was performed with
intraoperative radiation in 2 patients with hepatic arterial flow through the
pancreatoduodenal arcade from the superior mesenteric artery. 3 patients
underwent arterial reconstruction: end to end anastomosis (common hepatic
artery-stump celiac axis) was feasible in 2 patients; interposition of a PTFEt
prosthesis in 1 patient.
Results.Operative time ranged from 350 to 820 minutes. Red blood
transfusions from 3 to 8 units were administered intraoperatively. AST and
ALT on postoperative day 1 were 210620 and 130590 in the three patients
who underwent arterial reconstruction, and 1200 and 1080 in the patient
with Appleby procedure. AST and ALT recovered to the preoperative level
within 11 days. Abdominal pain was relieved immediately after surgery in all
patients.
Postoperative mortality (30 days) was 1/5. The patient, with neoadjuvant
therapy, died as a result of sepsis with multiorgan failure 15 days after the
operation. No vascular or digestive complications occurred.
Conclusions. Pancreatectomy with celiac axis resection to treat locally
advanced carcinoma of the body and tail of the pancreas is feasible, with high
resectabilty and radicality. An extremely selected population of patients could
benefit from radical surgery associated to arterial resection, in terms of
quality of life (relief of pain). Long-term outcome should be further studied.
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PANCREATIC TUBERCULOSIS  A RARE DUAL PRESENTATION
Jaikish Jayaraj, Subramanian M
SRMC & RI, Chennai, India
Introduction. TB of the pancreas is a rare disease and the incidence has
been reported to be around 04.7%. Various modes of presentation have been
reported including pancreatic abscess, acute or chronic pancreatitis, GI
bleeding, obstructive jaundice, portal vein obstruction and pancreatic mass
mimicking malignancy. Our case is an extremely rare presentation with
pancreatic abscess and colonic perforation.
Case Report. A 28 yr male patient was admitted to the casualty with
suspected feacal peritonitis 10 days after having undergone laparotomy and
drainage for pancreatic abscess at an outside hospital. He was put on
continuous peritoneal lavage. Patient gives history of vague back pain for past
6 months. The diagnosis was based on a CT scan done as he presented with
unexplained and nonresponding fever. CT showed multiple hypodense well
defined lesions behind the pancreas.
At the time of admission to our institution patient was in a state of severe
sepsis with ventilator and hemodynamic support. His abdomen was
distended and there was feculent discharge from the main wound and drain.
Patient underwent exploratory laparotomy which revealed 1 L of purulent
fluid and two perforations in the transverse colon, pancreas appeared
edematous and collection of pus behind the head of the pancreas. Limited
segmental excision of colon, peritoneal lavage, proximal colostomy and end
mucous fistula was done. Patient was managed in ICU in the post op period.
Patient continued to be in sepsis and was taken up for re exploration, lavage,
and laparostomy. The specimen on HPE revealed AFB on the serosal aspect
of the colon and hence patient was started on Streptomycin/INH/Rifampicin/
Ethambutol.
Patient progressed well in the post op period except for increased pancreatic
fluid in the drain tube. ERCP showed pancreatic ductal disruption and a
normal biliary tree. Pancreatic stenting was done. Two days later he was
taken up for wound closure. Patient improved with ATT/antibiotics/octreo-
tide/ionotropes and nutritional support and was discharged after two weeks.
Patient improved and had gained weight on follow up. Colostomy closure was
done after 6 months.
Discussion. TB of abdomen is commonly seen in 12% of patients with
miliary TB. Isolated involvement of the pancreas without military TB or
immunocompromised status is extremely rare. In view of non specific clinical
presentation and investigative features, the disease can elude diagnosis, but
once diagnosed they respond favorably to ATT. Pancreatic tuberculosis
should be considered as a DD when pancreatitis is atypical.
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THE WHIP-STOW PROCEDURE: AN INNOVATIVE MODIFICA-
TION TO THE WHIPPLE PROCEDURE.
Christos A Galanopoulos, MD, D Rohan Jeyarajah, MD
Methodist Dallas Medical Center, Dallas, TX
Background. Pancreaticoduodenectomy (PD) is the standard of care in the
treatment of benign and malignant diseases of the head of the pancreas. The
most studied aspect of this procedure is the method of anastamosis with the
pancreatic remnant. Many techniques have been described. This work
describes, for the first time, a safe and easy new technique for pancreatic
anastamosis after PD.
Methods. Seven patients underwent the Whip-Stow Procedure for the
management of the pancreatic remnant. The Whip-Stow- PD combined with
a Puestow (LP-lateral pancreaticojejunostomy), was completed using a single
layer, 30 running prolene suture in a duct-to-mucosa technique championed
by Puestow and Gillesby. Drains were monitored and pulled on day 5 if B
20cc of amylase poor fluid over 24 hours. The PD performed included
standard and pylorus preserving PD. The mortality, leak, and postoperative
bleeding rates were evaluated, as well as the skill level required to perform this
modification. This was compared to historical data of the PD and LP
procedures.
Results. Leak rates were compared among historical data of PD with respect
to end to side, end to end, invagination via pancreaticojejunostomy (PJ), and
pancreaticogastrostomy (PG). PJ historical leak rates are reported to be 11%,
and the leak rate for the PG is reported to be 12%. Mortality, leak, and post
operative bleed rates were 0% in all 7 Whip-Stow patients. The Whip-Stow
can easily be complete with neither loops nor microscope, while still achieving
a desired duct-to-mucosa anastamosis. The ability to complete the anasta-
mosis with a heavier 30 non-absorbable, single layer, running suture, allowed
for a decrease in complexity and time needed to complete the anastamosis.
Average time needed was 1215 minutes, as compared to the traditional, 50
or 60, interrupted, multilayered, anastamosis, taking an average 4050
minutes. The presence of a dilated pancreatic duct and fibrotic parenchyma
facilitated the use of the Whip-Stow, though normal pancreatic remnants with
ducts as small as 3 mm were used. Other benefits included a long segment
duct-to-mucosa PJ decreasing the possibility of strictures, no need for
stenting, resulting in no stent retention or migration, and a wide anastamosis
enabling access to the entire duct via endoscopy for surveillance of IPMN.
Conclusion. In the hands of skilled pancreatic surgeons, the Whip-Stow
procedure has shown promise in being a simpler, safer, and more effective
approach to the challenging pancreatic anastamosis during a PD. In the age
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of increasing IPMN tumor resection, this technique emphasizes the basic
principles of using a large anastamosis combined with complete intraopera-
tive ductal evaluation, with future benefits of duct surveillance.
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CONSERVATIVE TREATMENT IN PANCREATIC PSEUDOCYST
IN CHILDREN
Paraian Ioan, MD, PhD, Budusan Anca, Ordeanu Calin, PhD
University of Medicine and Pharmacy, Cluj-napoca, Romania; Children‘s
Hospital, Cluj-napoca, Romania
Aim. Pancreatic trauma and pseudocysts are uncommon in childhood.
Bicycle handlebar injuries are common mechanism and result in a pancreatic
injury, often complicates by pseudocyst development. The purpose of this
review is to present our experience in conservative treatment of PPS.
Material and Methods. From 2001 to 2007 4 patients with diagnosis were
admitted and treated in our clinic (3 boys and 1 girl, with ages ranging from
18 months to 11 years). The etiology of the cysts was abdominal trauma in all
cases.
Results. Clinical presentation included abdominal pain, vomiting, loss of
weight, abdominal mass, fever and anorexia. In all cases ultrasound and CT
revealed a cystic mass at the head of the pancreas, between 2 and 5 cm) none
of the patients had complications like gastric outlet obstruction or jaundice.
The diagnosis was confirmed by hyperamylasemia in 3 cases. One case (age
18 months) was admitted 7 months before with haemoperitoneum after
abdominal trauma, which needed drainage. All cases were successfully
managed nonoperatively using analgesia and total parenteral nutrition. Oral
feeding was gradually introduced between 11 to 27 days. Recovery was
uneventful and patients were discharged on a normal diet 21 to 50 days after
admission. All patients had complete resolution of the pseudocyst clinically
and radiologically after follow-up periods of 3, 6 and 12 months, respectively.
We had no deaths or semnificative complications in this series.
Conclusions. Non-operative management of non-complicated pancreatic
contusion and pseudocyst is effective and safe and does not appear to be
associated with sequeale.
For children with persistent symptoms or complications, surgical treatment is
the best choice.
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LAPAROSCOPIC DISTAL PANCREATECTOMY-SPLENECTOMY
FOR A DERMOID CYST OF THE PANCREAS-CASE REPORT
AND REVIEW OF THE LITERATURE
John George Zografakis, MD, Steven Wanek, MD, Adrian George Dan, MD
Summa Health System, Akron, OH
Background. Dermoid cysts are congenital abnormalities which originate
from disturbances in embryonic development. They have been reported in
numerous parts of the body, to varying degrees. However, a dermoid cyst of
the pancreas is an exceptionally rare germ cell neoplasm, which is typically
well-differentiated and benign. After a review of the published literature to
date, only 21 such neoplasms have been reported. While the evaluation of a
cystic mass in the pancreas may be facilitated by numerous available
diagnostic studies such as ultrasound (trans-abdominal or endoscopic), CT,
and MRI, the definitive diagnosis is usually made only after operative
intervention. We present the first reported case of a laparoscopic distal
pancreatectomy with splenectomy for curative resection of a dermoid cyst in
the distal pancreas.
Case Report. A 61 year old white male presented to the emergency
department with right upper quadrant pain. A CT scan of the abdomen
showed multiple gallstones, however a 5.2 centimeter bi-lobed cystic mass in
the pancreas was incidentally identified. The CA 199 was elevated at 80
(range 033), and a CEA was normal at 1.5. Upper gastrointestinal
endoscopy was unremarkable, and showed no obvious involvement of the
stomach. He was immunized for H. Influenza, Pneumococcus and Menin-
gococcus. Ten days later he underwent a successful laparoscopic distal
pancreatectomy with splenectomy and subsequent cholecystectomy.
Methods. Utilizing ‘‘split-leg’’ positioning, a laparoscopic distal pancrea-
tectomy with splenectomy was completed. The pancreas was divided distal to
the portal vein using a laparoscopic linear stapler with SeamGuard†
reinforcement (W.L. Gore & Associates, Inc., Tempe, AZ). Similarly the
splenic artery and vein were controlled using a laparoscopic linear stapler.
The specimen was removed using a wound protection device after enlarging
the left upper quadrant trocar incision.
Results. He tolerated the procedure without difficulty, was started on diet on
the second postoperative day and discharged four days after surgery. Histo-
logical evaluation revealed a benign dermoid cyst of the tail of the pancreas.
Conclusion. Determining the malignant potential for a cystic mass in the
pancreas is difficult. While characteristic findings on ultrasound, CT and
MRI have been documented, operative resection remains the definitive
means of diagnosis and treatment. While advanced laparoscopic skills are
necessary, a minimally invasive approach for resection of pancreatic
neoplasms, including dermoid cysts, is feasible.
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SURGICAL MANAGEMENT OF LOCALLY ADVANCED PAN-
CREATIC AND PERIPANCREATIC NEOPLASMS INVOLVING
MAJOR VISCERAL ARTERIES
Trina Steljes, MD, Jose Almeda, MD, Gagandeep Singh, MD, Linda Sher,
MD, Maria Stapfer, MD, Rodrigo Mateo, MD, Rick Selby, MD, Yuri Genyk,
MD
Keck School of Medicine, University of Southern California, Los Angeles,
CA
Introduction. Pancreatic and peri-pancreatic tumors invading major visceral
arteries have traditionally been deemed unresectable. Although en-bloc
resection of the portal vein to obtain tumor clearance has been reported,
little has been presented on the value of arterial resections. In this
retrospective study we reviewed our initial experience in surgical manage-
ment of locally advanced pancreatic and peri-pancreatic neoplasms involving
major visceral arteries.
Methods. Between December 2002 and September 2007 nine patients
underwent resection of pancreatic or peri-pancreatic neoplasms involving
visceral arteries. En-bloc resections of celiac trunk (n2), common hepatic
artery (CHA) (n3) and superior mesenteric artery (SMA) (n4) were
performed. Five patients also had resections of portal vein (PV) and/or
superior mesenteric vein (SMV). Concomitant arterial/venous reconstruction
was performed in 6 patients. All but two patients have received chemother-
apy, and two of them had chemo-radiation. Patient demographics, tumor
histology, operation performed and outcome are summarized in Table 1.
Results. There were no operative mortalities. Three of the 9 patients died at
2, 5, and18 months post-operatively as a result of malignancy progression.
Six patients are currently alive with the mean follow-up of 34 months (range,
1357 months). Three patients are alive with recurrent disease. The
remaining three patients are disease free at 13, 24 and 57 months post-
operatively.
Conclusions. Although appearing aggressive, surgical management of
locally advanced pancreatic and peri-pancreatic neoplasms involving major
visceral arteries can be performed with acceptable peri-operative mortality. In
the era of increasing sophistication of chemo- and radiation therapies,
evolving surgical techniques and improved peri-operative patient manage-
ment, extended resections with vascular reconstruction may provide addi-
tional survival benefits in selected group of patients.
Table 1. Patient characteristics and outcome.
Age/
Sex
Tumor Histology Operation Vascular resection Reconstruction F/U
(mos)
Outcome
60/M Pancreatic CA Distal pancreatectomy Celiac trunk None 57 Alive, disease free
70/F Pancreatic
neuroendocrine tumor
Pylorus sparing Whipple
operation
SMA and SMV Autogenous interposition
vein grafts
51 Alive, with recurrence
74/M Pancreatic CA Pylorus sparing Whipple
operation
SMA and PV/
SMV
Autogenous interposition
vein grafts
47 Alive, with recurrence
62/M Pancreatic CA Distal pancreatectomy CHA None 5 Died
50/M Pancreatic CA Distal pancreatectomy Celiac trunk Left gastric artery re-implantation 18 Died
36/M Pseudotumor Pylorus sparing Whipple
operation
SMA and SMV Autogenous interposition
vein grafts
24 Alive, disease free
73/F Pancreatic CA Whipple operation SMA and SMV Autogenous interposition vein
grafts
2 Died
76/F Pancreatic CA Whipple operation CHA and PV Autogenous interposition vein
grafts
13 Alive, disease free
65/F Metastatic colorectal CA Celiac lymphadenectomy CHA None 13 Alive, with recurrence
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TOTAL PANCREATECTOMY FOR NESIDIOBLASTOSIS: HOW
FAR SHOULD YOU GO?
Carla Fisher, MD, Katherine Morgan, MD, David Adams, MD
Medical University of South Carolina, Charleston, SC
Introduction. Nesidioblastosis, a rare disorder characterized by hypogly-
cemic hyperinsulinemia associated with hyperfunctioning pancreatic islets,
has been described in bariatric patients who have undergone gastric bypass
procedures. Surgical management of this disorder with pancreatic resection is
utilized with controversy related to amount of pancreatic resection necessary.
Methods. We describe a patient who developed nesidioblastosis after open
gastric bypass surgery who required total pancreatectomy for resolutions of
her symptoms.
Results. The patient is a 34 year-old woman who developed hypoglycemic
seizures intractable to medical management 4 years after gastric bypass.
Serologic studies confirmed elevations of insulin and C-peptide with
hypoglycemia. Localization studies, including computed tomography of the
abdomen and calcium infusion test, failed to identify a specific location on
the pancreas. She underwent distal pancreatectomy and splenectomy,
dividing the pancreas anterior to the superior mesenteric vein. Postopera-
tively, the patient did well for 5 months when symptomatic hypoglycemia
recurred. The patient underwent a duodenal preserving completion pancrea-
tectomy. Post operatively the patient has had no hypoglycemic episodes and is
maintained on an insulin regimen.
Conclusion. Distal pancreatectomy may be inadequate treatment for post
gastric bypass nesidioblastosis. A Child subtotal pancreatectomy or duodenal
preserving pancreatectomy may be indicated in some cases. Optimal
pancreatic resection volume in this disorder will require further experience
and analysis.
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A NOVEL USE OF THE HARMONIC ACE DURING PANCREATI-
CODUODENECTOMY WITH NO POST-OPERATIVE BLEEDING.
Christos A. Galanopoulos, MD, Allison Vo, RN, D. Rohan Jeyarajah, MD
Methodist Dallas Medical Center, Dallas, TX
Background. Dissection of the uncinate process off the superior mesenteric
artery and vein (SMA/SMV) can be the most tedious and time consuming
part of a pancreaticoduodenectomy (PD). New technology has allowed for a
more anatomic and less bloody surgery. The use of thermal energy adjacent
to the SMA to acquire negative uncinate margins has raised concern
regarding post-operative pseudoaneurysm formation or bleeding from the
SMA. This work examines the safety of using the Harmonic ACE (HA) near
the SMA during a PD and it’s effects on postoperative bleeding.
Methods. During the study period, 76 PD’s were performed for malignant
and benign disease by a single surgeon over a 2 year period. The HA was used
in the following order during surgery in all patients. Firstly, the mobilization
of the proximal jejunal mesentery to its mesenteric root, followed by taking
down of the 3rd and 4th portion of the duodenum and ligament of treitz.
Subsequently the posterior pancreatic fascia at the SMA margin was incised
followed by the dissection of the uncinate off the SMV and SMA by medial
retraction of the SMV and within millimeters of the SMA. Reconstruction
was performed using pylorus preserving (PPPD) or standard techniques
(SPD) depending on the patient and type of tumor. Blood loss, operative
time, and postoperative bleeding complications were reviewed.
Results. All 76 PD’s were successfully completed with the HA. Mean
operative time was 240 minutes, mean blood loss was 350 ml, and
postoperative bleeding rate was 0%. PPPD and SPD were performed in 28
and 48 patients respectively. Pathology specimens were found to have a more
uniform and reliable SMA margin than our historical controls, in which
standard clamp and tie technique was used. The SMA margin was found to
contain less tissue adjacent to the artery in situ, resulting in a more
comprehensive oncologic surgery. Stable post operative hematocrits sup-
ported that no bleeding had occurred acutely and several postoperative CT
scans during surveillance failed to reveal the presence of SMA pseudoaneur-
ysms.
Conclusion. During our 76 PD’s, the use of the HA on the jejunal
mesentery, ligament of treitz, and uncinate margin is safe and effective.
Specifically, concerns regarding post-operative bleeding from pancreatico-
duodenal vessels are not borne out in this study, as there were no bleeding
events from the SMA margin during the early and late post-operative periods.
The use of the HA decreased our operative time by simplifying 3 critical steps
during PD. Most importantly, it also solidified one of the bedrocks of
oncologic surgery for pancreatic head cancers, that being leaving less tissue
on the uncinate/SMA margin.
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SURGICAL MANAGEMENT OF PANREATIC AND PERI- AM-
PULLARY CARCINOMA BY KAUSCH-WHIPPLE OR WATSON-
TRAVERSO  A CONTROLLED RANDOMISED LONG TERM
SINGLE CENTRE TRIAL
Karl J Paquet, MD
Clinic Werlich-Barie´ Bad Kissingen, Bad Kissingen, Germany
Objective. Debate is going on whether pylorus preserving pancreatico-
duodenectomy (PPPD) or Kausch-Whipple procedure (KW) is method of
choice in resecting pancreatic head (PH) and peri- ampullary cancer (PA),
when R0-resection can be reached. There are arguments that show clear
postoperative superiority of PPPD, but there is a lack of long term data.
Summary Background Data. Long-term results of PPPD versus KW are
prospectively examined over twenty years. For the first time many endo- and
exocrine function parameters were obser- ved over a long period.
Methods. Prospective randomized trial over 20 years (01.01.1984
01.01.2004) with a median follow up of 14,5 years. From 161 patients
with PH and PA 40 were judged for intended curative resection, treated
either with PPPD (n19) or KW (n21). Datas like pathology, post-
operative morbidity, mortality, nutritional and gastrointestinal (endocrine,
exocrine) function parameters (glucose, daily glucose profile, oral glucose
tolerance test (OGTT), oro-cecal transit-time and pancreolauryl test), blood
loss, opera- ting-time, delayed gastric empting, perioperative complications,
morbidity and mortality, hospital stay and weight loss were analysed. Follow
up was made every 6 and thereafter every 12 month.
Results. The resection rate was 39 (25)%. 1 postoperative death (MOF-
KW). 3 pancreatic fistulas (2KW, 1 PPPD), 2 postoperative bleeding (KW,
PPPD), 9 other complications (6 KW, 3 PPPD). Significant better exocrine
function in PPPD group (oro-cecal-tran- sit time. 114/18 vs 78/32 and
pancreo- lauryl test, pB0,05 both). Median loss of body weight on discharge
was 8 (KW), 4,5 (PPPD) kg (p0,061). Median hospital stay was 16 (KW)
versus 14 (PPPD) days. 35% of patients with KW reached the preparative
body weight after 6, 43 after 12 months, 75% of patients with PPPD after 6,
86% after 12 months (pB0,05). There was no significant difference in blood
glucose measurement and OGTT between KW and PPPD group. Overall
mortality (no significant difference) was 2,5%. 13% five-year and 8,5% ten-
year survival in the KW-group, 17,5% 5 and 10 year survival in PPPD- group.
The twenty-year survival was 17,5% in the PPPD- and 0% in the KW- group
without significant difference.
Conclusions. PPPD is not only superior regarding previous described
advantages like more simple technique, operating time and blood loss,
early morbidity, shorter hospital stay and better early gastrointestinal
function. It is not longer an oncological safety risk when RO resection can
be reached, but although superior regarding long term survival, however
without signifi- cant difference. Early and long term exocrine function is
significantly better.
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VARIANT VISCERAL ARTERIAL ANATOMY AND PANCREATI-
CODUODENECTOMY (PD): INCIDENCE, RECOGNITION, AND
MANAGEMENT
John Stauffer, MD, Naciye Turan, MD, Mellena Bridges, MD, Justin H
Nguyen, MD, J. Kirk Martin, MD
Mayo Clinic, Jacksonville, FL
Background. Arterial anomalies in the region of the pancreas and liver are
commonly seen during pancreaticoduodenectomy (PD). Variant supply of
the right hepatic lobe is the most common and relevant. We report our
experience with PD and arterial anomalies.
Methods. All patients undergoing PD from February 2003 to June 2007
were identified. Those with aberrant right hepatic arterial anatomy (ARHAA)
were selected and retrospectively reviewed.
Results. Of 310 PD performed, 26 (8.4%) patients were identified as having
ARHAA. The indications for PD were: pancreatic adenocarcinoma (13),
duodenal adenoma (3), IPMN (3), neuroendocrine tumor (2), cholangio-
carcinoma (1), malignant stromal tumor (1), chronic pancreatitis (2),
duodenal carcinoma (1). The ARHAA included: replaced RHA from the
SMA in 20, accessory RHA from SMA in 4, accessory RHA from GDA in 1,
and replaced CHA from SMA in 1. Management included dissection and
preservation in 21, transection and primary re-anastomosis in 2, transection
with reconstruction to GDA by PTFE jump graft in 1, transection and
primary reconstruction with gonadal vein interposition graft in 1, and
transection with primary reconstruction into GDA in 1. Six of twenty one
preoperative CTor MRI interpretations remarked on ARHAA. Retrospective
review by a single experienced radiologist was able to accurately identify
ARHAA on preoperative imaging in 19 of 20 available radiographs. There
were no postoperative complications related to ARHAA.
Discussion. Successful recognition and management of ARHAA is critical
during PD as complications of injury include hepatic ischemia and biliary-
enteric anastomosis breakdown. Preoperative recognition by MRI or high-
quality CT can forewarn the surgeon. Decisions about the management of
the may be required intraoperatively and relate to tumor involvement and the
specific anatomical variations. The four options for ARHAA include: 1)
sacrifice without any implications if it is felt that the artery is an accessory
vessel or is of a very small caliber 2) preoperative embolization to allow
adequate collateralization to the right lobe and bile ducts before PD 3)
dissection free from the surrounding tissue and preservation 4) transection
and reconstruction via primary anastomosis or via implantation at a suitable
arterial site.
This series highlights the frequency that variant right hepatic arterial inflow is
encountered during PD. Our radiology department now routinely describes
the arterial anatomy on pancreatic cases. Although it may increase the level of
difficulty of PD, ARHAA can be managed in several ways which do not
increase perioperative morbidity.
42 Abstracts
61
USE OF PTFE FOR PORTAL VEIN RECONSTRUCTION DURING
PANCREATICODUODENECTOMY
John Andrew Stauffer, MD, Marjorie K Dougherty, PA-C, MPH, Denise M
Harnois, DO, George P Kim, MD, Justin H Nguyen, MD
Mayo Clinic, Jacksonville, FL
Introduction. Portal vein resection (PVR) during pancreaticoduodenectomy
(PD) has been shown to be a safe procedure associated with the same
morbidity and mortality as standard PD for properly selected patients. The
optimal method of venous reconstruction is a primary anastomosis but an
interposition graft is needed when the defect is greater than 3 cm. Various
materials have been used and reported in literature but few report patency
and durability of the grafts. In this study, we report our use of PTFE
interposition grafts in 9 patients and compare their patency to 19 patients
with non-PTFE interposition grafts.
Methods. The cases of PD’s that were performed during 5/2000 to 7/2007
were retrospectively identified and their charts were examined.
Results. During this period, 100 PD’s were performed. In this series, 29
patients had PVR during PD. The resected PV was reconstructed with
primary anastomosis in 10, autologous vein in 7, PTFE patch graft in 2, and
PTFE interposition graft in 9 patients. No portal reconstruction in 1 case.
The 10 PTFE interposition grafts in the 9 patients included 6 reconstructions
between portal vein (PV) and superior mesenteric vein (SMV), 3 SMV to
inferior vena cava (IVC) grafts, and 1 splenic vein (SV) to PV graft. All PTFE
grafts had externally ring-reenforced and all but one had a diameter 14 mm
or greater (1420 mm). Patency was assessed postoperatively with duplex
ultrasound in 9 and MRA in 7 cases of PTFE reconstruction. Patency at 30
and 180 days was 90% (9/10) and 100% (3/3) for PTFE interposition grafts
as compared with 60% (6/10) and 67% (4/6) for primary reconstructions,
and 86% (6/7) and 83% (5/6) for autologous vein, respectively. There was no
postoperative infection associated with PTFE grafts.
Conclusion. Use of PTFE can be effective alternative interpositional grafts
in portal vein reconstruction in PD. PTFE grafts have acceptable patency.
Further study is needed to define PTFE as a viable option for restoring porto-
mesenteric venous continuity during PD.
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ACCURACY OF MAGNETIC RESONANCE IMAGING IN ASSES-
SING LOCAL RESECTABILITY OF PANCREATIC CANCER.
Marc Sarti, MD, Reid B. Adams, MD, S. Lowell Kahn, MD, Todd W. Bauer,
MD, Eduard E. De Lange, MD
University of Virginia, Charlottesville, VA
Purpose. At our institution, Magnetic Resonance imaging (MRI) is used as
the primary modality in the evaluation of pancreatic tumors. Our study was
performed to determine the accuracy of MRI in assessing the surgical
resectability of pancreatic carcinoma in the routine clinical setting.
Methods. Prospective assessment of surgical resectability using gadolinium-
enhanced MRI was performed in 66 patients with suspected pancreas cancer
over a period of one year. Imaging consisted of axial, coronal and sagittal T2-
weighted images, axial T1-weighted images with and without gadolinium
enhancement, and gadolinium-enhanced MR angiography. Nine different
radiologists with varying clinical experience were involved in the study; each
study was interpreted prospectively and independently by a single radiologist,
the day they were clinically scheduled to cover abdominal MRI. Surgical
resectability was predicted based on involvement of the celiac axis, the
superior mesenteric artery (SMA), degree of tumor encasement of the portal
vein and/or superior mesenteric vein, and the presence or absence of distant
lymphadenopathy or metastases. In 24 of the 66 patients the imaging findings
and lack of co-morbidities led to surgery, consisting of resection of the mass
or laparotomy with biopsies. In 5 of the 24 cases local extent was not
determined at surgery because hepatic metastases were found and no
resection of the primary tumor performed (n3), or the mass was found
not to represent cancer (n2). In the remaining 19, local stage was
determined after surgery or at laparotomy. The accuracy of MRI in
determining resectability was correlated with surgical and pathologic data
in this group of 19 patients.
Results. Tumor resectability was correctly predicted using preoperative
MRI in 16 of the 19 patients. Two were incorrectly characterized as
unresectable by imaging (i.e. were believed to have celiac or SMA involve-
ment) and one was incorrectly characterized as resectable (i.e. was thought to
have lack of arterial involvement). Thus, accuracy of resectability and
specificity of vascular invasion for MRI/MRA were 84% and 89%, respec-
tively.
Conclusion. Using MRI, local resectablity of pancreatic carcinoma can be
accurately predicted in the routine clinical setting of multiple radiologists
with varying clinical experience.
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EVIDENCE IN FAVOUR OF STANDARDIZATION OF INDICA-
TIONS FOR OPERATIVE INTERVENTION IN PAINFUL
CHRONIC PANCREATITIS.
Nehal Shah, Ajith K Siriwardena
Hepatobiliary Surgery Unit, Manchester Royal Infirmary, Manchester,
United Kingdom
Background. Surgical treatment can provide good relief of symptoms in
symptomatic chronic pancreatitis (CP) with procedures being categorised
broadly as main pancreatic duct drainage, duodenum-preserving pancreatic
head resection (DPPHR) or Whipple-type pancreaticoduodenectomy.
Although many reports describe good outcome after surgery, there is little
information on the starting point for intervention, namely, the indications for
surgery; and thus this study examines contemporary indications for elective
surgical intervention in CP.
Methods. A computerised search of the National Library of Medicine’s
‘‘PUBMED’’, ‘‘EMBASE’’ & ‘‘COCHRANE’’ databases was undertaken for
the period January 1997 to March 2007 using the keywords ‘‘surgery’’ and
‘‘chronic pancreatitis’’. Of the 1232 resulting hits, exclusion of reports that
gave no original data provided a final study sample of 38 reports providing
outcome data on 3518 elective operative procedures for CP. Data were then
extracted on indication, type and outcome of surgery.
Results. Data were available on 3518 patients undergoing surgery for CP.
Abdominal pain was the principal indication for surgery in 85%, suspicion of
underlying cancer in 15%, weight loss in 14% and other indications in 8%.
DPPHR was the most commonly performed procedure with Puestow-type
lateral pancreaticojejunostomy (LPJ) being second and Whipple or pylorus
preserving tpancreaticoduodenectomy third. Most reports did not give
information on the relation between type of surgery selected and defined
indication for choice of procedure. The principal determinant of type of
procedure selected appears to be unit or clinician preference.
Conclusions. Although abdominal pain is the commonest indication
for surgery in CP, there is no evidence of standardisation of pain symp-
toms across units and elective procedures appear to be selected principally
by unit or clinician preference. This study highlights for the first time,
the need for standardisation of indications for surgery in CP. In turn, only
this standardisation will allow meaningful comparison of results across
units.
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ACCURACY OF CT IN PREDICTING MALIGNANT POTENTIAL
OF CYSTIC PANCREATIC NEOPLASMS
William E. Fisher, MD, Sally E. Hodges, Vivek Yagnik, MD, Fannie E.
Moro´n, MD, Meng Fen Wu, MS, Susan G. Hilsenbeck, PhD, Isaac L.
Raijman, MD, F. Charles Brunicardi, MD, Elkins Pancreas Center, Dan L.
Duncan Cancer Center, Michael E. DeBakey Department of Surgery, Baylor
College of Medicine, Houston, TX
Background. Cystic lesions of the pancreas are being identified more
frequently. The differential diagnosis includes benign lesions such as
pseudocysts and cystadenomas, premalignant lesions such as intraductal
papillary mucinous neoplasms (IPMN), mucinous cystic neoplasms (MCN),
and malignant lesions. Deciding which asymptomatic lesions can be safely
followed with serial imaging and which require resection due to malignant
potential is an increasingly common question. Current clinical practice is to
rely on characteristics of the lesions on CT scan, but additional information
from endoscopic retrograde pancreatography (ERCP), endoscopic ultra-
sound with fine-needle aspiration (EUS-FNA), and cyst fluid analysis is
sometimes used to assess malignant potential.
Hypothesis. Preoperative diagnosis of pancreatic cystic lesions by CT scan
alone is frequently inaccurate.
Methods. CT scans from 48 patients with cystic lesions of the pancreas were
stripped of patient identifiers and retrospectively presented to two expert
radiologists. The radiologists recorded specific characteristics of the lesions
thought to be important in the differential diagnosis and their opinion of the
likely diagnosis. Diagnostic accuracy was assessed by comparing the
radiologists’ diagnoses to the final pathologic diagnosis after resection. To
determine if clinical history, ERCP, or EUS-FNA findings improved
diagnostic accuracy, medical records were retrospectively reviewed and
scored as either supporting or not supporting malignant potential of the
lesion.
Results. Specific diagnoses based on CT findings alone were correct in only
42% of the cases, but when diagnoses were dichotomized as benign (24%) or
other (76%; IPMN, MCN, cancer), determinations of malignant potential
based on CT alone were accurate in 69% of cases. Accuracy rates were the
same for each radiologist, although there was only moderate agreement
between radiologists (Kappa0.45, pB0.05). When all clinical information
available including the history, physical exam, CT findings, ERCP, and EUS/
FNA with fluid analysis was considered together as a single dichotomous
indicator of malignant potential, the indicator was accurate in 84% of the
cases (p0.01, Fisher’s exact test).
Conclusion. Specific preoperative diagnosis of pancreatic cystic neoplasms
by CT alone is substantially inaccurate. Complementary tests such as ERCP
and EUS-FNA with fluid analysis should be recommended to improve
diagnosis especially if lesions are treated nonoperatively.
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LAPAROSCOPIC DISTAL PANCREATECTOMY FOR PANCREA-
TIC ADENOCARCINOMA: IS AN APPROPRIATE ONCOLOGIC
RESECTION POSSIBLE?
James E. Fisher, MD, Michael L Kendrick, MD
Mayo Clinic, Rochester, MN
Introduction. Laparoscopic distal pancreatectomy (LDP) has been de-
scribed for both benign and neoplastic lesions. Current series, however,
describe few, if any patients with pancreatic adenocarcinoma. Data specifi-
cally addressing outcomes of LDP in patients with adenocarcinoma is
lacking. Our aim was to evaluate the technical aspects and outcome of
patients undergoing LDP for pancreatic adenocarcinoma.
Methods. We retrospectively reviewed, prospectively collected data on all
patients having undergone laparoscopic distal pancreatectomy for pancreatic
adenocarcinoma at our institution. Follow up was complete in all patients for
a mean of 16 months.
Results. A total of 8 patients, mean age 66 years (range: 5277) were
identified. All patients underwent laparoscopic distal pancreatectomy with
splenectomy. In all patients an R0 resection was achieved, which required an
extended distal pancreatectomy (transection at pancreatic neck) in four
patients, and an adjacent organ resection in two patients. Median operative
time and blood loss was 242 minutes (range: 156337) and 150 ml (range:
50550) respectively. Mean tumor size and number of lymph nodes harvested
were 4 cm (range: 19) and 16 (range: 638). Final tumor stage was IA in 2
patients, IB in 2, and IIB in 3 patients. Median length of hospital stay was 7
days (range: 415). Perioperative complications occurred in 3 patients with
postoperative anemia and urinary retention, pancreatic fistula, and transient
chylous ascites occurring in one patient each. At follow-up, all but two
patients are alive without evidence of disease. One patient was found to have
liver metastases and carcinomatosis 6 months postoperatively and died of
disease at 21 months. In the second patient a lung metastases was identified 5
months postoperatively and is alive with disease at 16 months. No untoward
oncologic outcomes attributed specifically to the laparoscopic approach we
identified.
Conclusions. An adequate oncologic resection of pancreatic adenocarci-
noma of the distal pancreas can be achieved laparoscopically. An R0 resection
with adequate lymph node harvest and adjacent organ resection when
indicated are possible. Larger controlled, comparative trials are necessary
to substantiate these findings and validate the oncologic outcomes of
laparoscopic pancreatic resections.
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COMPARATIVE OUTCOME OF THE RETROPERITONEAL, EN-
DOSCOPIC AND LAPAROSCOPIC APPROACHES TO MINI-
MALLY INVASIVE NECROSECTOMY.
Benoy Idicula Babu, MBBS, A.k Siriwardena, MD
Manchester Royal Infirmary, Manchester, United Kingdom
Introduction. Blunt (non-anatomical) debridement of necrotic tissue at
laparotomy is the standard method of treatment of infected post-inflamma-
tory pancreatic necrosis. Recognition that laparotomy may add to morbidity
by increasing post-operative organ dysfunction has led to the development of
alternative, minimally invasive methods for debridement. There is a need for
consensus regarding optimal approaches and this study reports the status of
minimally invasive necrosectomy (MIN) by different approaches, using
standardised reporting methodology for comparison.
Methods. Searches of MEDLINE and EMBASE for the period 19972007
were undertaken using OVID with Boolean operators. Only studies with
original data and information on outcome were included to produce a final
population of 26 studies reporting on 345 patients undergoing MIN with the
median (range) number of patients per study being 8 (153). MIN was
categorised as retroperitoneal, endoscopic or laparoscopic and the following
data points were selected for comparison: delay from admission to necro-
sectomy, inpatient stay and procedure-related mortality. Data are presented
as medians (range).
Results. The retroperitoneal approach was undertaken in 130 (37.6%) with
a median delay from admission of 35 (1348) days, median in-pt stay of 74
(23100) days and overall mortality of 13.5 (827%). Endoscopic trans-
gastric ‘‘necrosectomy’’ was undertaken in 177 with a median inpatient stay
of 18 (1.549.5) days. The median number of interventions per patient in the
retroperitoneal approach was four and in the Endoscopic approach was 3.
Laparoscopic necrosectomy is reported in 38 patients.
Conclusion. These data show that MIN can be undertaken with acceptably
low mortality. The endoscopic approach has the most published support of
the MIN techniques. Despite these techniques being promoted by enthu-
siasts, no comment for superiority of MIN over percutaneous radiological
drainage of pancreatic abscess or contemporary small-incision necrosectomy
can or should be made without formal randomised trial.
67
MIDDLE PANCREATECTOMY IS A TECHNIQUE READILY IN-
CORPORATED INTO A PANCREATIC SURGEON’S CLINICAL
PRACTICE
Harish Lavu, MD, Jamie L Knuth, Marshall S Baker, MD, Nicholas J
Zyromski, MD, C Max Schmidt, MD, PhD, Attila Nakeeb, MD, Thomas J
Howard, MD
Department of Surgery, Indiana University School of Medicine, Indianapo-
lis, IN
Middle pancreatectomy (MP) is an operation designed to limit the degree of
pancreatic resection for benign lesions involving the neck and body of the
gland. Advantages of sparing pancreatic parenchyma have been counter-
balanced by a reportedly higher complication rate and unease among
surgeons with adopting a new technique. This study was designed to review
the introduction of MP in our own clinical practice focusing on the initial 38
consecutive patients operated on at a single institution between 11/1998 and
4/2007. Patients were divided into early (N19, 19982004) and late (N
19, 20042007) groups in our experience. We analyzed patient demo-
graphics, indications for operation, intra-operative variables and postopera-
tive complications related to incorporating this new technique at our
institution. Of the 38 patients, 26 (68%) had pancreatitis and 12 (32%)
had neoplasms. There were no significant differences in patient demo-
graphics, co-morbidities, operative indications, or tumor size. Thirty-four
reconstructions were by roux-en-y pancreaticojejunostomy and 4 were by
pancreaticogastrostomy. All pancreatic fistulas in this series were ISGPF
grade A (7) or B (5). There were no reoperations and no perioperative deaths.
MP is an operation that utilizes the judgment and techniques of resection and
anastomosis already within the skill set of a pancreatic surgeon. We identified
no significant differences associated with a ‘learning curve’ between our early
and late experience following introduction of this operation into our own
clinical practice. Based upon these results, the operative techniques used are
easily incorporated and we would advocate its increasing use for benign
lesions in the neck and body of the pancreas.
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RECURRENT LIVER ABSCESSES SECONDARY TO THE USE OF
PLEDGETS AFTER PENETRATING LIVER TRAUMA
Angel M Morales, MD, Steve H. Dougherty, MD
Texas Tech Health Sciences Center at El Paso, El Paso, TX
Introduction. We present the challenging case of a twenty-six year old male
who presented with large recurrent liver abscesses secondary to the use of
Teflon pledgets after a gunshot injury to the liver.
Case Presentation. A twenty-six year old male presented to the emergency
room complaining of three weeks of right upper quadrant pain, fever, and
weakness. Past medical and surgical history were remarkable only for a
gunshot wound to the abdomen nine months prior to this visit. Vital signs
were normal. Physical exam revealed a thin, well nourished male with
tenderness to palpation in the right upper quadrant.
Laboratory workup was normal. Computed tomography (CT) of the abdo-
men revealed a 1310 cm right-sided liver abscess containing foreign bodies
(Fig. 1). The patient underwent CT-guided percutaneous drainage of the
abscess. Medical records from his initial trauma admission revealed that he
had suffered severe damage to the right lobe of the liver. Teflon pledgets had
been used to repair the bleeding liver. The patient was offered surgical
removal of the pledgets. However, he refused, and was discharged on hospital
day nine.
Three months later the patient was seen in clinic with recurrent symptoms.
CT scan of the abdomen revealed a recurrent 14.411 cm liver abscess (Fig.
2). CT-guided percutaneus drainage of the abscess was repeated. A post-
drainage CT scan was performed which revealed persistent foreign bodies
within the liver (Fig 3). The patient underwent an open drainage of the liver
abscess with removal of foreign bodies. During the exploration, three small
pledgets were obtained. He recovered uneventfully and was discharged from
the hospital on postoperative day ten.
In another three months he presented to the emergency room again. CT scan
revealed a recurrent 1411 cm liver abscess containing foreign bodies (Fig.
4). After percutaneous drainage, the patient was taken to the operating room
for another open drainage and removal of foreign bodies. This time, twelve
pledgets were removed from the abscess cavity. The patient had an uneventful
CLINICAL DATA
Technical Variables Analyzed
Early
(N19)
Late
(N19) p
Operative Time (min) 259948 243971 0.56
Estimated Blood Loss (cc) 6769612 70391433 0.94
Perioperative Morbidity 8 (42%) 11 (58%) 0.52
Pancreatic Fistula Rate 4 (21%) 8 (42%) 0.30
Need for Interventional Radiology 0 2 (11%) 0.49
Hospital Length of Stay (Days) 1095 994 0.55
Hospital Readmissions 3 (16%) 2 (11%) 1.00
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postoperative stay and was discharged on postoperative day three. He
remains asymptomatic eighteen months after surgery.
Discussion. Penetrating injury to the liver has a high morbidity (51%) and
mortality (17%). Postoperative abscess formation is approximately 30%.
Standard techniques for control of bleeding and damage control laparotomy
have been described and should be employed in this setting. We found no
description in the literature of the use of pledgets for liver hemostasis. In the
patient described, Teflon pledgets, although possibly lifesaving initially,
probably increased his chances of developing recurrent liver abscesses.
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ROLE OF INTRAARTERIAL INFUSION CHEMOTHERAPY WITH
PROSTAGLANDIN E1 FOR HCC PATIENT WITH TYPE C CIR-
RHOSIS
Shinji Uchida, MD, Masanori Akashi, MD
Kurume University, Kurume, Japan
Introduction. A therapy for the hepatoma patient with jaundice is difficult
and we can’t find an effective therapy now.
Any way, we know prostaglandin E1 (following PGE1) as multifunctional
drug, e.g. hepatocyte protection, increase of hepatic blood flow, improvement
of microcirculation and promotion of liver regeneration.
We injected carcinostatic(cisplatin and 5-FU, following low dose FP) and
PGE1 from hepatic arterial infusion catheter for three patients with jaundice
and hepatoma.
Patients and methods. 1st patient was 69 years old man with cirrhosis of
HCV.
He was admitted to our hospital because of jaundice. Abdominal ultrasono-
graphy and abdominal CT scan showed tumor embolism in bile duct. That
tumor embolism progressed from the HCC of segment8, so we performed
PTBD. At first we gave PGE1 from hepatic arterial infusion catheter. One
week later, we had had hepatic arterial infusion chemotherapy for four weeks.
We found improvement of liver function in termination of hepatic arterial
injection. And abdominal CT showed reduction of HCC remarkably.
2nd patient was 61 years old man. We procedured transarterial chemoembo-
lization (following TACE) for HCC patient (segment3) with severe alcoholic
cirrhosis. After TACE, we injected of PGE1 from hepatic arterial infusion
catheter. However, his T.Bil was not change and he had distension of his
abdomen, so we stopped intraarterial infusion of PGE1 from hepatic arterial
infusion catheter. He died three months later because of hematemesis.
3rd patients was 78 years old man. He had had jaundice and 10 cm HCC with
tumor thrombus of right portal vein in right lobe of the liver. And he had
angina attack after admission. So we performed intraarterial infusion of
PGE1 and low dose FP from hepatic arterial infusion catheter. Abdominal
CT showed remarkably reduction of HCC after 2 weeks.
Results. For HCC patient with or without jaundice and HCC patient with
tumor thrombus, intraarterial infusion of PGE1 and chemotherapy was good
indication. But for sevior liver cirrhosis, it was not good indication to fibrosis
of liver.
Conclusion. We recommend intraarterial infusion of PGE1 and chemother-
apy for the cirrhotic patient(child class A or B). But we don’t recommend to
the severe cirrhotic patient like with pancytopenea.
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A TEN YEAR PROSPECTIVE STUDY COMPARING RIGHT AND
EXTENDED RIGHT HEPATECTOMIES WITH ALL OTHER LI-
VER RESECTIONS FOR COLORECTAL METASTASES.
Jeffrey T Lordan, MBBS, Nariman D Karanjia, MD, MBBS, Nial Quiney,
MBBS, William J Fawcett, MBBS, Tim R Worthington, MBBS, Jacky
Remington, B.Sc.
Royal Surrey County Hospital, Guildford, United Kingdom
Aims. Colorectal cancer metastasises to the liver in 50% of patients who
develop the disease. The gold standard treatment and only potential cure is
hepatic resection, often accompanied with adjuvant chemotherapy. Anecdo-
tally it was seen that patients who underwent right and extended right
hepatectomies in our institution had a higher incidence of operative
morbidity and mortality. Many studies have examined factors that predict
outcome, but none have compared right sided resections with left or
parenchymal sparing resections.
Patients and Method. 283 patients had successful hepatic resections for
colorectal metastases from September 1996 to November 2006 and were
prospectively studied. The early and late outcomes of those who had right
and extended right hepatectomies (RH) were compared with those who had
all other types of liver resection (AOLR). Adjuvant therapy and pre-operative
assessment were standardised. All patients who had synchronous or early
(B2 years) metachronous tumours received chemotherapy pre-operatively.
Results. The 1, 3 and 5 year overall survival rates in the RH group were
84.06%, 54.32% and 38.92% respectively. The 1, 3 and 5 year overall
survival rates in the AOLR group were 95.40%, 65.38% and 53.26%
respectively. The difference was statistically significant (p0.033). The 1,
3 and 5 year disease-free survival rates in the RH group were 69.45%,
34.40% and 25.48% respectively and 68.42%, 34.91% and 34.91%
respectively in the AOLR group (p0.455). Operative mortality was 3.9%
in the RH group and 0.65% in the AOLR group. Morbidity was 31.3% in the
RH group and 18% in the AOLR group. Of the 6 patients in total who died, 5
received an intra-operative Pringle’s manoeuvre.
During the first half of the series, 76 RH resections were performed (52 right
and 24 extended right hepatectomies) and 66 resections were performed in
the AOLR group. In the latter half of the series, there were 52 in the RH (32
right and 20 extended right hepatectomies) and 89 in the AOLR group. In
the first half of the series, 67 of the RH group had an intraoperative Pringle’s
manoeuvre compared with the latter half of the series where 23 patients in the
RH group received a Pringle’s manoeuvre.
Conclusion. Patients undergoing right and extended right hepatectomies for
colorectal metastases have a greater operative morbidity and mortality and
have a significantly worse overall survival compared to all other liver
resections for the same disease. The practice in this unit is already changing
towards parenchymal sparing hepatic resections and fewer intra-operative
Pringle’s manoeuvres.
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PATIENTS’ ECONOMIC IMPACT OF ORTHOTOPIC LIVER
TRANSPLANT IN ATLANTIC CANADA
Michele Molinari, MD, Amy Gillis, MD, Mark Joseph W, MD
Dalhousie University, Halifax, NS, Canada
Background. Data on the impact of OLT on the patients’ and their families’
financial status are lacking. Primary aim of this study was to assess the
personal and familiar annual income changes occurring after OLT.
Methods. From September 2006 to January 2007, a cross sectional study
was performed using a validated Societal Reintegration Questionnaire.
Participants were interviewed by phone or during follow-up visits and were
adults at least 3 years post OLT, without communication impairments. All
data were prospectively collected. Chi-Square was used to analyze categorical
data and Student’s t test for continuous variables; P values B0.05 with two
tail distribution were considered significant.
Results. Among 158 eligible patients, 47 were randomly selected. 45 (95%)
participated and 2 declined for personal reasons. 15 patients (33%) were full
time employed and 12 (52%) were employed in the same position as before
OLT. 13 individuals (28%) were on disability while the remaining were
students or housekeepers. 11 patients (24%) had retired. The overall annual
personal income of patients undergoing OLT decresed from $ 28,300 to
26,500 (pns) and the houshold annual income from $ 44,000 to 43,700
(pns) despite the expected 3% national discount rate. 35 individuals (77%,
pB0.05) reported that OLT had a negative impact on their personal and
familiar finances due to the increased expenses for medical therapy and 12
(26%) had to borrow money for medicine costs or travel expenses related to
OLT. Among them 42% had to interrupt immunosuppression medications
against medical advice because of financial restriction.
Conclusion. Although OLT provides better survival and quality of life to
patients with liver failure, the financial impact of this procedure on patients
and their families is significant. For low income patients, better financial
support should be considered to prevent suboptimal care and risks of chronic
graft rejection.
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SURGICAL VASCULAR PROCEDURES FOR MALIGNANCIES
WITH INFERIOR VENA CAVA INVOLVEMENT
Emilio Vicente, MD, Yolanda Quijano, MD, Carmelo Loinaz, MD, Ramon
D. Conradi, MD, Manuel Marcello, MD, Pablo Galindo, MD, Enrique
Esteban, MD, Fernando Lapuente, MD, Rafael Alvarez, MD, Luis Cordoba,
MD, Raul Macedo, MD
Hospital Madrid Norte Sanchinarro, Madrid, Spain
Due to its proximity to a number of important regional vascular structures,
tumors of the liver, biliary tract, pancreas, retroperitoneum area and kidney
are often associated with regional invasion or compresion of the inferior vena
cava (IVC). We describe our personal experience and policy concerning
technical considerations for inferior vena cava resection in selected cases of
locally advanced tumors.
23 patients (10 male, 13 female; ages ranging from 32 to 63 years, mean age
47 years) required a concomitant resection of IVC with and without
reconstruction in order to obtain a complete tumor resection with free
margins. The primary diseases were: liver metastasis from colon cancer (8),
ruptured hydatid cyst into IVC (1) with hydatid thrombus in IVC and atrium
and pulmonary dissemination (1), intrahepatic cholangiocarcinoma (1), renal
cancertumoral thrombus into IVC (5), tumoral thrombus into IVC (4),
tumoral thrombus into IVCliver infiltration (segment V) (1) and primary
tumor of the IVC (2). The level of the location and extent of tumor
involvement was: level I (renal veins): 8 cases; level II (retrohepatic IVC): 6
cases; and level III (hepatic veins and atrium): 9 cases. Total (1) and
retrohepatic (22) IVC resection was performed. In 16 patients we resected
IVC with hepatic veins (8) and renal veins bifurcation (8), respectively.
Multivisceral resection was performed: right hepatectomy (5), right hepa-
tectomy extended to segment IV (4), hepatic segmentectomy (segment V)
(1), total excision of hydatid cyst (2, one of them with IVC and atrium
trombectomy), and nephrectomy (5). Prosthetic replacement was performed
in 13 patients with reimplantation of left hepatic vein in 1 patient. Left renal
vein was not reimplanted.
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The general morbidity of the procedures was 21%, and morbidity related to
the vascular resection was 6%. The early and late patency vascular
reconstruction was 94%. 1 patient developed a graft thrombosis after IVC
resection and underwent graft replacement. 2 patients died in the post-
operative period due to liver failure.
We analyze the operative procedure (surgical approach, techniques of venous
control, hepatic vascular exclusion, hepatic and renal veins reconstruction,
prosthetic replacement and groin arterio-venous fistulae) according the
tumoral involvement. Our initial experience suggests that the IVC resection
can be performed in selected cases with a low risk of morbidity and mortality.
Pre and intraoperative evaluation to determine the extent of tumor is
imperative before the resection.
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LIVING DONOR LIVER TRANSPLANTATION: POST-OPERATIVE
IMAGING FOLLOW-UP OF 54 RIGHT LOBE DONORS WITH
CLINICAL CORRELATION
Suzanne Palmer, MD, Lusine Tumyan, MD, Eric Huang, Linda Sher, MD,
Yuri Genyk, MD
University of Southern California, Los Angeles, CA
Introduction. As the number of living donor liver transplant procedures
continues to increase, it becomes important to recognize the long term
complications that may result from liver donation and the regeneration of the
remaining lobe. The purpose of this study was to evaluate the regenerative
patterns following right lobe donation and correlate with the long term
outcomes of partial liver donation.
Methods. 54 right lobe donors were evaluated at a minimum of one year post
donation with interview, questionnaire, laboratory studies and magnetic
resonance imaging (MRI). Liver volumes were measured, the vascular
and biliary anatomy was evaluated and the regenerative pattern of the liver
was categorized. These findings were then correlated with the clinical
findings.
Results.Various morphologic patterns of the liver were identified and
correlation made with the long term symptomatology. In addition, in a large
number of patients, blind ended ducts (‘‘orphan ducts’’) were demonstrated
and correlation made with clinical and laboratory data to determine the
significance of these ducts.
Summary. With the increasing number of right lobe donations, it is
important to recognize not only the short term complications, but also the
long term complications of surgery. Long term follow up reveals that
although donors have excellent liver function and are in good health, many
of them complain of physical symptoms associated with the wound as well as
gastrointestinal symptoms. An understanding of the regenerative pattern of
the remaining lobe provides insight into etiology of these symptoms.
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A PROSPECTIVE STUDY OF ABDOMINAL PAIN AND FUNC-
TIONAL SYMPTOMS IN LIVING LIVER DONORS AFTER PAR-
TIAL LIVER DONATION AND GALLBLADDER REMOVAL
Karl Sondenaa, MD, PhD, Gabriel Gondolesi, MD, Sasan Roayaie, MD,
Sukru Emre, MD, Jody S. Goldman, RN, Trygve Hausken, MD, Myron E.
Schwartz, MD
University of Bergen, Bergen, N-5892, Norway; Adult Liver Transplantation
& Hepatobiliary Surgery and Recanati/Miller Transplantation Institute,
Mount Sinai Medical Center, New York, NY; University of Bergen, Bergen,
N-5020, Norway
Introduction. Abdominal complaints occur fairly frequently after removal of
the gallbladder in gallstone disease but the cause of this disorder has not been
ascertained. We wanted to examine the nature of possible abdominal
complaints after removal of the gallbladder and part of the liver in living
donors.
Method. Twelve patients referred for live donor operations were enrolled in
the study during a three-year period and followed up a 6 and 12 months.
There were nine men, aged 1845 years, and three women, aged 3246 years.
Ethnicity was mixed with caucasian (n7), hispanic (n3), asian and afro-
american origin. Patients filled out questionnaires including questions
pertaining to typical gallstone symptoms and functional abdominal com-
plaints (FAC) using a recognised questionnaire, Rome II.
Result. Abdominal pain occurred in 8 patients at 6 months but was reduced
to 5 patients at one year and FAC in 11 and 9, respectively. Pain was
accompanied by FAC in all instances, with the exception that 2 patients had
FAC but no abdominal pain at one year. A pain attack pattern only vaguely
similar to typical gallstone pain was only found consistently in one patient at
each follow-up. Irritable bowel syndrome (IBS) was found in the majority of
patients but functional dyspepsia (FD) was also observed. Dyspepsia
appeared de novo in all but one patient at the two follow-ups including
those two patients thought to have symptoms reminiscent of a gallstone pain
pattern.
Conclusion. Pain and FAC was fairly common after living liver donation but
pain waned with time during a one-year follow-up. Pain and FAC seemed to
indicate a general postoperative disorder, perhaps influenced by psychoso-
matic factors not evaluated further in this study, and not connected with
removal of the gallbladder in particular.
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INTRAOPERATIVE FLUORESCENCE IMAGING OF LIVER
TRANSPLANT ALLOGRAFTS USING INDOCYANINE GREEN
WITH LASER FLUORESCENCE: A REPORT OF 5 CASES.
Edmund Q Sanchez, MD, Srinath Chinnakotla, MBBS, Dmitriy Nikitin,
MD, Tariq Khan, MD, Sugam Vasani, MD, Henry Randall, MD, Greg
Mckenna, MD, Richard Ruiz, MD, Nicholas Onaca, MD, Marlon Levy,
MD, Robert Goldstein, MD, Goran Klintmalm, MD, PhD
Baylor University Medical Center, Dallas, TX; Baylor All Saints Medical
Center, Fort Worth, TX
Purpose. The success of liver transplant (LT) is highly dependent on
vascular technique. We present real time intraoperative fluorescence imaging
(IFI) using indocyanine green (ICG) and laser fluorescence with the SPY
imaging device (Novadaq Technologies Inc., Toronto, Canada). The applic-
ability of this imaging method was assessed.
Methods. 5 LT patients were assessed with IFI. 4 patients at time of
transplant, 1 post hepatic arterial revision (HAR). 0.51 ml intravenous
boluses of ICG (2.5 mg/ml) were administered intraoperatively after
revascularization for each imaging sequence (hepatic artery [HA] and portal
vein [PV]). Imaging of the perfusion of the entire LT, the bile produced by
the LT, and assessment of bile leak were performed. The follow-up period
was 30 days after liver transplantation.
Results. There were no adverse events with the use of ICG in LT or HAR.
Patency of HA and PV anastomoses was easily demonstrated. 1 of the 4 LT
patients experienced an arterial dissection day 2 after LT (not seen at time of
imaging). Arterial revision was uneventful. There were no intraop/postop bile
leaks or primary nonfunction (PNF) seen. Functional assessment and whole
organ perfusion of the LT were also easily assessed.
Conclusion. The SPY imaging system demonstrated multiple uses within
the LT operation: 1.) HA and PV patency, 2.) organ perfusion, 3.) functional
bile production, and 4.) bile leak detection. The diagnostic ability with this
device can be improved with more experience. Clinical correlations with the
intraoperative video sequences obtained could potentially be useful in
determining behavior of short-term graft dysfunction (i.e., delayed graft
function or PNF).
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BARIATRIC SURGERY AND LIVER TRANSPLANTATION: SIN-
GLE CENTER EXPERIENCE WITH SIX CASES
Hugo Bonatti, MD, Jennifer Slocum, RN, CNP, Rolland C Dickson, MD,
John Stauffer, MD, Denise Harnois, DO, Justin Nguyen, MD, Jaime Aranda-
michel, MD
UVA, Charlottesville, VA; Mayo Clinic, Jacksonville, FL
Introduction. Obesity has evolved as major epidemic worldwide. Obesity as
part of the metabolic syndrome can be associated with Non-alcoholic
steatohepatitis (NASH), NASH can lead to end-stage liver disease requiring
liver transplantation (LT). Bariatric surgery has been shown to effectively
reduce body weight and improve some metabolic components associated with
obesity.
Patients and Methods. Between 1998 and 2001, 467 liver transplants were
performed in 402 individuals at our center. Within this series six patients
were identified who had bariatric surgery pre (n5) or post (n1) LT.
Procedures included gastric bypass (n2), jejunoileal bypass (n2), gastric
banding (n1) and sleeve gastrectomy (n1)
Results. Median follow up for the six patients was 5.3 (range 4.0 to 6.5)
years, five patients are currently alive, one died five years post LT from lung
cancer. One patient required two retransplants due to PNF. Underlying
diseases were: NASH in three patients, alcoholic liver disease in two patients
and epitheliod hemangioedothelioma in the last patient. The median BMI at
last follow up in these patients was 38.2 (range 28.4 to 53.3) kg/m2. Three
patients remained with the same weight (BMI), one was able to loose 18 kg
and two patients gained more than 25 kg within five years post LT. The
patient who had sleeve gastrectomy post LTachieved good weight loss. At last
follow up, all six patients had a BMI 35 kg/m2. Accordingly, three suffered
from hyperlipedemia, one had IDDM, two NIDDM and two were borderline
diabetics. Three required antihypertensive medications, five suffered from
depression and one from significant insomnia. All six patients required
psychiatric evaluation and medications. Three were prescribed acid blocking
medications. Five had renal insufficiency with one patient requiring
hemodialysis.
Conclusion. Previous bariatric surgery is not a contraindication for LT;
patients who previously had jejunoileal bypass and develop NASH are
increasingly referred for LT. Morbid obesity cannot be considered a contra-
indication against LT. Bariatric surgery should be included in the manage-
ment of patients who experience significant weight gain post LT, however, the
optimal procedure still needs to be determined.
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LAPAROSCOPIC RESECTION OF HEPATIC TUMORS IN CIR-
RHOTICS
Ravi Nagubandi, MD, Mark Thomas, MD, Ravindra Kadiyala, MD, Amit
Tevar, MD, Steven Rudich, MD, Michael Marvin, MD, Joseph Buell, MD
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Jewish Hospital Transplant Center, University of Louisville, Louisville, KY;
University of Cincinnati, Cincinnati, OH
Liver resection in cirrhotics is a challenging endeavor. Patients with
good liver function (Child’s A or MELD of B12) tolerate the procedure
well. Recently laparoscopic techniques have been applied to resect the liver in
these patients. We reviewed our experience of laparoscopic liver resection in
cirrhotics and analyzed the complications with respect to degree of liver
dysfunction.
Methods. Retrospective review of 300 laparoscopic liver resections identified
29 cirrhotic resections (9.6%). Tumor characteristics, patient demographics
and MELD scores were correlated with morbidity and mortality.
Results. 29 resections were performed in 27 cirrhotics. Mean patient age was
58.5912.6 years with and average MELD score of 10. (Range 619). All but
2 patients were Child’s A. The mean number of segments resected was 1.5
with a mean operation time of 2.491.1 hours. The mean EBL was 250 ml
(range 501500) with 4 patients (14%) needing blood transfusion. The
resections included 17 uni-segments and 10 multi-segments (2 left lobes, 3
left lateral and 5 non-anatomical). Mean tumor size was 2.8 cm (range1.0
8.3). 22 patients had a malignancy (hepatoma in 16, cholangiocarcinoma in
3, colorectal cancer in 2 and non-colorectal cancer in 1) and 5 benign lesions.
The mean margin of resection was 0.690.46 cm. Six patients (22%) required
ICU stay. The average length of hospital stay was 4.493.2 days. Seven
patients (26%) incurred 12 complications: hepatic encephalopathy n2, car-
diac arrhythmia n3, COPD exacerbation n1, renal failure n1, colonic
ischemia n1 and post-operative bleeding n2. There were 2 peri-operative
deaths (7.4%) related to liver failure in one and ischemic bowel in another.
One additional death occurred 6 weeks later for a 90 day mortality of 11%.
We analyzed the complications based on MELD score-whether a MELD cut-
off of 10 or 15 identified higher morbidity. The morbidity and mortality
was more with a MELD score greater than 10 but was not statistically
significant.
Conclusions. Laparoscopic resection of liver in cirrhotics is feasible with
acceptable morbidity and mortality. Open liver resection in decompensated
cirrhotics (Child B or MELD 12) is fraught with the risk of liver
decompensation and mortality. Laparoscopy with the advantage of being
minimally invasive has the potential to be applied with a diminished risk of
decompensation. Larger studies need to be performed to explore this further.
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ABLATION VS. RESECTION FOR HEPATIC COLORECTAL ME-
TASTASIS: THERAPEUTICALLY EQUIVALENT?
Nathaniel P Reuter, MD, Charles E Woodall III, MD, Charles R Scoggins,
MD, Kelly M Mcmasters, Robert C Martin II, MD
University of Louisville, Louisville, KY
Introduction. Surgical resection remains the optimal first line in surgical
therapy of hepatic colorectal metastases (HCM). The role of ablation for
HCM metastases continues to evolve as ablation technology changes and
systemic chemotherapy improves. There are conflicting reports regarding the
efficacy of ablation compared to resection. The aim of this study was to
evaluate the therapeutic efficacy of hepatic ablation compared to surgical
resection.
Methods. A review of our 1105 patient prospective hepatic-pancreatico-
biliary database from 8/1995 to 7/2007 identified 194 patients with a
hepatic resection or ablation for HCM. 116 patients who had both
therapies were excluded from the analysis. Statistical Analysis was done
using SPSS.
Results. Seventy patients had an ablation vs. 124 patients who underwent
resection. Patients who underwent ablation had more favorable disease
evidenced by a lower Fong score (1.8 vs. 2.1 p0.05), smaller largest hepatic
tumor (3.5 vs. 5.3 cm, pB0.001), and less frequent nodal involvement of the
primary tumor (49% vs. 64% p0.04). There were no differences in the
presence of extrahepatic disease (14% vs. 10% p0.33) or mean number of
hepatic lesions (2.7 vs. 2.2 p0.18). Ablated patients received chemotherapy
prior to surgical management of HCM more often than resection patients
(65.7% vs. 59.7% (p0.003). There was no difference in the frequency of
chemotherapy after ablation/resection of HCM (10.0% vs. 14.5%, p0.36).
Median time to recurrence was shorter with ablation than resection 12.8 mo
(95% CI: 6.519.2) vs. 34.7 mo (95% CI: 20.049.4). Recurrence at the
ablation/resection site was more common with ablation than resection
occurring 22.5% vs. 3.6% (p0.003) of the time respectively. Distant
recurrence in the liver was also more common with ablation occurring in
51.0% of patients vs. 25.5% for resection (p0.007). Extrahepatic recur-
rence was not dependent on technique of treating hepatic disease occurring in
33.3% vs. 33.9% (p0.94) with ablation vs. resection respectively. Esti-
mated Kaplan-Meier mean survival was shorter with ablation (32.5 mo, 95%
CI: 25.739.3) than resection (51.3 mo, 95% CI: 39.463.1).
Conclusions. Surgical resection should remain as the optimal first line
surgical therapy in HCM, and hepatic ablation should be used in conjunction
with surgical resection or in patients not fit for resection.
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PREOPERATIVE PREDICTORS OF OUTCOME AFTER HEPATIC
RESECTION OF COLORECTAL METASTASES IN PATIENTS
TREATED WITH PREOPERATIVE CHEMOTHERAPY
Yoji Kishi, MD, Dan G Blazer, MD, Daria Zorzi, MD, Joshua M Mammen,
MD, Eduardo Palavecino, MD, Yun Shin Chun, MD, Steven Curley, MD,
Eddie Abdalla, MD, Jean-nicholas Vauthey, MD
M.D. Anderson Cancer Center, University of Texas, Houston, TX
Introduction. Increasingly, patients receive chemotherapy prior to hepatic
resection of colorectal metastases. Previously identified prognostic predictors
such as node status of the primary tumor, disease free interval (DFI),
preoperative CEA value, tumor size or number may not apply to patients who
have received preoperative chemotherapy.
Methods. A retrospective chart analysis of a prospectively collected single-
institution database between March 1993 and August 2006 was performed.
Disease-free survival (DFS) and overall survival (OS) were compared
according to primary lymph node status, DFI (B 1 yr vs. ]1 yr),
preoperative CEA value (]100 ng/ml vs. B100 ng/ml), maximal tumor
size (]5 cm vs. B5 cm), and multiplicity. Survival was compared by log-
rank test. Factors with a P value B0.1 were selected for multivariate analysis,
which was performed using the Cox-regression hazard model.
Results.A total of 236 patients underwent hepatic resection for colorectal
metastases following preoperative chemotherapy with irinotecan or oxalipla-
tin based regimens. The median age was 58 years (range 2381), and 61%
were male. With median follow up of 24 months, 1-, 3-, and 5-year DFS and
OS were 59%, 28%, 23% and 96%, 67%, 43% respectively. Univariate
analysis of DFS revealed positive lymph nodes as the only predictor (P
0.021). In addition, the difference in DFS according to DFI (P0.059),
tumor size (P0.056), and multiplicity (P0.061) were marginal. On the
other hand, high CEA (P0.0004) and large tumor size (P0.013) revealed
significantly worse OS. Multivariate analyses revealed only lymph node
metastasis (P0.020; relative risk, 1.56; 95% C.I., 1.072.32) as an
independent predictor of DFS and only two factors, high CEA (P0.034;
relative risk, 2.47; 95% C.I., 1.085.15) and large tumor size (P0.040;
relative risk, 1.86; 95% C.I., 1.033.30) remained as independent predictors
of OS.
Conclusions. Previously identified preoperative prognostic indicators do not
accurately predict outcome in patients who have received preoperative
chemotherapy. Further studies are necessary to define predictors of outcomes
of hepatic resection for colorectal metastases in the era of modern
chemotherapy.
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IMPROVING GLYCOGEN LIVER CONTENT IMPROVES POST-
OPERATIVE LIVER FUNCTION IN PATIENTS UNDERGOING
MAJOR LIVER RESECTIONS
M Hassanain, MD, R Lattermann, MD, G Carvalho, MD, H Karasek, B.Sc.,
H Molla, B.Sc., S Paglialunga, B.Sc., A Khankan, MBBS, D Valenti, MD, D
Vrochides, MD, P Chaudhuary, MD, T Schricker, MD, P Metrakos, MD
McGill University, Montreal, PQ, Canada
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Purpose. To prevent liver dysfunction after major hepatectomy
Design. Open-label clinical trial of 40 patients undergoing major hepatec-
tomies (3 or more segments) for the treatment of malignancy randomized to
perioperative carbohydrate (CHO) load vs. standard care.
Method. Patients in the study-group (n21) received high calorie, CHO
rich meals the day before the operation (35 kcal/kg, 60% CHO) followed by
intravenous dextrose 10% (2 mg/kg/h) for 16 hours until arrival to the
operating theatre. Intra-operatively a hyperinsulinemic normoglycemic clamp
of 2 units/kg/min was initiated. At the end of the procedure the clamp was
decreased to 1 unit/kg/min and continued until 16 hours postoperatively.
Dextrose 20%, supplemented with 30 mmol/L potassium-phosphate was
titrated to maintain blood glucose between 46 mmol/L. The control group
received routine management: fasting from midnight until 16 hours after the
operation. Blood glucose level above 10 mmol/L was treated with intravenous
insulin as per standard sliding scale. The preoperative preparation, intra and
postoperative management, including pain control were standardized.
Glycogen content in liver tissue was measured on exposure of the liver and
prior to closure of the fascia. Postoperative liver function was compared using
the Schindl functional score (lactic acid, total bilirubin, INR, and encephalo-
pathy).
Results. There were no significant difference between groups in: body mass
index, percentage of residual liver volume, operative duration, intraoperative
blood loss, intraoperative fluid therapy, timing of both liver biopsies, grade of
steotohepatitis and fibrosis, the duration of inflow occlusion when performed,
preoperative portal embolization, underlying pathology, and the preoperative
liver function tests.
The study group patients were older 54.299.4 vs. 63.8914.6 (P0.01) and
had a lower average blood glucose levels 7.590.8 vs. 5.890.5 mmol/L (P B
0.001). The initial liver glycogen content was 238.5994.3 in the control
group vs. 380.79114.4 mmol/kg in the study group (P0.003), and after
hepatectomy it was 178.7946.3 vs. 3059125.6 mmol/kg (P0.009).
Schindl functional score in the control group ranged from 17 and from 0
4 in the study group. Average score was 3.1591.6 in the control group vs.
1.8290.9 in the study group (P0.02).
Conclusion. Elevated liver glycogen content achieved by perioperative CHO
loading is associated with a lower rate and severity of post-operative liver
dysfunction. This may results in an improved postoperative morbidity.
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THE MELD BASED OBJECTIVE SCORING SYSTEM (MOSS):
NEW INSIGHTS INTO RISK STRATIFICATION OF CIRRHOTIC
PATIENTS WITH HEPATOCELLULAR CARCINOMA
Swee H Teh, MD, Susan L Orloff, MD, Brett C Sheppard, MD, Jonathan
Schwartz, MD, John Kaufman, MD, Stephen Cha, PhD, Ray W Kim, MD,
Patrick S Kamath, MD, David M Nagorney, MDOregon Health Sciences
University, Portland, OR; Mayo Clinic, Rochester, MN
Introduction. The MELD scoring system is a validated tool to ascertain
short term survival in patients with cirrhosis. There is lack of a consensus on
an ideal model to predict prognosis among patients with cirrhosis and
hepatocellular carcinoma (HCC) treated with modalities other than liver
transplantation. We therefore conducted a survival analysis and developed a
novel MELD-based objective scoring system (MOSS) to stratify survival of
HCC patients treated with non-liver transplant modalities.
Methods. A retrospective analysis of 204 patients with HCC diagnosed
between 1994 and 2004 was performed. Ninety patients were treated with
transarterial chemoembolization (TACE) and 114 patients were treated with
hepatic resection. Objective clinical variables that determined survival were
obtained using a Cox proportionate hazard regression model.
Results. The mean MELD score and tumor size for the TACE and hepatic
resection group were 10.7 vs. 9 and 5.2 cm vs. 5 cm, respectively. The median
survival for the TACE group was 1.2 years and the hepatic resection group
was 1.9 years. In a multivariate analysis, both MELD score and tumor size
were significant predictors of survival in both the TACE and the resection
groups. MELD score, tumor size, portal vein invasion and tumor multiplicity
were each allocated points for incorporation into the scoring system. Three
subgroups were then derived from the MOSS, based on their total points.
Table 1 demonstrated the median survival for MOSS Group I, II and III in
patients treated with TACE and hepatic resection.
Conclusion. MOSS, a scoring system that combines MELD and
tumor characteristics, accurately stratifies outcomes in cirrhotic
patients with HCC treated with TACE or hepatic resection. The parameters
used in MOSS are objective, non invasive and readily available clinically. If
validated, this scoring system would be important in predicting clinical
outcomes, optimizing resource utilization and designing trials of novel
treatments.
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YTTRIUM-90 INTRA-ARTERIAL BRACHYTHERAPY FOR
UNRESECTABLE HEPATOCELLULAR CANCER WITH PORTAL
VEIN OR IVC THROMBOSIS: SAFE AND CLINICALLY BENEFI-
CIAL?
Charles E Woodall III, MD, Charles R. Scoggins, MD, Susan F. Ellis, Clifton
M. Tatum Jr., MD, Michael J. Hahl, MD, James N Hiken, MD, Brain C.
Jones, MD, Kelly M. Mcmasters, MD, Robert C.g. Martin II, MD
University of Louisville, Louisville, KY; Norton Hospital, Louisville, KY
Introduction. Patients with multifocal HCC can present with portal vein
and/or IVC thrombosis. Recent reports have demonstrated that Yttrium-90
therapy is safe in these patients, but data is lacking as to clinical benefit.
Thus, the goal of this study was to examine the safety and potential benefits
of intra-arterial brachytherapy in this group.
Methods. Patients with unresectable HCC were enrolled prospectively from
1 January 2004 to 30 June 2007 under an IRB approved humanitarian use
device exemption protocol. All were evaluated by a multi-disciplinary team
prior to treatment.
Results. 47 patients were enrolled; 20 patients without thrombosis, 18
patients with thrombosis who were treated, and 9 patients (8 with
thrombosis) who were not treated due to pre-procedure screening failure.
Child’s score was similar between groups. 58 treatments were administered
with a median of 2 treatments per patient (range 13). Of the thrombosis
patients treated, 11 (29%) had portal vein, 1 (3%) had inferior vena cava, and
6 (16%) had both (15.8%). There were no treatment related deaths. 10
patients suffered a complication; 5 were simple overnight admissions for
hydration. The most serious AE was a distal aortic dissection related to the
endovascular approach. There was no difference in complications among
groups (p0.34). Treated patients without thrombosis had a median survival
of 13.9 months versus a median of 2.7 months for those treated with
thrombosis (p0.001); survival was not different between the treated group
with thrombosis versus the untreated group (5.2 months) given best
supportive care (p0.211).
Conclusions. Y90 is safe in patients with HCC; while it can be delivered to
all patients with minimal morbidity, the benefits on overall survival in patients
with portal vein or IVC thrombosis at the time of presentation cannot
be proven and are similar to best supportive care. Continued emphasis on
Table 1. The median survival for patients with cirrhosis and HCC treated with TACE and hepatic resection according to the MOSS group
MOSS Group I MOSS Group II MOSS Group III
TACE (n90),
months
23 15 5 pB0.0001 (c-stat 0.70, HR 1.3)
Hepatic Resection
(n114), months
54 24 9 p0.002 (c-stat 0.67, HR 1.2)
MELD score (6, 7, 83 points), (9, 10, 116 points), (12, 13, 149 points), (1512 points)
Tumor Size (B \5 cm0 point), (]5 cm2 points)
Portal Invasion (No0 point), (Yes1 point)
Multiplicity (single lesion0 point), (]2 lesions1 point)
Group ITotal points 5 points
Group IITotal points68 points
Group IIITotal points]9 points
48 Abstracts
multi-modality therapy in this population is needed in order to enhance
quality of life related to the expense and timing of Yttirum-90 therapy.
84
LAPAROSCOPIC VERSUS OPEN LIVER RESECTION FOR HE-
PATOCELLULAR CARCINOMA: A COMPARATIVE STUDY
Ibrahim Dagher, MD, PhD, Caroline Famechon, MD, Panagiotis Lainas,
MD, Jose G Tralhao, MD, PhD, Helene Agostini, MD, Dominique Franco,
MD, PhD
Antoine Beclere Hospital, Clamart, France
Background. Laparoscopic liver resection for hepatocarcinoma, especially
in cirrhotic patients, has recently been developed and could reduce morbidity.
However, it is limited to centers with experience in both laparoscopic liver
surgery and the management of cirrhotic patients. Very few series were
therefore reported. The aim of this study was to compare the postoperative
results and the 3-year patient outcomes between laparoscopic (LLR) and
open liver resection (OLR) for hepatocellular carcinoma (HCC).
Methods. From 1999 to 2006, we performed 35 laparoscopic resections for
HCC in selected patients. They were compared in a retrospective analysis
with patients who underwent open surgery for HCC selected from our liver
resection database. The two groups were well matched for age (65911 vs
6498 years, p0.69), gender, American Society of Anesthesiology (ASA)
class, tumor size, the type of liver resection and severity of liver disease
(cirrhosis: 74 vs 79%, p0.54; bilirubin, p0.20 and prothrombin rate, p
1.00). Child-Pugh class C and ASA class 3 were considered as non inclusion
criteria. Chisquare or T-Test were used to compare the 2 groups (respectively
Fisher exact test and Mann-Whitney U test when the validity conditions were
not verified).
Results. 137 patients were analyzed: 35 in LLR and 102 in OLR group. The
mean operative duration was similar in both groups (LLR, 240 min; OLR,
247 min; p0.47). Blood loss was significantly lower in laparoscopic
resections (LLR, 434 ml; OLR, 761 ml; pB0.001). However, the difference
in transfusion rates was not statistically significant (LLR, 13%; OLR, 23%;
p0.31). There was no statistically significant difference in postoperative
complications (LLR, 19%; OLR, 28%, p0.31); Nevertheless a statistical
trend was observed for pulmonary complications (LLR, 0%; OLR, 9%, p
0.08) and ascites (LLR, 6%; OLR, 20%, p0.10). The 1- and 3-year
survival rates were not different for LLR and OLR.
Conclusion. This study shows that laparoscopic resection for HCC results
in decreased blood loss and shorter hospital stay. A tendency was observed
for lower pulmonary complications and ascites in laparoscopy even if it was
not statistically significant. The 1- and 3-year survival rates were not different
for LLR and OLR.
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THE IMPACT OF AGGRESSIVE TREATMENT OF CHRONIC
COLORECTAL CANCER LIVER METASTASES ON QUALITY OF
LIFE
Gabriel Chan, MD, Mazen Hasssanain, MBBS, Nicolas Meti, Amy Neville,
MD, Prosanto Chaudhury, MD, Peter Metrakos, MD
McGill University, Montreal, QC, Canada
Introduction. A curative resection is possible in a small percentage of
patients with liver metastases. Neoadjuvant chemotherapy has expanded the
indications to select unresectable situations. An aggressive multimodal
approach including surgical resection, systemic and hepatic chemotherapy,
ablative therapies and angioembolization may be able to extend survival,
even in the face of recurrent or residual disease. The available literature
concerning quality of life is limited. The purpose of this study was to assess
the quality of life in patients treated for colorectal cancer metastasis, in
particular those who reach a chronic state in the liver (more than two years
from diagnosis).
Methods. The EORTC QLQ-C30 (v3.0) is a validated, self-administered
instrument that is widely used in cancer patients (Aaronson et al 1993,
Bjordal et al 2000). The questionnaire was applied to patients with a
diagnosis of colorectal cancer liver metastases presenting to the outpatient
clinic of the Hepatobiliary Service at the McGill University Health Centre
(MUHC). The study was approved by the Institutional Review Board of the
MUHC. Clinical data was collected through the prospective Hepatobiliary
database and confirmed by retrospective chart review.
Results. Completed questionnaires were collected from 75 patients with a
diagnosis of colorectal cancer metastases from February until August 2007.
The median age was 74 years. The treatments included surgical resection in
84%, chemotherapy in 94%, theraspheres in 10.7%, angioembolization in
9.3% and radiofrequency ablation in 5.3%. An overall survival greater than
two years was obtained in 61% and 29% of patients had no evidence of
disease. Patients with chronic disease had no significant difference in any of
the functional or symptomatic scales, except in the scale of diarrhea (DI) (p
0.035) when compared to patients with no evidence of disease. This sole
difference may reflect a higher portion of patients with residual disease
actively receiving chemotherapy. In addition, patients with chronic disease
had a statistically significant improvement in three of five functional scales
(role, emotional and cognitive)when compared to patients with metastasis
less than two years from diagnosis.
Conclusion. This clinical study shows that patients who attain a chronic
state of colorectal metastases can have a quality of life that is similar to that of
patients with no evidence of disease. Each patient with unresectable disease
warrants a trial of aggressive treatment. If disease control can be achieved, the
chronic state can be associated with an excellent quality of life.
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MAJOR HEPATIC RESECTION FOR HEPATOCELLULAR CAR-
CINOMA WITH OR WITHOUT PORTAL VEIN EMBOLIZATION:
PERIOPERATIVE OUTCOME AND SURVIVAL
Martin Palavecino, MD, Joshua M V Mammen, MD, Yun S Chun, MD,
Daria Zorzi, MD, Yoji Kishi, MD, Steven H Wei, PA-C, MPH, Manal M
Hassan, MD, Melanie B Thomas, MD, Steven A Curley, MD, Eddie K
Abdalla, MD, Jean N Vauthey, MD
MD Anderson Cancer Center, Houston, TX
Introduction. Preoperative portal vein embolization (PVE) is performed to
minimize perioperative risks before major hepatic resection (HR) for
hepatocellular carcinoma (HCC), but its effects on tumor growth and distant
metastases are ill-defined. Perioperative outcome and survival after major
hepatic resection for HCC, with or without preoperative PVE were
investigated.
Methods. Patients that underwent major HR (]3 segments) for HCC
between January 1998 and May 2007 were analyzed. Preoperative PVE was
performed in patients with liver disease or when the remnant liver volume was
predicted to be insufficient.
Results. Fifty-five patients underwent major resections for HCC (26 right
hepatectomies, 17 right extended hepatectomies, 3 left hepatectomies and 5
left extended hepatectomies), 21 patients underwent PVE (PVE group)
prior to resection and 34 patients proceeded to HR without PVE (non-PVE
group). PVE and non-PVE groups were similar in terms of hepatic fibrosis
(52% in the PVE group vs. 59% in the non-PVE group, p0.13), cirrhosis
(14% vs. 12%, p0.79), HCV (33% vs. 24%, p0.42), HBV (29% vs.
26%, p0.86), AJCC stage (p0.78), and preoperative transarterial
chemoembolization (33% vs. 12%, p0.11). Comparing PVE and non-
PVE groups, postoperative complications and positive margin (29% vs.
38% and 10% vs. 12%, respectively) were not significantly different
between the two groups. There were no perioperative deaths in the PVE
group and 6 (17.6%) in the non-PVE group (2 from multisystem organ
failure and 4 from hepatic insufficiency, p0.041). Median follow-up was
21 months. Excluding perioperative deaths in the non-PVE group, overall
survival (OS) rates at 1-, 3- and 5-years were 94%, 80% and 70% in the
PVE group and 93%, 62% and 54% in the non-PVE group (p0.29).
Similarly, disease-free survival (DFS) was not significantly different
between the two groups, with 1, 3 and 5 years DFS of 83%, 49% and
49% in the PVE group and 67%, 50% and 50% in the non-PVE group
(p0.64) (see figure).
Conclusion. PVE prior to major hepatic resection for HCC is associated
with improved perioperative outcome. Excluding perioperative mortality,
PVE is associated with similar OS and DFS.
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ANGIOTENSIN II INDUCES VASCULAR ENDOTHELIAL
GROWTH FACTOR IN PANCREATIC CANCER CELLS
Hwyda A. Arafat, MD, PhD, Galina Chipitsyna, PhD, Qioake Gong, MD,
Rathai Anandanadesan, MD, Charles J. Yeo, MD
Thomas Jefferson Univesity, Philadelphia, PA
Background. Vascular endothelial growth factor (VEGF) is a crucial pro-
angiogenic component in pancreatic ductal adenocarcinoma (PDA) and its
high expression levels are correlated with poor prognosis and early post-
operative recurrence. Angiotensin II (AngII), which induces VEGF produc-
tion in a variety of cancers, is actively generated in the pancreas. Targeting
AngII in hypertensive patients using AngII type1 receptor (AT1R) blockers
has been correlated with reduced cancer prevalence.
Objective. To explore the role of AT1R and AngII in PDA angiogenesis, and
to evaluate the expression of AT1R in relation to VEGF in premalignant and
invasive PDA lesions.
Methods. AT1R mRNA and protein in PDA cell lines PK9 and HS677T
were analyzed by real time PCR and Western immunoblotting. VEGF mRNA
and protein levels in PDA cells were measured by real time PCR and ELISA.
Total- and phospho-ERK1/2, total- and phospho-p38, and total- and
phospho- JNK MAP kinases were analyzed by Western immunoblotting.
The expression and localization of AT1R in relation to VEGF in intraductal
papillary mucinous neoplasms (IPMNs) n5, pancreatic intraepithelial
neoplasms (PanINs) n5, and in matched invasive human PDA (n25)
and surrounding non-malignant tissues were analyzed by real time PCR,
Western immunoblotting, and immunohistochemistry.
Results. PDA cells expressed AT1R that was mainly localized to the cell
membrane. Addition of AngII significantly enhanced VEGF production, an
effect that was prevented when cells were preincubated with an AT1R
blocker, losartan. Interestingly, the same treatment induced the expression of
AT1R mRNA and protein in PDA cells. AngII activated the phosphorylation
of ERK1/2, but not p38 or c-Jun NH2-terminal MAP kinases. Inhibition of
ERK1/2 activation reduced the AngII-induced VEGF synthesis. Immuno-
histochemical analysis showed increased expression of AT1R in most ductal
cells undergoing metaplasia. PanIN lesions showed more intense AT1R
staining when compared to IPMNs. In PDA, AT1R mRNA and protein levels
were significantly upregulated in 75% of the neoplastic tissues examined
when compared to matching controls. VEGF followed the same distribution
pattern of AT1R.
Conclusions. Increased AT1R expression in the premalignant and invasive
pancreatic lesions suggests its involvement in tumor progression and
angiogenesis. Our mechanistic findings provide the first insight into an
AngII-initiated signaling pathway that regulates PDA angiogenesis. An
AT1R-mediated VEGF induction suggests the possibility of using AT1R
blockers as a novel therapeutic strategy to control angiogenesis in PDA.
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MICRORNA-21 IS OVEREXPRESSED IN PANCREATIC CANCER
AND A POTENTIAL PREDICTOR OF SURVIVAL
Mary Dillhoff, MD, Wendy L Frankel, MD, James Liu, MD, Mark
Bloomston, MD
Ohio State University, Columbus, OH
Background. MicroRNAs are small (1822nt) non-coding RNAs involved
in post-transcriptional modification of many genes. One of these, microRNA-
21 (miR-21), has been shown to play a role in multiple hematologic and solid
organ malignancies. We sought to determine the expression pattern of miR-
21 in pancreatic cancers and its impact on clinicopathologic characteristics.
Methods. 80 resected pancreatic cancer specimens were microdissected and
tissue microarrays (TMA) created in duplicate. TMAs were also created for
benign pancreas (N12) and chronic pancreatitis (N45). In situ hybridi-
zation (ISH) was undertaken utilizing locked nucleic acid probes for miR-21.
RNA U6 and scrambled RNA served as positive and negative control,
respectively. ISH was scored as 0 (absent), 1 (faint/focal expression), or 2
(strong expression). Kaplan-Meier survival curves were constructed and
compared by log-rank analysis.
Results. MiR-21 expression was demonstrated in 63 (79%) pancreatic
cancers (1 in 49, 2 in 14) compared to 1/12 (8%, pB0.0001) benign
pancreas and 12/45 (27%, pB0.0001) chronic pancreatitis. None of the
benign tissues demonstrated strong miR-21 expression. Although miR-21
expression did not correlate with tumor size, differentiation, nodal status, or
T stage, strong miR-21 expression was predictive of poorer outcome
compared to absent or faint/focal miR-21 expression in patients with node-
negative disease (median 27.7 months vs. 15.2, p0.037)(Figure). Nodal
status was also predictive of survival (p0.029).
Conclusions. MicroRNA-21 is significantly overexpressed in pancreatic
cancers as detected by in situ hybridization. Its strong expression predicts
limited survival in patients with node-negative disease and may be an
important biologic marker for outcome.
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HEPATIC INTERFERON REGULATORY FACTOR-1 EXPRES-
SION DURING LIVER ISCHEMIA REPERFUSION INJURY IS
TLR-4 DEPENDENT
Jon S Cardinal, MD, Rajeev Dhupar, MD, Geetha Jeyabalan, MD, Allan
Tsung, MD, David Geller, MD
University of Pittsburgh Medical Center, Pittsburgh, PA
Introduction. The transcription factor interferon regulatory factor-1 (IRF-
1) is an important early mediator of liver damage during hepatic ischemia
reperfusion injury (IR). We have shown that the cytokine gamma interferon
(IFNg) is a potent stimulus for IRF-1 induction in cultured rat hepatocytes.
Furthermore, we have shown that toll-like receptor 4 (TLR-4) activation is
involved in the early, innate immune response following IR. In this study, we
tested the hypothesis that IFNg is the in vivo stimulus for IRF-1 up-
regulation, and that IRF-1 upregulation occurs in a TLR-4 dependent
manner.
Methods. IFNg wildtype (WT) and knockout (KO) mice as well as TLR-4
WT and mutant mice were subjected to a model of partial liver IR. Serum
ALT levels and IFNg levels were measured. Nuclear expression of IRF-1 was
determined by Western Blot analysis.
Results. ALT levels in the IFNg WT group (n7) were 1,891 (IU/ml),
while those of the IFNg KO group (n7) were 6,300 (IU/ml) (pB0.05 vs
WT). ALT levels in the TLR-4 WT group (n7) were 4,120 (IU/mL) vs
2,015 (IU/mL) in the mutant group (n7) (pB0.05 vs WT). Serum IFNg
levels were undetectable in the IFNg WT and KO groups as well as in the
TLR-4 WT and mutant groups. Nuclear IRF-1 protein expression was
unchanged in the IFNg WT group as compared to the KO group (Fig. 1);
however, there was significantly less IRF-1 expression in the TLR-4 mutant
group as compared to the WT group (Fig. 2).
Conclusions. Our results indicate that hepatic IRF-1 upregulation in a
murine model of liver IR injury occurs in a TLR-4 dependent manner. The
data also suggest that the presence of endogenous IFNg (perhaps in the local
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hepatic milieu), protects against liver damage as the IFNg KO mice exhibited
a 3.3-fold increase in serum ALT release. Furthermore, IFNg does not
appear to be an important in vivo stimulus for IRF-1 upregulation in this
model. Future studies will focus on elucidating the mechanisms involved in
IFNg-mediated hepatic protection, as well as the in vivo stimuli for IRF-1
upregulation to develop strategies for protecting against IR induced liver
damage.
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DIFFERENTIAL EXPRESSION OF PRO-INFLAMMATORY CY-
TOKINES AND EMC REMODELING ENZYMES BY ED2DIM HE-
PATIC MACROPHAGES VERSUS ED2HIGH KUPFFER CELLS IN
RAT LIVERS
Gordon D Wu, MD, Yao He, MD, PhD, Andrew S Klein, MD
Cedars-Sinai Medical Center, Los Angeles, CA
Objective Previously we reported identification and isolation of two subsets
of macrophages from rat livers. One exhibited ED2high/AFhigh flow cytometric
phenotype and characteristics of phagocytic Kupffer cells. The second one
displayed an ED2dim/AFdim phenotype with weak phagocytotic ability. The
current study was curried out to further investigate the functional aspects of
these two ED2 subsets in a rat model of cholestasis.
Methods ED2dim and ED2high subsets of macrophages were isolated via
FACS from cholestatic livers induced by bile duct ligation (BDL) or normal
rat livers. Expression of genes relating to inflammation (IL-1b, TNF-a, IFN-
g, RANTES and Fucos-R), fibrogenesis (TIMP-1 and MMP-9) and cell
proliferation (Ki67) was examined by quantitative real time PCR.
Results When compared with corresponding subset isolated from normal
livers, expression of IL-1b, TNF-a, RANTES and MMP-9 genes by ED2dim/
AFdim cells from the BDL livers was increased by 9.0-fold, 4.4-fold, 5.3-fold,
and 5.8-fold (PB0.01, respectively) while expression of IL-1b, RANTES and
TIMP1 by ED2high/AFhigh cells was increased by 2.7-fold (PB0.05), 10-fold
(PB0.01) and 2.5-fold (PB0.05). In BDL livers, the expression of TNF-a
(PB0.01), IFN-g (0.05), RANTES (PB0.01), TIMP-1 (PB0.01), and
MMP-9 (PB0.05) was significantly higher in ED2dim/AFdim subset than in
ED2high/AFhigh cells, whereas the expression of IL-1b (PB0.01) and Fucos-R
(PB0.01) was significantly higher in ED2high/AFhigh cells. In addition, Ki-67
expression by ED2dim/AFdim macrophages of the BDL livers was significantly
higher than that by ED2high/AFhigh cells and by normal ED2dim/AFdim cells
(PB0.05, respectively), indicating active cell proliferation.
Conclusions The data demonstrate that ED2dim/AFdim cells appear to be
the major producer of selected inflammatory cytokines and ECM remodeling
enzymes, suggesting they play important roles in liver inflammation and
fibrogenesis.
91
TLR4 SIGNALING CAUSES INCREASED DAMAGE TO STEATO-
TIC LIVERS AFTER ISCHEMIA/REPERFUSION INJURY
Justin D Ellett, B.Sc., Zachary P Evans, PhD, Michael G Schmidt, PhD,
Kenneth D Chavin, MD, PhD
Medical University of South Carolina, Charleston, SC
It is well established that steatotic livers (those with intracellular fat deposits)
are more sensitive to the effects of ischemia/reperfusion injury, an unavoid-
able part of liver transplantation. In human transplantation, endotoxin (LPS)
is thought to be a major contributing factor to the pathogenesis of ischemia/
reperfusion (I/R) injury. Upon portal occlusion, bowel congestion causes
endotoxin translocation and LPS is introduced into the portal circulation,
whereupon LPS is recognized by toll-like receptor 4 (TLR4). This leads to
downstream signaling and production of proinflammatory cytokines, causing
cellular inflammation, necrosis, and apoptosis. It is well known that steatotic
livers are highly sensitive to endotoxin as compared to their lean counterparts
post-I/R, and we have previously seen that blockade of endotoxin with a
monoclonal antibody dramatically improves animal survival after I/R. There-
fore, we propose the novel hypothesis that TLR4 is largely responsible for
increased cellular damage by necrosis after steatotic hepatic ischemia/
reperfusion. To test this hypothesis, we subjected male 4-week-old C57BL/
10 (control) or C57BL/10ScN (TLR4 deficient, TLR4KO) mice to a high-
fat diet for four weeks and then to 35 minutes of total hepatic ischemia and 1
or 24 hours of reperfusion. There was a significant improvement in animal
survival in the fat-fed TLR4KO animals versus control fat-fed animals at 24
hours (74% vs. 31% in control fat-fed animals, pB0.05). Accordingly, we see
corresponding increases in ALT in control fat-fed animals that we do not see
in TLR4KO fat-fed animals at 24 hours (283.99270.1 vs. 93.5937.7,
respectively). There was significantly more liver necrosis (as measured by a
grading scale from 03) in the control fat-fed animals as compared to the
TLR4KO fat-fed animals (1.490.3 in control vs. 0.490.2 in TLR4KO, pB
0.05). The fold changes in levels of IL-12 and IFN-g mRNA were increased
in the fat fed control animals at one hour versus baseline and were
significantly reduced in the fat fed TLR4KO animals (IL-12: 45.290.9 vs
9.290.81 respectively, pB0.05; IFN-g: 18.191.0 vs 4.791.2 respectively,
pB0.05). However, we see no differences in serum endotoxin levels between
groups at one hour, indicating there is an increased signaling independent of
increases in this TLR4 ligand. In conclusion, we have shown that TLR4 is
extremely important in the damage inflicted to the liver after warm ischemia/
reperfusion. There is a greater animal survival and decreased damage in livers
without TLR4. This is an important finding because it may lead to an avenue
of therapeutic intervention that would allow these livers to be used clinically.
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EXPLORATION OF ANTI-VEGF MECHANISMS IN EXPERIMEN-
TAL PANCREATIC CANCER
Niranjan Awasthi, PhD, Margaret Schwarz, MD, Srivani Konduri, PhD,
Varun Verma, MS, Clint Capiello, MS, Roderich E Schwarz, MD
UT Southwestern Medical Center, Dallas, TX; UMDNJ-Robert Wood
Johnson Medical School, New
Brunswick, NJ
Background. Functional angiogenesis is an essential component for
pancreatic ductal adenocarcinoma (PDAC) growth and progression. We
had observed a therapeutic benefit of the antiangiogenic agent endothelial
monocyte activating polypeptide II (EMAP II) against experimental pan-
creatic cancer in the past. Our mechanistic exploration of EMAP II focused
on vascular endothelial growth factor (VEGF)-associated effects.
Methods. Human ASPC PDAC cells were grown subcutaneously in nude
mice. Treatment with EMAP II (80 ug/kg i.p. daily) or the anti-VEGF-
antibody bevacizumab (2.5 mg/kg i.p. twice weekly) was initiated after 14
days. Tumor growth over 14 days was measured, and tissue specimens
examined via immunohistochemistry. For in vitro studies, human fetal lung
endothelial cells were grown on collagen-coated plates. Binding of mEMAP
II with VEGF receptors was analyzed via ELISA and pull-down assay.
Protein expression was observed by Western blot analysis. Endothelial tube
formation was determined using matrigel after 16-hour incubation and
assessed by spinning confocal microscopy.
Results. Compared to controls, EMAP II slowed PDAC growth to 42%,
and bevacizumab to 60%. In E-B combination, tumor growth reached 33%
(p0.01). Best results were seen after E-B in combination with gemcita-
bine (4%, pB0.001). EMAP II treated tumors had reduced microvessel
counts and VEGF expression. EMAP II binds to recombinant VEGF
receptors and inhibited binding of VEGF to its receptors VEGF R1 and
R2. Downstream VEGF signaling pathways (induction of phosphorylation
of AKT, ERK, p38 and Raf in endothelial cells by a factor of 2.8, 1.5, 2.2,
and 3.6, respectively) were abrogated by 20 uM mEMAP II pre-incubation
to levels at or below baseline control. EMAP II also treatment inhibited
endothelial cell tube formation, as the mean tube area with VEGF (132%
of controls) was reduced to 68% by EMAP II and 71% by EMAP II in the
presence of VEGF.
Conclusions. mEMAP II binds with recombinant VEGF R1 and R2 and
does inhibit VEGF induced activation of AKT, ERK, p38 and Raf proteins,
suggesting the VEGF signaling interference as one possible mechanism for
the anti-angiogenic activity of mEMAP II. This novel mechanism of EMAP
II not only explains its benefit in combination therapy in vivo, but also
suggests avenues for the experimental enhancement of anti-VEGF based
targeted PDAC therapy.
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FOCAL ADHESION KINASE (FAK) REGULATES THE META-
STATIC PHENOTYPE OF GASTROINTESTINAL CARCINOID
CANCER CELLS THROUGH THE RAF-1 SIGNALING PATHWAY
Li Ning, MD, Muthusamy Kunnimalaiyaan, PhD, Herbert Chen, MD
University of Wisconsin, Madison, WI
Background. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase
that plays an important role in cancer biology. We have recently reported that
activation of the Raf-1/MEK/ERK signaling pathway in gastrointestinal (GI)
carcinoid cancer cells alters cellular morphology and adhension. On this
basis, we investigated the possible role of FAK in Raf-1-associated metastatic
phenotype.
Methods. An estrogen (E2)-inducible Raf-1 GI carcinoid cell (BON-raf) was
utilized in this study. Western blot analysis was used to measure Raf-1/MEK/
ERK pathway activation, FAK induction, and neuroendocrine tumor marker
levels. Transwell assays were performed to measure the cell migration and
invasion activity. FAK was knocked down using small interfering RNA
(siRNA) in BON-Raf cells treated with estrogen. Furthermore, FAK was
over-expressed by transfecting constitutively active wild-type FAK plasmids
into BON cells.
Results. Estrogen treatment of BON-raf cells resulted in Raf-1 activation as
evidenced by increased levels of phospho-ERK1/2. Raf-1 activation led to a
significant increase in FAK accompanied by a dramatic reduction in the
invasion and migration ability of carcinoid tumor cells. Importantly, these
Raf-1-mediated events were abrogated with suppression of endogenous FAK
by siRNA. Furthermore, over-expression of FAK in BON cells also resulted
in a significant inhibition of carcionoid cell migration and invasion in vitro,
recapitulating the effects of Raf-1.
Conclusions. The raf-1/MEK/ERK pathway regulates the metastatic
phenotype of carcinoid tumor cells. Moreover, FAK is the key downstream
target which modulates the invasive and migration capacity of these
neuroendocrine cancers.
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COMBINED TRAIL AND HSP70-INHIBITION THERAPY IN-
DUCES APOPTOSIS SYNERGISTICALLY IN HUMAN PANCREA-
TIC CANCER CELLS
Daniel Borja-cacho, MD, Pawel Zwolak, MD, Vikas Dudeja, MD, Selwyn M
Vickers, MD, Ashok K Saluja, PhD
University of Minnesota, Minneapolis, MN
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) is a
new option in cancer treatment. It triggers the extrinsic apoptotic pathway
after it binds to the death receptors present in tumor cell membranes.
TRAIL’s efficacy is being evaluated in some clinical trails, including those for
patients with non-Hodgkin lymphoma and solid tumors. This therapy is
expected to be very specific to tumor cells because death receptors are only
present in tumor cells; most normal cells do not express them. Despite the
presence of death receptors, most pancreatic cancer cell lines are highly
resistant to TRAIL. We have recently shown that HSP70, a chaperon protein,
is overexpressed in pancreatic cancer cells, and the inhibition of its expression
using siRNA or drugs increases capase-3 activity and apoptosis. The aim of
this study is to ascertain whether or not HSP70 inhibition by triptolide, a
diterpene triepoxide derived from the Chinese plant Tripterygium wilfordii that
inhibits HSP70 expression, increases the effectiveness of TRAIL.
Methods. We exposed 4 different pancreatic cancer cells (MiaPaCa-2,
PANC1, ASPC1, and S2VP10) to different concentrations of triptolide,
TRAIL, or both in combination. We measured cell viability after 24 and 48
hours of exposure. We also measured an early marker of apoptosis, annexin V,
using flow cytometry after 24 hours of exposure.
Results. Triptolide decreased cell viability in all the cell lines except ASPC1
after 24 to 48 hours of exposure, while TRAIL decreased viability only in
MiaPaCa-2 cells. The rest of the cell lines were highly resistant, although the
therapy which combined TRAIL and triptolide effectively decreased cell
viability in all cell lines, including those resistant either to triptolide or to
TRAIL alone. The combination therapy significantly increased early apop-
tosis in all 4 cell lines tested. (The results are in Table 1)
Conclusions. Pancreatic cancer cell lines are very resistant to TRAIL-
induced apoptosis, however, the inhibition of HSP70 by triptolide increases
the number of cells undergoing apoptosis owing to TRAIL therapy. This
combination is effective in cell lines which are resistant to TRAIL or
triptolide alone. The therapy is highly selective because normal cells do not
express death receptors, and because HSP70 is overexpressed only in tumor
cells.
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SUPPRESSION OF PANCREATIC CARCINOID TUMOR CELL
GROWTH AND NEUROENDOCRINE HORMONE PRODUCTION
BY AKT-1 INHIBITION
Susan C Pitt, MD, Herbert Chen, MD, Muthusamy Kunnimalaiyaan, PhD
Endocrine Surgery Research Laboratories, University of Wisconsin, Madi-
son, WI
Introduction. In neuroendocrine (NE) tumors such as carcinoids, aberrant
phosphatidylinositol 3-kinase (PI3K)-Akt pathway signaling is thought to
promote tumorigensis by enhancing tumor cell proliferation and suppressing
apoptosis. In earlier studies, we found that inhibition of the PI3K-Akt
pathway by LY294002 in human carcinoid cells reduced active phosphory-
lated Akt, decreased tumor cell growth, and inhibited human acheate-scute
complex like-1 (ASCL1) and chromogranin A (CgA), both NE tumor
markers. However, the mechanism by which PI3K inhibition caused
decreased tumor cell growth and NE hormone production was still unclear.
The purpose of this study was to determine whether or not Akt inhibition is
required for growth reduction and NE hormone suppression in carcinoid
tumor cells. In addition, we aimed to identify which isoforms of Akt (Akt 1, 2,
or 3) mediate these effects.
Methods. Human metastatic pancreatic carcinoid BON cells were trans-
fected with control (non-specific, NS) and Akt-1 siRNAs at a dose of 75nM
for a 6 day time period. Cellular extracts were harvested every 2 days.
Western analysis was performed for Akt 1, 2, and 3 proteins as well as for the
levels of ASCL1 and CgA production. In addition, BON cell growth was
measured by MTT assay for 6 days after siRNA treatment.
Results. Transfection of Akt-1 siRNA into BON cells resulted in silencing of
Akt-1 protein expression, demonstrating successful RNA interference.
Additionally, no effect was seen on the levels of Akt-2 or Akt-3. With the
Akt-1 siRNA treatment, both ASCL1 and CgA expression was decreased.
Notably, transfection of BON cells with Akt-1 siRNA suppressed tumor cell
growth in addition to reducing NE hormone production.
Conclusion. Human pancreatic carcinoid tumor cell growth and NE
hormone production is suppressed by inhibition of Akt-1. Therefore, Akt-1
or components of the PI3K-Akt pathway may be potential targets for future
management of carcinoid tumors.
96
A COMPARISON OF PANCREATICODUODENECTOMY AND
DUODENAL SPARING HEAD RESECTION FOR THE TREAT-
MENT OF CHRONIC PANCREATITIS
Rebecca J Mcclaine, MD, Andrew M Lowy, MD, Andres Gelrud, MD,
Nathan Schmulewitz, MD, Shailendra Chauhan, MD, Laura E James, MS,
Jeffrey J Sussman, MD, Jeffrey B Matthews, MD, Syed A Ahmad, MD
University of Cincinnati, Cincinnati, OH; University of California, San
Diego, La Jolla, CA; University of Chicago, Chicago, IL
Background. Results of prospective trials conducted in Europe suggest that
duodenum-preserving head resections (DPHR), compared to the standard
Whipple procedure, provide similar degrees of pain relief and improvement in
quality of life, and may be associated with less peri-operative morbidity for
the treatment of chronic pancreatitis.
Objective. This study aims to analyze peri-operative characteristics and
quality of life outcomes for patients undergoing Whipple versus DPHR
procedures in a major North American pancreatic center.
Methods. Eighty-one patients underwent either a Whipple (n59), or
DPHR (Bern, Beger, or Frey procedure, n22) for the treatment of chronic
pancreatitis over a seven-year period. Quality of life was assessed cross-
sectionally with the European Organization for Research and Treatment of
Cancer (EORTC) Quality-of-Life Questionnaire (QLQ-C30) and pancreatic
Effect of Triptolide and TRAIL on early apoptosis
% Cells undergoing apoptosis
Cell line Control Triptolide 50 nM TRAIL 1.25 ng/ml Triptolide 50 nMTRAIL 1.25 ng/ml
MiaPaCa-2 7.7590.97% 16.6195.58% 11.2592.35% 39.6596.78% *
Panc-1 4.8691% 18.6494.99% 13.2392.8% 65.93910.8% *
ASPC1 8.6691.48% 8.8591% 8.1491.11% 29.3093.78%*
S2VP10 3.1192.51% 7.3292.09% 5.0991.78% 64.7393.90%*
* pB.001 when compared vs controln4 Run in duplicates
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cancer-specific supplemental module (QLQ-PAN26). The University of
Cincinnati Pancreatic Database was queried to determine patient character-
istics, operative details, and short- and long-term morbidity.
Results. There was no difference in age (47 years Whipple v. 45 years
DPHR, pNS), gender, etiology of pancreatitis, or pre-operative insulin
dependence (7% Whipple v. 9% DPHR, pNS) between the two groups.
Analysis of quality of life scores revealed no significant differences between
Whipple and DPHR groups in the 6 QLQ functional scales. DPHR patients
had significantly less symptoms than Whipple patients in 2 of 26 QLQ
symptom scales (diarrhea and dry mouth). While not significant, DPHR
patients tended to have better quality of life than Whipple patients on 30 of
32 scales. There were no differences between the two groups with regards to
post-surgical diabetes (36% Whipple v. 18% DPHR, pNS), exocrine
insufficiency (73% Whipple v. 82% DPHR, pNS) or narcotic use (65%
Whipple v. 55% DPHR, pNS). Length of procedure (360 v. 245 minutes,
pB0.01), length of hospital stay (14 v. 13 days, pB0.05), and estimated
blood loss (535 v. 214 mL, pB0.01) were all significantly less for DPHR.
Thirty-day morbidity and mortality did not differ significantly between the
two groups.
Conclusions. Our data demonstrate DPHR and Whipple procedures to
be equally effective in relieving abdominal pain and improving quality of
life parameters. DPHR may be easier to perform and should be
considered a viable option in any treatment algorithm for chronic
pancreatitis.
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FUNGAL INFECTION IN NECROTIZING PANCREATITIS
CAUSES A DRAMATIC RISE IN MORBIDITY AND MORTALITY.
Yuriy Zhukov, Thomas J Howard, MD, Lee Mchenry, MD, Evan L Fogel,
MD, Attila Nakeeb, MD, Henry A Pitt, MD, Keith D Lillemoe, MD,
Christian M Schmidt, MD, Nicholas J. Zyromski, MD
Indiana University School of Medicine, Department of Surgery, Indianapo-
lis, IN
Introduction. The practice of administering routine empiric broad-spec-
trum antibiotic prophylaxis to patients with necrotizing pancreatitis (NP) has
recently been challenged. This treatment strategy leads to a shift in the
predominant infectious organisms from enteric Gram-negative to Gram-
positive and fungi. We hypothesized that fungal infections would result in
worse clinical outcomes in patients with NP.
Methods. Review of 152 patients with NP (19922007) compared those
with and without fungal infection. Additionally, outcomes of patients with C.
Albicans infected necrosis were compared with atypical fungi (T. Glabrata,
etc.) infection. Student’s t-test and ?2 were applied where appropriate, with
pB0.05 considered significant.
Results. Of 152 patients with NP, 64 (42%) had fungal infection in one or
more organ systems; these patients had significantly increased length of stay
and greater numbers of re-operations and deaths when compared to patients
without fungal infection (Table). 133 patients had infected necrosis, of which
45 (34%) had fungal infection in the necrosis. There were no differences in
outcomes between patients with fungal vs. bacterial infection of the necrosis.
Of 45 patients with fungal infection of the necrosis, 22 (49%) harbored C.
Albicans and 23 (51%) had atypical fungi (T. Glabrata, etc.). Patients with
atypical fungus infection had significantly increased length of stay and greater
numbers of readmissions and operations required when compared to C.
Albicans group.
Data are mean9(% or range), *pB0.05 vs. Non-Yeast or C. Albicans
group.
Conclusions. From these data we conclude that in patients with
necrotizing pancreatitis: 1) Fungal infection is associated with significant
increase in length of stay, need for re-operation and death; and 2) infection
of necrosis with atypical fungus is associated with increased length of stay,
number of re-operations and readmissions. Given these findings we
recommend judicious use of antibiotics for proven bacterial infection in
patients with NP.
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DETERMINING PATTERN OF RECURRENCE FOLLOWING PAN-
CREATICODUODENECTOMY: EFFECT OF LYMPH NODE RA-
TIO AND NUMBER OF POSITIVE NODES
Bolanle Asiyanbola, MD, Joseph Herman, MD, Ana Gleisner, MD, Michael
Choti, MD, Christopher Wolfgang, MD, PhD, Richard Schulick, MD, John
Cameron, MD, Timothy M Pawlik, MD
Johns Hopkins, Baltimore, MD
Introduction. Recurrence following pancreaticoduodenectomy (PD) for
pancreatic adenocarcinoma is common with failure occurring both locally
and/or at distant sites. Identification of factors that predict pattern of disease
failure may help in guiding whether patients (pts) should be treated initially
with local vs systemic therapies. We sought to examine which factors may be
associated with patterns of recurrence following PD and chemo-radiation
therapy (CRT).
Methods. Between Jan 1995-Dec 2005, 905 pts underwent PD for
pancreatic adenocarcinoma; 154 pts received 5-FU based adjuvant CRT
and had complete pattern of recurrence data available. Demographics,
operative data, number of lymph nodes (LN) evaluated, number of LN
positive, pattern of recurrence, as well as long-term survival were collected
and analyzed. Lymph node ratio (LNR) was calculated by dividing total
number of positive LN by total number of LN evaluated.
Results. There were 93 men and 61 women with mean age of 63 yrs. The
median tumor size was 3 cm (range, 0.7 to 7 cm). On final pathologic
analysis, median number of LN evaluated was 18 (range, 2 to 57). 29
(18.8%) pts had no LN metastasis (N0) while 125 (81.2%) had positive LN
(N1). At median follow-up of 20.2 months, 102 (66.2%) pts recurred with
median time to recurrence of 16.2 mon. The 2 yr recurrence rate was similar
in pts with N0 vs N1 disease (64.3% vs 66.4%, respectively; p0.58). Most
pts initially recurred with distant disease only (45.5%), while 14.3% pts
recurred with local disease only; 10 (6.5%) pts recurred with localdistant
disease. Site of distant metastasis included liver (n41), lung (n29), or
other (n10). No clinicopathologic factor was associated with increased risk
of distant recurrence. In contrast, several factors predicted local recurrence:
poor tumor differentiation (HR 2.3), ]5 positive LN (HR 2.6), LNR0.4
(HR 2.9) (all pB0.05). Specifically, pts with ]5 metastatic LN had a 1.7-
fold higher risk of local recurrence at 2 yr (B 5 LN, 20.3% vs ]5 LN 34.2%;
pB0.05). LNR was also associated with an incremental increased risk of local
recurrence at 2 yr (LNRB0.2, 21.3% vs LNR ]0.2 to 0.4, 25.2% vs LNR
0.4, 40.4%; pB0.05). After controlling for tumor grade and size, LNR0.4
remained independently associated with an increased risk of local recurrence
(HR 3.7) compared with LNRB0.2 (pB0.05).
Conclusions. Recurrence following curative PD is common. Although most
pts will ultimately succumb to distant disease, 15% to 40% will recur locally.
A high number (]5) of metastatic LN and LNR0.4 may help identify
those pts at highest risk of local failure.
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THE LATENT PRESENTATION OF PANCREATIC FISTULAE
Wande Pratt, Mark Callery, MD, Charles Vollmer, MD
Beth Israel Deaconess Medical Center, Boston, MA
Background. Pancreatic fistula is traditionally suspected on the basis of
increased drain amylase levels. Yet, some patients, despite initially having low
amylase levels, will subsequently manifest with clinical evidence. We sought
to describe the prevalence and significance of latent presentations of
pancreatic fistulae.
Methods. 371 consecutive pancreatic resections were performed between
10/01 and 8/07. Amylase content was routinely measured from intraopera-
tively-placed drains on POD 6 after tolerance of solid diet. Evident fistulas are
defined by an initial amylase-rich effluent ( 300 IU/L) and clinical findings.
Latent fistulas initially lack amylase-rich effluent, yet, ultimately exhibit
clinical findings indicative of fistula. In this scenario, subsequent biochem-
ical, radiographic, or operative analysis confirms the diagnosis of pancreatic
fistula. This group was scrutinized to determine the clinical and economic
effect of latent presentations.
Results. Fistulas of any extent occurred in 102 cases (28%), half of which
were clinically-relevant (ISGPF Grades B/C). Latent fistulas occurred in 16
patients, comprising 4% of all resections, 16% of all fistulas, and roughly one-
third of all clinically-relevant fistulas. In these 16 patients, the median
amylase level on POD 6 was 33 IU/L (range: 3177 IU/L). Despite lacking
initial biochemical evidence, these patients later manifest clinical evidence of
fistula-radiographic findings (88%), abdominal pain (75%), fever (50%),
sinister effluent (44%), wound infection (25%)-usually on or after POD 10
(81%). Subsequent amylase levels, obtained during percutaneous or surgical
drainage of peripancreatic fluid collections, were markedly elevated (median:
16,200 IU/L, range: 1,77925,205 IU/L). When compared to the cohort of
Evident Fistulas, latent presentations were infected nearly twice as often
(44% vs. 23%), required more aggressive interventions (i.e. ICU manage-
ment, reoperation), and resulted in longer hospitalizations and greater
hospital costs (Table). These negative outcomes are largely driven by the
greater severity of latent fistulas (i.e. more Grade C).
Infection Any Site Fungus in Necrosis
Non-Yeast Yeast C Albicans Atypical
NUMBER 88 (58%) 64 (42%) 22 (49%) 23 (51%)
LENGTH OF
STAY
35 (4145) 58 (12179)* 38 (1599) 69 (28179)*
REOPERATIONS 0.9 (04) 1.4 (06)* 0.7 (06) 1.8 (06)*
READMISSION 1.4 (09) 1.9 (08) 1.2 (04) 2.3 (08)*
DEATH 5 (5.7%) 12 (18.8%)* 2 (4.4%) 6 (13%)
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Conclusion. Although the majority of patients with pancreatic fistula
demonstrate an initial amylase-rich effluent, a considerable proportion lacks
such evidence. This scenario portends significantly worse outcomes and
emphasizes the importance of the clinical course in fistula definition.
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SURVIVAL AFTER PANCREATICODUODENECTOMY IS NOT
IMPROVED BY EXTENDING RESECTIONS TO ACHIEVE NEGA-
TIVE MARGINS
Jonathan M Hernandez, MD, Desiree Villadolid, MPH, Paul Toomey, B.Sc.,
John Mullinax, MD, C Whalen Clark, MD, Lorraine Tomlinson, None,
Steven Goldin, MD, PhD, Alexander Rosemurgy, MD
University of South Florida College of Medicine Department of Surgery,
Tampa, FL
Introduction. Resection remains the only hope of cure for pancreatic
adenocarcinoma. Microscopically positive margins of resection negatively
impact survival. This study was undertaken to determine the survival benefit,
if any, of extending resections to obtain microscopically negative margins
after positive intra-operative frozen sections.
Methods. Since 1995, patients undergoing pancreaticoduodenectomy for
pancreatic adenocarcinoma are followed prospectively. Margin status has
been codified as micro-/macroscopically negative (R0) or microscopically
positive/macroscopically negative (R1). After resection, stage has been
assigned using AJCC guidelines, 6th edition. The impact of margin status
on survival was evaluated on a cross-section of patients utilizing survival
curve analysis (Log-rank test).
Results. Of 179 patients undergoing pancreaticoduodenectomy for pan-
creatic adenocarcinoma, complete tumor extirpation (R0) was initially
achieved in 134 patients, was ultimately achieved in 17 patients who required
extended pancreatic resections after initially positive intra-operative frozen
sections (R1?R0), and not achieved in 28 patients (R1). No correlation
between AJCC Stage and margin status was identified by regression analysis.
Patients undergoing R0 resections lived longer than patients undergoing R1
resections (Table). Survival was not improved if the pancreatic resections
were extended to obtain negative (R1?R0) margins (Table).
Conclusion. Although resection remains the only hope for cure for patients
with pancreatic cancer, even with resection survival is disappointing. Patients
undergoing less than complete tumor extirpation have particularly poor
survival. Survival after pancreaticoduodenectomy is not improved by
extending resections to achieve negative margins after positive intra-operative
frozen sections, suggesting the importance of ‘‘tumor specific’’ factors (e.g.,
infiltrating nature, tumor immunobiology,?) relative to margin status.
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PRESENCE OF SYMPTOMS, TUMOR SIZE, AND IMAGING
CHARACTERISTICS DO NOT RELIABLY PREDICT MALIG-
NANCY IN MUCINOUS CYSTIC NEOPLASMS OF THE PAN-
CREAS
Jayme B. Stokes, MD, Edward B. Stelow, MD, Marc Sarti, MD, Eduard E.
De Lange, MD, Reid B. Adams, MD, Todd W. Bauer, MD
University of Virginia, Charlottesville, VA
Objective. Appropriate management of cystic lesions of the pancreas
remains controversial. Recently published consensus guidelines recommend
resection of all mucinous cystic neoplasms (MCN) due to their malignant
potential and the inability to accurately predict malignancy preoperatively.
Further studies evaluating these guidelines are needed.
Methods. All patients undergoing pancreatic resection for MCN between
January 1998 and July 2007 were evaluated. Patient charts were retro-
spectively reviewed using a set of prospectively defined criteria. Imaging
studies (CT and MRI) were independently, retrospectively reviewed by two
blinded radiologists. Pathology slides were reviewed by a single pathologist.
MCN’s were categorized pathologically as Benign (Adenoma or Borderline)
or Malignant (Carcinoma In Situ or Invasive). Adverse radiographic features
(mural nodules, papillary projections, or septations) were noted.
Results. Twenty-two pancreatic resections for MCN were performed. Four
(18%) lesions were malignant and 18 (82%) were benign. The median age of
patients with malignant and benign lesions was 43.2 and 49.3 years,
respectively (p0.38). All patients were female and demographics were
similar in both groups. Abdominal pain was the most common presenting
complaint and no symptom (new/change in diabetes, jaundice, weight loss,
nausea or vomiting, pancreatitis, GI bleeding) was more likely in either
group. Twenty-five percent of the malignant lesions were discovered
incidentally compared to 22% of the benign lesions (p0.9). Malignant
lesions were typically larger than benign lesions, although this did not reach
statistical significance (6.1 vs. 5.0 cm, p0.57). One (25%) of the malignant
tumors was B2 cm in size. Eighty-eight percent of the benign MCNs were
located in the tail of the pancreas compared with 100% of the malignant
lesions (p0.48). Adverse radiographic features were present more often in
patients with benign tumors (83.3% vs. 25%, p0.08). Dilation of the main
pancreatic duct and the presence of atrophy or pancreatitis were similar in
both groups. None of the 4 malignant tumors demonstrated invasive
malignancy.
Conclusions. Presence of symptoms, size of lesion, and presence of adverse
radiographic features do not reliably predict malignancy in MCNs of the
pancreas. All patients with MCNs of the pancreas should be offered surgical
resection if they are suitable surgical candidates.
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CYBERKNIFE RADIOSURGERY FOR PANCREATIC CANCER
Anand Mahadevan, Michael Goldstein, Sanjay Jain, Mark Callery, Charles
Vollmer
BethIsrael Deaconess Medical center, Boston, MA
Introduction. Cyberknife is a robotic stereotactic radiation technique which
delivers high doses of precisely focused radiation in few treatments as
opposed to weeks of conventional radiation, with less potential toxicity. We
conducted a prospective study of Cyberknife with chemotherapy for locally
advanced and recurrent pancreas cancer. Patients with positive margins after
surgical resection were treated with Cyberknife boost followed by adjuvant
chemoradiation.
Methods. 48 patients with pancreas cancer were treated from Oct 05-July
07. 36 were unresectable, 4 had progressed after previous chemoradiation
and 8 had R1 resections. The Cyberknife radiosurgery system was used with
respiratory motion tracking. Fiducial gold seeds were implanted intraopera-
tively, percutaneously or endoscopically for image guidance in all locally
advanced and recurrent cancers. The target volumes were contoured in 3D
by the radiation oncologist and surgeon. In locally advanced/recurrent
cancers, the prescription dose was 2436 Gy in 3 treatments. In patients
with a positive margin, a 10 Gy boost was followed by conventional radiation
to the pancreatic bed to a dose of 4550.4 Gy with concurrent capecitabine.
Results. The 8 patients with positive margins were pT3N01. The treatment
characteristics of these and the unresectable (N36 patients) and recurrent
patients (N4) are listed in Table1. The median follow up was 14 months
(919 m) for patients with a positive margin and 12.5 months (223 m) for
the unresectable/recurrent group. The clinical outcomes for these patients are
listed in Table 2.
Side effects were minimal. Overall (25%) had Grade II nausea and only 4
patients had Grade III toxicity (2 Duodenal Ulceration 1 Gastric Bleeding
and 1 IVC thrombosis).
Conclusions. Cyberknife is an efficient and effective treatment for locally
advanced and recurrent pancreatic tumors with minimal toxicity. In patients
with positive margins local control can be maximized by delivering higher
doses to the resection margins using targeted radiosurgery along with
conventional chemoradiation.
Table. Clinical and economic impacts of evident and latent fistulae.
Outcomes
Evident
Fistula
Latent
Fistula
p-
value
Patients (% clinically relevant fistulae) 35 (69) 16 (31) 
Fistula Severity (%)
ISGPF Grade B (intermediate) .31 (89) .9 (56) .009
ISGPF Grade C (severe) 4 (11) 7 (44)
ICU Utilization (%) 1 (3) 3 (19) .050
Reoperation (%) 2 (6) 7 (44) .001
Readmission (%) 13 (37) 9 (56) .201
Duration of Stay (median, days)
Initial
Total (initialreadmission) .10 .10 .651
14 18 .027
Total Hospital Costs (median) $23,542 $31,229 .305
Resection
Number
of Pts.
Median
Survival
p-value Relative to
R1 Resections
R0 134 21 months p0.009
R10R0 17 11 months p0.343
R1 28 13 months N/A
Table 1
n Mean Target
Volume
Prescription
Dose
Mean
Isodose
Positive Margin (R1) 8 56.4cc 10Gy 80%
Unresectable/Recurrent 40 53.4cc 2436Gy
(mean 28.75)
81.3%
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ANTIBACTERIAL PROPHYLAXIS DOES PREVENT DEATH
FROM ACUTE NECROTISING PANCREATITIS, BUT NOT BY
PREVENTING INFECTION OF PANCREATIC NECROSIS
Eduardo A Villatoro, MD, Mubashir Mulla, MD, Richard I Hall, MD,
MBBS, Michael Larvin, MD, MBBS
University of Nottingham at Derby, Derby, United Kingdom; Derby
Hospitals NHS Foundation Trust, Derby, United Kingdom
A series of randomised controlled trials (RCTs) has led to confusion as to the
role of antibacterial prophylaxis in acute necrotising pancreatitis. To clarify
this we sought RCTs comparing antibacterial therapy versus placebo when
significant pancreatic necrosis was proven by CT. Six published RCTs were
found (Jan 1993-Aug 2007): four evaluated beta-lactams (n292) and two
quinolone/imidazole (n102). None was adequately powered. Only two
were double-blinded. Meta-analysis was performed using ‘RevMan 4.2’
software (Update, Oxford UK).
Overall analysis (n394) demonstrated significantly lower mortality with
therapy (6.5%) versus controls (14.4%), odds ratio 0.43 (95% CI 0.22,
0.84). However, infected necrosis rates were not significantly different. Non-
pancreatic infections were significantly lower with therapy (24.2%) versus
controls (35%), odds ratio 0.55 (95% CI 0.33, 0.91), although only 4 studies
(n308) offered such data.
Sub-group analysis showed beta-lactams to be associated with significantly
lower mortality (6.8%) versus controls (15%), odds ratio 0.42 (95% CI 0.19,
0.92), whilst no significant differences existed between quinolone/imidazole
and controls. Beta-lactam treatment was associated with less infected necrosis
(16.4%) versus controls (23.3%), but this was non-significant, odds ratio
0.62 (95% CI 0.34, 1.12). There were higher rates of infected necrosis after
quinolone/imidazole versus controls, but this was not significant. Non-
pancreatic infections were significantly lower after beta-lactams (22.4%)
versus controls (35.3%), odds ratio 0.48 (95% CI 0.27, 0.87), but only one
quinolone/imidazole study reported non-pancreatic infections with no
significant difference.
The results confirm previous meta-analyses suggesting that antibacterial
prophylaxis significantly reduces overall mortality, but not infection rates for
pancreatic necrosis. The mechanism is unclear, but contrary to the rationale
for these RCTs, it appears that prophylaxis is most likely to protect against
death from serious non-pancreatic infections such as severe respiratory
infection. It is possible that beta-lactams are more effective than quinolone/
imidazole regimens against non-pancreatic infections.
Further, adequately powered, double-blinded studies, perhaps targeting beta-
lactam agents, are still required to confirm efficacy, safety, and elucidation of
the mechanism.
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A GENETIC EXPRESSION PROFILE OF CHEMORESISTANT
PANCREATIC CANCER
Anthony Razzak, B.Sc., Abdul Saeid, MD, Jose Trevino, MD, Justin Hering,
MD, Joseph Espat, MD
Roger Williams Cancer Center, Providence, RI
Background. While the poor prognosis of pancreatic cancer (PC) is widely
recognized and often attributed to chemoresistance, the efforts to define the
molecular level characteristics that warrant such behavior are inadequate. In
this study, we examine the genetic expression profile of PC cell line L3.6pl,
considered a gemcitabine (GEM) sensitive cell line, and compare it to a
cloned variant, denoted as L3.6 clone (GEM RES), selected for experimen-
tally acquired gemcitabine resistance, allowing insight into the molecular level
changes governing PCs therapeutic ineffectiveness.
Methods. L3.6pl cells were cultured by standard protocol. GEM resistance
was induced by exposure to 500 ng/ml of GEM, 5 greater than the IC50,
for 48 hours, and increased to 3000 ng/ml in 500 ng/ml increments. GEM
resistance was confirmed by sustainment in DMEM (without GEM) for 6-
wks with no effect on proliferation when returned to maintenance GEM (125
ng/ml). Once the cell line was established, L3.6 pl and GEM RES were
isolated, homogenized and RNA extracted. RNA quality was assessed with
Agilent 2100 bioanalyzer. Microarray analysis was performed using Agilent
44 K whole human genome 60 mer oligonucleotide array, containing positive
and negative controls. The hybridization was performed by MOgene, LC,
using standard cy3 and cy5 labeled cRNA protocol. Data analysis was
performed using Agilent software. Data was normalized using LOESS
regression on all background corrected signal intensities. Comparative
analysis of L3.6pl and GEM RES was performed using expression relative
to control genes GAPD and/or b-actin (ACTB). Significant differential
expression (SDE) was defined as relative expression ]2 fold. Genes with
expression  median background intensity were assigned a signal intensity
value1.
Results. Comparatively, there were approximately 13800 genes differentially
expressed between L3.6pl and GEM RES, representing a multitude of gene
families and functions. Table 1 represents SDE genes of particular interest,
including genes of GEM metabolism, apoptosis, cell cycle regulation and
inflammation.
Conclusion. The data herein, provides the genetic level etiology of PCs
chemotherapeutic resistance. Future studies will include RT-PCR confirma-
tion of this data and experiments designed to target specific genes, with the
intention of increasing the sensitivity of PC to cytotoxic therapy.
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OUTCOMES USING GRAFTS FROM DONATION AFTER CAR-
DIAC DEATH DONORS: PRELIMINARY RESULTS
M. B. Majella Doyle, MD, Neeta Vachharajani, MD, Christopher D.
Anderson, MD, Jason R. Wellen, MD, Jeffrey A. Lowell, MD, William C.
Chapman, MD
Washington Universtiy, St Louis, MO
Because of the worldwide limitations on the availability of suitable donor
organs, there continues to be an adverse affect on the mortality rates in
candidates on the waiting list for organ transplantation. In order to increase
the donor pool, increasing numbers of grafts from Donation after cardiac
death (DCD) donors are being used for liver, kidney, pancreas, and lung
transplantation. The addition of warm ischemia prior to cold perfusion, not
encountered in standard brain-dead (BD) donation, puts DCD grafts at a
potentially increased risk of complications. We retrospectively reviewed the
DCD experience from our single center.
Methods. From January 2005 to August 2007 a total of 281 liver transplants
were performed at our institution. 18 recipients of primary whole organ
transplants received DCD grafts. A prospectively maintained database was
utilized for the current analysis. Donor and recipient characteristics,
complications and outcomes were compared with results from 238 patients
undergoing whole organ transplants using standard BD donors.
Results. The median age of DCD donors and BD donors was 27 and 42
years respectively. The median MELD score and age in DCD graft recipients
was 22.6 and 53.1 years respectively. Median DCD donor warm and cold
ischemia times were 16.9 minutes and 6 hours and 49 minutes respectively.
The median follow up was 14.2 months. The 1- and 2-year graft and patient
survivals in DCD were 88.9%. One- and 2-year patient survival rates in
standard BD recipients was 92.0 and 89.3%, with graft survival rates at 1-
and 2-years of 88.6 and 85.9% (vs DCD, pNS) Two patients who received
DCD grafts died (1 from graft failure 3-months after transplant and 1 from a
ruptured hepatic pseudo-aneurysm). There were 19 deaths in the BD
recipient group (p0.41). Four patients (22%) in the DCD group had
biliary complications including 1 stricture, 1 bile leak and 2 with diffuse
cholangiopathy, 1 of these associated with graft failure. No DCD recipient
had hepatic artery thrombosis or primary non-function.
Conclusions. Our early experience with DCD donors in liver transplanta-
tion suggests comparable results with standard BD donors in medium-term
followup. Long-term followup for the development of ischemic cholangio-
pathy will be required before more widespread use of this donor type. Careful
selection of DCD donors, especially regarding warm and cold ischemia times
may ensure satisfactory long-term Results.
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SIMULTANEOUS PANCREATECTOMY AND LIVER TRANS-
PLANTATION: A SINGLE INSTITUTION EXPERIENCE
Rajeev Dhupar, MD, J. Wallis Marsh, MD, Paulo A Fontes, MD, Michael E
Devera, MD, Jennifer L Steel, PhD, Herbert Zeh, MD, David A Geller, MD,
Amadeo Marcos, MD, T. Clark Gamblin, MD
University of Pittsburgh, Pittsburgh, PA
Background. Several centers have reported liver transplantation (LT) in
patients with metastatic neuroendocrine tumor in order to obtain complete
tumor resection. We report a single center experience with simultaneous LT
and total pancreatectomy or pancreaticoduodenectomy.
Methods. A retrospective database review of patients who underwent
simultaneous LT and total pancreatectomy or pancreaticoduodenectomy
was performed. We analyzed demographics, indications, approach, as well as
Table 2
Local Control Distant Metastasis Progression Free Survival Overall Survival
Positive Margin(R1) 8/8 (100%) 2/8 (25%) 6/8 (75%) 6/8 (75%)
Unresectable 28/36 (77.8%) 17/36 (47.2%) 14/36 (38.8%) 26/36 (72.2%)
Recurrent 3/4 (75%) 3/4 (75%) 1/4 (25%) 2/4 (50%)
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outcomes. Kaplan Meier analyses were employed to assess overall and
between group differences in survival post-transplant.
Results. Between 1991 and 2006, 11 patients (4 male, median age 51 years,
range 1767) underwent simultaneous LT and total pancreatectomy (n4)
or pancreaticoduodenectomy (n7). Indications for this included metastatic
neuroendocrine tumor (n5), hepatocellular carcinoma (HCC) (n2),
metastatic periampullary adenocarcinoma (n1), periampullary adenocar-
cinoma with end stage liver disease (ESLD) (n2), and IPMN with ESLD
(n1). The 3 patients with ESLD had NASH, PSC, or cryptogenic
cirrhosis. In the 2 patients with HCC, one had extension into the duodenum,
and the other had metastatic disease to a retroduodenal lymphnode. Median
post-operative length of stay was 31 days (21110 days). Five patients are
currently alive (116 years), and five patients lived 29 years after the initial
operation. One patient died 2 months postoperatively from sepsis. Overall
median survival was 101 months (95%CI70.6131.4). There was no
significant difference in survival in patients with pre-operative ESLD (p
0.87). One year survival was 91%, two year 90%, five year 67%, and 10 year
33%. Postoperative complications included: re-operation (n3); anastamo-
tic leak (n2); abdominal abscess (n2); organ rejection (n1).
Conclusion. We report a series of pancreatectomy or pancreaticoduode-
nectomy and simultaneous LT in patients with extensive malignancy or
localized tumor with ESLD. This series, although limited, did not show
differences in long-term survival in patients with ESLD compared to those
with metastatic disease. Combined resection and LT can be a strategy for
radical resection, and cases with ESLD that would otherwise preclude
operative intervention.
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A SAFE APPROACH FOR THE USE OF LIVER ALLOGRAFTS
FROM HEPATITIS B CORE ANTIBODY- POSITIVE DONORS.
Sameh Adel Fayek, MD, Timothy D. Siropaides, Oren Shaked, Kim M.
Olthoff, MD, K. Rajender Reddy, MD
University of Pennsylvania Hospital, Philadelphia, PA
Background. The gap between the demand and supply of liver allografts
continue to widen. Using livers from HBcAbve donor represents a mean to
expand the donor pool but carries a variable risk of HBV transmission.
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Prophylactic measures have been suggested, however the modality, dose and
duration of therapy is not standardized.
Methods. A retrospective review was conducted of all liver recipients who
received an allograft from HBcAbve/HBsAg-ve donor at a large trans-
plant program during the period from January 2000 through January 2007.
Patients who died within 30 days of OLT or lost to follow up were
excluded. The effectiveness of a prophylactic regimen to prevent hepatitis B
infection was evaluated by determining the rate of hepatitis B infection.
Prophylaxis consisted of HBIg administered intraoperatively and continued
to a variable period of time depending on the recipient HBsAg status in
addition to a daily oral nucleotide/nucleoside analog. New infection or
reactivation was defined as presence of both HBsAg and HBV DNA in
serum.. Patient and graft survival were compared to all transplants at same
study period.
Results. Thirty seven patients received HBcAbve/HBsAg-ve grafts. Of
these, 8 were excluded due to early death or lost to follow-up. Most
common indication for transplantation was HCV cirrhosis and HCV/
HCC. Mean follow up of the remaining 29 was 24.5 months. Only one
patient developed denovo hepatitis B infection after being non compliant
with his prophylactic medications. No hepatitis B infection was seen in the
compliant patients. The long term outcome in study group was
statistically not different to all transplants performed at same period
with 5 year patient survival of 76.7% versus 78.5% and graft survival of
69.5% versus 76.2% respectively (p value0.75 and 0.77). Four patients
died secondary to reasons not related to hepatitis B occurrence. Two
other grafts were lost secondary to chronic rejection and HAT. In 5
recipients a dual infected graft (HBcAbve /HCV ve) was used with
good outcome.
Conclusions. The incidence of hepatitis B infection following trans-
plantation with HBcAbve grafts is negligible if a simple prophylactic
regimen is maintained, and represents a valuable way to expand allograft
pool, with results similar to those achieved with HBcAb-ve grafts. The use of
dual infected allografts can also yield similarly good results in appropriate
patients.
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ADVANCED DONOR AGE DOES NOT AFFECT PATIENT OR
GRAFT SURVIVAL FOLLOWING LIVER TRANSPLANTATION
Christopher D Anderson, MD, Neeta Vachharajani, M. B. Majella Doyle,
MD, Jason R. Wellen, MD, Surendra Shenoy, MD, Jeffrey A Lowell, MD,
William C Chapman, MD
Washington University in St Louis, St Louis, MO; Washington University in
St Louis, St. Louis, MO
Introduction. Donors greater than 60 years in age represent an important
subset of organs available for orthotopic liver transplantation (OLT). There
are conflicting reports regarding the safety of their use for OLT. We
hypothesized that proper selection of donors over age 60 results in
comparable patient and graft survival to organs from donors less than 60
years old.
Methods. All OLTs performed at our center between 1/1/1990 and 7/31/
2007 were reviewed. Primary, liver only, whole organ cadaveric trans-
plants in adult recipients were included in the analysis. Non-heart beating
donors were excluded. Identified patients were divided into groups based
on donor age: donors 60 years old (60 group), donors 6069 years
old (6069 group) and donors 70 years old (70 group). The
comparison group (CG) contained all patients receiving a donor B60
years old. Graft and patient survival at 1, 3, and 5-years was analyzed
for each group. Statistical analysis was performed using Chi Squared
test.
Results. 1035 OLTs were performed during the study period. 741 met
inclusion criteria. There were 91 patients in the 60 group, 66 patients in
the 6069 group, and 25 patients in the 70 group. The CG contained
650 patients. Overall patient survival in the 60 group was 86.8%, 72.6%,
and 67.6% at 1, 3, and 5 years respectively. There was no significant
difference from the CG (87.1%, 81.8% and 75.5%; p0.99, 0.43 and
0.54). The 1, 3, and 5-year graft survivals for the 60 group were 82.4%,
65%, and 62.5% which were not significantly difference from the CG
(84%, 78.6% and 72.3%; p0.99, 0.17, and 0.27). The 6069 group had
1, 3, and 5-year patient survivals of 87.8%, 72.5%, and 69.7% and graft
survivals of 83.3%, 64.3%, and 61.5%. Neither patient survival, nor graft
survival in the 6069 group differed significantly from the CG (p0.98,
0.6, 0.8 and p0.99, 0.15, 0.3, respectively). The 1 and 3-year patient
survival for patients in the 70 group (84% and 74.7%) was not
significantly different from the CG (p0.99 and 0.55); nor was there
any significant difference in 1 and 3-year graft survival (80% and 70%; p
0.99 and 0.40). There were insufficient patients the 70 group to cacluate
5-year survival.
Conclusions. Patient and graft survivals following OLT using older
donors are acceptable and comparable to those obtained from donors
less than 60 years old. When properly selected, donors greater than 60
and 70 years old represent an important and safe expansion of the donor
pool.
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HEPATIC BLOOD FLOW PREDICTS ALLOGRAFT AND PATIENT
SURVIVAL FOLLOWING LIVER TRANSPLANTATION.
Austin L. Spitzer, MD, Andre A. Dick, MD, Ramasamy Bakthavatsalam,
MD, Jeffrey B. Halldorson, MD, Adam Levy, MD, Jorge D. Reyes, MD,
James D. Perkins, MD
University of Washington, Seattle, WA
Background. Most prognostic survival models use recipient and donor
factors to predict outcome after liver transplantation. Operative variables
have not been historically included in these models; however, if appropriately
discriminatory, they would represent an opportunity to measure and modify
outcome during liver transplantation.
Objective. We hypothesized that operative variables can predict allograft and
patient survival following liver transplantation.
Methods. We examined 629 consecutive liver transplants at the University of
Washington from 20012006. In addition to measuring systemic hemody-
namics and blood loss, we examined liver blood flow via ultrasonic flow
probe, reperfusion (quality, speed) and bile production. Logistic regression
was performed to determine the contribution of these variables on allograft
and patient survival at 30, 90, and 365 days.
Results. Hepatic blood flow was predictive of allograft and patient survival,
regardless of systemic hypotension. Specifically, portal vein blood flow
[1.990.7 versus 1.190.8 L/min, pB0.0001] was significant for allograft
and patient survival at 30, 90, and 365 days. Portal vein blood flow
combined with RBC transfusion [0.890.8 versus 2.494.4 L, pB0.002]
and complete reperfusion [97% versus 78%, pB0.01] provided a prognostic
model with a Receiver Operating Curve (ROC) C-statistic 0.77 at 30
and 90 days for patient survival. However, at 365 days, hepatic artery blood
flow [4229224 versus 3409212 mL/min, pB0.003] combined with portal
vein blood flow was most predictive of patient survival (ROC C-statistic
 0.7).
Conclusion. Hepatic blood flow is a significant predictor of allograft and
patient survival and represents an opportunity to modify outcome after
transplantation. During the initial 90 days after transplant, the liver survives
based on portal vein blood flow, regardless of hepatic artery flow; however,
subsequent biliary problems and patient demise are due to the contribution
of poor hepatic artery blood flow. This data supports the revision of
anastomoses and/or ligation of collaterals to maximize hepatic blood flow
and ultimate allograft and patient survival.
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SURGICAL PORTOSYSTEMIC SHUNTS FOR POTRAL HYPER-
TENSION IN THE ERA OF ORTHOTOPIC LIVER TRANSPLAN-
TATION: THE ROLE OF THE SPLENORENAL INTERPOSITION
H-GRAFT
Robert R Slater, MD, Atsushi Yoshida, MD, Dean Y Kim, MD, Marwan
Abouljoud, MD
Henry Ford Hospital, Detroit, MI
Introduction. The preferred portosystemic shunt in patients with refractory
portal hypertension potentially in need of future orthotopic liver transplanta-
tion (OLT) is debated. We reviewed our experience with surgically placed
portosystemic shunts (SPPSS) with special focus on the splenorenal
interposition H graft (SR-H).
Methods. We retrospectively reviewed all SPPSS at our institution from
1995 to present. We excluded charts with incomplete data, shunts placed for
etiologies other than portal hypertension, and esophago-gastric devascular-
ization procedures. Patient demographics, operative data, and outcomes were
abstracted.
Results. 36 patients were identified that met the inclusion criteria. The
shunts were placed from 10/18/95 to 8/27/07. The age range was 1172 years
old (mean 47.2, SD 12.72). Males accounted for 69.5%. The etiologies of
portal hypertension requiring a SPPSS included: portal vein thrombosis
(11%), PSC/PBC (5%), Budd-Chiari (8.3%), schistosomiasis (2.7%), and
alpha-1 antitrypsin (2.7%). The remainder (61.1%) had hepatitis B, hepatits
C, alcoholic cirrhosis, or a combination. 77.7% of patients had a procedure
for bleeding. The remainder had refractory ascites (13.8%) or hepatic vein
thrombosis (8.3%). A variety of shunts were utilized, at the discretion of the
operating surgeon: splenorenal interposition H-graft (SR-H) with 610 mm
PTFE in 22.2%, distal end-to-side splenorenal (DSRS) in 22.2%, mesocaval
(MC) with vein or 810 mm PTFE in 22.1%, portocaval H-graft (PC-H)
with 10 mm PTFE in 13.8%, mesorenal (MR) in 8.3%, side-to-side
portocaval (SS-PC) in 5%, side-to-side splenorenal (SS-SR) in 2.7%, and
Rex shunt in 2.7%. For all shunts, the 30 day complication rate was 58%, the
liver-related complication rate was 22%, and the 30-day mortality was 5.5%.
For the SR-H shunts, these rates were 50%, 25%, and 0% respectively. For
the remaining shunts, these rates were 60.7%, 21.4%, and 7.1% respectively.
Post-operative encephalopathy and ascites were similar between SR-H shunts
alone compared to all others. There were no 1 or 5 year rebleed rates in the
SR-H, compared to 11% and 21% in all other shunts. Overall, 7 of 36
patients required OLT. Of these, 28.6% previously had a SR-H, 14.3% SS-
SR, 42.9% MC, and 14.3% MR.
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Conclusion. SPPSS offer durable portal decompression for suitable
candidates. The SR-H shunt has been very effective, can be easily reversed
during OLT, and would maintain splenic contribution to portal flow. In our
experience, the SR-H shunt has similar complication rates and less mortality
compared to other SPPSS and is favored in potential OLT candidates in need
of surgical decompression.
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AUTOLOGOUS ISLET TRANSPLANTATION COMBINED WITH
TOTAL PANCREATECTOMY
Sonal Asthana, MD, Tatsuya Kin, PhD, Norman Kneteman, MD, Andrew
M J Shapiro, MD, PhD, David L Bigam, MD
University of Alberta Hospital, Edmonton, AB, Canada
Introduction. Total pancreatectomy (TP) for benign or malignant disease of
the pancreas carries a significant morbidity, especially the risk of developing
pancreaticogenic diabetes with attendant hypoglycemia and difficult glycemic
control. Islet autotransplantation (IAT) offers the possibility improving
glycemic control. We present the short and intermediate-term results of
IAT at a single-centre for patients undergoing TP.
Patients and Methods. All patients who had undergone IAT following TP
at this centre were included in the study. Islet isolation was performed after
pancreatic resection, and the unpurified digest was injected into the portal
vein at the initial operation in all patients but one. Data on postoperative
morbidity and follow-up in terms of insulin use, glycemic control and C-
peptide levels was collected prospectively. Statistical analysis was performed
using the Mann-Whitney test and the chi-square test as appropriate.
Results.Twelve patients underwent IAT during the course of the study (4
men, 8 women). Eight patients had TP for chronic pancreatitis, while 4 had a
Whipple’s resection followed by completion pancreatectomy for malignant
disease ( adenocarcinoma -3, cystadenocarcinoma-1). A median 214579 islet
equivalents (IE) were transplanted (Range 20,0006,21,190), with a median
packed cell volume of 13 ml. There was no significant difference in the islet
isolation between the benign and malignant resections (median IE 245,221
and 217,202 p0.8). There was no perioperative mortality, but one patient
developed portal vein thrombosis, which was managed conservatively. At a
median follow-up of 15.1 months (3.942.1 months), 4 patients were insulin-
independent, and the other patients had a median insulin requirement of 11
units/day (range 474 units). One patient had received a pancreas transplant
for poorly controlled diabetes, and two patients had died with recurrent
malignant disease.
Conclusion. Islet autotransplantation (IAT) can be performed safely in
patients undergoing TP. Although insulin independence may not be
achieved, IAT may decrease insulin requirements and improve glycemic
control.
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DOES BASE LINE BODY MASS INDEX INFLUENCE SHORT AND
LONG TERM OUTCOME AFTER LIVER TRANSPLANTATION
Jaime Aranda-michel, MD, Hugo Bonatti, MD, Rolland C Dickson, MD,
John Stauffer, MD, Denise Harnois, DO, Justin Nguyen, MD
Mayo Clinic, Jacksonville, FL; UVA, Charlottesville, VA
Introduction. Obesity continues to increase rapidly in the US. The effect of
obesity on early and late outcomes following liver transplantation (LT)
remains a matter of debate.
Methods. From 1998 to 2001 467 LTs in 402 patients were performed at
our centre. Transplant outcome including graft/patient survival and compli-
cation rates were analyzed according to the patient BMI (4 groups: BMI B25
kg/m2, BMI 2530 kg/m2, BMI 3035 kg/m2, BMI 35 kg/m2). BMI could
not be evaluated in 10 patients.
Results. Patients with the lowest BMI (B25 kg/m2) had the worse outcome,
in contrast, patients with a BMI 35 kg/m2 was not associated with poor
graft or patient survival. Patients with obesity had good short-term and long-
term survival, no increased surgical-, immunological- or infectious complica-
tion rate but had higher long-term metabolic complication rates as shown in
Table 1.
Conclusion. In our experience, severely obese patients have good short-term
graft and patient survival. Long-term outcomes following LT are impaired
and related to metabolic complications. Morbid obesity should not be
considered a contraindication for LT. However, more aggressive strategies
and treatments of obesity including bariatric surgery should be offered to
these patients before irreversible cardiovascular complications occur.
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OUTCOMES AND TRENDS IN LIVER TRANSPLANTATION AS
REPORTED IN THE SRTR REGISTRY
Hussein Saad, B.Sc., Atsushi Yoshida, MD, Dean Kim, MD, Marwan S.
Abouljoud, MD
Henry Ford Hospital, Detroit, MI
Objective. To explore trends in transplant rates and outcomes from all liver
transplant centers in the United States.
Materials and methods. Data was collected from the Scientific Registry of
Transplant Recipients (SRTR) website at www.ustransplant.org using the
Program reports for July 2007. Datasets included total number of patients on
waiting list, total number of transplants per center, mortality while on waiting
list, observed and expected mortality rate while on waiting list (MR),
observed and expected transplant rate (TR), observed and expected graft
survival rate (GSR) post transplant, observed and expected patient survival
rate (PSR) post transplant. We looked for trends in observed TR, MR, GSR
and PSR. We also compared mortality while on waiting list to total number of
patients on waiting list.
Table 1
BMI B25 kg/m2 BMI 2530 kg/m2 BMI 3035 kg/m2 BMI 35 kg/m2 p-value
in patients 120 142 75 55
transplants 145 166 85 60
male 61% 66% 62% 53% 0.398
caucasion 75% 80% 82% 92% 0.083
median MELD 15 15 14 13.6 0.241
median patient age 50 53.5 50 54 0.005
median patient BMI 22.1 27.1 31.2 39.5 B0.0001
% NASH 1% 4% 12% 37% B0.0001
extended criteria donor 59% 52% 49% 65% 0.176
Roux Y biliary reconstruction 28% 18% 11% 7% 0.004
biliary complication 19% 21% 17% 20% 0.856
fast track 46% 61% 60% 50% 0.176
early post LT pneumonia 12% 7% 6% 8% 0.389
Closhidium difficile culitis 9% 4% 7% 8% 0.384
post LT intraabdominal bleed 7.60% 6.60% 9.40% 5% 0.938
rejection rate 35% 34% 29% 30% 0.824
incision associated complications 8% 14% 18% 15% 0.580
wound dehiscense 1.4% 3% 6% 3.3%
abdominal wall burst 1.4% 2.4% 1.2% 3.3%
incisional hemia 5.5% 8.4% 10.8% 8.3%
5 year patient survival 75% 80% 82% 74% 0.548
5 year graft survival 55% 63% 69% 58% 0.251
in patient with long term FU 104 118 60 40
BMI last follow up 23.3 27.6 32.2 37.3 B0.0001
DM early post LT 23% 40% 46% 70% B0.0001
long standing DM post LT 14% 35% 43% 43% B0.000
hyperlipedimia 35% 54% 51% 60% 0.012
hypertension 61% 62% 74% 83% 0.022
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Results. Data was collected from 99 liver transplant centers in the United
States. 33 centers had significantly higher than expected TR; of those 28 had
MR as expected, 2 significantly lower, 3 significantly higher. There were 9
programs with MR higher than expected; of these 5 had lower TR than
expected. When TR was compared to MR we noticed that there was a slight
increase in the MR with an increase in TR but this was not significant. Only 2
programs had better than expected GSR and 3 programs with better than
expected PSR; none had higher than expected TR, 4 had lower TR and 1 had
significantly lower MR. 6 programs had lower PSR; of these only 1 had lower
TR. There was no noticeable trend between better GSR, MR and PSR.
Paradoxically, 5 centers with higher MR had a lower TR.
Conclusion. 1-The majority of liver programs report outcomes within
expected SRTR measures. 2-There is no clear relationship between TR, MR
and GSR or PSR in this dataset. 3- Practice styles cannot be judged from
SRTR data alone. 4- PSR remains the ultimate in outcome with only 6/99
performing below expected. 5- SRTR outcomes have to be interpreted with
caution in defining expectations in the era of expanded criteria liver donors
criteria and MELD. 6- SRTR data should guide policy makers to adopt a
quality improvement mindset and benchmarking methods to permit learning
from centers with sustained better outcome measures.
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A SIMPLIFIED UTILITARIAN BILE DUCT INJURY CLASSIFICA-
TION: BASED ON MORTALITY, FINANCIAL, AND RE-STRIC-
TURE DATA.
Ravi Nagubandi, MD, Michael Marvin, MD, Steve Rudich, MD, Ravindra
Kadiyala, MD, Amit Tevar, MD, Michael Nussbaum, MD, Andreas Gelrud,
MD, Jeff Mathews, MD, Tariq Shaqoor, MD, Joseph Buell, MD
Jewish Hospital, University of Louisville, Louisville, KY; University of
Cincinnati, Cincinnati, OH
Several classification systems exist for bile duct injuries (BDI). The role that
vascular injuries play in BDI has been previously described (Buell). However,
no simple, yet utilitarian classification system based on outcomes data exists.
Methods. We evaluated outcomes data including mortality, cost, re-stricture
rates and quality of life for 89 patients with BDI. Statistical modeling was
employed to determine the most efficacious classification system.
Results. While both a 5 and 3 tier classification system were examined, the
data analysis favored a simplified 3 tier system which included: Class I (n
7)-injuries to the duct of Luschka and aberrant ducts of the right ductal
system treated endoscopically. Class II (n65)-injuries of the common duct
(Bismuth levels I&II), confluence (Bismuth III), and above (Bismuth IV), all
without vascular injury. Class III (n17)-all BDI with vascular injury
(arterial or portal). The average cost of managing a Class I injury (n7,
7.8%) which did not require operative intervention was $14,790. This group
had no mortality or re-stricture. The cost of Class II injuries (n65) was
significantly higher at $46,290 (p0.025). In this group, there was 1
mortality (1.5%) and a re-stricture rate of 26.1% (n17). Class III (n
17) injuries incurred the highest cost irrespective of the Bismuth level with a
mean cost of $73,256 (pB0.01). However, no higher re-stricture rate was
noted in this class (n4; 23.5%: p0.9). Of note, and consistent with
previous reports, a higher mortality rate was noted when BDI was associated
with vascular injury (n2; 11.7%: p0.073, OR8.5). Quality of life
analysis was performed on average 3.5 yrs after BDI. The average number of
procedures and hospitalizations per patient were 7.4 and 2.3, respectively.
Despite SF36 scores within the normal limits of the population, over 10% of
patients were on chronic pain medication, and more than 85% of respondents
were dissatisfied with their initial surgeon, regardless of the level of injury.
Conclusions. This analysis advocates the simplification of BDI into a three
class system and confirms the significance of vascular injury on mortality and
overall costs. Moreover, these effects appear to be independent of the
Bismuth level of injury. In conclusion, we have developed a simple, pragmatic
classification system, based on outcome data, specifically mortality, cost, and
re-stricture rates that will enhance the care of BDI patients.
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CARCINOMA OF THE EXTRAHEPATIC BILE DUCTS: A COM-
PARISON OF PROXIMAL AND DISTAL LESIONS
Peter J Allen, MD, David Klimstra, MD, Michael D’angelica, MD, Ronald
Dematteo, MD, Yuman Fong, MD, Leslie H Blumgart, MD, Murray F
Brennan, MD, William R Jarnagin, MD
Memorial Sloan-Kettering Cancer Center, New York, NY
Purpose. Disease-specific survival (DSS) for proximal bile duct cancer has
been reported to be worse than for carcinoma of the distal bile duct. Patients
with proximal (hilar) cholangiocarcinoma often present with locally unre-
sectable disease. This study compares outcome of resected hilar and distal
cholangiocarcinoma from a single institution.
Methods. Review of two prospectively maintained databases identified 204
patients who underwent resection for extrahepatic cholangiocarcinoma (hilar:
n106, 52%; distal: n98, 48%) between Dec 1987 and Dec 2005. Hilar
tumors were defined as lesions arising in the extrahepatic bile duct proximal
to the insertion of the cystic duct. Patient, tumor, and treatment related
variables were reviewed. Analyses were performed to compare tumor
presentation, treatment, and disease-specific outcome between patients
with resected hilar and distal lesions.
Results. Median follow-up for the 204 resected patients was 26 months
(range 1163 months) and 56 months for those alive at last follow-up. Patient
age at presentation and gender was similar between patients with hilar and
distal lesions. Pancreaticoduodenectomy was performed in 92% of patients
with distal lesions and combined liver/bile duct resection was performed in
82% of patients with hilar lesions. Patients experienced similar postoperative
length of stay (median: hilar, 13 days vs. distal, 13 days) and operative (90-
day) mortality (hilar, 7% vs. distal, 7%). Margin positive rates were similar
(hilar, 23% vs. distal, 15%; p0.21). Patients with distal lesions were more
likely to have node positive disease identified (48% vs. 21%, pB0.001) and
less likely to present with tumors containing a papillary component (3% vs.
24%, pB0.001). Estimated 5-year DSS for all patients was 31%. Tumor
location (hilar vs. distal) was not associated with 5-year estimated DSS (hilar,
28% vs. distal, 35%; p0.77, FIGURE). Factors associated with 5-year DSS
included stage at presentation (node negative, 38% vs. node positive, 17%;
pB0.001) and the presence of a papillary component (papillary, 46% vs.
non-papillary, 29%; p0.01).
Conclusions. The results from this study suggest that patients with resected
hilar and distal cholangiocarcinoma will experience similar operative out-
comes and disease-specific survival.
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‘‘SIDEWAYS’’: RESULTS OF REPAIR OF BILIARY INJURIES
USING A POLICY OF SIDE-TO-SIDE HEPATICO-JEJUNOST-
OMY (HJ).
Emily R Winslow, MD, Elizabeth A Fialkowski, MD, David C Linehan, MD,
William G Hawkins, MD, Steven M Strasberg, MD
Washington University School of Medicine, Saint Louis, MO.
Introduction. The Hepp-Couinaud technique involves side-to-side HJ to
the left hepatic duct but a side-to-side approach is not consistently used when
repairing other bile ducts. Side-to-side anastomoses have the theoretical
advantage of requiring less dissection thereby preserving better blood supply
to the bile ducts, and wider anastomoses are usually possible compared to
end-to-side repairs.
Methods. We report the results of treatment of 113 consecutive biliary
injuries with intention to perform side-to side anastomosis in all.
Results. 113 biliary injuries, 109 associated with cholecystectomy, were
treated from 19922006. Injury types were B (7 patients, 6%); C (10
patients, 9%) (B and C are aberrant duct injuries); E1 (8 patients, 7%); E2
(36 patients, 32%); E3 (20 patients, 18%); E4 (24 patients, 21%); E5 (8
patients, 7%). No A or D injuries were treated. 26 patients (23%) had prior
repairs (8 duct-to duct; 18 HJs). 19% of our repairs were performed within a
week of cholecystectomy, 58% were delayed until at least 6 weeks after
cholecystectomy, and 23% were late re-operations for recurrent strictures. In
92% of cases a side-to-side repair was actually accomplished. 33/113 (29%)
had wedge liver resections of segment 4 b or 5 to facilitate exposure. 23/113
(20%) developed postoperative complications and in 7 (6%) they were
serious complications requiring an invasive procedure for management.
There was one postoperative death. Mean follow-up is 4.6 years and median
follow-up 3.9 years. Excellent anastomotic function was achieved in 107/113
(95%). ‘‘Poor’’ results occurred in 6 patients. One patient with patent
anastomoses has had bouts of cholangitis due to Roux Loop malfunction.
Two patients with E4 injuries had biliary stents left across anastomoses for 
3 months. Three patients developed postoperative strictures requiring
percutaneous dilation-one shortly after an early repair, the others 2 and 10
years post-repair. No patient has required re-operation for anastomotic
problems such as stricture. No other patients have had biliary symptoms.
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Conclusions. HJ using side-to-side anastomosis has theoretical advantages
of improved blood supply and larger anastomosis. With the exception of some
high right-sided injuries it is almost always possible. In our experience, 95%
of patients had excellent anastomotic function and no patients required later
surgical reconstructions. These results compare favorably with other pub-
lished reports, especially given the liberal definition of ‘‘poor’’ results used.
We believe that side-to-side technique should be used whenever possible
when performing HJ for biliary injuries.
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BILE DUCT INJURIES ASSOCIATED WITH LAPAROSCOPIC
CHOLECYSTECTOMY: TIMING OF REPAIR DETERMINES
LONG TERM OUTCOMES
Simon C Chow, Ajay K Sahajpal, Elijah Dixon, Paul D Greig, David R
Grant, Bryce R Taylor, Mark Cattral, Steve Gallinger, Alice C Wei
Division of General Surgery, University of Toronto, Toronto, ON, Canada;
Mayo Clinic, Rochester, MN; University of Calgary, Calgary, AB, Canada;
Toronto General Hospital, University Health Network, Toronto, ON,
Canada; Mount Sinai Hospital, Toronto, ON, Canada
Purpose. Bile duct injury (BDI) is a serious complication that may occur
following laparoscopic cholecystectomy. The purpose of this study is to
report a single large institutional experience with BDI and to examine the
factors that influence long term outcomes.
Methods. Patients who underwent a surgical repair of a laparoscopic
cholecystectomy-bile duct injury (LC-BDI) between January 1, 1992 and
Sept 1, 2007 were identified by retrospective chart review at two university-
affiliated hospitals. Univariate statistical analysis was used to identify risk
factors for post-operative complications.
Results. 69 patients were identified: 24 males, 45 females, and a median age
of 50. 13 immediate repairs (within 72 hours of LC), 34 early repairs
(between 72 hours and 6 weeks), 22 late repairs (after 6 weeks) were
performed. The BDI’s were Strasberg: Type A in 1 patient (1%), Type D in 2
patients (3%), Type E1 in 22 patients (32%), Type E2 in 16 patients (23%),
Type E3 in 22 patients (32%), Type E4 in 4 patients (6%), and Type E5 in 2
patients (3%). The most common presentation of BDI was bile leak, which
occurred in 33 patients (48%). BDI’s in 10 patients (14%) were recognized
intra-operatively. 43 hepaticojejunostomies (62%), 21 choledochojejunos-
tomies (30%), 4 right hepatic lobectomies with biliary reconstruction (6%),
and 1 primary CBD repair (1%), were performed. The overall morbidity rate
was 29% (20 patients). The mortality rate was 1% (1 patient). 13 patients
(19%) developed short-term postoperative complications; the most common
was cholangitis, which occurred in 7 patients (10%). There were no
significant relationships between timing of BDI repair and early post-
operative morbidity ((Dindo grades I-V, p0.95). The most common
long-term complication was biliary stricture, which occurred in 10 patients
(14%). Patients who were repaired early were more likely to develop biliary
stricture than patients repaired in the immediate or late periods (p0.035). 9
patients in the early phase developed biliary stricture, compared to 1 patient
in the immediate phase and 0 patients in the late phase.
Summary. Our results suggest that timing of BDI repair is an important
determinant of long-term outcome. Early BDI repairs were significantly
associated with the development of post-operative biliary stricture. Thus,
repairs should be undertaken either immediately (072 hours), or later (6
weeks) after LC-BDI.
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THE INFLUENCE OF BODY MASS INDEX ON THE INCIDENCE
AND SEVERITY OF BILIARY INFECTIONS
Lygia Stewart, MD, J Mcleod Griffiss, MD, Gary A Jarvis, PhD, Lawrence W
Way, MD
UCSF/SF VAMC, San Francisco, CA; UCSF, San Francisco, CA
Obesity is a known risk factor for gallstone disease. But little is known about
the influence of body mass index (BMI) on the clinical manifestations of
gallstone disease. We studied this utilizing clinical factors associated with
biliary infections.
Methods. 337 patients with gallstones were studied. Gallstones, bile, and
blood (as applicable) were cultured. Stone type was noted. Severity of the
acute illness was classified as: none (no inflammatory manifestations), SIRS
(fever, leukocytosis), severe (abscess, cholangitis, empyema), or MODS
(bacteremia, hypotension, organ failure). The association between BMI and
biliary bacteria, gallstone type, and severity of illness was examined using
bivariate analysis; and multivariate analysis utilizing clinical factors associated
with biliary infections (age, sex, choledocholithiasis, pigment stones).
Results. As expected, cases with cholesterol stones had a higher BMI than
those with pigment stones (table), and this association held on multivariate
analysis. On bivariate analysis, BMI inversely correlated with biliary bacteria
(P0.001), bactibilia (P0.006), and bacteremia (P0.037); but BMI did
not independently predict these factors on multivariate analysis. BMI
inversely correlated with illness severity on both bivariate and multivariate
analysis. And, this correlation was present for all cases, including the sub-
group with biliary bacteria (see graph).
Conclusions. This study showed that while obesity was a risk factor for
cholesterol gallstone disease, patients with a lower BMI had more serious
biliary infections. This finding was partially explained by an inverse
correlation between BMI and pigment stones as well as biliary bacteria.
But, multivariate analysis demonstrated that lower BMI was an independent
risk factor for severe biliary illness among cases with biliary bacteria, even
when pigment stones and choledocholithiasis were included as variables. This
suggests that obesity may be protective in biliary infections. This is the first
study to demonstrate a correlation between BMI and severity of biliary
infections.
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SURGICAL SPECIALIZATION AND OPERATIVE MORTALITY IN
HPB SURGERY
Nicholas Csikesz, B.Sc., Shimul A Shah, MD
University of Massachusetts, Worcester, MA
Surgeon specialization has been shown to result in improved outcomes. While
the importance of transplant training and expertise when performing hepato-
pancreato-biliary (HPB) surgery is recognized, specialty specific volume and
perioperative outcomes in the United States (US) have never been measured.
Methods. Using the Nationwide Inpatient Sample (NIS), discharge records
for all non-transplant pancreatic (n7,433) and liver surgery (n5,178)
were examined from 19982005. Surgeons were divided into two groups,
transplant (TX) or non-transplant (GI), and the proportion for each
determined using the unique surgeon identifier of NIS. Hospital identifiers
were used to categorize transplant centers. The Elixhauser index adjusted for
patient comorbidity. We created a logistic regression model to examine the
relationship between surgeon type, hospital type and operative mortality
while accounting for patient and hospital factors.
Results. 3,980 surgeons [169 TX (4%), 3,811 GI (96%)] performed HPB
surgery in 675 [68 transplant (10%), 607 non-transplant (90%)] hospitals
across 12 states over the 8-year period. 46% of surgeries were performed at
transplant hospitals. GI surgeons performed the majority of pancreatic
procedures (n7,161; 96%) and to a lesser extent, the liver procedures
(n3,999; 77%)(Table 1; partial list of procedures). After adjusting for
patient and hospital factors, there was no difference in mortality when HPB
surgery was performed by a GI or TX surgeon (p0.59). Significant factors
for inpatient death after HPB surgery included increasing age, male gender,
public insurance and black or Hispanic race (pB0.05). In addition, surgery
BMI
Bivariate
P
Multivariate
P
Cholesterol Stones 30 0.005 0.015
Pigment Stones 27 0.005 0.015
Sterile Biliary Tract 30 0.001 0.184
Biliary Bacteria 27 0.001 0.184
Illness severity (all cases) see graph 0.0001 0.007
Illness severity (cases w/ biliary
bacteria)
see graph 0.005 0.03
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performed at a transplant center had a 28% lower odds of perioperative
mortality (OR 0.72; 95% CI 0.60.9) (Table 2).
Conclusions. GI surgeons performed the majority of pancreatic and liver
surgery in the US from 19982005. Hospital factors, but not surgical
specialty (TX or GI), appear to impact operative mortality. Improved
outcomes after HPB surgery in centers that support transplantation may
reflect differences in perioperative services and practice environment.
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IMPACT OF TUMOR EXTENT AND LYMPH NODE INVOLVE-
MENT ON SURVIVAL IN GALLBLADDER ADENOCARCINOMA.
Victor Zaydfudim, MD, Irene D. Feurer, PhD, C. Wright Pinson, MD, MBA
Vanderbilt University Medical Center, Nashville, TN
Background. Gallbladder adenocarcinoma is an aggressive malignancy with
surgical resection as the primary treatment option. The combination of
tumor extent (T stage) and lymph node involvement (N stage) significantly
impacts survival in patients with gallbladder adenocarcinoma. We investi-
gated whether T stage and N stage are independent predictors of survival in
patients with gallbladder adenocarcinoma.
Methods. We conducted a retrospective, population-based cohort analysis of
the Surveillance Epidemiology and End Results (SEER) database for patients
who underwent surgical resection for gallbladder adenocarcinoma between
1988 and 2004. Kaplan-Meier and Cox proportional hazard regression
methods were used to test univariate effects of demographic and clinical
covariates and develop multivariate models of survival. Summary data are
presented as mean9SD or percentages.
Results.3824 patients with complete staging data who survived the
immediate perioperative period (age70.9912.5, 26.0% male, 81.2%
Caucasian) were identified. Age, gender, race, radiation treatment, tumor
grade, tumor extent and lymph node status had significant independent
effects on survival (all pB0.05). Overall survival differed by stage (pB
0.001). Patient survival (1- and 5- year rates indicated) was better for:
T1N0-Stage IA (74% & 37%), T2N0-Stage IB (67% & 28%), T1N1-Stage
IIB (60% & 19%), and T2N1-Stage IIB (68% & 21%) disease; than for:
T3N0-Stage IIA (43% & 10%), T3N1-Stage IIB (45% & 7%), Stage III
(24% & 0%) and Stage IV (14% & 0%) disease (all Log-rank pB0.05).
SEER defined extent of surgical resection did not affect survival in the
multivariate model (p0.69), or in patients with T3 disease (all Log-rank
p]0.10).
Conclusions. Presence of T3 and N1 disease confers independent increased
risk of death in patients with gallbladder adenocarcinoma. Survival in
patients with node positive disease is significantly improved if their tumor
does not violate the serosal layer.
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TIMING OF REFERRAL IMPACTS SURGICAL OUTCOMES IN
PATIENTS UNDERGOING REPAIR OF BILE DUCT INJURIES
Craig P. Fischer, MD, MPH, Bridget N. Fahy, MD, Thomas A. Aloia, MD,
Barbara L. Bass, MD
Weill Medical College of Cornell University, Houston, TX
Purpose. To determine the impact of referral timing on outcomes for
patients undergoing repair of laparoscopic cholecystectomy-related bile duct
injuries (BDI).
Methods. From 20012007, 72 patients were referred for management of
BDI; 44 of whom underwent operative repair and are the subject of this
report. Study variables identified in our prospective surgical database
include: Amsterdam injury classification, Bismuth injury level, number of
pre-referral interventions, timing of surgical referral, postoperative outcomes,
and inpatient length of stay. In this study, early referral was defined as within
72 hours of injury and delayed referral as greater than 72 hours after injury.
To allow portal inflammation to subside and to determine the level of biliary
ischemia, BDI repair was delayed in most patients for a period of 6 weeks.
During this interval, bilomas were percutaneously drained and all patients
underwent biliary drainage with percutaneous transhepatic biliary drains.
Results. Of the 44 study patients, 15 were referred within 72 hours and 29
patients after 72 hours. The early and delayed referral groups were similar for
classification and level of injury. The majority of injuries were Bismuth I-III
but approximately 25% of injuries were high (Bismuth IV-V). The type and
frequency of postoperative complications, including perioperative death,
anastomotic leak, cholangitis, early reoperation, and long-term biliary
stricture, were similar between the two referral groups (see Table). In
contrast, the incidence of postoperative intraabdominal abscess/biloma and
prolonged intensive care unit stay were more frequent in patients referred
after 72 hours (both pB 0.05).
Conclusions. Despite similar BDI characteristics, a significant association
between timing of surgical referral and postoperative complications and
outcomes was noted. These data suggest that early referral to a center with
multidisciplinary experience in the management of complex biliary duct
injuries optimizes postoperative outcomes.
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THE OBSTRUCTED PANCREATO-BILIARY LIMB: PRESENTA-
TION, MANAGEMENT AND OUTCOMES
David Odell, MD, Wande Pratt, Mark Callery, MD, Charles Vollmer, MD
Beth Israel Deaconess Medical Center, Boston, MA
Introduction. Obstruction of the pancreato-biliary (PB) drainage limb in
patients following major PB resection creates unique challenges in diagnosis
and management. We describe its prevalence and causes, as well as diagnostic
and therapeutic approaches.
Methods. Individuals with eventual PB limb obstruction were identified
from a cohort of 250 patients undergoing PB resection for benign and
malignant disease from 9/03-7/07. Their presentation, management, short-
term outcomes and survival were analyzed.
Results. Ten patients (4%) developed PB limb obstruction with a mean time
to presentation of 17 months (0.542 mo) (Table). Presenting symptoms
were reflective of limb obstruction (elevated LFTs 7, jaundice 6, cholangitis
4, pancreatitis 3). CT scan demonstrated dilation of the PB drainage limb
from obstruction in all ten patients, and evidence of intrahepatic biliary
dilatation in 6 patients. Endoscopy was not valuable for either diagnostic or
therapeutic purposes in the 3 patients evaluated in this manner. Percutaneous
transhepatic biliary drainage was pursued in 3 patients and was definitive
treatment in one case, while the other two were temporized by this modality
prior to a definitive operation. Operative management occurred in 9 of 10
patients. Causative lesions were not predicted accurately by preoperative
imaging and included adhesions, limb volvulus, abscess, malignant nodal
recurrence, solitary metastatic disease, and carcinomatosis. Surgical inter-
ventions varied (5 enteric bypasses, 3 adhesiolyses, and 1 external venting
drainage). There was no perioperative mortality, and limited morbidity (one
myocardial infarction & one wound dehiscence). No patients have had
subsequent recurrence of PB obstruction. The median duration of post-
operative hospital stay was 7.5 days and no patient required readmission. In
follow-up, 4 patients are deceased with a median survival of 7 months (210
mo). The remaining patients are alive at a median follow-up of 3.5 months
(1.530 mo).
Conclusion. Drainage limb obstruction following PB resection occurs
relatively frequently, and from a variety of reasons. Decisive operative
intervention affords the accurate assessment of the cause and extent of the
problem. Furthermore, it provides a definitive remedy with minimal
morbidity and a reasonable length of survival.
Table 1. Operative Volume
Surgery Type GI Surgeon Cases TX Surgeon Cases
Liver-Lobectomy 961 (65%) 524 (35%)
Liver-Wedge Resection 1441 (78%) 399 (22%)
Pancreas-Distal Pancreatectomy 1207 (96%) 46 (4%)
Pancreas-Whipple 2878 (96%) 122 (4%)
Pancreas-Total Pancreatectomy 152 (80%) 38 (20%)
Table 2. Logistic Regression of Operative Mortality
Variable Odds Ratio 95% CI p value
Age 1.0 1.01.02 B0.001
Comorbidity count 1.4 1.11.8 0.02
Female gender 0.6 0.50.8 B0.001
Private insurance 0.6 0.50.8 B0.001
Black race 1.3 1.01.8 0.03
Hispanic race 1.4 1.11.8 0.02
Teaching status 0.8 0.71.0 0.05
Transplant center 0.7 0.60.9 0.004
Transplant surgeon 1.1 0.81.6 0.59
. Timing of Referral and Complications
Early Referral
n15 (%)
Delayed Referral
n29 (%)
Amsterdam Class B (major injury/leak) 1 (7) 2 (7)
Amsterdam Class D (transection) 14 (93) 22 (76)
Amsterdam Class other 0 (0) 5 (17)
Bismuth I-III 11 (73) 21 (72)
Bismuth IV-V 4 (27) 8 (28)
Postoperative abscess/biloma 1 (7) 9 (31) *
ICU stay 7 days 1 (7) 8 (28) *
Reoperation 0 1 (3)
Biliary stricture 0 2 (7)
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LAPAROSCOPIC SPLEEN-PRESERVING TOTAL PANCREA-
TECTOMY FOR MULTIFOCAL IPMN
Michael L Kendrick, MD
Mayo Clinic, Rochester, MN
Background. Laparoscopic pancreatic resections are becoming widely
accepted.
Aim. This Video submission aims to demonstrate the technique of a
laparoscopic spleen-preserving total pancreatectomy (LSPTP).
Patient. A 71 year old female who presented with symptomatic diffuse
multifocal pancreatic intraductal papillary mucinous neoplasia. Following a
full clnical evaluation and discussion of risks and benefits, informed consent
was obtained.
Outcome. A laparoscopic spleen-preserving total pancreatectomy was
performed. Histology demonstrated diffuse main and branch duct IPMN
with high grade dysplasia. Her postoperative course was uncomplicated.
Conclusion. LSPTP is feasible and may offer the typical advantages
demonstrated with other laparoscopic pancreatic resections.
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LAPAROSCOPIC DISTAL PANCREATECTOMY WITH SPLENIC
PRESERVATION
Richard A Mackey, MD, R. Matthew Walsh, MD, St. Joseph Medical
Center, Towson, MD
Cleveland Clinic, Cleveland, OH
Laparoscopic distal pancreatectomy with or without splenectomy has evolved
with the advent of better equipment, endoscopic stapling devices and
experience. Splenic preservation is controversial but gaining acceptance for
some pancreatic lesions, namely, cystic neoplasms. The spleen may be
conserved with preservation or ligation (Warshaw technique) of the splenic
artery and vein. If ligated, the left gastroepiploic and short gastric arteries
should be preserved to reduce splenic complications. The laparoscopic
approach confers additional benefits such as decreased blood loss, less pain, a
shorter hospital stay and earlier return to work. This video demonstrates a
laparoscopic distal pancreatectomy with preservation of the splenic artery
and vein for a mucinous cystic neoplasm.
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CENTRAL PANCREATECTOMY WITH PANCREATICOGAS-
TROSTOMY FOR MUCINOUS CYSTADENOMA OF THE PAN-
CREATIC NECK
David A Kooby, MD
Emory University, Atlanta, GA
The patient is a 56 year old woman with a 2 year history of a cystic neoplasm
of the pancreatic neck. During interval follow up the lesion grew from 4 to 5.5
cm in largest diameter on cross-sectional imaging. Endoscopic ultrasound
and aspiration yielded mucin and a cyst fluid CEA level of 1600 mg/dL. The
patient was advised to have the lesion removed surgically, and underwent a
central pancreatic resection with pancreaticogastrostomy. She tolerated the
operation well and was discharged on postoperative day 7 without complica-
tions. Final histological analysis confirmed a 5.5 cm mucinous cystadenoma,
which was completely excised. Operative technique is highlighted.
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‘‘PANCREATOGENOUS ADULT HYPERINSULINEMIC HYPO-
GLUCEMIA SYNDROME’’
Juan Pekolj, MD, Diego Lucas Ferna´ndez, MD, Juan Antonio Salceda, MD,
Mariano Bregante, MD, Eduardo De Santibann˜es, MD
Hospital Italiano Buenos Aires, Buenos Aires, Argentina
Background. Insulinoma and Nesidioblastosis constitute an important
cause of pancreatogenous adult hyperinsulinemic hypoglucemia syndrome.
Both can be managed through miniinvasive surgery.
Objective. To show two PAHH Syndrome cases resolved by laparoscopic
approach.
Population and Methods. A 26 year-old female and a 54-year-old female
with PAHH syndrome are presented here. CT scan did not show any tumor
in either of them.Angiography showed an insulinoma on tail of pancreas in
the second case.The 48-hour fast test was positive in both cases.Calcium
stimulation was positive in splenic artery and in splenic and gastroduodenal
artery in the first? case.
Results. Both patients were approached by laparoscopy.The first case
was resolved through a laparoscopic spleen-preserving distal pancrea-
tectomy.The second case was resolved performing a laparoscopic distal
Patient Presentation and Management
1 Original Diagnosis
Duodenal Mass-Benign
Fibrosis
Original Operation
Pancreaticoduodenectomy
Time to Obstruction
(Months) 8.5
Findings Afferent Limb
Syndrome; Single
adhesion obstructing PB
limb
Management
Adhesiolysis (Single
Band)
2 Chronic Pancreatitis Pancreaticoduodenectomy 42 Inframesenteric PB limb
obstruction from
adenoCA of the distal
pancreas
Bypass of PB Limb:
(jejuno-jejunostomy)
3 Pancreatic CA Pancreaticoduodenectomy 36 PB Limb Volvulus Adhesiolysis
4 Pancreatic CA Pancreaticoduodenectomy 0.5 Retroperitoneal abscess
cavity compressing the
PB limb
External drainage of
abscess
5 Pancreatic CA Pancreaticoduodenectomy 13 Local recurrence in PB
limb in 2 positions
(closed loop obstruction)
Bypass of PB limb:
(Jejuno-jejunostomy x2)
6 Ampullary CA Pancreaticoduodenectomy 19 Diffuse carcinomatosis
with PB limb obstruction
PB limb venting tube for
decompression
7 Ampullary CA Pancreaticoduodenectomy 18 Solitary mesenteric
recurrence causing PB
limb obstruction;
Near-obstructing colonic
mass
Bypass of PB limb
(Jejuno-jejunostomy);
Left colectomy
8 Distal
Cholangiocarcinoma
Pancreaticoduodenectomy 10.5 Local recurrence in
mesentery obstructing
PB limb
PTC; percutaneous PB
limb metal wall stent
9 Proximal
Cholangiocarcinoma
R Hepatectomy, Bile Duct
Resection; Roux-en-Y
Hepatico-jejunostomy
14 Discrete metastasis at
entero-enterostomy
obstruction both PB and
gastric limbs
Bypass of PB and gastric
limbs: (Jejuno-jejunost-
omy x2)
10 Distal
Cholangiocarcinoma
Radical Cholecystectomy,
Bile Duct Resection;
Roux-en-Y Hepatico-
jejunostomy
8 Tumor recurrence in
Porta Hepatis
obstructing PB limb
Bypass of PB limb:
(Jejuno-jejunostomy);
Gastroenterostomy
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pancreatosplenectomy. Patients were discharged at day 5 and 6, respectively,
without postoperative complications.Post-operative 48-hour fast test was
negative.Hypoglucemia and diabetes were not observed in the follow- up.
Conclusion. PAHH syndrome should be surgically managed. Laparoscopic
surgery allowed us to resolve both cases satisfactorily.Symptoms were
controlled without any complications and without hypoglucemia or diabetes
in the follow-up.
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DISTAL PANCREATECTOMY WITH EN BLOC CELIAC AXIS
RESECTION FOR LOCALLY ADVANCED PANCREATIC BODY
CANCER
Satoshi Kondo, MD, Satoshi Hirano, MD, Eiichi Tanaka, MD, Toshiaki
Shichinohe, MD, On Suzuki, MD
Hokkaido University Graduate School of Medicine, Sapporo, Japan
Locally advanced cancer of the body of the pancreas often involves the
common hepatic artery and/or celiac axis with perineural invasion in the
nerve plexus surrounding these arteries, and is regarded as an unresectable
disease. To treat the disease, we have employed distal pancreatectomy with en
bloc celiac axis resection (DP-CAR) without the need for arterial reconstruc-
tion. The operative procedure by our original right-sided approach will be
presented by video.
We reported our experience with 23 patients between May 1998 and
September 2005 (Ann Surg 2007;246: 4651). The procedures routinely
included en bloc resection of the celiac, common hepatic, and left gastric
arteries, the celiac plexus and ganglions, the nerve plexus around the superior
mesenteric artery, a part of the crus of the diaphragm and the Gerota’s fascia,
the left adrenal gland, the retroperitoneal fat tissues bearing lymph nodes
above the left renal vein, the transverse mesocolon covering the body of the
pancreas, and the inferior mesenteric vein. Resection of the portal vein and
the middle colic vessels was optional. In general, no reconstruction of the
arterial system was required because of early development of the collateral
arterial pathways via the pancreatoduodenal arcades from the superior
mesenteric artery. Preoperative coil embolization of the common hepatic
artery was routinely used to enlarge the collateral pathways and prevent
ischemia-related complications. In addition, with preservation of the sto-
mach, no reconstruction of the alimentary tract was required. Finally, the
gallbladder was also preserved unless the arterial blood supply was
compromised.
The postoperative mortality rate was 0%, despite a high morbidity rate
(48%). The chief postoperative complications were pancreatic fistula and
ischemic gastropathy. Contrary to expectations, postoperative diarrhea was
mild. Preoperative intractable abdominal and/or back pain in 10 patients was
completely alleviated immediately after surgery. The surgical margins were
histologically negative in 21 patients (91%). The estimated overall one- and
five-year survival rates were 71% and 42%, respectively, and the median
survival was 21.0 months. The sites of recurrence were the liver in six patients
and local recurrence in two.
DP-CAR offers a high R0 resectability rate and may potentially achieve
complete local control in selected patients. The persisting early hepatic
recurrence may indicate DP-CAR for the treatment of less advanced disease.
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LAPAROSCOPIC DISTAL PANCREATECTOMY AND SPLENECT-
OMY
Alexander Rosemurgy, MD, Harold Paul, None, Desiree Villadolid, MPH,
Mark Shaprio, B.Sc., Sharona B. Ross, MD, Donovan Tapper, MD, Sarah M
Cowgill, MD
University of South Florida College of Medicine Department of Surgery,
Tampa, FL
Use of laparoscopic and minimally invasive techniques for applications in
general surgery is becoming increasingly more commonplace. Retroperito-
neal and intraabdominal resections that used to require open techniques are
now undertaken by aggressive and skilled laparoscopic surgeons. Laparo-
scopic pancreatic surgery has been shown to be feasible and safe for benign or
premalignant lesions in the pancreas. In this video we demonstrate a
laparoscopic distal pancreatectomy with splenectomy. We have employed
minimally invasive techniques to pancreatic resection, allowing this patient to
have the benefit of a time-tested operative intervention, without the short and
long-term morbidity of celiotomy.
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DUODENAL GASTRO INTESTINAL STROMAL TUMOR. LA-
PAROSCOPIC TREATMENT
Sergio E Bustos, MD, Jorge Eduardo Nefa, MD, Pablo Esteban Omelanczuk,
MD
Italian Hospital of Mendoza, Mendoza, Argentina
Background. The Gastrointestinal Stromal Tumors (GIST) are 30% of the
digestive system.The diagnostic is confirmed by the positivemarker for the CD-
117 antigen who excludes other tumors as Leiomyomas and Schwannomas.
Objective. The purpose is to show the Laparoscopic resection of a Duodenal
Tumor (GIST)
Method. A 64 years-old woman presenting duodenal tumor after laparo-
scopic cholecystectomy, was approached by relaparoscopy. Before surgery a
duodenoscopic biopsy evidenced Gastric Choristoma.
Through a Pyloromiotomy a submucosal duodenal tumor was resected. The
mucosa was sutured and the access closed performing an Heinecke-Mickulicz
technique.
Results.The hospital stay was 3 days and the patient is free of symptoms 8
months after the procedure. The pathology and histoquimic examination
diagnosed an stromal tumor of the duodenum.
Discussion. Albeit duodenal tumors are uncommon should be in the
differential diagnostics of biliary disease.
Conclusion. Duodenal tumors without malignity signs can be approached
by Laparoscopy although they could need a major resection by laparotomy.
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TOTALLY LAPAROSCOPIC CENTRAL HEPATECTOMY
Andrew A Gumbs, Brice Gayet, MD, PhD
Columbia University College of Physicians and Surgeons, New York, NY;
Institut Mutualiste Montsouris, Paris, France
Introduction. Since the first report of a laparoscopic liver resection in 1992,
laparoscopic resection of peripheral hepatic segments has become increas-
ingly more common in the surgical treatment of both benign and malignant
tumors. The minimally invasive approach to major hepatectomies, however,
is still only being currently performed in highly specialized centers. This is
principally because of concerns for gas embolism and difficulty in controlling
major hemorrhage via the laparoscopic approach. This video will demon-
strate the relevant technical maneuvers in the performance of a totally
laparoscopic central hepatectomy.
Method. This video will illustrate the pertinent issues regarding instrument
selection, trochar placement, intra-operative monitoring and steps necessary
to perform central hepatectomy using totally laparoscopic techniques. The
principal steps of this procedure include: control of hepatic inflow, division of
hepatic parenchyma, control of hepatic outflow, mobilization of the liver and
specimen removal.
Results. This procedure has been attempted and performed successfully
once at our institution by totally laparoscopic techniques in a 43 year old
patient with a colorectal metastasis to the liver. The tumor measured 18 cm
and the patient lost 1000cc during an operation that lasted 420 minutes. The
post-operative course was complicated by an abscess along the resection line
that was treated by a drain placed by interventional radiology. The patient
was discharged home on day 18 and was alive and free of disease on 6-month
follow-up.
Conclusion. Minimally invasive techniques for central hepatic resections are
feasible, and high volume centers that specialize in these procedures can have
results similar to historical open series.
Totally laparoscopic central hepatectomy should currently only be performed
by surgeons with expertise in laparoscopy and hepatobiliary surgery.
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TOTALLY LAPAROSCOPIC EXTENDED LEFT HEPATECTOMY
Andrew A Gumbs, Barak Bar-zakai, MD, Brice Gayet, MD, PhD
Columbia University College of Physicians and Surgeons, New York, NY;
Institut Mutualiste Montsouris, Paris, France
Introduction. Laparoscopic resection of peripheral hepatic segments has
become increasingly more common in the surgical treatment of both benign
and malignant tumors. The minimally invasive approach to major hepatec-
tomies is still only being currently performed in highly specialized centers.
This video will demonstrate the relevant technical maneuvers in the
performance of a totally laparoscopic extended left hepatectomy including
resection of segment I. Common pitfalls and areas of concern will also be
discussed.
Method. This video will illustrate the pertinent issues regarding pre-
operative patient selection, necessary minimally invasive equipment, trochar
placement, intra-operative monitoring and steps necessary to perform a left
hepatectomy including control and resection of the middle hepatic vein and
the left aspect of segment VIII using totally laparoscopic techniques. The
techniques for removal of segment I will also be demonstrated. The five
principal steps of this procedure include: mobilization of the liver, control of
hepatic inflow, division of hepatic parenchyma, control of hepatic outflow
and removal of the specimen.
Results. At our institution a total of 3 extended left hepatectomies have been
performed with totally laparoscopic techniques. These procedures included
left hepatectomies with the addition of resection of the middle hepatic vein
and complete or partial resection of segments V and VIII. Complications
included bile leak in one patient that responded to endoscopic placement of
biliary stents. Out short and long-term results have been similar to our open
historical controls. No mortalities have been observed. Conclusion. Mini-
mally invasive techniques in left hepatic resections are feasible, and high
volume centers that specialize in these procedures can have results similar to
historical open series. Totally laparoscopic extended left hepatectomy should
currently only be performed by surgeons with expertise in laparoscopy and
hepatobiliary surgery.
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USE OF THE RADIOFREQUENCY ABLATION DEVICE (HABIB -
4X TM) IN LAPAROSCOPIC HEPATIC PARENCHYMAL TRANSEC-
TION.
Alejandro Mejia, MD, Stephen Cheng, MD
Liver Institute at Methodist Dallas, Dallas, TX
Introduction. The laparoscopic approach for resection of benign and
malignant liver tumors is a technique in evolution and only used in a few
centers in the US.A limiting factor for wider applicability of the procedure
has been the lack of efficient tools for parenchymal transection. The Habib
device has offered new options in open resections and a newly released
laparoscopic variation of the instrument has been released for minimally
invasive liver techniques.
Methods.A 58 yo Asian Male with history of hepatitis B, developed an
enhancing lesion in the left lateral segment.The patient underwent a
laparoscopic left lateral segmentectomy with the use of the laparoscopic
Habib device.The video of the operation with the technical details of the
parenchymal transection is submitted.
Results.The operation was completed in 72 minutes without the use of
blood transfusions.The patient was discharged home the next day.At 1 -year
of follow up the patient has had no recurrence and continues therapy for
Hepatitis B.
Conclusion. The new laparoscopic Habib device offers a promising
alternative for a safe parenchymal transection during laparoscopic liver
resection cases.
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LAPAROSCOPIC, ROBOTIC-ASSISTED COMPLETION CHOLE-
CYSTECTOMY
John B Martinie, Juan Carlos Vasquez, MD, Geoffrey P. Kohn, MD
University of North Carolina, Chapel Hill, NC
Background. Gangrenous cholecystitis is a serious, life-threatening condi-
tion which may present a formidable challenge to general surgeons. Often the
full extent of the inflammation and necrosis is not determined until the time
of exploration, and many prudent surgeons choose to convert to an open
procedure. The intensity of the inflammatory response, tissue friability and
bleeding near the porta hepatis often makes formal anatomic dissection of the
gallbladder structures unsafe or impossible. Surgeons often choose to simply
"unroof" or amputate the gallbladder high up, away from the common bile
duct in order to avoid iatrogenic injury. Surgical drains are left to control the
anticipated bile leakage, which usually closes spontaneously with time and
conservative management. Occasionally, a patient may develop a persistent
biliary fistula or symptomatic gallbladder remnant, which may operative
intervention.
Methods. Three consecutive patients underwent open cholecystectomies at
outside hospitals for acute, gangrenous cholecystitis. All developed biliary
leaks, managed with surgically placed drains, and then with endoscopically
placed biliary stents. All three had sizeable gallbladder remnants visible on
ERCP. All three had undergone repeated endoscopies and stent placements
but ultimately were deemed failures, either due to persistent leakage or
symptoms.
Due to the anticipated complexity of performing a laparoscopic completion
cholecystectomy, the Da Vinci robot (Intuitive Surgical, Sunnyvale, CA,
USA) was utilized. Dissection was performed using two robotic instrument
arms via 8 mm ports, as well as assistant ports for suction/irrigation devices,
clips, and endostaplers.
Results. All 3 procedures were completed laparoscopically, with no
complications, and all 3 patients went home the same day of surgery. At
follow-up, all were free from biliary leaks or symptoms.
Conclusion. Laparoscopic Robot-assisted completion cholecystectomy is
safe and feasible option in the setting of a reoperative, hostile abdomen.
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VIDEO: OPEN LEFT HEMIHEPATECTOMY FOR COLORECTAL
METASTASES UTILIZING THE GYRUS OPEN FORCEPS FOR
PARENCHYMAL TRANSECTION
Matthew R Porembka, MD, William G Hawkins, MD
Washington University in St Louis, Saint Louis, MO
Objective. A 7-minute video will be presented to demonstrate an open left
hemihepatectomy using the Gyrus Open Forceps (Gyrus Medical) for
metastatic colorectal cancer.
Background. During the last two decades, advancements in surgical
technique and perioperative care have dramatically improved outcomes for
the increasing number of liver resections performed. Liver transection
remains a critical step during resection; however, the optimal transection
method has not yet been determined. Despite improvements in surgical
technology, over 40% of hepatobiliary surgeons continue to utilize the clamp-
crushing method of transection with inflow occlusion. Several alternative
methods for transection, including the harmonic scalpel and ultrasonic
dissector, have shown reductions in intraoperative blood loss, transfusion,
and perioperative complications. The Gyrus Open Forceps, which utilizes
bipolar cautery, is one such new device for parenchymal transection.
Material. A 32 year-old white male presented with colorectal cancer and
synchronous hepatic metastases to segments II and IVA. After neoadjuvant
chemoradiation, he underwent a combined low anterior resection and open
left hemihepatectomy.
Results. The patient underwent an open left hemihepatectomy with
extension into segment VIII. After extrahepatic division of the hepatic artery
and portal vein, parenchymal transection was accomplished using the Gyrus
Open Forceps. No inflow occlusion was required. The transected area
measured approximately 187 cm2, required 58 minutes to complete, and
resulted in a 200 ml blood loss. Postoperatively, the patient had no
complications, and was discharged home 10 days after surgery.
Conclusion. The Gyrus Open Forcep is a safe and efficient method for liver
transection.
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KASSABACH-MERRITT SYNDROME DUE TO GIANT LIVER
HAEMANGIOMA TECHNIQUES FOR HAEMOSTASIA AND VAS-
CULAR CONTROL
Eduardo De Santiban˜es, MD, Juan Pekolj, MD, Juan Antonio Salceda, MD,
Rodrigo Sanchez Claria, MD, Diego Lucas Fernandez, MD, Mariano Luis
Bregante, MD
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background. Liver haemangiomas are frequently seen and controlled, but
giant haemangiomas may cause several complications such as bleeding,
coagulopathy and Kassabach-Merritt syndrome. Treatment options such as
radiotherapy, embolization, enucleation, liver resection and transplantation
are described.
Materials and Method. We present a case of a 59-year-old female patient
with a giant liver haemangioma and Kassabach-Merritt syndrome treated
with arterial embolization and posterior surgery.
Enucleation was performed with total vascular control. Arterial inflow
control was used during the enucleation and Pringle maneuver was used
only in two 20-minute periods.
Results.The patient had a normal post-operative course with 2 days in
intensive care unit and was discharged at 6th day.
Conclusion. Enucleation for giant liver haemangiomas appears to be a safe
and feasible option to treat this kind of lesions, thus avoiding liver
transplantation.
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ROBOTIC LEFT LATERAL SEGMENT RESECTION
Marwan Abouljoud
Henry Ford Hospital, Detroit, MI
Introduction. In recent years, laparascopic techniques have become more
widely used and accepted means for performing various types of liver
resections. In this presentation we share our early experience with a novel
approach for minimally invasive hepatic resection.
Case Report. This is a 29 yo Caucasian male who presented with early
satiety and epigastric discomfort. Evaluation revealed a large liver lesion in
the left sector consistent with probable liver cell adenoma. Surgical resection
was offered using minimally invasive technique. We have established safety of
a laparoscopic technique for performing liver resection using vapor pulse
coagulation. In this instance, patient was offered laparoscopic left liver
sectorectomy using the DaVinci Robot assisted technique. A 4 port technique
was used: camera port, 2 robot arms, and assistant port. Hilar dissection and
vascular isolation were performed and facilitated by the 3 dimensional field
view and articulated robot arms. Parenchymal transaction along the falciform
was done using Olympus Sonosurge harmonic device. Division of hilar plate
and left hepatic vein were accomplished with vascular endo-GIA. Procedure
was completed uneventfully and patient was discharged on postoperative day
3 without any adverse events. Blood loss was minimal.
Conclusions. Laparoscopic hepatic resection is safe in trained hands and
can be used in many clinical scenarios. The DaVinci Robot assisted
technique adds the benefit of better surgical field visualization, excellent
optics, 3 dimensional views and the precision of articulated and calibrated
finger/hand motion. This technique shows promise for wider application in
the future albeit with need for more trained personnel to assist in smooth
operation and expert assistance during the procedure.
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LIVER REGENERATION AND RECANALIZATION TIME-
COURSE FOLLOWING REVERSIBLE PORTAL VEIN EMBOLIZA-
TION
Panagiotis Lainas, MD, Lyes Boudechiche, PhD, Angel Osorio, PhD, Anne
Weber, PhD, Daniele Pariente, MD, Dominique Franco, MD, PhD, Ibrahim
Dagher, MD, PhD
Antoine Beclere Hospital, Clamart, France; INSERM, Kremlin Bicetre,
France
Introduction. Permanent portal vein embolization (PVE) is both a safe and
widely practiced technique for inducing liver regeneration. In a previous
study, we used PVE prior to hepatocyte transplantation and demonstrated
that it improved engraftment and proliferation of transplanted cells. How-
ever, the long term effects of permanent embolization with non-absorbable
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material in an unresected liver are not known. The aim of this study was to
evaluate the efficiency of reversible PVE on hepatic regeneration and analyze
the revascularization time-course using powdered absorbable material.
Methods. Nine Macaca mulatta monkeys, weighing 3.690.5 kg, were used.
The left and right anterior portal branches were embolized with powdered
Curaspon†. Animals underwent repeated portograms until complete revas-
cularization of the embolized liver was achieved. Hepatocyte proliferation
rates were assessed on days 3, 5 and 7 after embolization by BrdU
incorporation. The volume of the liver segments was measured by CT scan
imaging using PTM3D volumetry software. This was performed once prior
to reversible PVE, once after one month and once after one year.
Results. Reversible PVE induced significant hepatocyte proliferation in non-
embolized segments. Proliferating hepatocytes in non-embolized liver repre-
sented 13.591.0%, 10.590.8% and 9.192.0% on days 3, 5 and 7,
respectively. One month after embolization, the non-embolized liver volume
increased from 37.5% to 53.9% of the total liver volume. Proximal portal
recanalization and complete revascularization occurred 6 to 8 days and 12 to
16 days, respectively, after reversible PVE.
Conclusion. These results suggest that reversible PVE is effective in
inducing liver regeneration. Furthermore, the use of absorbable material
avoids long-term scarring of the liver, suggesting that such material could be
suitable for several medical indications in humans, including cell transplanta-
tion.
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N-O DONOR DRUGS IMPROVE HEPATOCYTES TRANSPLAN-
TATION IN MOUSE LIVER
Ibrahim Dagher, MD, PhD, Lyes Boudechiche, PhD, Panagiotis Lainas,
MD, Michelle Hadchouel, MD, PhD, Anne Weber, PhD, Dominique
Franco, MD, PhD
Antoine Beclere Hospital, Clamart, France; INSERM, Kremlin Bicetre,
France
Introduction. Hepatocytes transplantation is an adequate therapy for some
genetic hepatic disorders caused by hepatocyte dysfunction and currently
treated by liver transplantation. This therapy is still limited by the loss of
many transplanted cells in the portal radicles before their entry into the
sinusoids to engraft.
Methods. In this study we examined the Glyceril-trinitrate (GTN) vasodi-
lator effect on hepatic sinusoids and assessed its efficiency on hepatocytes
engraftment in a syngenic mice model.We first assessed the effect of GTN
portal infusion on the parenchymal spreading of colored microspheres.
Hepatocytes transplantation in a syngenic mice model was then performed
concomitantly with GTN infusion. The distribution of transplanted hepato-
cytes and their ultimate engraftment were analysed.
Results. After GTN perfusion 27% of microspheres shifted from the portal
to the sinusoidal zone. Transplanted hepatocytes distribution changed
significantly in the portal and parenchymal zones from respectively 5392%
and 46.892% in control animals to 32.592.4% and 67.592.4% in GTN-
treated animals (p0.04). At days 7 and 15, we noted a significantly better
engraftment in GTN group vs. controls (6094 vs. 3792 transplanted
hepatocytes in 20 fields x40; p0.02).
Conclusion. Portal perfusion of GTN improved the access of microspheres
and transplanted hepatocytes to the sinusoidal bed. This probably explains
the better engraftment of transplanted hepatocytes. These results suggest that
drug vasodilatation prior to transplantation increases the efficiency of
hepatocyte grafting.
138
STEATOSIS CAUSES IMPAIRMENT OF HEPATOCYTE META-
BOLISM
Justin D Ellett, B.Sc., Eric R Hall, Ed L Lecluyse, PhD, Kenneth D Chavin,
MD, PhD
Medical University of South Carolina, Charleston, SC; CellzDirect, Pitts-
boro, NC
It is well established that livers that have high levels of intracellular fat
(steatosis) have a number of physiologic disturbances, both at baseline and
after significant stress. For example, steatotic livers have increased sensitivity
to endotoxin, poor ischemic tolerance, and impaired regenerative capacity. In
addition, the increasing number of steatotic livers presents an additional
hurdle to the isolation of primary hepatocytes for research. These hepatocytes
are more sensitive to the stresses of the isolation procedure, as well as being
differentially dense, so that they are more difficult to isolate from the
remainder of the nonparencymal cell population. Once isolated, the question
then arises whether or not these hepatocytes will function in vitro the same as
lean hepatocytes. To address this question, we determined whether steatotic
hepatocytes have diminished metabolic activity in vitro as compared to lean
hepatocytes. A retrospective analysis of primary human hepatocytes from 82
liver resections with varying levels of steatosis was performed. Once these
cells were isolated, the metabolism of two compounds was assessed. The first,
7-ethoxycoumarin (7-EC), is a substrate for the cytochrome P450 family of
enzymes that function in phase I metabolism. The second, 7-hydroxycou-
marin (7-HCG), is a substrate for phase II metabolism, particularly the
UDP-glucuronosyltransferase enzymes. The metabolism of these compounds
can be used to investigate the rates and efficiency of their respective phases of
metabolism. When we grouped the cells based on steatosis into three groups
(none, minimal/mild, moderate/severe), we found that there was a drop in
phase I metabolism from the group with no steatosis (143.089121.7) to the
group with moderate/severe levels of steatosis (87.92974.7) that approached
significance (p0.09). However, a significant drop in phase II metabolism
was observed between the group with minimal/mild steatosis (708.239
610.91) and the group with moderate/severe steatosis (467.39301.9, pB
0.05). In conclusion, we see that severely steatotic hepatocytes have impaired
phase I and II metabolism as compared to hepatocytes with little or no
steatosis. This has important implications both clinically in terms of liver
health and in vitro in terms of the study of drug metabolism.
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THE EFFECT OF TISSUE INHIBITOR OF METALLOPROTEI-
NASE-3 (TIMP-3) ON TNF-a LEVELS IN RATS UNDERGOING
SUB-LETHAL TOTAL HEPATIC ISCHEMIA
Ari J Cohen, MD, O. Rama Swamy, PhD, Zhenya Tang, MD, PhD, Ian
Carmody, MD, Nigel Girgrath, MD, George Loss, MD, PhD
Ochsner Clinic Foundation, New Orleans, LA
We previously reported that TIMP-3, a specific inhibitor of Tumor Necrosis
Factor-alpha-converting enzyme (TACE), significantly decreases circulating
levels of TNF-a and ameliorates biochemical and histological hepatic injury
in a partial warm ischemia model. In this study, we tested the ability of
TIMP-3 to lessen liver injury in a sub-lethal total hepatic ischemia model.
Methods. Male Wistar rats (n18) were intraperitoneally injected with
TIMP-3 (a TACE specific inhibitor) at a dosage of 0 (normal saline, control
group) or 1000 ng/Kg body weight. One hour later, all animals were
subjected to 30 minutes of total warm hepatic ischemia followed by
reperfusion for 24 hours, 48 hours or 7 days. Serial serum TNF-a levels
were measured by ELISA. Serum ALT levels and hepatic histology were
examined.
Results. All animals survived sub-lethal hepatic ischemia for the duration of
the study. The serum TNF-a levels of TIMP-3 treated animals were
significantly lower at 24 hours, 48 hours and Day 7 compared to controls
(PB0.01). The serum ALT levels were significantly reduced in the TIMP-3
treated group at 24 and 48 hours (PB0.01) and were not different by day 7.
Conclusion. TIMP-3 treatment resulted in lower circulating TNF-a levels
for at least 7 days following sub-lethal ischemic hepatic injury. Circulating
hepatic transaminases were also reduced with TIMP-3 treatment for the first
48 hours following injury. This model suggests that TIMP-3 may potentially
play a clinically relevant role in protecting livers undergoing ischemic insult.
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FOCAL ADHESION KINASE IS A KEY REGULATOR OF PAN-
CREATIC CANCER CELL MIGRATION
Jayme B. Stokes, MD, Paul W. Wright, Jill K. Slack- Davis, PhD, J. Thomas
Parsons, PhD, Todd W. Bauer, MD
University of Virginia, Charlottesville, VA
Background. Growth factor receptors, integrins, vitronectin (VN), and focal
adhesion kinase (FAK) mediate cell migration in pancreatic cancer. However,
the cooperation between these different molecules in regulating pancreatic
cancer cell migration is not well characterized.
Methods. Transwell migration assays were performed with the human
pancreatic cancer cell line L3.6pl. Cells were pretreated with IgG, aVb5, or
aVb3 inhibitory antibodies (ab) then treated with phosphate buffered saline
(PBS), insulin-like growth factor-I (IGF-I), or hepatocyte growth factor
(HGF). To evaluate the effect of VN on growth factor-mediated migration,
chambers were coated with VN or left uncoated then stimulated with PBS,
IGF-I, or HGF. To evaluate the role of FAK in IGF-I-mediated migration,
cells were pretreated with DMSO or FAK inhibitor (PF-562,271) then
stimulated with PBS or IGF-I. To evaluate cell signaling, cells were
pretreated with FAK inhibitor or aVb5 ab, then stimulated with IGF-I,
HGF, or VN, and then subjected to Western blotting for pFAK and total
FAK.
Results. IGF-I and HGF led to a 7.0 90.2-fold (pB0.0001) and 7.090.3-
fold (pB0.0001) increase in cell migration, respectively. aVb3 ab did not
affect migration, whereas aVb5 ab decreased IGF-I- and HGF-mediated
migration by 29% 93% (pB0.0001) and 20% 95% (pB0.005), respec-
tively. VN alone led to a 2.090.2-fold (pB0.0001) increase in migration and
augmented IGF-I- and HGF-mediated migration by 54%93% (pB0.0001)
and 62%95% (pB0.0001), respectively. FAK inhibitor decreased IGF-I-
mediated migration by 43% 98% (p0.005). IGF-I and HGF increased
FAK phosphorylation and this was blocked by the FAK inhibitor. VN
increased FAK phosphorylation and this was blocked by aVb5 ab.
Conclusions. FAK signaling regulates pancreatic cancer cell migration
induced by IGF-I, HGF, and VN in an aVb5-dependent manner. A better
understanding of this complex signaling will help devise rational combina-
tions of targets for therapy.
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POST SURGICAL ABDOMINAL WOUND INFECTION DUE TO
NON TUBERCULOUS RAPID GROWING MYCOBACTERIA:
DIGNOSIS AND MANAGEMENT
Vijaya Lakshmi Nag, MD, T N Dhole, MD, Nihar Ranjan Dash, MS
Sanjay Gandhi Post Graduate Institute Of Medical Sciences, Lucknow,
India; All India Institute Of Medical Sciences, New Delhi, India
Background. Post surgical abdominal wound infections by non tuberculous
rapid growing mycobacteria (NTMWI) is an emerging problem.This can be
difficult to diagnose and manage. In a common scenario, a simple reporting
of AFB positivity in the wound discharge smear, masks the diagnosis of NTM
and lands the patient into ineffective treatment with standard antitubercular
regimen.
Objective. To describe our experience of nine suspected cases of NTMWI
and suggest steps for accurate diagnosis and effective management.
Material and Methods. During 2006, nine cases of post surgical abdominal
wound problem of recurrent discharging sinuses with or with out surface
nodularity, were referred to the mycobacteriology lab in SGPGIMS,
Lucknow.The median duration of chronicity was 2 months. Five of them
had received some form of antitubercular treatment. The specimens (FNAC-
4; Discharges -9) were smeared and stained with Z-N. All were cultured in L-
J media & then incubated at 370 C, maximum up to 8 weeks. Each isolate
further underwent biochemical and molecular characterization. The samples
were also simultaneously processed for bacteria, nocardia and fungi.
Antimicrobial susceptibility checked by disc diffusion method.
Result. NTM were detected in five cases, on more than two occasions (26)
in each case. M.fortuitum and M.chelonae were isolated in two cases each.In
one case the species could not be identified. All the 5 strains were sensitive to
Levofloxacin and Linezolid. All were resistant to Ampicillin-sulbactum.The
sensitivity to other antibiotics was widely varied on case per case basis. In two
cases no organism could be isolated. Two cases showed pseudomonas as the
only isolate. The cases were treated with wide excision and combination of
Levofloxacin and Linezolid for six months. The wounds were completely
healed by 4 months. One case had developed nodules underneath the healed
wound after one month of completion of therapy. The FNAC did not show
any isolate.
Discussion and Conclusion. Post surgical chronic non healing wounds
with nodularity and watery discharging sinuses should be subjected to
complete bacteriological, fungal and mycobacteriological examination. As
simple AFB positivity cannot confirm tuberculosis or rule out NTM, further
isolation techniques, as described in our cases, are required. NTM usually do
not respond to standard antitubercular regimen. Timely examination of
multiple samples at different stages can diagnose non tuberculous mycobac-
teria and suggest effective therapy.
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OXALIPLATIN IMPAIRS POST-HEPATECTOMY LIVER REGEN-
ERATION IN A MURINE MODEL
Perry A Soriano, MD, Nian Liu, MD, Erick Castillo, Brock Foster, Avo
Artinyan, MD, Joseph Kim, MD, Wendong Huang, PhD, Lawrence D
Wagman, MD
City of Hope National Medical Center, Duarte, CA
Introduction. Chemotherapy is integral to the multidisciplinary treatment
of liver metastases. Its effect on hepatic regeneration which may influence
subsequent timing or extent of surgery has not been established. We examine
a murine model of 70% hepatectomy for the evaluation of hepatic
regeneration in the setting of oxaliplatin therapy.
Methods. Eight week old C57BL/6 non-tumor bearing mice were rando-
mized to receive intraperitoneal oxaliplatin, 15 mg/Kg, or control solution. At
14 days post-treatment, 70% hepatectomy was performed. Animals were
sacrificed and liver remnants were harvested at the following postoperative
time points: 2 hrs; 1, 2, 3, and 7 days. Hepatic regeneration in the treatment
and control arms was compared using t-tests for independent samples.
Results. Twenty-two animals proceeded to hepatectomy with 13 in the
oxaliplatin group and 9 in the control group. Pre-operative animal weights in
the two arms were similar. At hepatectomy, the liver parenchyma in the
treated animals was consistently pale in appearance compared with those of
control animals. Percent hepatic regeneration did not differ at day 1 when
comparing the oxaliplatin and control groups (56.1% vs 52.5%, respectively,
p0.312). At day 2, regrowth was less in the treatment arm (57.6% vs
73.0%, p0.154). Regeneration was significantly less in the oxaliplatin arm
at day 3 (70.0% vs 89.0%, p0.048). There was no significant difference in
regeneration at day 7 (89.8% vs 99.0%, p0.214).
Conclusions. Oxaliplatin administration results in impaired hepatic regen-
eration at 3 days post-hepatectomy in a murine model. Despite initial
impairment, there is equivalent regeneration in the treatment and control
groups by day 7. This initial report demonstrates that early hepatic
regeneration may be hindered by current chemotherapeutic agents and
reinforces the need for careful timing when planning hepatectomy in patients
receiving multimodality treatment.
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RELATIONSHIP BETWEEN DENDRITIC CELLS GENERATION
FROM PERIPHERAL BLOOD MONONUCLEAR CELLS AND
MORBIDITY AND MORTALITY AFTER PANCREATIC SURGERY
Andre S Matheus, MD, PhD, Mariza Treglia, Jose Jukemura, MD, PhD, Jose
Eduardo Monteiro Cunha, Marcel Cerqueira Cesar Machado, MD, PhD,
Jose Alexandre Barbuto, MD, PhD
University of Sao Paulo, Sao Paulo, Brazil
Dendritic cells are the most potent antigen-presenting cells and play an
important role in the maintenance of an immune response. However, in some
conditions as cancer and malnutrition DC generation and function may be
deficient, compromising the immune system function. Here, we describe the
in vitro generation of DC from peripheral blood mononuclear cells (PBMC)
obtained from patients submitted to pancreatic surgery and related this
phenomenon with the occurrence of postoperative complications.
Methods. Twenty-five patients undergoing major oncological pancreatic
surgeries as duodenopancreatectomy, distal pancreatectomy and palliative
surgeries were investigated for dendritic cells generation from peripheral
blood mononuclear cells and related with the occurrence of postoperative
complications. PBMC were separated from blood obtained from the patients.
Adherent cells were cultured with GM-CSF and IL-4 (50 ng/mL) for 7 days.
On the 5th day, TNF-Alpha (50ng/mL) was added for DC activation.
Cultures were performed in 10% JP or normal plasma (NP). Non-adherent
cells were harvested at day 7, labeled with FITC- or PE-conjugated
monoclonal antibodies against CD86, CD80, CD1a, CD11c, CD14,
HLA-DR and analyzed by flow cytometry.
Results. Patient cells with high incidence of postoperative complications
showed significantly (pB0.05) lower expression of CD11c, CD80, CD86
and HLA-DR.
Conclusion. This study demonstrated a clear relation between immunologic
status and occurrence of postoperative complications, implicating in the
development of the postoperative systemic immunoinflammatory state to
reduce morbidity and mortality.
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OPIOID GROWTH FACTOR MEDIATED INHIBITION OF HEPA-
TIC CARCINOMA IN VITRO
Diego Avella, MD, Luis J Garcia, MD, Hephzibah Tagaram, PhD, Mandeep
Shembey, None, Serene Shereef, MD, Eric Kimchi, MD, Patricia Mclaugh-
lin, None, Ian Zagon, PhD, Kevin Staveley-o’carroll, MD, PhD
Penn State University, Hershey, PA
Introduction. Opioid growth factor (OGF) is an endogenous peptide that
interacts with OGF receptor (OGFr) to modulate cell proliferation. In
previous studies with human colon and pancreatic carcinoma cell lines, OGF
was shown to inhibit cellular proliferation in a receptor-mediated manner
targeting the cyclin dependent inhibitory kinase pathways. The current study
examined the effects of OGF on human hepatic carcinoma cell lines.
Methods. SK-Hep1 and HepG2, two human hepatic carcinoma cell lines,
were grown in culture using MEM, Alpha 1X. The presence of OGFr on
SKHep1 and HepG2 cells was demonstrated via immunohistochemis-
try(IHC). SKHep1 cells were treated with the long acting opioid antagonist,
Naltrexone, at 106 M every 24 hrs and growth assessed over 96 hrs. Both
cell lines were treated with 106 M OGF every 24 hrs and cell growth
assessed daily over 96 hrs. To determine the dose of OGF required for
optimum inhibition, SKHep1 cells were treated with 103 to 108 M OGF
for 72 hrs. To examine whether the inhibitory effect of OGF is mediated by
an opioid receptor, SK-Hep1 cells were treated daily with 106 M OGF and
106 M Naloxone, a short acting opioid antagonist and counted at 72 hrs. To
determine whether OGF mediated inhibition was reversible, cells were
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treated with OGF for 48 hrs and then media replaced with drug free media;
growth was measured at 72 and 96 hrs.
Results. The presence of OGFr on SKHep1 and HepG2 cells was
demonstrated via IHC. At 24, 48, and 72 hours, cellular growth was
significantly increased in the cells treated with Naltrexone which blocks the
interaction of OGF and OGFr when compared to controls; maximal effect
was seen at 72 and 96 hours (PB0.0001). At 24, 48, and 72 hours, cellular
growth was significantly inhibited in both cell lines treated with OGF relative
to controls; maximal inhibition was seen at 72 hours (44% inhibition, PB
0.0001). OGF inhibited cell growth at dosages of 103 to 107 M OGF
(PB0.001); 108 M dosages had no effect on growth. Concomitant
administration of OGF and naloxone blocked the inhibitory effects of
OGF, suggesting an opioid receptor mediated mechanism. Following
discontinuation of OGF treatment, treated cultures resumed growth kinetics
similar to untreated controls. At 96 hours cell number was significant (PB
0.0001) when comparing cells treated with OGF and those no longer
receiving OGF, suggesting that OGF is not cytotoxic.
Conclusion. Our results demonstrate that OGF significantly inhibits cellular
proliferation of human hepatocellular cancer cells in vitro. In addition,
cellular inhibition is not cytotoxic but rather related to binding of OGF to the
OGFr.
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SURGICAL TREATMENT AND OUTCOME OF HILAR CHOLAN-
GIOCARCINOMA
Kazuhiro Otani, MD, PhD, Kazuo Chijiiwa, MD, PhD, Masahiro Kai, MD,
PhD, Motoaki Nagano, MD, Kazuyo Tsuchiya, MD, Kazuhiro Kondo, MD,
PhD
Miyazaki University School of Medicine, Miyazaki, Japan
Bakground. Hilar cholangiocarcinoma (Klaskin tumors) is a morbid disease
with poor prognosis. Because of its rare incidence and low resectability rate,
prognostic factors and effect of chemotherapy after surgery are not fully
evaluated. The aim of this study is to assess the surgical outcome of hilar
cholangiocarcinoma.
Methods. Between 1990 to 2005, 27 of 74 patients with hilar cholangio-
carcinoma were treated by surgical resection (8 bile duct resection only, 18
bile duct resection plus hepatectomy, 1 hepatopancreatoduodenectomy).
Preoperative managements consisted of biliary drainage and, in some
patients, portal vein embolization. Postoperative chemotherapy was under-
went in 12 patients. We retrospectively analyzed the short-term and long-
term results after resection.
Results. There was no operative mortality and the morbidity rate was 37%.
Curative resection(R0 resection) was obtained in 19 (70%) of 27 patients.
Overall estimated survival rates at 3 and 5 years after tumor resection were
44% and 27%, which were significantly higher than those of patients who did
not undergo resection (3.5% at 3 years and 0% at 5 years, pB0.0001).
Survival of patients with cancer-cell positive margins (R1/2 resection) was
poor without 5 year survivors; however, it was still better than unresected
patients (median survival: 22 months vs 9 months, p0.0007). Univariate
analysis revealed that lymph node metastases (p0.043) and lack of adjuvant
chemotherapy (p0.0428) were significant prognostic factors for poor
survival after surgery. Multivariate analysis identified lack of adjuvant
chemotherapy as the independent prognostic factor (p0.0422). The
longest median survival was observed in patients with R0 resection with
chemotherapy (101 months), followed by R 1/2 resection with chemotherapy
(41 months), R0 resection without chemotherapy (23 months), and R1/2
resection without chemotherapy (22 months).
Conclusions. In patients with hilar cholangiocarcinoma, only R0 resection
offer a chance of long-term survival. Resection should be considered a first
option because patients even with cancer-positive margins show a survival
advantage. Adjuvant chemotherapy may be beneficial for better long-term
survival.
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AN EVALUATION OF NOVEL ELECTROSURGICAL DEVICES IN
BILIARY TRACT SURGERY
William W Hope, MD, William L Newcomb, MD, Thomas M Schmelzer,
Jessica J Heath, B.Sc., Amy E Lincourt, PhD, B. Todd Heniford, MD, David
A Iannitti, MD
Carolinas Medical Center, Charlotte, NC
Traditionally, metallic clips have been used for ligation of the cystic duct
during laparoscopic cholecystectomy. The purpose of this study was to
evaluate two novel electrosurgical devices in biliary tract surgery.
Porcine common bile ducts were sealed with two electrosurgical devices, the
Harmonic† Ace (Ethicon Endosurgery, Cincinnati, OH) and LigasureTM
Advance (Valleylab, Boulder, CO, USA). Metallic clips (Endoclip, Ligaclip
ERCA, Ethicon Endo-Surgery, Cincinnatti, OH, USA) were used for
control. Half the animals underwent bile duct ligation followed by immediate
burst pressure testing and histologic evaluation. The remaining halves
underwent bile duct ligation and were survived for one week or until signs
of sepsis. Proximal bile duct pressures were documented.
The study included 23 pigs that underwent bile duct ligation, 11 acute and 12
chronic. Seal failure rate for the acute study was 50% for both electrosurgical
devices. There were no seal failures for the Endoclip. Acutely, the Endoclip
had significantly higher burst pressures than the LigasureTM Advance (6469
282 mmHg vs. 73986 mmHg, p0.002) and Harmonic† Ace (6469282
mmHg vs. 72989 mmHg, p0.002). No difference in burst pressure was
noted between the LigasureTM Advance and Harmonic† Ace (73986 mmHg
vs. 72989 mmHg, pNS) acutely. In the chronic study, obvious bile leaks
were noted in 2 animals (50%) in the Harmonic† Ace group and 1 animal
(25%) in the LigasureTM Advance group. There were no obvious bile leaks
noted in the Endoclip group. Burst pressures were unable to be obtained for
the bile ducts ligated with Harmonic† Ace and LigasureTM Advance
secondary to disruption of the seal with minimal dissection. Average chronic
burst pressure for the Endoclip was 10889922. The average proximal bile
duct pressure from seven animals was 16.194 mmHg.
The novel electrosurgical instruments studied cannot be recommended for
routine use in sealing biliary structures secondary to the failure rate
associated with the seals. The porcine common bile ducts sealed in this
study may not be an ideal surrogate for the human cystic duct.
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ENDOSCOPIC MICROWAVE COAGULATION IS EXTREMELY
EFFECTIVE AT LOCAL CONTOROL OF MALIGNANT BILIARY
OBSTRUCTION
Ogata Kenji, MD, PhD, Maeshiro Kensei, Yamashita Yuichi, MD, PhD,
Ikeda Seiyo, MD, PhD
Fukuoka university school of medicine, Fukuoka, Japan
Background. While a biliary stent for malignant narrowing of the biliary
tract has become common therapy, adverse effects from stents have also been
seen over the long-term. Currently, a major complication is occlusion of the
stent in association with local tumor growth. To maintain stent patency,
appropriate treatments to reduce the volume of the tumor is required.
Aims. To evaluate the clinical efficacy of endoscopic microwave coagulation
therapy (EMCT) to gain local control of non-resected bile duct cancer.
Methods. By April 2006, stent treatment (EMS: 57, TS: 60) was performed
for 117 cases of non-resected bile duct carcinoma. Among them, 16 patients
ranged in age from 5696 years-old with stent occlusion (EMS: 9, TS: 7)
were treated with EMCT. Patient survival and duration of stent patency after
EMCT were examined.
Results. In all cases, occluded stents were successfully recanalized without
any complications. The median survival after EMCT was 293 days (range
1341200 days). Six out of 16 patients received with EMCT underwent the
stent removal (EMS: 4, TS: 2). In 5 patients, additional stent was not
required since the obstruction was completely resolved by the EMCT. In
those cases, the median survival was 240 days (range 134780 days). Other
11 patients received insertion of a second stent (EMS: 3, TS: 8) after EMCT.
The median length of stent patency after EMCT was 242 days (range 120-
570 days). The stent patency after EMCT was better than that of the first
stent ( 242 days vs 120 days). In those cases, internal drainage from a single
route was possible in all cases.
Conclusions. Thus, the present study shows that EMCT has beneficial
effect on immediate resolution of stent occlusion, facilitating to prolongation
of the patency period of the stent. In addition, tumor reduction caused by
microwave coagulation may offer prolonged survival time. EMCT may
provide a safe and less invasive procedure with an acceptable clinical
outcome.
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TIMING OF OPERATION AND FREQUENCY OF ATTACKS DO
NOT INFLUENCE PATIENT SATISFACTION 1 YEAR FOLLOW-
ING LAPAROSCOPIC CHOLECYSTECTOMY (LC).
Samaad Malik, MD, MSc, Bruce Reeder, MD, FRCP, Roger Keith, MD,
FRCP
University of Saskatchewan, Saskatoon, SK, Canada
Introduction. After cholecystectomy, 2030% of patients continue to have
abdominal pain. Studies show longer duration of symptoms and frequency of
attacks predict higher incidence of persistent pain and dissatisfaction after
LC. This study hypothesizes that patients with symptoms less than 3 months
duration and fewer than 3 attacks will achieve complete cessation of
symptoms 1 year after LC.
Methods. In the 18 months following January 1, 2004, patients who
underwent LC for uncomplicated gallstone disease were eligible to enter
the study. A validated questionnaire identified duration of symptoms and
frequency of attacks before LC. A validated scoring system stratified
symptom severity for two groups of patients: Group I patients (16)
and Group II patients (B16). Scores B16 identified patients having
primarily epigastric pain. Complete cessation of symptoms was defined by
postoperative scores  6. Patient satisfaction was measured using a 3 point
Likert scale (not satisfied, satisfied and very satisfied).
Results. The survey response rate was 43% (as per the AAPOR calculation),
of 942 patients eligible to receive the questionnaire. Of 343 patients, 264
achieved scores ]16 (Group I); Group II achieved scores B16 (N79).
Group I had a mean duration of symptoms 36.4971.5 months; Group II had
a mean duration of symptoms 19.2943.8 months (p0.10). Of 64 patients
from Group I with symptoms  3 months, 13 (20.3%) had postoperative
scores 6. Of 200 Group I patients with symptoms 3 months, 36 (18.0%)
had scores  6 (p0.16); Of 36 Group II patients having symptoms3
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months, 23 (63.9%) had scores  6. Of 43 Group II patients having
symptoms 3 months, 21 patients (48.8%) had scores  6 (p0.23).
Group I patients had a mean frequency of 6.897.8 attacks; Group II had a
mean frequency of 4.291.9 attacks (p0.26). Of 82 Group I patients having
 3 attacks, 19 had scores  6 (23.2%). Of 182 Group I patients having 3
attacks, 30 patients (16.5%) had scores  6 (p0.001). Of 50 Group II
patients having  3 attacks, 31 patients (62.0%) had scores  6. Of 29
Group II patients having 3 attacks, 13 patients (44.8%) had scores  6
(p0.38). Of Group I patients (N264), 93.6% were satisfied or very
satisfied, and 96.2% of Group II patients (N79) were satisfied or very
satisfied 1 year after LC.
Conclusions. Patients with uncomplicated gallstone disease regardless of
severity, duration and frequency of symptoms report overall satisfaction 1
year after LC. However, the majority of patients, with severe symptoms, do
not achieve complete cessation of symptoms.
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BILIARY CYSTADENOMA: CASE REPORTS AND REVIEW OF
THE LITERATURE
C K Chang, MD, T M Macpherson, MD, R C Liu, MD, S K Liu, MD, P R
Fuchshuber, MD, PhD
Kaiser Permanente, Walnut Creek, CA
A 32 year old female presented with fever, chills, elevated white count and a
large cystic mass in the left lobe of the liver 9.8 cm in size which was initially
diagnosed as a hepatic abscess. Percutaneous drainage was performed with
resolution of her symptoms. Her symptoms recurred with re-accumulated of
the fluid cavity after the drainage catheter was removed. A partial cystectomy
was performed laparoscopically but again with return of her symptoms and
cyst. An open completion resection was performed without any post-
operative complication. A small posterior communicating bile duct was
identified and closed off. The second patient is a 41 year old female with a 5
cm cyst in the left liver identified incidentally. A repeat CT scan several
months later showed an increased heterogeneous cyst with polypoid projec-
tions from the wall. She underwent an open resection without any post-
operative events. A small communicating duct was also identified and closed
off.
Biliary cystadenoma are uncommon benign neoplasm with malignant
potential, often being misdiagnosed as hydatid cyst or abscess. There is a
strong female propensity, suggesting a hormonal component. The majority of
biliary cystadenoma are intrahepatic originating from congenital aberrant bile
ducts. Around 200 cases have been reported in the United States. Malignant
transformation into biliary cystadenocarcinoma has been reported as high as
30%, thus correct pre-operative diagnosis and surgical resection is important.
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MIRIZZI SYNDROME TYPE II-LAPAROSCOPIC APPROACH.
Juan Pekolj, Mariano Luis Bregante, MD, Diego Lucas Ferna´ndez, MD,
Juan Antonio Salceda, MD, Victoria Ardiles, MD, Eduardo De Santiban˜es,
MD
Hospital Italiano Buenos Aires, Buenos Aires, Argentina
Background. Common hepatic duct obstruction secondary to compression
by gallstones impacted at the gallbladder neck or cystic duct could induce a
cholecystobiliary fistula or ‘‘Mirizzi Syndrome’’ (MS) type II which is a rare
complication of prolonged cholelithiasis. Its laparoscopic treatment seems
controversial at present.
Aim. To show a health center experience in HPB surgery and laparoscopic
treatment for MS type II
Place. Private Community Hospital.
Design. Retrospective analysis.
Material and method. Between November 1999 and December 2004,
6107 laparoscopic cholecystectomies for gallstones were performed. Esti-
mated biliary fistula incidence, in particular cholecystobiliary fistula(MS type
II), its laparoscopic treatment, conversion incidence, resolution, morbidity
and mortality were assessed. All the patients underwent preoperative
laboratory test and two or more imaging studies. Intraoperative cholangio-
graphy was perfomed in all cases.
Results. Biliary fistula, 38 patients (0.6%); MS type II,0.2% with common
hepatic duct gallstones in 58.3%. Female patients: 76.3%, mean age: 68
years. Laparoscopic treatment resolution in MS type II: 66.7%. Conversion
rate: 33.3%. Morbidity: 25%. Mortality: 0%.
Conclusion. MS is a rare and major complication of prolonged cholelithia-
sis. The use of the laparoscopic or the open approach depends on the
surgeon’s experience. Its diagnostic presumption is an important issue
regarding its resolution,since patients’referral to specialized centres has
resulted in lower short-term and long-term morbidity and mortality rates
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NAVIGATION AND VISUALISATION IN LIVER SURGERY-CUR-
RENT STATUS
Lutz Mirow, MD, Philipp Hildebrand, Markus Kleemann, Uwe Roblick,
MD, Hans-peter Bruch, MD, PhD
University Hospital of Schleswig-Holstein, Lu¨beck, Germany
Since less than ten years increasing efforts are undertaken within the
framework of international projects through of a few teams, to facilitate the
application of navigation techniques also for the liver surgery. Up to now the
use of navigated instruments was possible only in surgical compartments that
dealt with the therapy at inflexibleBA[inflexiblejrigid] anatomical struc-
tures (Bone) or at soft parts surrounded with bones (Brain).
Succeeded first of all for the prefunctional planning in developing
different software-systems that contribute to a better evaluation and patient
selection. There are currently in the testing phase several alternative
approaches for the transformation of the planning results. For the conven-
tional liver resection a navigation tool could be used already successfully.
Within the framework of the FUSION-project a prototype is now also for the
first time developed and tested for the intraoperative tracking of laparoscopic
instruments.
Future developments on the field of the navigation technology let on the one
hand significant progress in the therapy surgical relevant liver illnesses’ and to
expect also considerable synergy effects to other concerning health-economic
consequences.
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YEAR 2: AN UPDATE OF A HIGH VOLUME NON-UNIVERSITY
REFERRAL CENTER PANCREATICODUODENECTOMY FEASI-
BILITY STUDY
Christos A. Galanopoulos, MD, Allison Vo, RN, D. Rohan Jeyarajah, MD
Methodist Dallas Medical Center, Dallas, TX
Background. In recent years, multiple studies have concluded that out-
comes for pancreaticoduodenectomy (PD) are better at high volume
University Pancreas Centers (UPC). But recent data have challenged this
assumption by supporting the idea that high volume pancreatic centers in
Non-University Community Medical Centers (NUMC) can produce patient
outcomes equaling those of University based pancreatic centers (UPC).
Method. Our retrospective review of 76 consecutive PD’s done at high
volume NUMC by a single surgeon over a 2-year period (20052007). Data
on the number of PD’s, morbidity, mortality, pathology, length of stay
(LOS), blood loss (EBL), and operative times (OPT) were accumulated and
analyzed. These data were then compared to our 1st 45 PD done in the year 1
as well as acceptable historical data. High volume was defined by Leapfrog
Group criteria (11 pancreatic resections). The designated pancreas team
consists of gastroenterologist, surgeons, nursing staff, operating room team,
and floor nursing. Charts were reviewed and data was gathered by an
oncology nurse. The analysis was completed and reviewed by the attending
surgeon and the HPB/GI Surgery fellow.
Results. Morbidity rates (number of patients who suffered some type of
complication) dropped to 38% from 53% after 2 years. Mortality rates
remain similar at 2.6% (2 patients), compared to 2.2% during the 1st 45
PD’s done in year 1. Pylorus preserving PD (PPPD) and standard PD were
28 and 48 respectively. Pancreatic fistula rates dropped from 6.6% down to
5.3% at 2 years. Changes in mean operative times (240 minutes), mean blood
loss (350 ml.), and mean length of stay (10 days) were minimally impacted
with increased experience. There were 56 malignant tumors and 11 benign
tumors. Nine patients had pancreatitis. Seven patients underwent a com-
bined PD and Puestow (Whip-Stow).
Conclusion. There is consensus that increased surgeon volumes are
correlated with improved patient outcomes, but this is one factor of a
complex multifactorial problem. The multidisciplinary approach to each
patient’s care has made it possible for a NUMC to achieve university level
outcomes. The improved abilities of the operating room staff, pre- and post-
operative nursing care, and intra-operative anesthesia care has help continue
the trend towards minimizing patient morbidity and mortality. This study
reports that a NUMC considered high volume can achieved a standard of
care equal to a UPC’s, as long as future technologies are embraced and there
is a multidisciplinary approach to patient care.
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TRENDS IN THE REGIONALIZATION OF PANCREATIC RESEC-
TION PROCEDURES TO HIGH-VOLUME PROVIDERS
John E Scarborough, MD, Ricardo Pietrobon, MD, PhD, Rebekay R White,
MD, Bryan M Clary, MD, Douglas S Tyler, MD, Theodore N Pappas, MD
Duke University School of Medicine, Durham, NC
Purpose. The purpose of our study was to determine whether pancreatic
resection procedures are being regionalized to high volume providers.
Methods. The Nationwide Inpatient Sample database was used to conduct a
longitudinal analysis of provider volume and patient outcomes for pancreatic
resections performed in the United States over five time periods (Period I
19881990, Period II19911993, Period III19941996, Period IV
19971999, and Period V20002003).
Results. 15,616 patients undergoing pancreatic resection were included in
the analysis. The percentage of these procedures performed by low-volume
surgeons decreased significantly from Period I to Period V (63.1% vs. 45.7%,
pB0.001), while the percentage performed by high-volume surgeons
increased over the same time period (12.8% in Period I vs. 31.5% in Period
V, p B0.001). Similarly, the percentage of pancreatic resections performed at
low-volume hospitals decreased from Period I to Period V (53.2% vs. 26.3%,
p B0.001), while the percentage performed at high-volume hospitals
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increased (20.9% vs. 40.5%, p B0.001). Over the sixteen year study period,
risk-adjusted in-hospital mortality after pancreatic resection decreased
significantly (8.3% in Period I vs. 5.2% in Period V, p0.012).
Conclusion. An increasing percentage of pancreatic resections in the United
States are being performed by high-volume surgeons and at high-volume
centers. This trend towards regionalization is associated with a decline in the
risk-adjusted in-hospital mortality rate after pancreatic resection.
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MAGNETIC RESONANCE IMAGING IS A POWERFUL TOOL FOR
CHARACTERIZING THE IMPACT OF RADIOFREQUENCY AB-
LATION IN A MURINE MODEL OF SPONTANEOUS HEPATO-
CELLULAR CANCER
Serene Shereef, Diego Avella, MD, Luis Garcia, MD, Hephzibah Rani S
Tagaram, PhD, Nihraj Gusani, MD, Mehrdad Nikfarjam, MD, Eric Kimchi,
MD, Kevin Staveley-o’carroll, MD, PhD
Penn State Milton S Hershey Medical Center, Hershey, PA
Introduction. Hepatocellular cancer (HCC) is the most common primary
liver cancer. Radiofrequency ablation (RFA) is an effective modality for used
either as an adjunct to surgical resection or in patients who are otherwise not
candidates for either surgical resection or transplantation. RFA induces
tumor necrosis by thermal ablation and its effects can be demonstrated with
various imaging modalities including Magnetic Resonance Imaging (MRI).
Critical information regarding the mechanisms of action of RFA and its effect
on tumor progression/regression is not well understood. There are currently a
limited number of small animal models available to study the effects of RFA
on HCC. We propose a novel model of spontaneous hepatocellular cancer
and the use of contrast-enhanced magnetic resonance imaging (MRI) to
study the impact of RFA.
Methods. Tumorigenic hepatocytes from MTD2 mice, which spontane-
ously develop HCC secondary to transgenic expression of the T antigen
from SV40 virus, were injected intrasplenically into syngeneic C57BL/6
mice. These mice, designated as ISI mice, reliably develop HCC by 8 weeks
of age.
RFA was performed using Tissuelink DS3.5-CTM Dissecting Sealer on a defined
small surface area of the HCC nodule to compare RFA effects with
surrounding tumor tissue. We obtained gadolinium enhanced 7 Tesla MRI
scans prior to performing RFA and 7 days status post RFA to evaluate the
radiographic changes associated with RFA.
Results. One millimeter axial sections produced high quality images
demonstrating normal liver anatomy in C57BL/6 mice. In the ISI group,
T1 images obtained at 8 wks demonstrated focal hepatic nodules (black arrow
in Fig. 1) that were easily distinguished from normal liver parenchyma(small
white arrow in Fig. 1). Post-RFA MRI shows patchy areas of necrosis
consistent with ablative changes (large white arrow in Fig. 1). RFA induced
injury seen on MRI was verified histologically.
ConclusionsMRI provides a powerful tool for the evaluation of hepatic
tumor and its response to RFA in our model of spontaneous HCC. This
unique model is excellent for studying potential synergistic therapeutic
modalities with RFA.
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HISTOLOGICAL EVALUATION OF LIVER RECOVERY AFTER
RADIOFREQUENCY ABLATION-ASSISTED RESECTION
Peng Yao, PhD, Javed Akhter, PhD, David Lawson Morris, MD, PhD
University of New South Wales, Sydney, Australia
Background. Surgical resection is the gold standard for liver carcinomas.
Control of intraoperative blood can be a real challenge. Recently radio-
frequency ablation (RFA) has been introduced into liver resection for
precoagulation. The principle of this technique is that RFA seals small
arterial and venous vessels after deployment into the liver parenchyma,
haemostasis then can be achieved.
Aim. We histologically investigated the liver recovery following a RFA-
assisted hepatic resection in animal model.
Methods. Twelve New Zealand White Rabbits were tested in this study.
Bipolar RFA device-InLine (ILRFA) and RITA 1500 radiofrequency
generator were used to create RFA precoagulation. The animals were
randomly assigned into three groups, the animals in group A were sacrificed
in postoperative Day 0, group B in Day 3, and group C in Day 14. During
surgery ILRFA was inserted into one lobe of the liver, the generator was
connected and turned on. After complete RFA coagulation by ILRFA, the
liver resection was performed using scalpel. Liver tissue samples from the
ablated area and untreated liver parenchyma were stained with H&E and
Trichrome.
Results. Postoperatively no blood, bile, pus or other fluid were identified.
Histological examination revealed a typical post RFA lesion evolution. Day 0
revealed prominent cytoplasmic enlargement and eosinophia of hepatocytes,
and thrombosis in normal parenchyma bordering necrotic areas. On day 3,
liver parenchyma show 3 zones structure. On 14 days, fibrous tissue and
mononuclear cell infiltration was prominent.
Conclusion. Histological study of liver recovery has demonstrated that
RFA-assisted liver resection is a safe procedure.
157
A RANDOMISED CONTROLLED STUDY OF THE EFFICACY OF
FIBRIN GLUE IN REDUCING FLUID COLLECTIONS FOLLOW-
ING LIVER SURGERY
Peng Yao, Francis Chu, MBBS, David Lawson Morris, MD, PhD
University of New South Wales, Sydney, Australia
Background. Surgical resection is the optimal treatment for liver malig-
nancies. With the advances in understanding of hepatic anatomy and
improvements in operative techniques, there are significant decreases in
mortality. However, abdominal fluid collection and bile leak can be great
problems during the postoperative period.
Aim. We investigated the effect of fibrin glue (Tisseel (Baxter)) sealing of the
hepatic resection area, which achieved a significant decrease of postoperative
fluid collections.
Methods. Study was approved by local authority, 120 patients were
randomized into two group: fibrin glue treatment and control. During
surgery, an ultrasonic aspirator was used for parenchymal transaction, large
vessels and bile ducts were secured by suturing. Then argon beam was further
deployed for hemostasis. For the treatment group, fibrin glue was used to
spray on the resected raw liver surface, for the controls, no topical agents were
used. An abdominal drainage was placed closed to the liver surface to
monitor the volume of fluid collections. The volume of everyday drainage was
recorded in standard data sheet.
Results. The type of liver resections performed was very similar in both
groups, which including 38 major resections (more than 2 segments) and 22
minor resections in fibrin glue and 36 major resections and 24 minor
resections in the control group. The mean duration of drainage was 692 days
in the fibrin glue and 894 days in controls. Using fibrin glue, postoperative
fluid amounts were significantly lower through the postoperative period with
5659390 ml versus 100791231 ml (PB0.05). There was also significant
decrease of bile leakage in the fibrin glue group with only 1 versus 5 in the
control group (PB0.05).
Conclusion. There was a significant decrease in post-operative fluid
collection and bile leakage in the fibrin glue treatment group.
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CONTINUOUS HEMOFILTRATION OF HEPATIC VENOUS EF-
FLUENT ALLOWS REGIONAL DELIVERY OF HIGH-DOSE MEL-
PHALAN VIA A MINIMALLY INVASIVE APPROACH
Edmund Bartlett, Erin R Gardner, Richard E Royal, MD, Udai S Kammula,
MD, William D Figg Sr, PharmD, James F Pingpank Jr, MD, Surgery
Branch, NCI, NIH, Bethesda, MD
Clinical Pharmacokinetics Section, NCI, NIH, Bethesda, MD
Introduction. Unresectable hepatic metastases represent a significant
clinical challenge. Peripheral hepatic perfusion (PHP) is a minimally invasive
regional therapy designed to deliver high-dose hepatic arterial chemotherapy
while minimizing systemic exposure utilizing a double balloon catheter
(Delcath Systems, Inc.) positioned in the retrohepatic inferior vena cava
facilitating hepatic venous effluent hemofiltration. Described are the regional
and systemic toxicities and pharmacokinetics associated with a 30 minute
infusion of melphalan (MEL) via PHP.
Methods. Between August 2001 and August 2007, 81 pts underwent 220
PHPs with MEL on an IRB approved phase I, II, or III trial for treatment of
metastatic melanoma (n30), neuroendocrine tumors (n19), colorectal
carcinoma (n11), HCC (n8), and others (n13). Laboratory tests were
performed daily during hospitalization and at regular intervals thereafter.
Toxicities were divided into acute ( 5 days post-PHP) and delayed ( 5
days post-PHP). A 2nd generation charcoal filter was utilized for the most
recent 98 procedures. In 24 pts, MEL pharmacokinectics were measured
from the pre- (PRE) and post-filter (POST) perfusion circuit as well as
systemically (SYS).
Results. 160 treatments were performed at doses from 2.53.0 mg/kg. MEL
dose was 2.5 mg/kg for 35/160 treatments and 3.0 mg/kg for 120/160
treatments. Acute grade 3/4 hematologic toxicities were anemia (46/160,
29%) and thrombocytopenia (75/160, 47%). Delayed grade 3/4 hematologic
toxicities were anemia (48/160, 30%), thrombocytopenia (76/160, 48%), and
neutropenia (118/160, 74%). Acute grade 3/4 hepatic toxicities included
elevated bilirubin (18/160, 11%) and LFTs (26/160, 16%). Delayed hepatic
toxicity occurred in 32/160 (20%).
Average maximum PRE concentration of MEL was 10.4 ug/mL. POST MEL
levels fell to 2.0 ug/mL with the SYS average maximum of 1.4 ug/mL. The
area under the curve (AUC) in the concentration-time graph yielded a PRE
mean of 258,000 ng/ml*min. POST AUC fell to 56,000 ng/ml*min, with
SYS of 42,000 ng/ml*min. PRE AUC was significantly higher in the patients
receiving 3.0 mg/kg compared to 2.5 mg/kg (mean of 286,000 vs. 195,000,
p.03). Using the PRE and POST AUC, mean filter efficiency was
calculated to be 77%.
Conclusion. PHP achieves high regional concentration of MEL with
predictable myelosuppression. PHP demonstrates a potential advantage for
MEL administration versus other regimens, with deliverable doses above the
MTD of systemic (.5 mg/kg) or other regional (1.5 mg/kg) MEL dosing
strategies.
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IMPLEMENTATION OF A MULTIDISCIPLINARY TREATMENT
TEAM FOR HEPATOCELLULAR CANCER AT A VETERANS
AFFAIRS MEDICAL CENTER IMPROVES SURVIVAL
Tammy T. Chang, MD, PhD, Rajiv Sawhney, MD, Alexander Monto, MD, J.
Ben Davoren, MD, PhD, Jacob G. Kirkland, Lygia Stewart, MD, Carlos U.
Corvera, MD
University of California, San Francisco, San Francisco, CA
Hepatocellular carcinoma (HCC) is a complex disease with a unique set of
clinical challenges. Multidisciplinary collaboration and multimodality treat-
ments may be essential for effective management of HCC. We established a
multidisciplinary treatment team (MDTT) and compared patient outcomes
3 years before and after its establishment.
Implementation of the MDTT achieved several improvements in patient
outcomes. The total number of HCC patients referred for treatment doubled
from 62 to 112. Through the improved referral system, significantly more
patients were evaluated with earlier stages of HCC (pB0.0001). Whereas
40% of the patients pre-MDTT presented with stage 4 metastatic HCC,
post-MDTT nearly 30% percent of the patients evaluated had stage 1 disease
and another 33% had stage 2 disease. As a result, a greater proportion of
patients received either curative or palliative treatments (37% pre-MDTT vs.
64% post-MDTT, pB0.0001).
Importantly, the MDTT improved overall HCC patient survival. Only 13 of
62 patients (21%) survived during the pre-MDTT follow-up period. A
significantly higher percentage, 79 or 121 patients (65%), survived post-
MDTT (pB0.0001). This observation was especially remarkable consider-
ing that the median length of follow-up was also significantly increased post-
MDTT (4.5 months pre-MDTT vs. 9.5 months post-MDTT, pB0.05). The
overall survival odds ratio post-MDTT was 7.10 compared to pre-MDTT
(pB0.0001) indicating a substantial survival advantage. Further, stage-by-
stage comparisons indicated that the aggressive treatment strategies adopted
post-MDTT gave a survival advantage to patients with HCC at each stage of
disease and in particular to stage II patients (odds ratio 15.50, pB0.001).
In conclusion, the MDTT significantly increased the number of patients
evaluated at earlier stages of disease and treated more patients with either
palliative or curative therapies. It significantly improved overall survival and
length of follow-up. Stage-by-stage comparisons showed that aggressive
multimodality therapy conferred significant survival advantage to patients
with stage II HCC. This study supports our multidisciplinary philosophy and
aggressive multimodality treatment approach toward hepatocelluar carci-
noma.
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IS THE EARLY RECURRENCE RELATED WITH SURVIVAL
AFTER SURGICAL RESECTION OF HEPATOCELLULAR CAR-
CINOMA?
Andrea Ruzzenente, Calogero Iacono, Silvia Pachera, Paola Nicoli, Monica
Fontana, Alfredo Guglielmi
University of Verona, Verona, Italy
Objective. Evaluate prognostic significance of early recurrence among
patients with hepatocellular carcinoma (HCC) after R0 surgical resection
and identify factors related with early recurrence.
Methods. One hundred thirty patients with HCC submitted to surgical
resection from 1996 to 2006 were included in this retrospective study.
Surgical resection of HCC was the treatment of choice for Child-Pugh class
A patients with single HCC, surgery was applied also in a selected group of
patients with oligofocal HCC and/or with Child-Pugh class B7 cirrhosis.
Follow up protocol included clinical, laboratory and imaging evaluation at 6-
months intervals after surgery. All patients with recurrence were evaluated for
a new treatment with surgery, RFA, PEI, TACE or supportive therapy
according to stage of HCC and degree of hepatic decompensation.
Results. Median follow up time was 27 months. The overall median survival
was 44 months with actuarial 3 and 5-year survival rates of 59% and 43%.
Fifty-nine patients showed intrahepatic recurrence of HCC with a median
disease free survival of 36 months, and an 3- and 5-years actuarial disease free
survival of 43 and 25%, respectively. According to time to recurrence 24
patients recurred before 1 year and 35 patients after 1 year. Survival analysis
showed that survival was significant related with time-to-recurrence with a
median survival of 12 and 64 months, respectively (p0B001). With
univariate analysis we identified that the following factors were related with
early recurrence: tumor size grater than 5 cm (p0.02), serum alpha
fetoprotein level grater than 100 ng/dL (p0.03) and poor differentiation
degree (p0.007).
Conclusions. Surgical resection of HCC have good results in selected
patients, early intrahepatic recurrences of the disease are frequent and are
significant related with shorter survival. we identify factors that should
improve patients selection before surgical resection. Tumor size, higher alpha
-fetoprotein level and poor differentiation were related to early recurrences.
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A NOVEL TECHNIQUE FOR RADIOFREQUENCY ABLATION OF
HEPATIC DOME NEOPLASMS USING IATROGENIC HYDRO-
THORAX
Francis E Rosato Jr, MD, Lawrence Needleman, MD, Ernest L Rosato, MD
Thomas Jefferson Univeristy, Philadelphia, PA
Radiofrequency ablation is an accepted treatment modality for unresectable
primary and metastatic tumors of the liver. Intraoperative ultrasound is
necessary to evaluate probe placement and completeness of ablation. When
lesions are found high on the dome of the liver ultrasound imaging becomes
extremely challenging. In an effort to improve the visibility of hepatic dome
neoplasms, the Authors have used an iatrogenically induced hydrothorax at
the time of ablation.
Methods. Six patients, five with metastatic colonic adenocarcinoma and one
with primary hepatocellular carcinoma, had either a single hepatic dome
lesion (4 patients) or bilobar disease with a subphrenic lesion. Mean tumor
size was 3.5 cm (range 1.05.5 cm). Once access to the right pleural space
was attained (thoracoscopically or percutaneously) instillation of 1 Liter of
Normal saline solution was performed. A surgeon and radiologist performed
all procedures in conjunction using the Radionics radio frequency ablation
device. All patients received a chest tube postoperatively.
Results. All dome lesions were successfully visualized. Average operative
time was 60 min (45145 min). No procedure related mortalities were
observed. Morbidities included a chest wound cellulitis with shortness of
breath in one patient and prolonged intercostal discomfort in another. All
chest tubes were removed within the first 24 hours except for the one patient
who complained of shortness of breath. All lesions were successfully ablated,
two patients remain disease free, three patients have stable disease and one
patient is deceased at 36 months follow up.
Conclusion. Iatrogenic hydrothorax represents a safe and valuable tool for
allowing the visualization of high dome liver lesions during radiofrequency
ablation.
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HEPATIC ADENOMA IN PREGNANCY, RESECTION VERSUS
OBSERVATION
Nabil N. Dagher, MD, Juan D Arenas, MD
UT Southwestern Medical Center, Dallas, TX
Hepatic adenomas diagnosed during pregnancy are rare. Few case series
describe hepatic resection for adenoma during the gestational period. In
contrast to other benign liver masses like hemangioma and focal nodular
hyperplasia, adenomas have a risk of malignant change and a propensity to
grow and rupture with often disastrous consequences to mother and fetus.
In this report, we present 2 recent cases. The first is a 26 year old Gravida 1
Para 0 female with elevated liver function tests at approximately 5 weeks
gestation. Abdominal Ultrasonography revealed a 6.0 cm mass in the right
lobe of the liver consistent with an adenoma. Repeat Ultrasound 3 months
later showed enlargement of this mass to 7.6 cm in greatest dimension. The
patient began to report intermittent right upper quadrant pain. CT imaging
confirmed the size of the lesion and characteristics consistent with hepatic
adenoma. Due to enlarging size and concern for rupture, at 22 weeks
gestation a right hepatic lobectomy was performed. Surgery was without
complication; the patient was discharged home on post operative day 5.
Pre- and Post-MDTT Survival by HCC Stage
Pre-MDTT Post-MDTT
Alive Dead Alive Dead Survival Odds Ratio p value
Stage I 2 1 26 9 1.4 not significant
Stage II 2 9 31 9 15.5 B0.001
Stage III 5 18 14 23 2.2 not significant
Stage IV 4 21 4 1 21.0 B0.05
Overall 13 49 79 42 7.1 B0.0001
Follow-up 4.5 months 9.5 months  B0.05
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Pathology confirmed the diagnosis with free margins. No fetal complications
were noted and the fetus remains viable at 30 weeks gestation.
The second case is a 36 year old Gravida 1 Para 1 female without past
medical history who developed severe pre-eclampsia at 37 weeks gestation.
Labor was induced and she proceeded to vaginal delivery without complica-
tion. Two days post delivery, she developed severe right upper quadrant pain.
CT examination revealed a large 9.613.521 cm subcapsular hematoma
over the right lobe of the liver. She was transferred to our intensive care for
blood pressure control and monitoring. Visceral angiography did not show
evidence of hepatic artery extravasation but did show multiple vessels in
vasospasm. She was taken to the operating room for a right hepatic
lobectomy. The procedure and recovery were uncomplicated. Though a
discreet focus of adenoma was not identified on pathology, there were several
areas of hepatic infarction and an underlying lesion could not be ruled out.
These cases highlight the main challenge in management of hepatic
adenomas in gestational and post-natal periods-resection versus observation.
A review of the literature suggests that in non-pregnant and pregnant
patients, adenomas greater than 5 cm, or rapidly growing lesions, should
be resected. This aggressive approach is warranted in the gravid patient as
maternal and fetal mortality from rupture is exceptionally high. If resection is
necessary, surgery in the second trimester leads to improved surgical outcome
and reduced abortion and preterm labor rates. If observation is chosen in the
gravid patient, follow-up should be close as one third of ruptures occur in the
post partum period.
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IS THERE A ROLE FOR AGGRESSIVE HEPATIC RESECTION IN
METASTATIC OVARIAN CARCINOMA?
S Rudich, MD, PhD, T Doty, RN, J Basil, MD, H Schellhas, MD, A
Marshall, RN, J Buell, MD, A Tevar, MD, E S Woodle, MD
Univ of Cincinnati Med Ctr, Cincinnati, OH; Good Samaritan Hospital,
Cincinnati, OH
Ovarian carcinoma (Ov Ca) occurs in 1 in 70 women; nearly 26000 new cases
are diagnosed annually. The most common route of spread is transperitoneal.
Cytoreductive surgery is a key determinant of survival, which has been
correlated with the amount of residual tumor. Rarely, patients have hepatic-
only (or hepatic-dominant) disease after an initial cytoreductive surgery.
Purpose. To review our large, single center experience with pts having
metastatic Ov Ca in which the site of metastasis is primary (or only in) the
liver. The question addressed is: does aggressive liver surgery/resection have a
benefit for this pt population?
Methods. A retrospective chart review was performed of 20 pts who were
referred to our hepatobiliary program over a 6 yr period with Ov Ca in which
liver metastases were noted following GYN surgery/chemotherapy.
Results. All 20 pts were Caucasian, with an average age at time of initial
diagnosis of Ov Ca of 56.0913.0 yrs (range 33 to 77 yrs). 60% presented
with a papillary/serous histologic type, 3/20 with endometrioid and 3/20 with
a granulosa cell tumor (2 pts had unknown histology). 12/20 pts presented
with advanced Stage IIIC disease, 3 others with Stage IIIA/B disease, and the
remainder with Stage I or II. Only 1 pt presented initially with hepatic
metastases. All pts underwent an initial cytoreductive surgery and che-
motherapy. Median time to presentation of hepatic disease was 49 months
(range 6 to 468 mo) following original diagnosis and debulking. 75% of pts
were referred when either 1 or 2 lesions were noted in the liver, the median
size of which was 3.0 cm (range 0.6 to 14 cm). All pts undergoing liver
resection had MELD scores B12 (average 6.9). Two pts had no hepatic
procedures (1 with multiple lesions was unresectable and another had
significant comorbidities). 12/18 operated pts had a partial hepatectomy of
not more than 3 segments, only 3 pts required a formal lobectomy. However,
at surgery, 8/18 pts required additional surgery, mostly resections of
contiguous diaphragm. With a mean follow-up of 29 mo, 3 pts initially
referred have died, none related to the hepatic procedure. A single recurrence
was found 14 mo following a right lobectomy. No other hepatic lesions have
been identified in this pt cohort.
Conclusions. In select pts with hepatic (9diaphragmatic) disease noted
following appropriate initial surgical/medical treatment for advanced Ov Ca,
an aggressive hepatic resectional approach can lead to prolonged patient
survival. Pts presenting with limited hepatic tumor burden should be offered
resectional therapy for metastatic ovarian carcinoma.
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USE OF INLINE MULTICHANNEL RADIOFREQUENCY DEVICE
REDUCES BLOOD LOSS AND THE NEED FOR PORTAL TRIAD
CLAMPING DURING HEPATECTOMIES.
Hamed Kargozaran, MD, Amrik Singh, MD, Laurel Beckett, PhD, Yueju Li,
MS, Stephen Wilkendorf, None, Vijay P Khatri, MD
University of california Davis medical center, Sacramento, CA
Introduction. Intraoperative blood loss remains a significant predictor of
morbidity and mortality in hepatic resections of primary and metastatic
tumors. Portal triad clamping (PTC), in addition to the use of innovative
energy devices, has facilitated the parenchymal transection phase of
hepatectomies. The major drawback of PTC is warm ischemic-reperfusion
injury, particularly in patients with cirrhosis. InLine† multichannel radio-
frequency device (ILMRD, Resect Medical, Inc., Fremont, CA) is a novel
energy device that produces coagulative necrosis along the transection plane.
We examined the impact of ILMRD on blood loss and the need for PTC in
hepatic transections.
Patients and Methods. In this retrospective study, we compared outcomes
of liver transections with or without the use of ILMRD. Group A consisted of
24 patients (20 metastatic disease, 3 hepatoma, and 1 hemangioma) in which
ILMRD was not used during hepatic transections. In group B, 24 patients
(18 metastases, 5 hepatoma, and 1 focal nodular hyperplasia) had hepatic
transections performed with the aid of ILMRD.
Results. In group A the mean age of the patients was 57 years, 18 patients
were pretreated with chemotherapy and there were no cases of cirrhosis. The
mean patient age in group B was 61 years, 14 patients were pretreated with
chemotherapy, and 1 patient had cirrhosis. There were 8 major hepatec-
tomies (greater than 2 segments) in group A and 13 in group B. The mean
CVP was 1 cmH20 (range: 05) in both groups. The mean operative time in
group A and B were 357 and 356 minutes, respectively. The mean PTC time
in group A was 29.9 minutes as compared to 8.4 minutes in group B,
indicating a significant decrease in vascular occlusion time (P B0.001). A
significant difference was also seen in the estimated blood loss between the
two groups (804 ml group A and 241 ml group B, P B0.001). Eight patients
received blood transfusions in group A, compared to 4 in group B. The length
of hospital stay was comparable in the two groups with a mean of 9.6 days in
group A and 8.8 days in group B (P0.05). In group A there were 8 major
and 2 minor complications with 2 mortalities. While in group B, there were 4
major and 4 minor complications with no mortality.
Conclusion. The use of ILMRD is an innovative approach that minimizes
blood loss during the parenchymal phase of hepatic transection and
significantly decreases the need for PTC.
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HEPATIC RESECTION FOR CHOLANGIOCARCINOMA IN EL-
DERLY PATIENTS
George Collis, MD, John Stauffer, MD, Marjorie Dougherty, MS, PA-C,
George Kim, MD, Denise Harnois, DO, Justin H Nguyen, MD
Mayo Clinic, Jacksonville, FL
Hepatic resection is treatment of choice for resectable intrahepatic cholan-
giocarcinoma (CCCA). The role of liver resection in patients who are 70
years or older is incompletely defined. In this study, we assess the
perioperative morbidity and mortality of liver resections for CCCA in
patients over the age of 70.
Methods. Retrospective analysis of liver resections at our institution from
April 1999 to April 2006. Those who underwent partial hepatectomy for
CCCA were reviewed. Principle variables were operative time, length of
hospital stay, biliary anastomotic leak, intra-abdominal abscess, and peri-
operative mortality. P value was computed using Fisher’s exact test.
Results. There were 220 liver resections at our institution from 4/1999 to 4/
2006 performed including 39 cases for CCCA. Of these 39, 13 were 70 years
or older (7694), and 26 younger than 70 years (57910). For those older
versus those younger than 70 years, operative times were 3579129 vs. 3879
132 min (p0.52), estimated blood loss 10869684 vs. 10039928 ml (p
0.83), RBC requirements 292 vs. 394 units (p0.40), and length of
hospital stay 16916 vs. 16928 days (p0.95). There were no statistical
significant differences between the 2 study groups in biliary leak rate 31% vs.
15%, intra-abdominal abscesses 31% vs. 27%, and peri-operative mortality
15% vs. 12%. The tumor sizes were 5913 cm in older patients and were 794
cm in younger group (p0.13). In contrast, the mass of the resected liver
portion was significantly smaller in older patients with 3909179 g as
compared to 8869516 g in younger group (p0.01).
Conclusion. Hepatic resection for CCCA is relatively safe in patients 70
years or older. Postoperative morbidity and mortality are comparable to
younger age group. The extent of liver resection in older patients needs to be
further clarified.
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THE HEPATIC RESEARCH REGISTRY; THE FOUR YEAR EX-
PERIENCE
Eric R Hall, Kristen E Mcginty, MPH, Heather A Rollins, Ed L. Lecluyse,
PhD
CellzDirect, Inc, Pittsboro, NC
Purpose. The aim of the Hepatic Research Registry is to advance
hepatocellular clinical and basic research fields by 1) establishing a nation-
wide program to procure resected liver tissue; 2) compiling patient and
research data into a comprehensive biomedical database; 3) making isolated
primary hepatocytes and the comprehensive database available to academic
and industry researchers; and 4) facilitating research collaborations between
participating scientists. This poster represents the four year experience of the
program. To accomplish these goals, CellzDirect has partnered with many of
the leading academic medical centers in the country to develop a novel
database centered on patients having liver resection surgery. To date, the
Registry has generated four abstracts at major national meetings as well as
numerous collaborative projects in the areas of metabolism, cold preservation
and apoptosis.
Methods. Study subjects undergoing planned liver resections or liver
transplants as part of the standard procedure of care are identified and
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consented by participating institutions. Collected liver tissue samples are
preserved with cold-preservation solution, shipped to and processed at
CellzDirect. The participating institutions provide de-identified demo-
graphic, medical and surgical data to the Hepatic Research Registry, and
histological data is gathered during hepatocellular isolation.
Results. In four years, CellzDirect has partnered with 18 institutions to
enroll 873 subjects in the Registry. Liver resections were performed in 92% of
cases, while liver transplants account for 8% of the database population. Data
points collected include basic demographics (age, sex, race, BMI, etc.),
medical and social history, labs, operative notes, pathology reports, histolo-
gical data and cell quality data on the isolated hepatocytes. This poster looks
at this four year experience by examining the most common disease states,
the demographic of the database population, the outcome of the isolation
process and any correlations between these factors. The Registry program
provides a precious commodity for the academic and industrial research
community.
Conclusions. To our knowledge, this is the first databank dedicated to
hepatocellular isolation, with collection of clinical, radiological and histolo-
gical data. The creation of this registry and this database may have major
clinical and fundamental research implications as it continues to evolve.
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THE RISK OF MAJOR LIVER RESECTION FOR COLORECTAL
LIVER METASTASES AFTER A CHEMOTHERAPY ASSOCIATED
WITH BEVACIZUMAB IS INCREASED A PROSPECTIVE STUDY
OF 23 PATIENTS
Be´atrice Aussilhou, MD, Safi Dokmak, MD, Sandrine Faivre, MD, Olivier
Farges, MD, PhD, Catherine Paugam, MD, Vale´rie Paradis, MD, Jacques
Belghiti, MD
Hospital Beaujon, Clichy, France
Introduction. The risk of liver resection for colorectal liver metastasis
(CRLM) in patients treated with bevacizumab remains debated. The aim of
this prospective study was to report the postoperative course of liver
resections after a chemotherapy associated with bevacizumab.
Patients and Methods. From January 2006 to July 2007, 23 patients (mean
age59 years [39 -76]) underwent a liver resection for CRLM after a
chemotherapy administration associated with bevacizumab (Folfox n9,
Folfiri n9, FolfoxFolfiri n5). The liver resections were performed 59
days (range: 21228) after the end of the chemotherapy administration and
73 days (range: 27240) after the end of bevacizumab. Minor resection (B 2
Couinaud segments) was performed in 13 patients, including one associated
with the primary tumour. Major resection ( 3 sgts) was performed in 10
patients and one was associated with extrahepatic resection of the primary
tumor. Right portal vein occlusion was performed in 6 (60%) patients in
whom right hepatectomy was considered. Parenchymal transsection was
performed with intermittent pedicular clamping.
Results. There was no mortality. Among the 13 patients who underwent
minor resection, overall morbidity was 15%, blood loss was 308 ml (range
501000) and mean hospital stay was 10 days (range 540). In the group of
10 patients with major resections (1 left hepatectomy and 9 right hepatec-
tomies) blood loss was 685 ml (range 1002500 ml), one patient was
transfused (6 blood units), mean hospital stay was 21,4 days (range 867) and
the overall morbidity was 71% including 3 patients (30%) with serious
complications: liver insufficiency, prolonged jaundice (bilirubin level150
750mmol/L), uncontrolled ascitis, with a hospital stay from 30 to 67 days.
These 3 patients were males, aged 69, 74 and 76 years respectively and
underwent preoperative PVE for 2 of them. The macroscopic aspect of the
liver was normal for 2 of them and no patient showed significant lesions
induced by chemotherapy at the histologic analysis.
Conclusion. Our results showed that major liver resection for CRLM in
aged patients who received preoperative bevacizumab is at risk. Neither the
absence of histological changes nor preoperative PVE seems to abolish this
risk.
168
LACK OF IMPROVED OUTCOMES FOR ACETAMINOPHEN
(APAP)-INDUCED ACUTE LIVER FAILURE (ALF) FOR ORTHO-
TOPIC LIVER TRANSPLANTATION (OLT) FROM 19952004
Rebecca Y Tam-bensler, PharmD, John M Vierling, MD, Natasha S Becker,
MD, Christine A O’mahony, MD, Norman L Sussman, MD, John A Goss,
MD, Rise J Stribling, MD
St. Luke’s Episcopal Hospital and Baylor College of Medicine, Houston, TX;
Baylor College of Medicine, Houston, TX
Background. The incidence of APAP-induced ALF has dramatically
increased in the U.S. during the last decade and is now the dominant
indication for OLT among patients with ALF. It has been postulated that the
universal use of n-acetylcysteine and advancements in critical care have
increased the survival of patients with APAP-induced ALF without the need
for OLT.
Aim. To assess changes in survival with medical therapy, need for OLT and
death on the waiting list for patients with APAP-induced ALF.
Methods. The UNOS database added the category of drug-induced acute
hepatic necrosis in 1994. Therefore, we analyzed the outcomes of all adult
patients (n484) who were listed for OLT due to APAP-induced ALF from
19952004. We compared the proportions of patients surviving with medical
therapy, undergoing OLTor dying on the waiting list using the Kruskal-Wallis
test.
Results. Listing for OLT for APAP-induced ALF increased over time;
however, this trend was not statistically significant. Fig. 1 shows the outcomes
of the 484 listed patients.
The percentage of patients who medically improved and were removed from
the waitlist actually decreased from a mean of 39%/yr from 19951999 to
33% from 20002004 (p0.581).
Although the percentage of patients undergoing OLT increased from a mean
of 24%/yr from 19951999 to 35%/yr from 20002004, this trend was not
statistically significant (p0.066). While the percentage of patients dying on
the waitlist decreased from a mean of 32%/yr from 19951999 to 25%/yr
from 20002004, this trend was also not significant (p0.414).
Conclusions. These data refute the postulate that advancements in medical
therapy for APAP-induced ALF have improved survival or decreased the
need for OLT. Indeed, the trend for improvement with medical therapy alone
decreased over time, while the percentage of patients undergoing OLT
increased. Unfortunately, a substantial percentage of patients continued to
die on the waitlist. To prevent the need for OLT in patients with APAP-
induced ALF requires improvements in both medical therapy and intensified
efforts to reduce intentional and unintentional APAP overdoses.
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LIVER TRANSPLANTATION AND PANCREATIC RESECTION
John Stauffer, MD, Hugo Bonatti, MD, Marjorie Dougherty, PA-C, MPH,
Hannes Goegele, MD, Ronald Hinder, MD, PhD, Jaime Aranda-michel,
MD, Rolland C Dickson, MD, Timothy Schmitt, MD, Denise Harnois, DO,
Justin Nguyen, MD
Mayo Clinic, Jacksonville, FL; UVA, Charlottesville, VA
Introduction. Liver transplantation (LT) has emerged as excellent treat-
ment option end stage liver disease with excellent long term survival. Little
data are availability on patients who underwent LT and pancreatic resection
(PR).
Aim. to retrospectively analyze the clinical course and outcome of seven
individuals who a pancreatic resection for various indications either prior,
together with or post LT.
Methods. A total of 402 patients underwent 467 consecutive LTs between
1998 and 2001 at Mayo clinic Jacksonville, and seven individuals were
identified who also had a pancreatic resection. These patients were studied in
detail.
Results. There were three man and four women with a median age of 43
(3061) years at LT. Three had PR prior (3.6, 3.8, 8.1 years prior to LT),
another three together with LT and one 2.6 years post LT. There were four
Whipple procedures, two distal and one total pancreatectomies and the
indications were gastrointestinal stromal tumor (n1), neuroendocrine
tumor (n2), pancreatic cancer (n1), periampullary adenocarcinoma
(n1), distal cholangiocarcinoma (n1) and duodenal polyp with high
grade dysplasia in the course of familial adenomatous polyposis in the only
patient who had PR post LT. This is the only patient who is currently alive
three years post PR. The patient with the GIST underwent two LTs and
several other interventions and received GLEEVEC therapy and ultimately
died from tumor progression 11 years after the PR and 7 years post LT.
Another patient underwent several surgical interventions with tumor debulk-
ing and chemotherapy for recurrent NE tumor and died three years post LT
(seven years post PR) from the malignancy. One patient died two years post
LT (together with PR) and two patients died within one year (one from
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recurrent cancer 8 months post LT/PR and one within one month from
intraabdominal sepsis in the course of a pancreatic anastomotic leak).
Conclusion. LT and PR remains an infrequent scenario. One patient in this
series died related to surgical complications and one death was due to
intraoperative cardiac arrest. In selected cases good outcome can be achieved,
however due to the nature of the underlying malignant disorder, recurrence is
common and the main limiting factor for outcome.
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GLUTATHIONE AND ALBUMIN TURN-OVER IN HUMAN LI-
VERS IN NORMAL AND DISEASE TRANSPLANTED GRAFTS.
PRELIMINARY RESULTS.
Juan R Sanabria, ScD, MD, Rime Abbas, MD, H Kombo, PhD, V Anderson,
PhD, Steve Pravis, PhD, Henry Brunengraber, MD, PhD
University Hospitals-Case Medical Center, Cleveland, OH; Case Western
Reserve University, Cleveland, OH
Liver disease has increased significantly during the last decade. Increasing
prevalence of HCV infection and epidemic rates of both obesity and diabetes
are the most contributory etiologies. Liver transplantation is an established
therapy for end stage liver disease with recipient and graft survival rates above
90% at one year. Further implementation of this form of therapy is limited
due to the scarcity of organs available for transplantation. Different
mechanisms of hepatocyte injury involve common intercellular and intracel-
lular pathways that render into the exhaustion of mitochondrial ATP
production with membrane instability and cell termination. The present
studies were designed to evaluate metabolic pathways patterns of human liver
in normal and diseased organs as well as in liver grafts after implantation.
0.5% and 0.05% of the total body water of 1) normal individuals, of 2)
patients in the waiting list for liver transplantation and of 3) patients after
liver transplantation with normal liver graft function was labeled with a
mixture of Deuteriun (2H2O) and H2O
18 waters, respectively. The turn-over
rates of Glutathione (GS), and Albumin (Alb) were found following
Isotopomer analysis Methods. Gas chromatography-mass spectrometry
data were integrated using a previously developed method for consolidating
peaks that amplifies the apparent labeling while improving the precision of
the measurements. Protocols were IRB approved and patients were tested at
the GCRC facility at Case University.
Conclusions. It appears patients waiting for liver transplant has a decreased
turn over of reduced/oxidized Glutathione compared with normal
subjects and patients after liver transplant. Albumin turn over follows similar
pattern.
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THE ROLE OF LIVER TRANSPLANTATION FOR HEPATIC ADE-
NOMATOSIS IN THE PEDIATRIC POPULATION: CASE REPORT
AND REVIEW OF THE LITERATURE
Jason R Wellen, MD, Christopher D. Anderson, MD, M. B. Majella Doyle,
MD, Surendra Shenoy, MD, PhD, William C Chapman, MD, Jeffrey A
Lowell, MD
Washington University, St. Louis, MO
Purpose. Hepatic adenomas are benign lesions often found in young women
during their childbearing age. These tumors are associated with the usage of
oral contraception pills. These tumors are often solitary but can also be
multiple in which case it is referred to as hepatic adenomatosis (HA).
HA is defined as having to 10 adenomas within an otherwise normal
liver. There is a known but weak association between glycogen storage
diseases and HA. There is a higher incidence of HA in females, but unlike
solitary hepatic adenomas, these tumors are not associated with the usage of
oral contraception. To date there are only 2 reports of teenagers, without an
underlying glycogen storage disease, who have undergone a liver transplant
for HA.
Data. We reviewed our series of patients who underwent liver transplantation
between January 1998 and June 2007 at our institution. During this period
we performed 804 orthotopic liver transplants of which 107 were in the
pediatric age group and 1 was for a diagnosis of HA.
This patient was a 16 y/o African American female who presented with severe
abdominal pain and was found to have extensive HA on CT scan.(Image 1).
There were greater than 30 adenomas in both hepatic lobes, ranging in size
from 5 mm to 10 cm. (Image 2). These lesions were not deemed resectable,
without total hepatectomy and because of on-going symptoms and risk of
hemorrhage and malignant degeneration, she underwent liver transplanta-
tion. Her procedure was uneventful and she was discharged from the hospital
on post-transplant day 8.
Conclusion. The treatment of HA remains controversial. Despite
these tumors being benign, they have a reported risk of rupture with
hemorrhagic complications of 46% to 62%. Abdominal pain resulting from
tumor rupture is the most common symptom that often leads to diagnosis of
this entity.
Liver transplantation should be considered for patients with symptomatic HA
due to rapid enlargement or hemorrhage that cannot be surgically resected or
patients whose lesions are at risk of malignant transformation.
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HISTOLOGIC FINDINGS IN POST-REPERFUSION AND FOL-
LOW-UP BIOPSIES IN LIVER TRANSPLANT PATIENTS: IS
THERE ANY CORRELATION?
Mohammad Raoufi, MD, Chan Ma, MD, Adrian Ormsby, MD, Veena Shah,
MD, Kimberly Brown, MD, Mary Ann Sherbondy, MD, Dilip Moonka,
MD, Marwan Abouljoud, MD
Henry Ford Hospital, Detroit, MI
Background. Currently, there is no consensus to perform time zero biopsy
in liver transplant (LT) setting. In this study, we examined the donor liver
biopsies at the time of transplant, and evaluated progress of pathologic
findings in subsequent biopsies.
Design. Between Jan-May 2007, we selected 40 consecutive liver transplant
patients. All patients underwent protocol liver biopsies at the end of the LT
procedure. The post-reperfusion and follow-up biopsies were reviewed by
one expert pathologist.
Result. Only patients with at least one follow-up biopsy (20 males and 7
females) were included in the study and a total of 260 pathology slides (H and
E, iron and trichrome stains) were reviewed. Mean age was 52.4 years (SD9
9.5) in the recipient group and 44.2 years (SD917.5) in the donor group.
Mean cold and total ischemic time were 47 and 443.5 minutes (SD92.38;
SD9104.10), respectively. Mean follow-up time was 197.2 days (SD935.7).
Mean time between post-reperfusion biopsy and follow-up biopsy was 55.4
days (SD951.1) for the first, 110 days (SD958.1) for the second, 93 days
(SD961.7) for the third follow-up biopsies. Histologic findings in post-
reperfusion biopsies consisted of: Mild to moderate preservation injury (18
cases), micro- and macrovesicular steatosis (6 and 4 cases, respectively), mild
periportal chronic inflammation and fibrosis (3 cases), and pericellular
fibrosis (3 cases). In follow-up biopsies, major histologic findings included
acute cellular rejection (5 cases) and recurrent hepatitis C (5 cases). Of those
histologic findings in post-reperfusion biopsies, only the following pathology
were present in subsequent biopsies: Mild preservation injury (2 cases),
minimal chronic periportal inflammation and fibrosis (2 cases), and mild
residual micro- and macrovesicular steatosis (1 case each).
Conclusion. This preliminary report indicates that in most instances, the
histologic findings in post-reperfusion liver biopsy are subtle and do not
persist in follow-up biopsies. This may question the value of time zero biopsy.
However, there are some instances whereby the pathologic process cannot be
assessed in follow-up biopsies without having a baseline, especially when it
comes to degree of steatosis and fibrosis. Given the low morbidity of such
biopsies and continued expansion of donor criteria, post-reperfusion biopsy is
appropriate to better understand the long term impact of baseline pathologic
findings.
Table 1. Glutathione reduced (GSH) and Glutathione oxidized (GSSG) turn over in three populations.
Control-(n3) Control-(n3) Waiting OLTx (n2) Waiting OLTx (n2) Post OLTx (n2) Post OLTx (n2)
Time (h) GSH GSSG GSH GSSG GSH GSSG
0 0 0 0 0 0 0
2 0.4590.09 0.2690.18 0.0990.1 0.5490.12 0.4990.04 0.2390.08
4 0.7790.14 0.4290.18 0.290.07 0.6990.23 0.5990.22 0.3990.19
6 1.0190.07 0.6190.30 0.2990.11 1.0790.08 1.2190.1 0.5490.21
8 1.2990.15 0.9190.24 0.2790.2 1.3290.21 1.3190.09 0.8890.17
24 1.4090.14 1.1290.27
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COMPLICATIONS OF PERCUTANEOUS LIVER BIOPSY FOL-
LOWING LIVER TRANSPLANTATION
Timothy Schmitt, MD, Hugo Bonatti, MD, Charles Jeanpierre, MD, John
Stauffer, MD, Rolland C Dickson, Justin Nguyen, MD, Denise Harnois, DO,
Jaime Aranda-michel, MD
UVA, Charlottesville, VA; Mayo Clinic, Jacksonville, FL; Mayo Clinic,
Jacksonville, VA
Background. Percutaneous biopsy following liver transplantation is indi-
cated to assess graft dysfunction due to rejection, vascular, biliary complica-
tions or recurrence disease (HCV). Information gained from biopsies is
helpful in the management of liver transplant recipients. This benefit must be
weighed against the serious complications that can occur.
Methods. From 1998 to 2001 467 LTs in 402 patients were performed. All
patients underwent protocol biopsy within one hour post reperfusion, day 7,
100 and thereafter annually. Additional biopsies were obtained whenever
clinically indicated.
Results. More than 2000 liver biopsies were retrospectively reviewed during
a follow up of 58 years. A total of 13 patients developed serious
complications following liver biopsy. Six complications occurred within 4
weeks post LT, another four between 2 and 4 months post LT and three were
observed several years post LT. In specific there were four cases of
hematothorax, two intrahepatic hematomas, one rectus sheath hematoma
and four intraabdominal hemorrhages (one in combination with a bile duct
lesion). In addition we observed one injury of the Roux limb and one colonic
perforation in the setting of Chileiditi syndrome. Six cases were managed
conservatively. Interventions included ERCP (n1), chest tube placement
(n1), thoracoscopy (n1), thoracotomy (n1), laparotomy (n3). Two
deaths and one graft was lost directly related to a biopsy complication.
Conclusions. The risk for significant complications associated with liver
biopsy should not be neglected. Immediate intervention is the basic principle
of treatment. The data suggest that protocol biopsies may be reduced and
tailored to the underlying disease and quality of the graft.
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SELECTIVE INTERNAL RADIATION THERAPY FOR AD-
VANCED HEPATOCELLULAR CARCINOMA: IS THERE A BEN-
EFIT?
S Rudich, MD, PhD, C Schatzman, RN, A Tevar, MD, J Buell, MD, E S
Woodle, MD, T Doty, RN, A Marshall, RN, R Ristagno, MD, D Zuckerman,
MD
Univ of Cincinnati Med Ctr, Cincinnati, OH
The treatment options for patients presenting with advanced hepatocellular
cancers (HCC) are limited. If outside of Milan or UCSF criteria,
transplantation (OLT) does not provide optimal Results. For those not
transplant or surgical candidates, either downstaging (for possible OLT) or
palliation might be provided through non-surgical means. Currently, selective
internal radiation therapy (SIRT) is being used to treat patients with larger
lesions, whom, for various reasons, are not deemed immediate surgical
candidates.
Purpose. To review our initial experience with the use of SIRT for patients
presenting with advanced stage HCC (stages III and IV) in which surgery
(either resection, ablation, or OLT) was not an immediate option at the time
of presentation.
Methods. Medical records were reviewed of 30 consecutive patients referred
for SIRT between April 2006 and August 2007.
Results. The most frequent diagnosis in this patient population was hepatitis
C viral infection, followed by alcohol liver disease. The median MELD score
was 9.0 (mean 10.2). 87% of patients had an ECOG status of either 0 or 1. A
single patient had a Child-Pugh score of C, the remainder were either A or B.
Median age at diagnosis of HCC was 60 yrs (range: 20 to 85.5 yrs). Three of
the 30 treated patients underwent successful liver transplantation. Of the 26
patients with follow-up imaging, 16/26 underwent a single SIRT treatment,
whereas 6 had 2 treatments, and 2 each underwent 3 and 4. The average
amount of radiation provided to the treated liver per SIRT session was 1269
60 Gy. Only 11 patients presented with an AFP 400 ng/ml, of which 4
demonstrated a sizeable decrease (from 38 to 97%). Only 1 of these patients
died. Of the 30 patients treated, 16 died, with a mean time from treatment to
death of less than 10 months. In approximately 25% of patients a partial
radiologic response was noted, although because of the size and infiltrative
nature of many lesions, definitive imaging analyses were quite difficult.
Conclusions. This early experience with the use of SIRT for advanced HCC
(stages III and IV) does not show favorable Results. No advantage, in terms
of overall survival or disease-free survival, was observed. The use of this
technology, as a single therapy for advanced HCC, cannot be supported by
our data. The use of SIRT, in combination with other treatment modalities,
needs to be investigated in multi-center trials.
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LIVER TRANSPLANTATION SURGICAL PRINCIPLES IN THE
MANAGEMENT OF EXTENSIVE RETROPERITONEAL TU-
MORS.
Manoj K Singh, MD, Caroline Rochon, MD, Juan P Rocca, MD, Patricia A
Sheiner, MD, Manuel I Rodriguez Davalos, MD, Majid Eshghi, MD, David
M Schwalb, MD, Muhammad Choudhury, MD, Marcelo E Facciuto, MD
Westchester medical center, New York Medical College, Valhalla, NY
Introduction. The potential for massive hemorrhage imposes additional
challenge in the management of retroperitoneal tumors. Surgical techniques
applied for transplantation surgery can achieve access and vascular control of
retrohepatic IVC that allows resection and reconstruction of IVC while
maintaining hemodynamic stability.
Methods. Retrospective chart review of patients who underwent surgery for
extensive retroperitoneal tumors using techniques for liver transplantation
from December 2002 to August 2007 was done. The variables noted were
patient demographics, operative technique, 30-day postoperative morbidity,
mortality and length of stay.
74 Abstracts
Results. 22 patients underwent major retroperitoneal surgery between
December 2002 and August 2007. There were 13 males and 9 females
with mean age 57 years (range 2980 years). Renal cell carcinoma was seen in
16 patients, 2 patients had adrenal carcinoma; other diagnoses were
leiomyosarcoma, metastatic endometrial spindle cell sarcoma, transitional
cell carcinoma and cholangiocarcinoma.Mean tumor dimension was 11.6 cm
(range 323 cm).
Abdominal exposure was achieved via bilateral subcostal incision with upper
midline extension. Right hepatic lobe mobilization and isolation from the
IVC was performed in all cases for complete exposure and retrohepatic IVC
control. Fourteen patients had IVC involvement by tumor thrombus,
extending into infrahepatic IVC in 6, retrohepatic in 5 and intra-atrial in 3
patients. Tumor thrombus was removed by cavotomy in 7 cases, resection
and plasty in 4, IVC graft reconstruction in 3 cases and 1 patient required
IVC and atrial graft reconstruction. Liver resection was needed in 6 patients
to achieve R0 resection.
Total liver vascular isolation was required in 7 cases, transdiaphragmatic
intrapericardial IVC control in 1, veno-venous bypass in 2 and cardio
respiratory bypass in 1 patient.The remaining 8 patients had proximal and
distal retrohepatic IVC isolation in order to achieve vascular control.
Mean operative time was 6.3 hours with estimated average blood loss of 1500
ml requiring mean 3.5 units of PRBC transfusion. There was no intraopera-
tive or postoperative mortality and mean length of stay was 13 days.
Conclusion. Successful excision of extensive retroperitoneal tumors remains
a technical challenge that requires careful preoperative planning and team
approach. Liver transplantation surgical principles help achieve exposure and
vascular control of major vascular structures that enable safe resection of
these tumors.
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‘‘LAPAROSCOPIC LIVER RESECTIONS: INITIAL EXPERIENCE’’
Juan Pekolj, MD, Diego Lucas Ferna´ndez, MD, Mariano Luis Bregrante,
MD, Juan Antonio Salceda, MD, Eduardo De Santibann˜es, MD, Rodrigo
Sanchez Claria´, MD
Hospital Italiano Buenos Aires, Buenos Aires, Argentina
Background. laparoscopic liver surgery had had an important development
in specialized centers, and laparoscopic liver resections are the most complex
procedures in this area.
Objectives. to value the results of an initial experience of laparoscopic liver
resections.
Institution. HPB and Liver Transplant Unit in a teaching Hospital.
Materials and Methods. age, sex, pre and postoperative diagnosis,
indications for resection, number size and localization of the lesions,
procedure performed, pedicle clamping, technique of parenquimal section,
operative and clamping time., associated procedures, conversion rate.,
postoperative stay, morbidity and mortality, long term results in malignant
cases.
Results. In 25 patient we indicated laparoscopic liver resection. This is the
5.2% of all our resections in the same period. In 87,5 was by benign lesions,
and in 12.5 by malignant tumors. Two patients (8,3%) were converted. The
resections were minor in 21 cases and major in 1. Pringle maneuvere was
performed in 50% of the cases. Mean operative time was 170 min, and the
mean length of stay was 3 days. We had no mortality and only one
postoperative bile leak self limited (4.1%). In all malignant patient a safety
minimal margin of 1 cm was obtained.
Conclusions. laparoscopic liver resections, are safe and effective procedures
for selected patients with benign and malignant liver lesions if it is performed
by well trained surgeons.
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RADICAL SURGICAL MANAGEMENT FOR HEPATIC HYDATID
CYSTS IN AN HPB CENTER FROM ARGENTINA
Javier C Lendoire, MD, Fernando Duek, Pablo Barros Schelotto, MD,
Carlos Quarin, MD, Gabriel Raffin, MD, Vero´nica Garay, MD, Oscar
Imventarza, MD
Hospital Dr Cosme Argerich, Buenos Aires, Argentina
Background. The echinococcosis is a common parasitic cystic disease in our
country. Most usual localization is the liver (70%). Surgical management is
still debated betweeen radical and more conservative treatments. The
purpose of this study is to analyze the radical surgical approach in a
consecutive series of hepatic hydatid cysts treated at the same institution.
Patients and Methods. In a 10 year period (19962006) 55 patients
underwent surgical treatments for hepatic hydatid cysts in our unit. Diagnosis
was made by US and CT. Variables analyzed were: age, sex, initial symptoms,
cyst characteristics, treatments, complications, average hospital stay, mortal-
ity and long term follow up. Standard pericystectomy technique consisted of
total or subtotal ( 75%) excision of the cyst with the fibrous capsule.
Follow up was performed by US every six month during the first year and
then annually.
Results. 64.3% of the patients were female with a mean age of 44.2914 (23
68) Symptoms were present in 93% and pain was the most common (83%).
Right lobe was the most frequent localization (66.7%), mean size 9.2 cm and
43% were greater than 10 cm. Only 5 patients (12%) presented multiple
lesions and the intrabiliary rupture was verified in 3 (7.1%). 45 radical
pericystectomy and 10 liver resections were performed. A total pericystect-
omy was performed in 25 (55%). Surgical approach was conventional in
97.6% and laparoscopic in (2.4%). Morbidity rate was 28.6%, (Clavien’s
classiffication) grade I10 (18%), grade II1 (1,8%) and grade III3
(5,4%). There were no statistical differences between incidence of complica-
tions and cystic size or surgical technique (partial 75% or total pericys-
tectomy). Average hospital stay was 8,7 days. No mortality was reported in
this series.
Conclusion. Standard pericystectomy and liver resection are radical safe
procedures for the treatment of hepatic hydatid cyst with low incidence of
morbidity. Should be the first option for the treatment of echinococcosis of
the liver.
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CHEMOTHERAPY AND SELECTIVE INTERNAL RADIATION
TREATMENT WITH Y-90 MICROSPHERES (CHEMO-SIRT) IM-
PROVES OBJECTIVE RESPONSES IN PATIENTS WITH COLOR-
ECTAL CANCER LIVER METASTASES COMPARED TO
CHEMOTHERAPY ALONE
Seza A Gulec, MD, Richard Hostetter, MD, Geraldine Mesoloras, MS,
Thomas Fischbach, MD, Daniel Bruetman, MD, Kenneth Pennington, MD
Center for Cancer Care at Goshen Health System, Goshen, IN
Introduction. Selective Internal radiation Treatment (SIRT) with Yttrium-
90 (Y-90) microspheres has a high therapeutic ratio in delivering safe and
effective radiation doses to the metastatic liver lesions of colorectal cancer.
This study was designed to compare the objective tumor responses of
combined use of chemotherapy and Y-90 microspheres (Chemo-SIRT) to
chemotherapy alone as a front-line therapy in patients with colorectal cancer
liver metastases (CRCLM).
Methods. Patients with CRCLM with liver-only or liver-predominant
disease undergoing front-line systemic therapy were studied. The patients
started chemotherapy with FOLFOX or FOLFIRI regimens, and were
administered Y-90 resin microspheres (Sirtex Medical, Wilmington, MA) in a
single lobe on day 2 of the first chemotherapy course. Chemotherapy was
then repeated on a biweekly schedule for a period of time as clinically
indicated. The patients underwent a liver-protocol FDG-PET/CT prior to,
and 4-weeks after the protocol treatment. Functional Tumor Volume (Vf),
and Maximal Glycolytic Index (MGI: The product of functional tumor
volume and maximum standard uptake value) were determined in both
Chemo-SIRT and chemo-only treatment fields.
Results. 13 patients were treated with a 100% objective response rate in the
Chemo-SIRT treated lobe. 2 of the patients showed tumor progression in the
lobe receiving chemo-only. Mean decreases in Vf in liver field receiving
chemo-SIRTand chemo-only were 85.2% and 43.8% respectively (pB0.01).
Tumor Vf decrease was 90% in the target lobe in 6/13 (46%) patients.
Mean decreases in MGI in liver field receiving chemo-SIRT and chemo-only
were 91.3% and 27.0% respectively (pB0.01). Pathologic response corre-
lated with PET/CT parameters of objective response in patients who
subsequently underwent resection.
Conclusion. Chemo-SIRT as front-line therapy demonstrated significantly
improved objective tumor responses as determined by decrease in functional
tumor volume and maximal glycolytic index in comparison to chemotherapy
alone. Chemo-SIRT concept needs to be further evaluated for its potential
role in surgical downsizing, and its impact on recurrence and survival.
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STAGED LIVER RESECTION FOR EXTENSIVE BILOBAR COL-
ORECTAL LIVER METASTASES
Peter Metrakos, MD, Amy Neville, MD, Mazen Hassanain, MD, Gabriel
Chan, MD, Nicholas Meti, Dionisios Vrochides, MD, Prosanto Chaudhury,
MD
McGill University, Montreal, QC, Canada
Objective. To assess the outcomes of patients undergoing two-stage liver
resection for extensive bilobar colorectal cancer (CRC) metastases.
Background. Approximately 50% of patients with CRC will develop liver
metastasis. Liver resection has been shown to improve long term survival and
offers the only potential for cure. By present standards, only 20% of patients
are eligible for resection at the time of presentation due to the extent of
hepatic disease. Staged resection, with or without portal vein embolization,
allows for regeneration of the liver between procedures and permits more
extensive resection. Staged liver resection can increase the number of patients
eligible for resection with curative intent.
Methods. Patients who were planned to undergo staged resection for CRC
metastases at the McGill University Health Center were identified. The
resection strategy was based on preservation of the middle hepatic vein and a
liver remnant consisting of segments 1 and 4. The first stage consisted of
clearance of one lobe of the liver by either right lobectomy or left lateral
segmentectomy with wedge resections of segments 1 and 4 as necessary. The
second stage operation consisted of resection of the contralateral lobe. All
patients received neoadjuvant chemotherapy prior to the initial hepatic
resection, as well as adjuvant chemotherapy following each liver resection to
prevent disease progression. Ten patients (41.7%) underwent portal vein
embolization as part of the staged procedure.
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Results. Twenty-three patients (15 male, 8 female) were identified between
January 2003 and April 2007. The median age was 53 years. The average
number of lesions on preoperative CT scan was 5.5 and the median clinical
risk score was 3 (Fong et al 1999). Sixteen patients (69.6%) completed the
staged resections. The overall 1- and 4-year survivals were 93.3% and 78.8%
in the group that completed the staged resections, and 57.1% and 28.6%
respectively for the group who did not complete the staged procedure. The
difference in survival was statistically significant (p0.01). There were no
cases of liver failure from inadequate residual functional liver.
Conclusions. Staged liver resection based on preservation of the middle
hepatic vein can be achieved in a significant number of patients presenting
with initially unresectable CRC liver metastases and results in excellent
overall survival. This strategy increases the number of patients eligible for
resection with curative intent. Patients who do not complete the staged
resection seem to benefit from better than expected survival compared to
patients in published series who received only chemotherapy.
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LAPAROSCOPIC LIVER RESECTION: DISTRIBUTION OF COM-
PLICATIONS
Ravi Nagubandi, MD, Kadiyala V Ravindra, MD, Mark Thomas, MD,
Michael Marvin, MD, Steve Rudich, MD, Amit Tevar, MD, Joseph Buell,
MD, Jewish Hospital, University of Louisville, Louisville, KY, Louisville, KY
Jewish Hospital, University of Louisville, Louisville, KY; University of
Cincinnati, Cincinnati, OH
Laparoscopic liver resection is emerging as an acceptable alternative to its
open counterpart with comparable morbidity and mortality. However, this
approach is currently limited to high volume centers experienced with the
technique. We present our experience of a large series.
Methods. 237 patients undergoing 284 laparoscopic liver resections between
‘01 and ‘07 were entered into a prospective database. We analyzed the
demographics, operative parameters, hospital stay, morbidity, mortality and
follow up of these patients.
Results. 60 patients underwent major and 177 underwent minor resections.
There were 28 cirrhotic and 209 non-cirrhotic patients. Overall complication
rate was 14% with a mortality rate of 1.7%. An average of 1.2 resections were
performed per patient involving 2.4 segments with an average blood loss of
220 ml and a mean operative time of 2.7 hours. On an average12 stapler loads
were used. The average tumor size was 5.3 cm with a margin of 0.8 cm.
The cohort including the cirrhotic patients (n28) had a complication and
mortality rates of 25% (p0.07) and 7% (p0.006) respectively. 25% (p
0.006) of these patients required ICU stay with an average hospital stay of 4.5
days. 3 (11%) of them required transfusions. There were no open conver-
sions. The non-cirrhotic cohort had a complication rate of 12.5% and a
mortality rate of 1%. About 6% of these patients required blood transfusions
and 8% required ICU stay. The mean hospital stay was 3.3 days and there
was a 1% open conversion rate.
Conclusions. Laparoscopic liver resection is a viable alternative to open
surgery in the hands of experienced hepatic surgeons. In cirrhotic patients the
morbidity rate approaches significance whereas the mortality rate is sig-
nificantly higher than non-cirrhotics.
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MULTI-MODALITY THERAPY OF HEPATIC NEUROENDO-
CRINE METASTASES
Matthew H Katz, MD, James Yao, MD, Daniel Anaya, MD, Steven Curley,
MD, Eddie K Abdalla, MD, Jean-nicolas Vauthey, MD
MD Anderson Cancer Center, Houston, TX
Introduction. Although hepatic resection currently represents the only
potentially curative therapy for patients with hepatic neuroendocrine (NET)
metastases, previous studies indicate only 20% resectability rates with
complete resection in approximately 10%.
Patients/Methods. At our institution, an individualized strategy of che-
motherapy (CTX), hepatic artery embolization (HAE), radiofreqency abla-
tion (RFA), portal vein embolization, (PVE), and one- or two-stage hepatic
resection is selected for each patient with hepatic NET metastases by a
multidisciplinary group to control symptoms and maximize the potential for
curative therapy. In order to evaluate the results of this approach, we
identified all patients who presented with NET between 1999 and 2006 in a
prospectively maintained, single-institution database. Patients with metas-
tases apparently isolated to the liver, with or without primary tumor intact,
were reviewed.
Results. 986 patients with NET were evaluated during the study period. 281
of these (n77 pancreatic NET, n150 carcinoid, n54 unclassified) had
metastatic disease confined to the liver based on preoperative staging. 91
(33%) patients underwent surgical resection, of whom 80% of had multifocal
and 63% had bilateral disease. 57 major and 34 minor hepatectomies were
performed; 30% (n27) patients underwent concomitant RFA. 48% (n
44) patients had prior CTX or HAE; PVE was used as an adjunct to 6 one-
stage and 2 two-stage hepatectomies. 31 patients underwent synchronous
resection of their primary tumor. 80% (n73) of operations were macro-
scopically complete; in 63% (n57) an R0 resection was achieved. 90-day
mortality was 1%. Median recurrence-free survival was 25 months. Of 40
patients who recurred during the study period, 11 underwent successful
reoperation. From the date of first evaluation with metastatic disease, 1-, 3-
and 5-year survival rates of patients having surgery were 96%, 91%, and
76%. The corresponding 1-, 3- and 5-year survival rates of patients treated
non-operatively were 82%, 61%, and 38% (PB0.001).
Conclusions. Using a multimodality approach, one third of patients with
NET liver metastases are candidates for surgery. Every method should be
considered to achieve complete treatment including chemotherapy, emboli-
zation and bilateral liver resections.
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HEPATIC HYDATIDOSIS SUCCESSFULLY MANAGED WITH
PAIR (PERCUTANEOUS ASPIRATION, INJECTION, AND REAS-
PIRATION)
William Scott Helton, MD, Christine Donaldson, MD, MPH, Marco
Fischela, MD
Hospital of Saint Raphael, New Haven, CT; university of illinois at chicago,
Chicago, IL; University of California San Francisco, San Francisco, CA
Percutaneous aspiration, injection and reaspiration (PAIR) with a scolicidal
agent (23% NaCl) followed by sclerotherapy with ethyl alcohol combined
and oral albendazole has recently been reported to be as effective but less
morbid than surgery in the treatment of liver hydatidosis. Herein we report
the first case in the world of a patient with Hepatic and splenic hydatidosis
successfully treated by laparoscopic splenectomy and hepatic PAIR under
laparoscopic guidance.
Methods. A 20 year old immigrant from Bulgaria with upper abdominal pain
was found to have a 676 cm hydatid cyst in the segment 7 of the liver and
a 17 cm15 cm cyst in the spleen contiguous with the hilar vessels. ERCP
showed no communication between the biliary ductal system and the cyst, a
precondition for performing safe PAIR. She was treated with Albendozole
(400 mg BID) for 4 weeks preoperatively. Hydrocortisone 100 mg IV,
Benadryl 50 mg IV and famotidine 20 mg IV were given at anesthesia
induction. Laparoscopic splenectomy was performed without incident and
the spleen extracted through an infraumbilical incision. Laparoscopic
ultrasonography of the liver demonstrated that the hepatic cyst was
contiguous with the posterior chest wall. The patient was repositioned in
the left lateral decubitus position and under extracorporeal ultrasound
guidance, a 20 gauge needle was inserted percutaneously into the hydatid
cyst in segment 7 of the liver. A 10-French pigtail catheter was introduced
over a 0.018 guide wire which was used to aspirate the cyst, inject it with a
hypertonic, 23% NaCl, sterile solution, and re-aspirate. Injection and re-
aspiration was repeated using 25 cc aliquots of saline until the cyst contents
became progressively thinner and were able to be completely aspirated
(confirmed by laparoscopic ultrasound). Laparoscopy was used to be certain
there was no spillage of cyst fluid intraperitoneally. This was followed by the
injection and aspiration of 50 ml of absolute ethyl alcohol. Total operative
time was 215 minutes and blood loss was less than 50 ml. Recovery was
uneventful and the patient was placed on a four-week course of albendazole
(400 mg BID). She returned to work on POD #10 and delivered a healthy
baby 10 months later. At 18 month follow-up she has no abdominal
discomfort and CT shows only a ghost lesion in her liver.
Conclusion. PAIR is safe and effective treatment for hepatic hydatid cysts
which do not communicate with the biliary tree. This approach should be
considered prior to open surgical treatment in patients with simple sympto-
matic hydatid cysts of the liver.
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EVALUATION OF HEMOSTATIC FACTORS IN PATIENTS UN-
DERGOING MAJOR HEPATIC RESECTION AND WHIPPLE PRO-
CEDURES
Juan M Sarmiento, MD, Fania Szlam, MD, Kenichi Tanaka, MD, Jerrold H
Levy, MD
Emory University, Atlanta, GA
Introduction. Major surgery can be complicated by large blood losses that
contribute to increased perioperative mortality1,2. Bleeding occurs from the
hepatic wound surface, inferior vena cava, hepatic vein, but also as a result of
tissue injury and hemostatic activation during tissue injury. If we can better
understand the perioperative hemostatic changes that occur, therapeutic
Non-cirrhotic % Cirrhotic % p
Number 209 28
Complications 26 12.5 7 25 0.07
Death 2 0.96 2 7 0.006
Transfusion 13 6.2 3 10.7 0.2
ICU stay (n) 17 8 7 25 0.006
Total length of stay (d) 3.3 (167) 4.5 (28) 0.08
Conversions 2 0.96 0 0 0.08
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strategies can be potentially developed to further reduce bleeding, the need
for transfusions, and otheradverse changes that occur in our patients. We
therefore evaluated data from patients undergoing major hepatic surgery and
Whipple procedures to understand the hemostatic changes that occur as part
of this procedure.
Methods. After IRB approval, records from 91 patients were evaluated from
a single surgeons, database. Both preoperative and postoperative fibrinogen,
antithrombin III (ATIII), platelets, partial thromboplastin times, and
prothrombin times (defined as international normalized ratios-INR).
Results. Preoperative ATIII levels ranged from 5196% (mean 80%), and
postoperative ATIII levels ranged from 3781% (mean 50%). Normal ATIII
levels are 80120% Preoperative INRs ranged from 0.971.45 (mean 1.1),
and postoperative values from 0.971.55 (mean 1.3). Preoperative fibrinogen
levels ranged from 240775 mg/dL(mean 498), and 24 hour postoperative
levels ranged from 193969 mg/dl (mean 491). Normal fibrinogen levels are
200350 mg/dL.
Conclusions. The hemostatic effects of hepatic surgery alone have variable
effects on hemostatic changes. We noted no correlations among bleeding,
transfusions, and INR or PTT values. Of equal importance, there were a
significant number of patients who were at risk postoperatively for hypercoa-
gulability based on low ATIII levels and/or increased fibrinogen levels. This is
important when considering the additional need for postoperative prophy-
laxis for venous thromboembolic complications. Our preliminary data
suggests that additional hemostatic values, including tests of clot strength
based on evaluating viscoelastic properties of blood using thromboelasto-
graphy (TEG) or thromboelastometry (ROTEM) need to be evaluated better
assess patients undergoing major hepatic surgery. Current studies are under
way to assess these additional tests as being a predictor of bleeding in major
gastrointestinal surgery.
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SURGICAL MANAGEMENT OF HEPATIC ENDOMETRIOSIS: A
RARE LIVER LESION
Nicole P Bernal, MD, Kian Modanlou, MD
Saint Louis University Hospital, Saint Louis, MO
Objective. To describe an unusual case of endometriosis of liver with
diaphragmatic invasion and to determine an algorithm for management
based on reported experiences.
Design. Case report and review of literature.
Patient. 36 y/o female who was otherwise healthy, with 6 mo history of
worsening epigastric and right upper quadrant pain. She was initially
diagnosed as subcapsular liver hematoma in the postpartum period. Repeat
studies revealed a rapidly enlarging mass with solid and cystic components
that were hemorrhagic in nature. She was referred to our center for surgical
management of this acutely enlarging liver tumor. She had a remote history of
endometriosis treated with different estrogen regimens which she had
stopped taking several months prior to pregnancy. Initially laparoscopic
resection was attempted, however, conversion to an open procedure was
necessary due to invasion into the right hemi-diaphragm. A right hepatect-
omy with en-block resection of diaphragm was performed. The diaphrag-
matic defect was repaired with mesh. Pathologic examination revealed
endometrial tissue.
Results. Few cases of hepatic endometriosis have been reported in literature,
and only 2 documented involvement of diaphragm. There have been some
reports of medical therapy to reduce the size of lesion prior to resection.
However, there have also been at least 2 reports of malignant degeneration
discovered within resected tumor.
Conclusion. Hepatic endometrioma is a rare manifestation of extrapelvic
endometriosis. Although benign in nature, the possibility of extension into
surrounding tissues, difficulty differentiating from adenoma or hemangioma
on CT or MRI, and potential for malignant degeneration supports surgical
resection as the main therapeutic modality.
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PERCUTANEOUS VERSUS OPEN/LAPAROSCOPIC RADIOFRE-
QUENCY ABLATION: IS THERE A DIFFERENCE?
Evan S Ong, MD, Mohamed A Alassas, MD, Alan Litwan, MD, Peter Loud,
MD, John Gibbs, MD, Boris Kuvshinoff, MD
Roswell Park Cancer Institute, Buffalo, NY
Introduction. Described by Rossi et al. in 1996, radiofrequency ablation
(RFA) has gained acceptance in the management of tumors in the liver.
However, studies that report outcomes from RFA treatment are difficult to
interpret because of a mixture of technical, tumor and patient variables that
make these studies incomparable. Therefore, the purpose of our study was to
determine the differences in outcomes, complications and survival among the
different technical approaches to RFA (radiological vs. surgical approach).
Methods. Retrospective review of 44 patients that underwent either
percutaneous RFA (CTor US-guided) or surgical RFA (open or laparoscopic
approach) at our institution from 20042006. Data on patient and tumor
characteristics, treatment, complications, and recurrence-free survival were
analyzed. Median follow-up was 17 months. Student’s t-test was used for
comparisons with significance at the pB0.05 level.
Results. Median age was 68 (range 4588) and 64% were male. Seventeen
patients underwent percutaneous RFA (CT 5, US 12), while 23 patients
underwent surgical RFA (open 10, laparoscopic 13) and 4 patients received
both modalities. Twenty-eight percent of the surgery group also had a
concomitant surgical resection. Patient characteristics were similar including
47% of patients in both groups having 3 or more co-morbidities. Tumor
histologies included colon cancer (73%), hepatoma (8%), and neuroendo-
crine (6%). Sixty-four lesions were ablated in the 27 surgical procedures and
28 lesions in the 21 percutaneous procedures. Fifty-four percent of the
lesions treated percutaneously were in the anterior locations (segments 3,4,5)
versus only 28% in the surgical group. The median lesion size was 2 cm
(range 15 cm) in both groups, while the percutaneous group had a larger
average ablation size (5.5 cm vs. 4 cm, pB0.002). The surgical group had
twice the morbidity (21% vs. 10%) with no mortality in either group.
Ablation site recurrence was 35% in the percutaneous group versus 17% in
the surgical group. Overall recurrence rate was 70% in the percutaneous
group versus 59% in the surgical group. Median recurrence-free survival was
significantly better in the surgical group (11 months vs. 5 months, pB0.023).
Conclusions. Percutaneous RFA was performed more commonly in lesions
of the anterior segments and resulted in a larger ablation size than surgically
treated patients. Surgical RFA was associated with a greater number of
complications, although this included patients with concomitant procedures.
The surgical RFA group had a lower local recurrence rate and longer median
recurrence-free survival compared to percutaneously treated patients.
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RADIOFREQUENCY COAGULATION IN LAPAROSCOPIC LIVER
RESECTION: EVALUATION OF A NOVEL LAPAROSCOPIC DE-
VICE.
Ravi Nagubandi, MD, Kadiyala Ravindra, MD, Michael Marvin, MD, Mark
Thomas, MD, Steve Rudich, MD, Amit Tevar, MD, Joseph Buell, MD
Jewish Hospital, University of Louisville, Louisville, KY; University of
Cincinnati, Cincinnati, OH
Use of radiofrequency coagulation for liver resection has been described in
open liver resection resulting in reduced need for blood transfusion
requirements. The application of this principle for laparoscopic liver resection
resulted in variable transfusion requirements and complications. We evalu-
ated a novel laparoscopic device.
Methods. 237 patients underwent 284 laparoscopic liver resections between
‘01 and ‘07 at our institute. A radiofrequency coagulation device (HabibTM
4 Laparoscopic XL, Angiodynamics Incorporated, Queensbury, NY
12804) was used for coagulating the resection plane in 25 patients. The
patient demographics, blood transfusion requirements, duration of operation,
morbidity and mortality were analyzed.
Results. There were no statistically significant differences in morbidity and
mortality rates, estimated blood loss and transfusion requirement, hospital or
ICU stay and the operative time.
Conclusions. The new laparoscopic radiofrequency coagulation device
allows pre-coagulation of the resection line and allows cutting of the liver
parenchyma along the avascular plane thus created. In our initial experience
this device was helpful despite no statistically significant advantage. Further
analysis is warranted with more number of resections using this device.
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MESH REINFORCEMENT OF A STAPLED PANCREATIC TRANS-
ECTION LINE REDUCES THE RATE OF LEAK
Fabian Johnston, MD, Antonino Cavataio, Nicholas Hamilton, MD, Peter
Simon, MD, Brent Mathews, MD, Michael Brunt, MD, Christopher Eagon,
MD, David Linehan, MD, Steven Strasberg, MD, William Hawkins, MD
Washington University in St. Louis, St. Louis, MO
Background. Pancreatic leak following distal pancreatectomy remains a
common source of morbidity and frustration for patients and surgeons. For
the last few years our group has sporadically utilized mesh to reinforce the
pancreatic transection line in an effort to reduce pancreatic leak. Here we
review our experience with distal pancreatectomy and attempt to identify
factors which might influence leak rates.
Methods. One hundred and seventy one distal pancreatectomies were
performed (open and laparoscopic) between 2000 and 2007. Review of the
computerized medical records and physician office records was performed for
Non-Habib Habib P
Number 212 25
Complications 35 (16.5%) 4 (16%) 0.94
Death 4 (1.8%) 0 0.48
Transfusion 16 0 0.15
ICU stay (n) 23 (10.8%) 1 (4%) 0.28
Length of stay (Days) 2.68 3.53 0.33
Duration of operation (Hours) 2.77 2.42 0.11
Estimated blood loss 222 224 0.96
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all 171 patients. The principle outcome measure was defined as absence of a
clinically relevant leak from the pancreatic stump within the first 30 days of
the post operative period. Utilizing recently published recommendations we
defined leak as an amylase rich fluid (30 ml) obtained from the drain at or
beyond postoperative day 10. We also included all symptomatic fluid
collections requiring intervention (drain placement or antibiotics). Univariate
and multivariate analyses were performed to determine factors which might
influence the incidence of pancreatic leak.
Results. Perioperative mortality was zero. Pancreatic leak was the most
common perioperative complication. Pancreatic leak was identified in 32 of
171 patients (19%). The data set was analyzed for factors which might
influence leak rate. Analysis included patient and disease characteristics
including; age, sex, BMI, diagnosis, consistency of the pancreas and history
of pancreatitis, as well as intraoperative variables including; surgeon, mesh
utilization and operative approach. Utilization of mesh was significant by
both univariate and multivariate analysis. Leak was identified in 7 of 70
patients (10%) when an absorbable mesh was utilized, and 25 of 101 patients
(25%) when mesh was not utilized (p B0.02). Not surprisingly patients who
had received mesh reinforcement were less likely to require that a drain be
placed by interventional radiology in the post operative period (pB0.05).
Conclusion. These data suggests that application of this mesh reinforcement
may significantly reduce the rate of pancreatic leak following distal
pancreatectomy. To eliminate unrecognized confounding variables, a pro-
spective randomized trial of mesh reinforcement has been initiated.
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BRAUN ENTEROENTEROSTOMY IS ASSOCIATED WITH RE-
DUCED DELAYED GASTRIC EMPTYING AND EARLY RESUMP-
TION OF ORAL FEEDING FOLLOWING PANCREATI-
CODUODENECTOMY
Steven N Hochwald, MD, Stephen R Grobmyer, MD, Eleanor Curran, PA-
C, MPH, David A Bloom, PhD, Matthew Delano, MD, Alan W Hemming,
MD, Kevin E Behrns, MD, Stephen B Vogel, MD
University of Florida College of Medicine, Gainesville, FL
Introduction. Morbidity rates following pancreaticoduodenectomy remain
high with delayed gastric emptying and slow resumption of oral diet
contributing to increased postoperative length of stay. A Braun enteroenter-
ostomy has been shown to decrease bile reflux following gastric resection. We
hypothesize that addition of Braun enteroenterostomy during pancreatico-
duodenectomy would reduce the sequelae of delayed gastric emptying.
Methods. We retrospectively evaluated 130 patients from 20012006
undergoing pancreaticoduodenectomy with reconstruction utilizing a single
loop of jejunum. Those undergoing an additional Braun enteroenterostomy
(Braun, n70) with a double stapled technique were compared to those
undergoing standard reconstruction (no Braun, n60). Braun was per-
formed at the discretion of the attending surgeon. Peri-operative erythromy-
cin was not routinely utilized in either group. Postoperative development of
delayed gastric emptying (10 days without tolerating liquid diet), incidence
of vomiting, NG tube reinsertion rates, median time to tolerating liquids and
solids, median length of stay and pancreatic fistula rates were recorded. Bile
reflux into the stomach was assessed utilizing a quantitative HIDA scan.
Results. Patients undergoing a Braun had NG tubes removed earlier (Braun:
2 d, no Braun: 4 d, p0.01) and no significant change in postoperative
vomiting (Braun: 27%, no Braun: 38%, p0.19) or NG tube reinsertion
rates (Braun: 17%, no Braun: 27%, p0.2). Median postoperative day with
tolerance of oral liquids (Braun: 5, no Braun: 7, p0.001) and solid diets
(Braun: 7, no Braun: 9, p0.001) were significantly improved in the Braun
group. Delayed gastric emptying (Braun: 10%, no Braun: 28%, p0.01) and
median length of stay (Braun: 10 days, no Braun: 13 days, p0.002) were
significantly reduced in those undergoing a Braun. The rate of pancreatic
anastomotic failure was similar in the two groups (Braun: 17% vs no Braun:
12%, p0.6). Median bile reflux was 0% in those undergoing a Braun as
measured by quantitative HIDA scan.
Conclusions. In patients undergoing pancreaticoduodenectomy, Braun
enteroenterostomy is associated with a reduction in delayed gastric emptying
and its sequelae. Further studies of Braun enteroenterostomy in larger
randomized trials of patients undergoing pancreaticoduodenectomy are
warranted.
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HEPATIC RESECTION WITH PANCREATODUODENECTOMY:
BE AWARE OF THE PANCREAS
Emmanuel Melloul, MD, Mircea Chirica, MD, Re´za A Kianmanesh, MD,
Alain Sauvanet, MD, Jacques Belghiti, MD
Hospital Beaujon, Clichy, France
Background. Liver resections associated with pancreatoduodenectomy
(PD) is a procedure which is indicated for some biliary cancers. However
this intervention is rarely performed because of its high risk. We aimed to
present in this study the first homogenous western series.
Patients and Methods. From year 2001 to 2006, 10 patients with a median
age of 53 years (range 3470) underwent liver resection with PD for stage IV
gallbladder carcinoma (n7), neuroendocrine tumor of the pancreas (n1),
GIST (n1), and main bile duct carcinoma (n1), respectively. All patients
had a PD associated with major hepatectomy in 4, which was prepared by
portal vein embolisation (PVE) and biliary drainage in all cases, and with
minor hepatectomy consisted of bisegmentectomy IV-V in 6.
Results. Mean operative time was 480 minutes (range 345720) and
operative blood loss 850 mL (range 1501700). The mortality rate was
nihil. Only one patient experienced major liver morbidity with episodes of
angiocholitis due to biliary anastomosis stenosis. There was no postoperative
liver failure. Pancreatic complications included fistulas in half of patients,
requiring pancreatico-jejunal anastomosis refection in one. The pancreatic
fistula rate was 75% after major hepatic resection. The mean ICU/hospital
stay after PD with major and minor hepatectomy was 18/56 and 7/27 days,
respectively.
Conclusions. Liver resection with PD is a procedure which can be
performed safely, providing that major hepatectomy is prepared by both
biliary drainage and PVE. Results of this study showed that pancreatic
complications are underestimated with a high rate of fistulas.
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NON-DYSPLASTIC MUCINOUS CYSTS (NDMC) OF THE PAN-
CREAS
Patrick Ross, MD, Charles Vollmer, MD, Jeffrey Goldsmith, MD, Ivan
Pedrosa, MD, Mandeep Sawhney, MD, Alphonso Brown, MD, Mark
Callery, MD
Beth Israel Deaconess Medical Center, Boston, MA
Background. Mucinous neoplasms of the pancreas (IPMN & MCN) are
under increasing scrutiny given their propensity for malignant transforma-
tion. However, a less well characterized subclass of mucinous cysts, showing
no histologic characteristics of dysplasia is emerging.
Methods. The clinical, imaging, and pathologic features of all pancreatic
cystic lesions that underwent operative resection at a tertiary-referral
pancreatic disease center from 2/056/07 were reviewed.
Results. During this period, 67 operations were performed for suspected
pancreatic cystic neoplasms. Final pathology revealed 33 IPMN, 6 MCN, 10
serous cystadenomas, 4 pseudocysts, 2 carcinomas, 1 neuroendocrine tumor,
and 5 other cystic lesions. Six cases of mucinous cysts devoid of dysplastic
features (NDMC) were identified, representing 9% of all resected cysts, and
13.3% of the 45 mucinous cysts. The average age was 71 years, and 5/6
patients were female. 3 patients were symptomatic, and 2 patients had first
degree relatives with pancreatic cancer. With respect to radiological
characteristics, the average size at presentation was 19 mm (1326 mm). 1
cyst was situated proximally, 2 distally, and 3 were diffusely located. 5/6 were
unilocular, 4/6 showed cystic calcifications, and 2/6 were septated. 5/6 had
normal pancreatic ducts, with 1 cyst causing distal obstruction, and 5
appeared to have no communication with the main duct. None showed cystic
enhancement, nodularity, atrophy, or parenchymal calcification. 5 patients
underwent endoscopic ultrasound, with 4 having fine needle aspiration.
Cytology was atypical in 4 cases. Aspirate CEA levels were elevated in all four
patients in which it was checked, with two patients having remarkably high
values of 4416 and 4788. Operative indications were pain (2), enlarging cyst
(1), and atypical cytology (4). 2 patients received Whipple resections and the
remainder underwent distal pancreatectomy. On pathological analysis, all
cysts showed a simple columnar epithelium with a pancreatobiliary pheno-
type. There was no evidence of cytologic dysplasia, papillary growth, or
ovarian type stroma in any of the cases. Conclusion. Non-dysplastic
mucinous cysts are a subset of pancreatic cysts that masquerade clinically,
radiographically, and biochemically as true mucinous cystic neoplasms of the
pancreas. It is yet uncertain whether these cysts are entirely benign or
represent a part of the neoplastic spectrum of mucinous cysts. This
underappreciated entity requires further analysis in order to find unifying
characteristics that would prevent unnecessary resections in patients harbor-
ing these seemingly benign lesions.
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SURGICAL MARGIN, LYMPH-NODE STATUS, TUMOR DIFFER-
ENTIATION, UICC STAGE AND ADJUVANT THERAPY ARE
RELEVANT PROGNOSTIC FACTORS AFTER RESECTION IN
PANCREATIC CANCER
Calogero Iacono, MD, Andrea Ruzzenente, Chiara Zugni, Tommaso
Campagnaro, Luca Bortolasi, Alessandro Valdegamberi, Alfredo Guglielmi
University of Verona, Verona, Italy
Background and Objective. Prognosis after surgical resection of pancreatic
cancer is still poor. Several strategies have been applied in order to improve
the long term Results. The aim of this study is to identify the prognostic
factors related with survival in a cohort of patients who underwent to
modified extended pancreaticoduodenectomy (MEPD).
Methods. Eigthy four patients were submitted to MEPD for pancreatic and
periampullary tumors from 1994 to 2005, 54 pts with pancreatic ductal
adenocarcinoma were included in this study. After MEPD 20 pts received
adjuvant chemotherapy: 15 with intra-arterial chemotherapy employng
FLEC regimen (in 7 pts followed by systemic gemcitabine) and 5 with other
adjuvant regimens.
Results. Median follow up time for surviving pts was 46 months (range 26
157). In 44 pts (82%) MEPD had negative margin resection; all pts with R1
resection showed positive retroperitoneal margin. Negative lymph nodes were
found in 10 pts, positive N1 in 33 pts, positive N1N2 in 9 pts and positive
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N2 in 2 pts. The overall median survival was 18 months with actuarial 3 and
5-year survival rates of 29% and 19%, 10 pts survived more than 36 months.
During follow up 3 pts (7%) presented local recurrences, 23 pts (52%)
distant recurrences and 8 pts (18%) local and distant recurrences. At
univariate analysis we identified that factors related with survival were:
histological grading (p0.01), lymph-nodes status (p0.04), radical resec-
tion (p0.01), UICC TNM stage (p0.005). We did not identify statistical
differences between survival in pts with positive N1 and N2 lymph node,
however all 11 pts with N2 lymph node metastases died within 46 months.
With multivariate Cox regression analysis we identified that only histological
grading was related with survival (HR2.4, p0.01). Further analysis in pts
with R0 resection showed that factors related with survival in multivariate
analysis were adjuvant chemotherapy (HR 0.39, p0.04), histological
grading (HR2.5, p0.02) and lymph-nodes status (HR1.95, p0.04).
Conclusions. Our study confirm the prognostic significance of R0 resection
that can be achieved with a accurate clearance of lymphatic, neural and
connective tissue at the right side of superior mesenteric artery. Other factors
that had been implied with good surival was N0, low grade of tumor
differentiation and low UICC-stage. Adjuvant chemotherapy improved
significantly long term survival after R0 resection while in R1 it did not
show benefit.
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A NOVEL USE OF ON Q PAIN PUMPS DURING PANCREATICO-
DUODENECTOMY: CELIAC GANGLIA PLACEMENT
Christos A. Galanopoulos, MD, Gong A. Lee, MD, Girish P. Joshi, MD, D.
Rohan Jeyarajah, MD
Methodist Dallas Medical Center, Dallas, TX; University of Texas-Sowth-
west, Dallas, TX
Background. Pain control after pancreaticoduodenectomy (PD) is a
continuing challenge. Use of regional techniques, such as pre-operative
epidural anesthesia, can be beneficial, but delays the start of deep venous
thromobosis prophylaxis in these high risk patients and is associated with
patient pain and anxiety. We present, for the 1st time in the literature, a new
technique of placement of On Q pain pump catheters adjacent to the celiac
ganglia, the major plexus responsible for pancreatic pain.
Methods. Patients operated on for benign and malignant diseases of the head
of the pancreas were examined. At the completion of the PD, 5cc of 0.2%
ropivacaine was injected into the left and right celiac ganglia via intra-
abdominal approach. Standard landmarks were used to identify these
structures on the left (to the left of the aorta at the level of the celiac axis)
and right (between the vena cava and aorta at the same level). Two (1 each
side) 1-inch antimicrobial soaker catheters were placed transabdominal
approximately 35 cm into the retroperitoneum at the same location as our
injections. This was done prior to closure of the abdomen and primed with 2
ml. of ropivacaine each.
Results. Celiac blocks and transabdominal intra-celiac catheters were placed
in 15 patients. Injection of the ganglia intra-operatively resulted in a 1020
mmHg gradual drop in blood pressure at approximately 10 minutes post-
injection, suggesting precise placement of agent. Catheters were removed
(4872 hours post-operatively) at the bedside, safely and intact. Patients
achieved early ambulation and early anticoagulation on post-operative day 1,
along with excellent pain control.
Conclusion. This novel technique of intra-operative transabdominal celiac
ganglia placement of On Q pain catheters after PD is logical, feasible, and
safe. Patients can benefit from excellent pain control, initiation of early
anticoagulation therapy, and the avoidance of the pain and anxiety associated
with pre-operative epidural placement. Future studies are in the works and
will randomize patients to placebo versus transabdominal celiac ganglia
catheter placement.
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PATTERN OF RECURRENCE AFTER PANCREATODUODE-
NECTOMY WITH STANDARD VERSUS EXTENDED LYMPHA-
DENECTOMY FOR PANCREATIC HEAD ADENOCARCINOMA
Thomas Schnelldorfer, MD, Michael G. Sarr, MD, Tamela R. Dahl, RN,
Nathan R. Foster, MS, Randall K. Pearson, MD, Suresh T. Chari, MD,
Michael B. Farnell, MD
Mayo Clinic, Rochester, MN
Background. Controversy exists about the benefit of extended lymph node
resection in the setting of pancreatoduodenectomy for pancreatic adenocar-
cinoma. Recent prospective randomized trials showed no added benefit,
including a trial at our institution (Surgery 2005). The current study provides
follow-up of our trial assessing incidence and pattern of disease recurrence.
Methods. 72 patients with resectable adenocarcinoma of the head of
pancreas (65 patients with ductal adenocarcinoma, 7 with invasive IPMN)
were randomized to standard pancreatoduodenectomy (standard PD; n38)
or pancreatoduodenectomy with extended lymphadenectomy (PD/ELND;
n34) from 1997 to 2003. Recurrence was determined according to cross-
sectional imaging reported from different institutions. Median follow-up was
5.3 years.
Results. Demographics, disease stage, and operative margin status were
similar in both groups. When comparing standard PD versus PD/ELND,
respectively, median number of lymph nodes retrieved was greater with
ELND (15 vs. 36; pB0.001), without a difference in median number of
positive lymph nodes found (1 vs. 1; pNS). ELND found positive lymph
nodes in 12 of 34 patients which would not have been detected with standard
PD, including 3 patients which would have had negative lymph nodes
according to standard PD. Adjuvant chemoradiation treatment was adminis-
tered in 83% of patients (84% vs. 82%, pNS). There were no significant
differences in overall survival (median 26 vs. 20 mo; hazard ratio 0.87
(95%CI 0.511.46)) and disease-free survival (median 16 vs. 17 mo; hazard
ratio 0.95 (95%CI: 0.561.59). 75% of patients had recurrence (81% vs.
68%, pNS)). The recurrence pattern was similar in both groups (loco-
regional recurrence: 6% vs. 7%, pNS; distant recurrence: 65% vs. 54%,
pNS) with liver being the most common site of initial recurrence.
Conclusion. Despite long follow-up, overall survival, disease-free survival,
and recurrence patterns were similar. Hence, ELND does not appear to
provide added benefit in terms of loco-regional control of resectable
adenocarcinoma in the head of pancreas.
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PORTAL VENOUS RECOLLATERALIZATION AFTER A PAN-
CREATICODUODENECTOMY
Justin H Nguyen, Marjorie Dougherty, MS
PA-C, Mayo Clinic, Jacksonville, FL
Introduction. Portal vein resection and reconstruction (PVR) are occasion-
ally required in pancreaticoduodenectomy. Portal vein occlusion/thrombosis
is a potential complication associated with PVR. Consequences of portal or
mesenteric venous thromboses associated with PVR are poorly understood.
In this study, we describe a case of portal venous recollateralization after a
pancreaticoduodenectomy with thrombosed PVR.
Case Study. A 49 year-old man had persistent diarrhea and 35-lb weight
loss. Endoscopic examination showed duodenal polyp, which histology
showed neuroendocrine carcinoma. CT revealed a mass in the pancreas
head of 5.2 cm with involvement of portal vein (PV) and superior mesenteric
vein (SMV). He underwent a pancreaticoduodenectomy with en-bloc
segmental PV and SMV resections. PV was reconstructed primarily. End-
to-side duct-to-mucosa pancreatojejunostomy, end-to-side choledochojeju-
nostomy and antecolic end-to-side loop gastrojejunostomy were completed.
The pathology report showed a neuroendocrine carcinoma of 6.55 cm
invading the pancreatic ducts, ampulla, duodenum, and mesenteric veins.
Parapancreatic lymph nodes 17 were free of tumor. Postoperative US showed
no flow in main PV. MR venogram showed PV and SMV thromboses.
Hepatic artery and vein were patent. Percutaneous transhepatic portogram
demonstrated a diffuse mesenteric venous thombosis. PV anastomosis was
stented with 4010 mm Zilver stent. Intravenous mesenteric tPA was
administered, followed by systemic heparinization, and subsequent coumadin
therapy. Pateitnt was discharged from the hospital on postop day 21. Patient
had significant ascites; diuretics were started. Patient had 4 therapeutic
paracenteses over 4 months. The follow-up MRI at 6 month showed nearly
complete resolution of ascites with collateralized portal flow into the liver
(Figure 1, arrows). (Circle in Figure showed the artifact of MR image).
Conclusion. Portal venous recollaterization do spontaneously form with
following an occlusion of the portal vein reconstruction procedure after a
pancreaticoduodenectomy. Further studies are needed to understand the
natural history of mesenteric recollateralization.
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TUMOR LOCATION DETERMINES SURVIVAL IN PANCREATIC
CANCER
Avo Artinyan, MD, Perry A Soriano, MD, Tracey Low, Joshua D Ellenhorn,
MD, Joseph Kim, MD
City of Hope National Medical Center, Duarte, CA
Background. Resectable pancreatic cancers of the body and tail (BT) may
be associated with worse survival compared to head (HD) lesions. The
objective of this study was to determine the relationship between tumor
location and survival.
Methods. The Surveillance, Epidemiology, and End Results registry was
queried for patients with pancreatic adenocarcinoma between 19882004.
Rates of metastatic disease and cancer-directed resection for BT and HD
tumors were determined. Kaplan-Meier and multivariate Cox-regression
analyses were used to determine differences in survival between resected BT
and HD cancers, adjusting for other clinicopathologic factors.
Results. 33,752 patients with pancreatic adenocarcinoma were identified;
6443 patients underwent cancer-directed surgery. BT tumors had a higher
rate of distant metastases (67% vs. 36%, pB0.001) and a lower rate of
cancer-directed resection (16% vs. 30%, pB0.001) than HD tumors. Overall
median survival was significantly lower for BT compared to HD lesions (4 vs.
6months, respectively, pB0.001). In comparison with BT, resected HD
patients had more harvested nodes (9.7 vs. 7.7 for BT, pB0.001), more T3/
T4 lesions (77% vs. 70%, pB0.001), and greater node-positivity (60% vs.
50%, pB0.001). On multivariate analysis, BT location was a significant
prognostic factor for decreased survival when adjusting for age, T-stage, and
nodal status (HR 1.11, 95% CI 1.001.23, p0.05).
Conclusion. Patients with operable BT pancreatic cancer have lower
survival compared to those with HD tumors. The association of distal lesions
with a lower number of harvested nodes may account for the observed
disparity in outcome following surgical resection.
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ENDOSCOPIC KYSTO-GASTROSTOMY USING AN EXPAND-
ABLE METALLIC WALLSTENT AS SALVAGE OF A FAILED
ENDOSCOPIC DRAINAGE OF PANCREATIC PSEUDOCYSTS:
REPORT OF 2 CASES.
Franck Vandenbroucke, MD, Marylene Plasse, MD, Richard Letourneau,
MD, Michel Dagenais, MD, Real Lapointe, MD
Andre Roy, Hopital Saint Luc-CHUM, Montreal, PQ, Canada
Introduction. We report 2 cases where we used a metallic Wallstent (Boston
Scientific) for drainage of a pancreatic pseudocyst through endoscopic kysto-
gastrostomy after failed drainage with plastic stenting.
Case reports. The first case was a 67 year old man with a past medical
history of alcoholic chronic pancreatitis. Few weeks after an acute bout of
acute on chronic pancreatitis, he presented with epigastric pain, nausea and
anorexia. Abdominal CT-scan showed a 15 cm diameter pancreatic pseudo-
cyst without any other significant finding. Endoscopic drainage with double
pigtail stent was performed. Three days post stenting, the patient presented
again with fever and abdominal pain. Control CT-scan of the abdomen
showed a residual pseudocyst. Repeat endoscopy was performed. The cyst
cavity was filled with thick pus and small debris. The pigtail stent was
replaced by a metallic Wallstent (1040 mm) with generous irrigation of the
cystic cavity. The patient fully recovered without any more incident. Six
months later, the Wallstent was removed.
The second patient was a 15 year old morbidly obese man who presented
with acute biliary pancreatitis. Laparoscopic cholecystectomy was performed.
One month post surgery, the patient complained of epigastric pain.
Abdominal CT-scan showed a 11.5 cm diameter pseudocyst. The patient
underwent endoscopic drainage using a 10Fr by 5 cm plastic double pigtail
stent. The patient was reassessed one month later after complaining of
abdominal pain and fever. Abdominal CT-scan depicted a recurrent
pseudocyt caused by the migration of the plastic stent. An expendable
metallic Wallstent (10 mm40 mm) was inserted with copious irrigation of
the cavity. The patient remained symptom free after treatment. The Wallstent
was removed six months later.
Conclusion. Expendable metallic Wallstent insertion for drainage of
pancreatic pseudocyst is a valuable option in the case of failure of endoscopic
drainage with standard double pigtail plastic stents.
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EXTENDED LEFT-SIDED PANCREATECTOMY WITH SPLEEN
PRESERVATION
Arash Mohebati, MD, Roderich E Schwarz, MD, UMDNJ-RWJMS, New
Brunswick, NJ
UT Southwestern Medical Center, Dallas, TX
Background. Left-sided or distal pancreatectomy (DP) is frequently
performed in conjunction with splenectomy, although splenectomy can be
linked to various untoward effects, and sparing of the main splenic vessels
(SV) is not necessary for successful spleen preservation (SP).
Methods. We reviewed clinical records of all patients undergoing DP in a
single-surgeon practice to assess feasibility and outcomes of SP.
Results. Between 1997 and 2007, 41 of 177 pancreatic resections involved a
DP (23%). There were 14 men (34%) and 27 women (66%), with a median
age of 60 years (range: 3486). Resection indications included 26 solid
masses, 10 cysts, 4 combinations thereof, and one diffuse process. Four
procedures were en bloc resections, 2 total pancreatectomies, while 8 of the
remaining 35 DPs were performed laparoscopically. SP was accomplished in
33 of 34 possible cases (spleen preservation rate 97%), despite SV resection
in 27 of these (82%). The postoperative complication rate was 24%, and
there was no postoperative death. The median length of stay was 6 days (4
24). Pancreatic fistulae occurred in 2 patients (5% of patients at risk), and
one SPDP led to splenic infarct. At a median follow-up of 16 months (2.5
89), no other clinically relevant problems specific to SP have become
apparent. One patient after DP with splenectomy expired from postsple-
nectomy sepsis.
Conclusions. Pancreatic fistula rate and other outcomes in this small DP
experience compare favorably to many other DP series. Few spleen-specific
complications and the radicality of resection support the liberal use of SP
with SV resection, irrespective of an open or laparoscopic approach.
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ASSESSMENT OF DELAYED GASTRIC EMPTYING FOLLOWING
CLASSICAL AS WELL AS PYLORUS PRESERVING PANCREATI-
CODUODENECTOMY: SOLID STATE SCINTIGRAFIC SCAN OR
CLINICAL CRITERIA OR BOTH?
Nihar R Dash, MS, Ghatak Supriyo, MS, Mukund Kulkarni, MS, Sujoy Pal,
MS, Peush Sahni, MS, Tushar Kanti Chattopadhyay, MS
All India Institute Of Medical Sciences, New Delhi, India
Background. Difference of opinion still exists regarding the incidence of
delayed gastric emptying (DGE) following the classical Whipple’s procedure
(WPD) and its pylorus preserving version (PPPD).Moreover different
methods of evaluation of DGE were shown to yield different results in a
given procedure.
Objective. To compare the clinical criteria and radionuclide gastric
emptying scan (RGES) findings in assessing DGE in WPD and PPPD.
Patients and Methods. Between Jan2005 and Dec2006 all patients meeting
the inclusion criteria were studied prospectively. All patients had baseline
RGES preoperatively (GE1). Patients then underwent iether WPD or PPPD.
Postoperative RGES was done on day 7(GE2-7d)and 10(GE2-10d) and
again at 3 months(GE3) followup.The linear fit T1/2 value was considered
normal when the observed value was between 30150 minutes. Clinically
gastric emptying was assessed by the day of removal of Ryle’s tube (RT),
starting of oral liquids and oral solids.DGE was coined when the RT aspirate
was 300 ml or more with patient being unable to tolerate per oral.
Results. 87 patients underwent PD.Only 43 met the inclusion criteria.24
patients had WPD and 19 had PPPD.One in each group died in early
postoperative period and were excluded.The difference in mean t1/2 between
GE1 and GE2-7d was significant in WPD (56.8954.5 min v/s106.3996.4;
p0.038) but not in PPPD (54.2961.2 v/s 117.19117.3; p068). There
was no difference between GE2-7d and GE2-10d.The values of Ge1 or GE2
were not significantly different from GE3 in both WPD and PPPD.Above all
the difference of GE1 v/s GE2 or GE1 v/s GE3 were not significant between
WPD and PPPD.
On clinical assessment WPD had 5 (20.8%) cases of DGE and PPPD had 8
(42.1%) on Day7.The values were 3 (12.5%) and 4 (21%) respectively at
Day10.The differences were not significant. On the other hand on RGES,
GE1 showed delayed emptying in 2 patients (WPD1, PPPD1). GE2-
10d was delayed in 10 patients (WPD5; 20.8% and PPPD5; 26.3%.p
0.67).
Clinical or scintigrafic DGE did not show any correlation with physical,
haematological, biochemical parameters, preoperative biliary drainage or
cholangitis,per operative blood loss and duration of surgery.
Conclusion. When pitted against clinical criteria, the sensitivity and
specificity of RGES in detecting DGE was 50% and 87.1% respectively on
day7 as against 42.9% and 80.6% on day10. Above all no significant
difference was noted in case of DGE following WPD or PPPD.
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INTRAOPERATIVE RADIATION THERAPY (IORT) IMPROVES
LOCAL CONTROL BUT DOES NOT IMPACT SURVIVAL IN
PATIENTS UNDERGOING PANCREATICODUODENECTOMY
(PD) FOR PANCREATIC ADENOCARCINOMA-A CASE-CON-
TROL SERIES.
Adam C Berger, MD, Atul Rao, MD, Pramila Rani Anne, MD, Cataldo
Doria, MD, Francis E. Rosato Sr., MD, Ernest L Rosato, MD
Thomas Jefferson University, Philadelphia, PA
Introduction. Locoregional recurrence remains an important factor in
patients undergoing PD for pancreatic adenocarcinoma. IORT administered
to the resection bed theoretically improves local control, but has an unknown
impact on survival.
Methods. We performed a retrospective analysis of all patients who under-
went PD between January, 1995 and January, 2005 (n144) to identify all
patients who underwent resection with IORT. We also attempted to identify a
matched group of patients in the same period that had PD without IORT.
Data collected included age, sex, postoperative length of stay (LOS),
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estimated blood loss (EBL), complications, adjuvant therapy use, margin
status, stage (AJCC 6th edition), survival, and recurrence. Survival was
estimated using Kaplan-Meier Methods.
Results. Between 1995 and 2005, 43 patients underwent PD for
periampullary cancer with IORT, 37 of these were for pancreatic adeno-
carcinoma. In the same period, 64 patients underwent PD for periampullary
malignancies without IORT; 38 of these patients had pancreatic cancer.
There were 2 perioperative deaths in the IORT group (5.4%) and none in
the non-IORT group. Complications rates were similar in the 2 groups
(46% vs. 40%, respectively). There were 33 documented recurrences_17 in
the PD alone group and 16 in the IORT group. The locoregional recurrence
rate for patients undergoing PD plus IORT was 19% compared to 41%
for non-IORT patients. The median survival of patients undergoing
PD/IORT for pancreatic cancer was 18 months which was not significantly
different than PD/non-IORT patients (21 months, p0.779). There was
no difference in survival for IORT vs. non-IORT when groups were
compared by R0, R1, node-negative, or node-positive resections. Finally,
median blood loss and length of stay were actually similar in both groups of
patients (700 vs. 850 ml and 13 vs. 13 days, for non-IORT and IORT,
respectively).
Conclusion. Pancreaticoduodenectomy with IORT for pancreatic cancer
can be performed safely with acceptable morbidity and mortality. IORT
improves local control but does not appear to improve survival for patients
undergoing potentially curative resection. IORT should be used in a clinical
trial setting in conjunction with novel chemotherapeutics in order to attempt
to improve survival of patients with pancreatic cancer.
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SURVIVAL AFTER PANCREATICODUODENECTOMY FOR PAN-
CREATIC ADENOCARCINOMA VS. DISTAL CHOLANGIOCAR-
CINOMA IS EQUIVALENT, INDEPENDENT OF STAGE AND
STAGING SCHEMES
John Mullinax, MD, Desiree Villadolid, MPH, Jonathan Hernandez, MD,
Kevin Drummond, None, Nasreen Vohra, MD, Steven Goldin, MD, PhD,
Alexander Rosemurgy, MD
University of South Florida College of Medicine Department of Surgery,
Tampa, FL
Introduction. Relative to pancreatic adenocarcinoma, cholangiocarcinoma
is thought to carry a favorable prognosis following resection. This is
possibly because cholangiocarcinomas cause jaundice early in their course
and are thus detected at an earlier stage. This study was undertaken to
determine if there are differences in prognosis after resection and if
ostensible differences in prognosis after resection are a consequence of
differences in staging.
Methods. The tumors of patients undergoing pancreaticoduodenectomy for
pancreatic adenocarcinoma or cholangiocarcinoma were staged utilizing
AJCC guidelines, 6th edition. Survival was stratified by tumor cell type and
stage. Tumors were then cross-staged and survival was again stratified by cell
type and stage. Survival analyses were computed by Kaplan-Meier survival
curves.
Results. 28 patients underwent pancreaticoduodenectomy for cholangiocar-
cinoma and 112 patients for pancreatic adenocarcinoma. There were no
differences in survival between patients with Stage I or II cholangiocarcino-
mas vs. Stage I or II pancreatic adenocarcinomas (Table).
When all tumors were staged using guidelines for pancreatic adeno-
carcinoma, there were no differences in survival between patients with Stage
I or II cholangiocarcinomas vs. Stage I (p0.5764) or II (p0.5740)
pancreatic adenocarcinomas. When all tumors were staged using guidelines
for cholangiocarcinoma, there were no patients with pancreatic cancer
of Stage I; as well, there were no differences in survival between patients
with Stage II cholangiocarcinomas vs. Stage II pancreatic adenocarcinomas
(p0.99).
Conclusions. Survival following pancreaticoduodenectomy for cholangio-
carcinoma or pancreatic adenocarcinoma is disappointing and not mean-
ingfully different between the cancers. After pancreaticoduodenectomy,
consternation over cell type of cancer seems unnecessary, particularly given
the propensity towards ambiguous cell types. Given current knowledge,
considerations that a given cancer is a cholangiocarcinoma or a pancreatic
adenocarcinoma, independent of stage and staging scheme, should not
impact considerations about prognosis.
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HEPATO-PANCREATO-BILIARY SURGERY: EFFECT OF SURGI-
CAL CASEMIX ON PERI-OPERATIVE MORTALITY
Hari Nathan, MD, Michael Choti, MD, Richard D Schulick, MD, Timothy
M Pawlik, MD
Johns Hopkins, Baltimore, MD
Introduction. Hepato-pancreato-biliary (HPB) surgeons are expected to
specialize in a domain of procedures that involve both liver and pancreas.
Although the relationship between procedure-specific surgeon volume and
outcome is established, its specificity is not known. Specifically, the effect of
HPB casemix on surgical outcomes remains ill-defined. We sought to
characterize the specificity of surgeon volume-outcome relationships for
high-risk HPB surgery.
Methods. Using the 19992002 State Inpatient Databases for Florida,
Maryland, and New York, we identified all patients (pts) undergoing major
hepatic resection (mHR) (]lobectomy) and pancreatic resection (PR).
Individual surgeon case volumes were tabulated for specific HPB procedures.
Multiple logistic regression was used to explore the relationship between in-
hospital mortality and surgeon volumes, adjusting for pt demographics and
comorbidities. Risk-adjusted mortality rates are reported as rate [95%
confidence interval].
Results. There were 1274 and 4498 pts who underwent mHR and PR,
respectively. Increasing surgeon mHR volume was associated with lower
mHR mortality (odds ratio (OR) 0.27, P0.001). In contrast, increasing
surgeon volumes for hepatic wedge resection, pancreatic surgery, and other
HPB procedures were not associated with a protective mHR mortality effect
after adjusting for mHR volume (all P0.05). Specifically, mortality
following mHR was 1.8% [0.9%-4.9%] for high-volume (highest tercile)
mHR surgeons compared with 6.5% [4.8%-8.7%] for surgeons who were
high-volume HPB surgeons but low-volume (lowest tercile) mHR surgeons.
Similarly, increasing surgeon PR volume was associated with lower PR
mortality (OR 0.29, PB0.001). However, surgeon volumes of liver proce-
dures and other HBP procedures had no independent effect on PR mortality
(both P0.05). Mortality following PR was 0.9% [0.6%-1.4%] for high-
volume PR surgeons compared with 5.0% [4.0%-6.2%] for surgeons who
were high-volume HPB surgeons but low-volume PR surgeons. To further
investigate the specificity of the PR relation, we examined pancreaticoduo-
denectomy (PD). Increasing PD volume was significantly associated with
lower mortality for PD (OR 0.26, PB0.001). However, surgeon volumes of
total pancreatectomy and distal pancreatectomy had no independent effect
on PD mortality (both P0.05).
Conclusions. In HPB surgery, the association between surgeon volume and
in-hospital mortality is very specific to the procedure in question. High
volume expertise in one area of HPB surgery does not translate into improved
outcomes for related procedures. These data may have implications for
patient safety as well as HPB surgical training.
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ACCURATE RADIOLOGICAL DIAGNOSIS OF MICROINVASION
OF PORTAL VEIN IN HEPATOCELLULAR CARCINOMA BY
DISTORTION OF THE CORONA ENHANCEMENT, TUMORAL
ARTERIOPORTAL SHUNT AND PERILESIONAL HYPERIN-
TENSE RIM
Ryohei Miyata, MD, Akihiro Tanimoto, MD, Go Wakabayashi, MD, Masaki
Kitajima, MD
Tokyo Dental College, Chiba, Japan; Keio University, Shinjuku Tokyo, Japan
Purpose. To diagnose microinvasion of the portal vein in hepatocellular
carcinoma from preoperative radiological findings and to construct a scoring
system.
Methods. 47 patients (38 males and 9 females; median age 66.8 years) who
underwent hepatic resections for hepatocellular carcinoma were selected
retrospectively. Microscopically, 22 had portal vein invasion (PVI) and 25
had no PVI. All patients were examined preoperatively with superparamag-
netic iron oxide-enhanced magnetic resonance imaging (SPIO MRI) and
computed tomography during hepatic angiography (CTHA). Perilesional
enhancement on T1-weighted imaging on MRI (T1 ring), tumorous
arterioportal (AP) shunt (wedge- or fan-shaped enhancement during the
arterial dominant phase of CTHA adjacent to tumors, especially peripheral
to tumors), and distortion of corona enhancement (contrast ring-shaped
enhancement surrounding the tumor appearing in the late phase of CTHA)
were assessed. Relative risk for PVI in terms of clinical and tumor
characteristics were also assessed. The relative contribution to PVI was
determined by the coefficient of stepwise logistic regression. Each variable
was given a score relative to the coefficient.
Results. On univariate analysis, the distortion of corona enhancement,
tumorous AP shunt, T1 ring and tumor size indicated a higher prevalence of
PVI. The PVI predictive score was calculated as: Total score(maximum
size in cm)(T1 ring;1, 0) (tumorous AP shunt;3,-0) 
(distortion of corona;10,0). The PVI () group scored 4-fold
higher than the PVI () group (16 vs 4). At a cut-off score of 10, the
sensitivity, specificity, and accuracy were 82%, 84%, and 86%, respectively.
Conclusions. The distortion of corona enhancement, tumorous AP shunt,
T1 ring and tumor size are good predictors of the risk of PVI. This scoring
system is simple and worth using clinically.
Cancer
Cell Type
Number Survival
(median, mean9SD)
Survival Compared
To Pancreatic Cancer
(by stage)
Cholangiocarcinoma
Stage I 10 16 months, 21 months911.8 p0.3403
Stage II 16 17 months, 39 months948.7 p0.5386
Pancreatic Adenocarcinoma
Stage I 30 22 months, 29 months923.0 n/a
Stage II 79 14 months, 16 months912.2 n/a
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OUTCOMES ASSOCIATED WITH CYTOREDUCTIVE SURGERY
AND INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY
FOR COLORECTAL CANCER PATIENTS WITH PERITONEAL
CARCINOMATOSIS AND HEPATIC METASTASES
Oliver A Varban, MD, Edward A. Levine, MD, John H. Stewart, MD,
Thomas Mccoy, MS, Perry Shen, MD
Wake Forest University Medical Center, Winston-salem, NC
Introduction. Cytoreductive surgery and intraperitoneal hyperthermic
chemotherapy (IPHC) can improve outcomes for select patients with
peritoneal carcinomatosis (PC) from colorectal cancer. The use of this
procedure in patients with hepatic metastases (HM) in addition to PC is
controversial. The purpose of this study was to compare the overall
survival of patients with HM to those without and examine predictive
factors.
Methods. This was a retrospective study of patients undergoing cytoreduc-
tive surgery and IPHC between 1991 and 2007. Clinicopathologic informa-
tion was obtained from a prospectively collected database and electronic
medical record. Univariate and multivariate analyses were performed to
evaluate variables predictive for overall survival.
Results. There were 144 who underwent cytoreductive surgery and IPHC
for PC from colorectal cancer, with 17 (11.8%) patients noted to have
HM at time of operation. For HM patients with available data, median
number and size of liver lesions was 1 (range, 17) and 1.8 cm (range,
0.45.6), respectively. Twelve patients had data on type of liver treatment
performed: 2 cryosurgeries, 2 radiofrequency ablations, 7 wedge resections,
and 1 combined wedge resection/cryosurgery. Median overall survival for
patients with and without HM was 22.7 months [t1] (95% CI[14.6,
27.6]) and 15.8 months (95% CI[13.4, 20.4]), respectively (p value
0.78). Two and four year survival rates for the HM patients were 34.0%
(95% CI[11.2, 58.8]) and 11.3% (95% CI[0.73%, 38.1%]), respec-
tively. Cox regression analysis demonstrated the presence of malignant
ascites to be a significant predictor of decreased survival in patients with
HM (p0.02).
Conclusions. Patients with PC and HM undergoing cytoreductive surgery
and IPHC for colorectal cancer had no significant difference in overall
survival compared to those without HM. Most patients had a single small
lesion treated with a minor hepatic resection. Malignant ascites predicted a
poor outcome. In select patients with PC and HM, cytoreductive surgery and
IPHC may have some benefit.
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SOCIETAL REINTEGRATION AND ECONOMIC IMPLICATIONS
FOLLOWING ORTHOTOPIC LIVER TRANSPLANT
Michele Molinari, MD, Amy Gillis, MD, Mark Joseph Walsh, MD
Dalhousie University, Halifax, NS, Canada
Background. Data on the impact of OLT on the patients’ integration in
their communities and its financial consequences at a personal and
familiar level are lacking. Primary aims of this study were to assess
employment rate, productivity and activity index of patients after OLT in
Atlantic Canada.
Methods. From September 2006 to January 2007 a cross sectional study
was performed using validated Work Productivity and Societal Reinte-
gration Questionnaires. Participants were interviewed by phone or during
follow-up visits and were adults at least 3 years post OLT, without
communication impairments. All data were prospectively collected. Catego-
rical data were analyzed by Chi-Square and Student’s t test for continuous
variables; P values less than 0.05 with two tail distribution were considered
significant.
Results. Among eligible 158 patients, 47 were randomly selected. 45 (95%)
participated and 2 declined for personal reasons. 15 patients (33%) were full
time employed and 12 (52%) were employed in the same position as before
OLT. 13 individuals (28%) were on disability while the remaining were
students or housekeepers. 11 patients (24%) had retired. After OLT, 19
patients (42%) experienced financial restrictions preventing access to care or
necessary medications due to significant reduction in their annual personal
($28,300 vs 26,500, PB0.005) and household income (44,000 vs 43,700,
PB0.05). Overall, 77% patients reported that OLTx had a negative impact
on their financial status in comparison to their pre-OLT status (PB0.005).
However, productivity and activity index showed overall acceptance of
current societal role and sequlae of OLTx had little impact on activities of
daily life at this time.
Conclusion. In Atlantic Canada, patients undergoing OLTx for end
stage liver disease have an employment rate of 33%, consistent with avai-
lable literature. Socially, 84% of patients are satisfied with their current
role in society and are able to perform most daily activities without diffi-
culty.
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OUTCOMES IN PANCREATIC RESECTION ARE NEGATIVELY
INFLUENCED BY PREOPERATIVE HOSPITALIZATION
Wande Pratt, Charles Vollmer, MD, Mark Callery, MD
Beth Israel Deaconess Medical Center, Boston, MA
Background. Quality improvements in elective pancreatic resection increas-
ingly rely on clinical pathways to streamline patient care and to maximize
cost-efficiency. Yet, it remains unclear whether immediate preoperative
hospitalization (non-elective resection) influences operative performance,
and to what extent it alters the postoperative course.
Methods. 371 consecutive pancreatic resections were performed for benign
and malignant disease between 2001 and 2007. Preoperative physiology and
operative performance were analyzed according to POSSUM criteria. Out-
comes for both elective and non-elective operations were scrutinized, and
correlated with deviations from our clinical pathway. Observed-to-expected
(O/E) morbidity ratios were calculated for each.
Results. Overall, 32 patients (9% overall) required immediate preoperative
hospitalization, 20 (62%) of which were transferred from another hospital.
The most common indications included gastric outlet obstruction (28%),
pancreatitis (28%), and gastrointestinal bleeding (16%). Elective and non-
elective patients similarly harbored malignant pathology 44% of the time.
Although non-elective cases were sicker initially (higher Physiologic Score),
patient acuity improved considerably after preoperative hospitalization
(median 6d; range 119d). Through this in-patient process, 56% of patients
received biliary drainage; 34% required nutritional support; 18% received
antibiotics; and 18% were transfused blood products. Yet, this preoperative
scenario, at a cost of $9,000 per patient, had no measurable impact on
operative performance (i.e. blood loss, operative time). Postoperatively, non-
elective patients suffered more complications, contributing to a higher O/E
ratio (1.20 vs. 0.91). These outcomes resulted in significantly more
deviations from our clinical pathway and an additional $5,000 per non-
elective case (Table). Multivariate analysis reveals that preoperative hospita-
lization is predictive of complications (p.026) and pathway deviations (p
.041).
Conclusion. Preoperative hospitalization ameliorates patient acuity prior to
pancreatic resection, but has no meaningful impact on operative perfor-
mance. Deviations from a standardized clinical pathway are far more likely
after non-elective pancreatic resection, and result in more severe clinical and
economic outcomes.
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PROSPECTIVE EVALUATION OF 65 PANCREATIC CYSTS-MAG-
NETIC RESSONANCE DIFUSION IMAGING AS A TOOL TO
DIFFERENTIATE MUCINOUS CYSTS
Vladimir Schraibman, MD, Alberto Goldenberg, MD, Suzan M Goldman,
MD, Jacob Szjenfeld, MD, Edson Lobo, MD, Thiago Abud, MD
Federal University of Sao Paulo, Sao Paulo, Brazil
Purpose. To determine whether diffusion-weighted magnetic ressonance
imaging (MRI) can help differentiate intraductal papillary mucinous tumors
Table. Elective and Non-Elective Pancreatic Resections
Elective Non-Elective
N339 N32 p-va-
lue
Physiologic Score (median) . . 0.004
Admission 19 22 0.014
Preoperative 19 20 0.556
Operative Score (median) 15 15 0.923
Intraoperative Blood Loss (median,
ml)
350 350 0.089
Operative Time (median, min) 355 394 .
Complications (%) . . 0.365
Minor 121 (36) 14 (44) 0.009
Major 47 (14) 10 (31) .
Postoperative Interventions (%) . . 0.038
Antibiotics 90 (26) 14 (44) 0.002
Hyper-alimentation 34 (10) 9 (28) 0.048
Blood Transfusion 50 (15) 9 (28) 0.007
Clinical Pathway Deviations (%) 76 (22) 14 (44) 0.069
Duration of Stay (median, days) 8 9 .
Hospital Costs (median) . . –
Preoperative  $8,978 0.579
Postoperative $17,842 $22,810 0.018
Total $17,842 $32,009
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(IPMT) and mucinous cystoadenomas/carcinomas from other pancreatic
lesions.
Methods. Diffusion-weighted 1.5T MRI was performed in 60 patients
presenting cystic lesions in the pancreas diagnosed by any diagnostic image
modality (ultrasound, computerized tomography and magnetic ressonance
imaging). All the patients were followed or submitted to endoscopic
ultrasound cyst aspiration or submitted to surgery to confirm the nature of
the lesion. Mean follow-up was 16 months (324). From all the lesions:
mucin-producing tumors (n9), pseudocysts (n3), serous cystoadenomas
(n12), polycystic disease (n1), pancreatic abscess (n1), simple cysts
and small (i.e.B2 cm) cystic lesions (n34). Surgical and histopathologic
correlation was obtained for 38 patients (9 mucin-producing tumors, 1
abscess, and 3 pseudocyst) while size stability was determined for 25 patients
after a follow-up of more than 6 months. 23 patients are still under
investigation.
Results. All cystic lesions were associated with very high signal intensity at
T2 images. IPMTs and mucinous cystoadenomas/carcinomas had high signal
intensity at 500, 700 and 1000 sec/mm2 and a decreased ADC, potentially
representing diffusion restriction indicative of the presence of mucinous
products. Simple cysts, pseudocysts and abscesses did not show signs of
restriction for all values of b. Just one patient presenting positive signal on
MRI has a pancreatic abscess.
Conclusion. Diffusion-weighted MRI can help characterize cystic lesions of
the pancreas differentiating mucin-producing tumors from others lesions.
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NEW ABDOMINAL INTRAOPERATIVE ULTRASOUND PHAN-
TOM REPLACING THE ANIMAL LAB TO TEACH SURGEONS
Leo Villegas, MD, Junji Machi, MD, Maurice Arregui, MD, Takayuki Ohara,
Toshi Takayama, Hidenobu Katayama
University of Missouri Kansas City, Kansas City, MO; n/a, Honolulu, HI; n/
a, Indianapolis, IN; Kyoto Kagaku, Torrance, CA
Background. Intraoperative ultrasound (IOUS) and laparoscopic ultra-
sound (LUS) are difficult skills for surgeons to learn in the operating room.
From 2000 to 2005, the American College of Surgeons (ACS) offered
courses for teaching abdominal ultrasound to surgeons, including IOUS and
LUS, using an animal lab for skills training. The lack of a realistic human
anatomy, increasing animal protection issues and cost led us to evaluate other
alternatives. The aim of our study was to evaluate a new inanimate
Abdominal IOUS Phantom, which was used at the 2006 ACS course.
Methods. The Abdominal IOUS Phantom was developed in collaboration
with the authors and Kyoto Kagaku Inc. (Japan). This phantom consists of
rubber-based simulated solid abdominal organs, such as liver, biliary,
pancreas, spleen and kidney, cast from a human cadaver with ultrasound
mimicking materials for both IOUS and LUS. The Phantom also has certain
pathology such as biliary stones, liver cysts and tumors. Retrospectively, we
evaluated several cost-effective factors to compare the use of the animal (pig,
2005) vs. the inanimate (phantom, 2006) lab.
Results. Six training stations with 6 pigs and 1 backup pig (in case of pig
mortality) were used for 29 students in 2005, and 6 training stations with 6
phantoms (no backup needed) were used for 31 students in 2006. The pig lab
had increasing animal protection issues; the pig liver anatomy was poly-
lobulated, which was anatomically different than the human body; it was
difficult to accommodate for teaching purposes in a regular convention
center; students experienced fatigue from pig’s odor; and Veterinarian
services charged $4,583 per pig per station for a 4-hour session. In contrast,
the Abdominal IOUS Phantom created no conflict with animal protection; it
was more anatomically correct with the capability of showing various
simulated pathology; it did not have an odor; it did not decompose because
it is made of durable materials that can last more than 10 years, allowing for
multiple uses and easy transportation; and was more cost-effective with a
one-time cost of $4,600 per phantom.
Conclusion. The Abdominal IOUS Phantom is a more anatomically
correct, cost-effective educational tool and has replaced the traditional
animal lab at the ACS IOUS-LUS course. This new Phantom can potentially
expand the skills training opportunities that are tailored to the surgeon’s
needs.
211
HIGH DOSE INTRA-ARTERIAL MELPHALAN DELIVERED VIA
PERCUTANEOUS HEPATIC PERFUSION (PHP) FOR PATIENTS
WITH UNRESECTABLE HEPATIC METASTASES FROM PRI-
MARY NEUROENDOCRINE TUMORS
James F Pingpank Jr, MD, Richard E Royal, MD, Udai S Kammula, MD,
Anthony W Kam, MD, Bradford J Wood, MD, H. Richard Alexander Jr,
MD, Steven K Libutti, MD, Marybeth S Hughes, MD, Susan E Ohl
RN, BSN, Surgery Branch, NCI, NIH, Bethesda, MD; Diagnostic Radiology
Division, CCR, NCI, NIH, Bethesda, MD; Department of Surgery,
University of Maryland, Baltimore, MD
Introduction. Patients hepatic MNET are faced with multiple treatment
strategies including resection, ablation, and a variety of regional therapies
which have been successfully utilized in this heterogeneous group of patients.
Treatment options for patients with diffuse hepatic disease are more limited.
This study examines a minimally invasive PHP with melphalan (MEL) for
patients with isolated or predominant hepatic metastases from MNET.
Methods. Between December 2001 and July 2007, 21 MNET patients
(mean age: 47 y; M: 13, F: 8; pancreatic neuroendocrine: 17, carcinoid: 4)
were enrolled on one of two IRB approved PHP protocols. Analysis included
PHP parameters, complications, toxicities, response, progression-free (PFS)
and overall survival (OS). PHP consisted of a 30 minute hepatic artery
infusion of MEL via a percutaneously placed catheter with hepatic venous
hemofiltration using a double balloon catheter (Delcath Systems, Inc.)
positioned in the retrohepatic inferior vena cava with in-line charcoal
filtration. Treatment course consisted of four PHPs every 2835 days.
Survival curves were estimated by the Kaplan-Meier method.
Results. Twenty patients received 60 treatments (median: 3/pt); 1 patient
was not treated due to hepatic arterial anatomic limitations. Mean MEL dose
was 183 mg (median: 186, range: 90220). Reversible grade III/IV toxicities
observed were hematologic (53%) and hepatic (27%). Mean hospital stay
was 2.5 days/PHP. An overall radiographic response was seen in 12 of 16
evaluable patients (75%; complete n2, partial n10) with an additional
minor response (21% tumor reduction persisting for 43 months). At a
median potential follow-up of 21 months, progression of intrahepatic disease
has been observed in 3 patients (43, 24, 18 months, respectively) and two
additional patients have died secondary to progression of extrahepatic
disease. There was one treatment related mortality (5%) and 1 patient had
disease progression on therapy (5%). Median duration of ongoing hepatic
response is 12 months (mean: 16, range: 531) in 8 patients. Median PFS
and OS have not been achieved.
Conclusions. This study shows that PHP with MEL has efficacy in patients
with diffuse MNET of the liver too extensive for resection, ablation, or
embolization strategies. Responses to therapy tend to be durable, with repeat
therapy effective upon progression.
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A COMPARATIVE ANALYSIS OF CRUSH/CLAMP, STAPLER,
AND DISSECTING SEALER HEPATIC TRANSECTION METH-
ODS
Eric T Castaldo, MD, MPH, T. Mark Earl, MD, Irene D Feurer, PhD, C.
Wright Pinson, MD, MBA
Vanderbilt University, Nashville, TN
Introduction. Several methods for hepatic parenchymal division exist. The
primary aim of this study was to assess differences in post operative bile leaks
and operative blood loss between 3 transection Methods. crush/clamp (CC),
stapler (SP), or dissecting sealer (DS; TissueLink).
Methods. A single institution, retrospective cohort study was performed on
data collected over a 3-year period in patients undergoing elective liver
resection using the CC, SP, or DS. Patients were excluded if multiple
methods of transection were used or for intraoperative death. A bile leak was
defined as 1) bile drainage for 7 days after surgery 2) post operative
imaging demonstrating a fluid collection confirmed to be bile with
percutaneous drainage and/or 3) reoperation in which a bile leak was
identified. Blood loss was characterized as minor if B1000 mL and major
if ]1000 mL. The association of bile leak with transection type was assessed
with a chi-squared test. A multiple logistic regression model was used to
assess whether major blood loss was associated with transection method
(reference group CC), vascular isolation, extent of liver resection (B2
Couinaud segments or ]2 segments), and other concurrent major opera-
tions as covariates.
Results. Analyses included 141 patients (51 CC, 66 SP, and 24 DS). The
overall rate of bile leak was B3% and the risk of bile leak was no different
between the three methods (p0.23). The risk of major blood loss (see
Table) was increased with DS compared to CC (OR3.09, p0.04), with
no difference between SP and CC (p0.18). Major blood loss was not
associated with extent of liver resection (p0.21) and a concurrent other
major operation (p0.30) but was associated with vascular isolation (OR
3.53, p0.03).
Conclusion. The risk of post operative bile leak is no different for
hepatectomies using CC, SP, and DS. However, hepatectomy using DS is
associated with an increased risk of major operative blood loss when
compared to CC.
Multiple logistic regression for major blood loss (]1000 mL)
Variable
Odds
Ratio
95% Confidence
Interval p value
Resection Type: SP vs. CC 0.51 0.191.37 0.18
Resection Type: DS vs. CC 3.09 1.039.24 0.04
Major Resection 1.89 0.705.10 0.21
Other Major Operation 1.62 0.654.01 0.30
Vascular Isolation 3.53 1.558.06 0.03
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THE SURVIVAL PARADOX OF ELDERLY PATIENTS AFTER
MAJOR LIVER RESECTIONS
Alexander J.c. Ijtsma, MD, Liselotte M.s. Boeve´, Christian S. Van Der Hilst,
B.Sc., Marieke T. De Boer, MD, Koert P. De Jong, MD, PhD, Paul M.j.g.
Peeters, MD, PhD, Annet S.h. Gouw, MD, PhD, Robert J. Porte, MD, PhD,
Maarten J.h. Slooff, MD, PhD
University Medical Center Groningen, Groningen, The Netherlands
Objective. The objective of this study is to assess the outcome of liver
resections in the elderly in a matched control analysis.
Methods. From a prospective single center database of 628 patients
undergoing a liver resection, 132 patients were aged 60 years or over and
underwent a primary major (3 segments) liver resection. Of these patients,
93 could be matched on a one-to-one basis with a control patient, aged less
than 60 years, with the same diagnosis and the same type of liver resection.
Results. The mean age difference between matched and control patients was
16.7 years. The matched elderly patients had a significantly higher American
Society of Anesthesiologists (ASA) grade. All other demographics and
operative characteristics were not different.
In-hospital mortality and morbidity was higher in the matched elderly
patients compared to controls repectively 11 vs. 2% (p0.017) and 47 vs.
31% (p0.024).
One, three, and five year survival rates in the matched elderly patients were
81%, 58% and 42%, respectively compared to 90%, 59% and 42% in the
control patients (p0.558).
In unified model Cox regression analysis, resection margin status and ASA
grade, and not age,proved to be independent predictors of patient survival.
ASA grade 3 or 4 patients had an increased chance of long term mortality
compared to ASA grade 1 patients with a hazard ratio of 2.21.
Conclusion. Despite a higher peri-operative mortality and morbidity in the
elderly long term survival was not different between the elderly and matched
controls. Determining factors for survival were resection margin status and
ASA grade. This finding underlines the important fact that in patient
selection for major liver resections ASA grade is more important than patient
age.
214
ELEVATED PREOPERATIVE NEUTROPHIL TO LYMPHOCYTE
RATIO PREDICTS SURVIVAL FOLLOWING HEPATIC RESEC-
TION FOR COLORECTAL LIVER METASTASES.
Karim J Halazun, Amer Aldoori, MD, Hassan Z Malik, MD, Ahmed Al-
mukhtar, MD, K Rajendra Prasad, MD, Giles J Toogood, MD, Giles J
Toogood, MD, Peter A Lodge, MD
St. James’ University Hospital, Leeds UK, Leeds, United Kingdom
Background The neutrophil-lymphocyte ratio (NLR) provides an indicator
of inflammatory status. An elevated NLR has been shown to be a prognostic
indicator in primary colorectal malignancy. The aim of this study was to
establish whether NLR predicts outcome in patients undergoing resection for
colorectal liver metastasis.
Design Retrospective analysis of the white cell and differential counts for 440
patients undergoing liver resections for colorectal liver metastasis between
January 1996 and January 2006. A NLR ]5 was considered to be elevated.
Results 289 males and 151 females were included. 78 patients (18%) had an
elevated NLR, 55 of whom died, giving elevated NLR a positive predictive
value (PPV) for death of 71%. 60 of the 78 patients had recurrent disease
giving raised NLR a PPV for recurrence of 78%. The 5 year survival for
patients undergoing resection with high NLR was significantly worse than
that for patients with normal NLR (22% vs. 43%, pB0.0001). Univariate
analysis of factors affecting survival revealed raised NLR, number of
metastases 8, tumour size 5 cm and age 70 significantly affected
outcome. All factors except tumour size remained significant predictors of
term survival on multivariate analysis (NLR:-HR2.261 CI1.6543.129
pB0.0001, Metastases 8:-HR1.611 CI1.0062.579 p0.047, Age 
70:-HR1.418 CI1.0491.930 p0.027). Elevated NLR was found to be
the sole positive predictor of recurrence on Univariate analysis (HR4.521
CI2.4758.257 pB0.0001).
Conclusion Elevated NLR increases both risk of death and the risk of
recurrence in patients who undergo surgery for CRLM. Preoperative NLR
measurement in may therefore provide a simple method of identifying
patients with a poorer prognosis.
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LAPAROSCOPIC LIVER RESECTION WITH PRIOR VASCULAR
CONTROL
Ibrahim Dagher, MD, PhD, Hadrien Tranchart, MD, Panagiotis Lainas,
MD, Alessio Carloni, MD, Dominique Franco, MD, PhD
Antoine Beclere Hospital, Clamart, France
Introduction. The magnification of laparoscopy allows a very precise
dissection of the portal pedicles. The aim of this study was to evaluate the
effect of prior vascular control (PVC) on parenchymal dissection in 105
consecutive patients undergoing laparoscopic liver resections.
Methods. Between 1999 and 2006 we have performed 105 laparoscopic liver
resections. Portal vessels and the hepatic vein were controlled and divided
before parenchymal transection, only in formal anatomic resections. Opera-
tive duration, blood loss, conversion rates and postoperative complications
were compared with patients undergoing laparoscopic non anatomic resec-
tions without PVC.
Results. We studied 49 laparoscopic liver resections with PVC and 56
without PVC. There were 25 major resections (3 segments) in the PVC
group and only 3 in the group without PVC. There was no difference in
operative time between the two groups (244 vs. 218 minutes in the PVC and
non-PVC, respectively; pns). Seven patients underwent conversion, only
one in the group with PVC and 6 in the group without PVC (p0.07). Blood
loss and transfusion rate were lower in the group with PVC (201 vs. 543 ml,
pB0.01; transfusion: 2 vs. 14%, p0.03). Morbidity, specific and general,
was not significantly different between the two groups (PVC, 4%; non-PVC,
12.5%; p0.1).
Conclusion. In our experience, blood loss and transfusion rates were
significantly lower in the laparoscopic liver resections with PVC despite the
higher percentage of major resections in this group. A tendency for lower
conversion rates was observed in PVC group even if it was not statistically
significant. In laparoscopic surgery, liver resection appears to be safer when
PVC is obtained.
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CIRCULATING TUMOR CELLS IN PATIENTS UNDERGOING
SURGERY FOR HEPATIC METASTASES FROM COLORECTAL
CANCER
Pavlos Papavasiliou, MD, Joseph Kuhn, MD, John Nemunaitis, MD, Jeffrey
Lamont, MD
Baylor University Medical Center, Dallas, TX; Mary Crowley Cancer
Research Center, Dallas, TX
Objective. Identify the frequency of circulating tumor cells (CTCs) detected
preoperatively, intraoperatively, and postoperatively in patients undergoing
surgery for colorectal hepatic metastases.
Background. Patients with colorectal liver metastases are at risk for
intrahepatic and extrahepatic recurrent disease following surgical treatment.
CTCs have been detected in patients with a variety of metastatic cancers,
including colorectal. The detection of CTCs may be a significant prognostic
variable in patients with liver metastases.
Methods. Patients undergoing surgical excision or ablation of liver metas-
tases from a colon or rectal primary tumor were prospectively enrolled in this
trial. Four 7.5 cc vials of peripheral blood (total volume 30 cc) were drawn
pre-operatively (PreOp) and at 2 weeks post-operatively (PostOp). An
additional 30 cc blood draw was obtained during mobilization of the liver
or at the beginning of radiofrequency ablation. The samples were centrifuged
and the sera combined to a final volume of 7.5 cc, and the CellSearch
(Veridex, LLC) system was used to identify circulating epithelial cells. Data
was collected on other prognostic factors contributing to a Fong preoperative
risk assessment score for each patient.
Results. 20 patients were enrolled in the trial. There were 13 males and 7
females. Mean Fong criteria score was 1.25 (range 0 to 3). Eighteen patients
were treated with preoperative systemic chemotherapy. Patients underwent
hepatic ablation (n5, 25%), hepatic resection (n7, 35%), or resection
and ablation (n8, 40%). Fourteen patients (70%) had peripheral CTCs
identified PreOp, with a mean value of 3.9 (range 056). PostOp levels were
drawn in 18 patients and 8 had identifiable CTCs (44%). Mean PostOp
CTCs was 1.0 (range 09). Six patients with PreOp CTCs had no CTCs
PostOp. Sixteen patients (80%) had CTCs identified in peripheral blood
during liver or tumor manipulation with a mean value of 28.2 (range 0315).
At a median follow up of 7 months (range 219), three patients (15%) are
dead of disease, six patients (30%) show no evidence of disease, and eleven
patients (55%) are alive with disease. Of the patients free of disease, two of six
had PostOp CTCs (range 01).
Conclusions. Circulating tumor cells are present and quantifiable in many
patients with colorectal hepatic metastases. Peripheral CTCs are present in
greater quantity during intraoperative liver manipulation. The significance of
CTCs on the risk of recurrence is uncertain. Further study on the prognostic
significance and molecular characterization of CTCs is ongoing.
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DOES SURGICAL TECHNIQUE AFFECT RECURRENCE AND
SURVIVAL IN PATIENTS UNDERGOING RESECTION OF COL-
ORECTAL LIVER METASTASES?
Anthony Bonavia, B.Sc., Umut Sarpel, MD, Alexis Grucela, MD, Sasan
Roayaie, MD, Myron E. Schwartz, MD, Daniel M. Labow, MD
Mount Sinai School of Medicine, Ny, NY
Introduction. Some have postulated that anatomic resection of colorectal
liver metastases (CLM) may offer a survival advantage because 1) this
method removes the functional hepatic unit as a whole and 2) nonanatomic
hepatic resection has been reported to have a higher incidence of positive
surgical margins.
Methods. A retrospective review was performed of all patients undergoing
hepatic resection for CLM from 10/01/878/01/07. 183 patients met
inclusion criteria of undergoing either anatomic or nonanatomic resection
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with the aim of removing all gross disease. Positive margin status was defined
as the presence of tumor within 1 mm or less of the cut margin.
Results. The mean age was 61 years (range 3190) with 57% being male. 89
patients (49%) underwent nonanatomic resection, the remaining 94 (51%)
had anatomic resection. Average duration of inflow occlusion was 10
minutes. The average length of stay was 7.4 days. There were 3 deaths,
yielding a 1.6% 30-day mortality rate. Overall, there was a 14% (n22)
positive margin rate, with no difference between anatomic and nonanatomic
resections. The risk of recurrence was 28%, 55% and 59% at 1, 3, and 5-
years respectively. Overall survival was 89%, 67%, and 55% at 1, 3, and 5
years respectively. Positive margins were not associated with a higher
recurrence rate or shorter survival. Type of resection (anatomic or non-
anatomic) was not associated with significant differences in recurrence rates
or overall survival. As previously described in the literature, transfusion is
highly correlated with poorer survival (p0.001).
Conclusion. Hepatic resection for CLM can be performed safely and offers
select patients with Stage IV colorectal cancer prolonged survival. Margin
status appears to be less important than previously reported, perhaps due to
newer, more effective chemotherapy regimens. Therefore, the choice of
anatomic or nonanatomic resection should be dictated by the number and
location of tumors, rather than based on oncologic principles. An emphasis
on the preservation of hepatic parenchyma may be of increasing importance
with the growing awareness of chemotherapy-associated steatohepatitis.
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